🕷️ Crawler Inspector

URL Lookup

Direct Parameter Lookup

Raw Queries and Responses

1. Shard Calculation

Query:

Response:

Calculated Shard: 178 (from laksa057)

2. Crawled Status Check

Query:

curl -X POST \
  'http://laksa178.int.ahrefs:8124/' \
  -H 'Content-Type: text/plain' \
  -H 'X-ClickHouse-Database: crawler3' \
  -H 'Authorization: Basic YXBpOg==' \
  -d 'SELECT getAhrefsURLFromUnparsed(src_unparsed) AS found_url, ifNull(toUnixTimestamp(download_stamp), 0) AS crawl_time, ifNull(toUnixTimestamp(props_url_first_seen), 0) AS first_indexed_time, download_http_code AS http_code, src_unparsed AS src_unparsed, src_root_hash AS src_root_hash, history_drop_reason AS history_drop_reason, meta_title AS meta_title, meta_descriptions AS meta_descriptions, attrs_boilerpipe_text AS attrs_boilerpipe_text, attrs_markdown AS attrs_markdown, attrs_readable_markdown AS attrs_readable_markdown, meta_canonical AS meta_canonical FROM crawler3.page_info_local FINAL PREWHERE (src_root_hash, src_unparsed) IN ((getAhrefsRootHashFromUnparsed(getAhrefsUnparsedNoserviceFromURL(\'http://www.immunize.org/ask-experts/topic/covid-19/\')), getAhrefsUnparsedNoserviceFromURL(\'http://www.immunize.org/ask-experts/topic/covid-19/\'))) FORMAT JSONEachRow'

Response:

{"found_url":"http:\/\/www.immunize.org\/ask-experts\/topic\/covid-19\/","crawl_time":1776427796,"first_indexed_time":1725467128,"http_code":200,"src_unparsed":"org,immunize!www,\/ask-experts\/topic\/covid-19\/ h80","src_root_hash":"15214894206049953578","history_drop_reason":null,"meta_title":"Ask The Experts About Vaccines: COVID-19 | Immunize.org","meta_descriptions":["Read answers by medical experts to healthcare provider questions on vaccines and COVID-19."],"attrs_boilerpipe_text":"The COVID-19 questions were last reviewed on November 16, 2025. See CDC’s\nUse of COVID-19 Vaccines in the United States Interim Clinical Considerations \nfor more information. To keep up with the current available COVID-19 resources from CDC, FDA, and Immunize.org, see Immunize.org’s\nChecklist of Current Versions of U.S. COVID-19 Vaccine Guidance and Clinic Support Tools\n, updated at least monthly. For alerts about new Immunize.org or CDC COVID-19 resources, subscribe to our weekly e-newsletter, \nIZ Express\n.\nResults (89)\nCOVID-19 is the name given to the disease caused by infection with the SARS-CoV-2 coronavirus. This virus was first detected as a cause of human illness in late 2019 in Wuhan, China, and triggered a global pandemic that began in 2020. The virus spreads mainly from person to person through respiratory droplets and small particles produced when an infected person coughs, sneezes, or talks. The virus spreads easily in crowded or poorly ventilated indoor settings. Some people who are infected have no symptoms of illness, while the severity of symptomatic illness ranges from mild to life-threatening. Older adults and people of any age with underlying medical conditions are at higher risk for severe illness.\nThe incubation period after exposure ranges from 2–14 days, with an average of about 5 days. People with COVID-19 are generally considered potentially infectious up to 48 hours before symptom onset and up to 10 days after onset, though people with severe illness may be infectious longer. Symptoms may include fever or chills, cough, shortness of breath or difficulty breathing, fatigue, muscle or body aches, headache, new loss of taste or smell, sore throat, congestion or runny nose, nausea or vomiting, and diarrhea.\nLast reviewed: \n\t\t\t\tNovember 16, 2025\nThe list of underlying health conditions and other factors shown to increase the risk of severe COVID-19 illness is long. Advanced age remains the strongest risk factor. In addition to age, CDC states that data has shown that compared to non-Hispanic White people, people from racial and ethnic minority groups are more likely to be infected with SARS-CoV-2. Once infected, people from racial and ethnic minority groups are more likely to be hospitalized, be admitted to the ICU, and die from COVID-19 at younger ages. CDC provides a list of at-risk conditions at this website:\nwww.cdc.gov\/covid\/hcp\/clinical-care\/underlying-conditions.html\n. The conditions are stratified by strength of published evidence.\nImmunize.org provides an age-appropriate list of high-risk conditions with conclusive or suggestive published evidence as part of each of its standing orders templates for use of 2025-2026 COVID-19 vaccines, all of which may be found on the COVID-19 main page:\nwww.immunize.org\/vaccines\/a-z\/covid-19\/\n.\nLast reviewed: \n\t\t\t\tNovember 16, 2025\nThe CDC has assembled clinical information about COVID-19 at this site:\nwww.cdc.gov\/covid\/hcp\n.\nLast reviewed: \n\t\t\t\tNovember 16, 2025\nThe ACIP recommended on September 18, 2025, that all people age 6 months and older in the United States may receive one or more doses of an age-appropriate 2025–2026 Formula COVID-19 vaccination based on individual decision-making, following shared clinical decision-making discussion with a healthcare professional (e.g., a nurse, doctor, or pharmacist). The decision to vaccinate may be influenced by the presence of conditions that increase the risk of severe COVID-19 illness.\nProduct options include three FDA-licensed mRNA vaccines: Comirnaty (Pfizer-BioNTech, ages 5 years and older); Spikevax (Moderna, ages 6 months and older); mNexspike (Moderna, ages 12 years and older). There is one FDA-licensed adjuvanted protein subunit vaccine: Nuvaxovid (Sanofi-Novavax, ages 12 years and older). Schedules vary by age and immunocompromised status.\nAlthough the FDA licenses limit use of COVID-19 vaccines among recipients younger than age 64 to those with one or more conditions that increases the risk of severe COVID-19, the fact that ACIP did not include any restrictions in its shared clinical decision-making recommendation means that it is an acceptable standard of care for people younger than age 65 without a high risk condition to be vaccinated when desired.\nLast reviewed: \n\t\t\t\tNovember 16, 2025\nPeople who are moderately or severely immunocompromised are at increased risk for severe COVID-19 illness. ACIP and CDC recommend individual decision-making (also known as shared clinical decision-making) after a discussion with a healthcare professional (nurse, doctor, or pharmacist) for people age 6 months and older who are moderately or severely immunocompromised. They are recommended to receive at least 2 doses during the season. The CDC vaccination schedule for people with moderate or severe immunocompromise is available here:\nwww.cdc.gov\/covid\/hcp\/vaccine-considerations\/immunocompromised.html\n.\nThe Infectious Diseases Society of America (IDSA) strongly recommends administration of age-appropriate 2025–2026 COVID-19 vaccinations to all adults and children with compromised immunity. They also recommend that household members and close contacts of immunocompromised people should be up to date with COVID-19 vaccination. See IDSA recommendations for full details:\nwww.idsociety.org\/Seasonal-RTI-Vaccinations-in-Immunocompromised-Patients\/\n.\n \nLast reviewed: \n\t\t\t\tNovember 16, 2025\nIn past seasons, CDC recommended that all doses of COVID-19 vaccine given to children age 6 months through 4 years be from the same manufacturer. However, in the 2025–26 season, only Moderna’s Spikevax mRNA vaccine is licensed and recommended for use in children younger than age 5 years. All children in this age group who are vaccinated against COVID-19 should receive Spikevax, regardless of the brand they received in previous seasons. If the child is age 6 months through 23 months and received an incomplete (1- or 2-dose) initial COVID-19 vaccination series with Pfizer-BioNTech, a 3-dose initial series should be completed with Spikevax. It is not necessary to repeat the initial series.\nIn previously unvaccinated people age 5 years or older with moderate or severe immunocompromise, the same manufacturer is recommended for all initial COVID-19 vaccine series doses (either 2 doses of Nuvaxovid [if age 12 years or older] or 3 doses of an mRNA product). After completion of the initial series, any age-appropriate COVID-19 vaccine may be used in this age group.\nCDC sets out conditions when it is acceptable to use an age-appropriate COVID-19 vaccine from a different manufacturer in any situation where the same manufacturer is recommended:\nSame vaccine not available at the time of the clinic visit\nPrevious dose unknown\nPerson would otherwise not receive a recommended vaccine dose\nPerson starts but unable to complete a vaccination series with the same COVID-19 vaccine due to a contraindication\nLast reviewed: \n\t\t\t\tNovember 16, 2025\nIndividuals with moderate to severe immunocompromise who have completed an initial COVID-19 series should receive two dose of 2025–2026 Formula COVID-19 vaccine this season with the second dose given 6 months later (minimum interval 2 months for Comirnaty, Spikevax, and Nuvaxovid; minimum interval 3 months for mNexspike).\nIn previous seasons, CDC recommended that additional doses of COVID-19 vaccine may be administered (with a minimum two-month interval) based on the clinical judgment of the individual’s healthcare provider and the recipient’s personal preference and circumstances. For the 2025–26 season, CDC has removed this general statement from its interim clinical considerations document (\nwww.cdc.gov\/covid\/hcp\/vaccine-considerations\/immunocompromised.html\n). The CDC clinical considerations document now states, “On a case-by-case basis, providers caring for these patients may administer Moderna, Novavax, and Pfizer-BioNTech COVID-19 vaccines outside of the FDA and CDC dosing intervals when, based on their clinical judgment, the benefits of vaccination are deemed to outweigh the potential and unknown risks for the recipient who is immunocompromised.”\nLast reviewed: \n\t\t\t\tNovember 16, 2025\nJanssen (Johnson & Johnson) COVID-19 vaccine is no longer produced. The last remaining doses expired May 7, 2023. The history of Janssen vaccine use is relevant only to evaluation of an adult with moderate or severe immunocompromise because such individuals are recommended to receive an initial series of COVID-19 vaccine. History of a single dose of Janssen COVID-19 vaccine constitutes a complete initial series. A person with this history should follow the vaccination schedule recommended for an immunocompromised person who has already completed an initial vaccination series.\nLast reviewed: \n\t\t\t\tNovember 16, 2025\nYes. Vaccination should be offered regardless of history of prior SARS-CoV-2 infection or long COVID.\nBecause COVID-19 illness temporarily boosts immunity, people who have recently had SARS-CoV-2 infection may consider delaying a 2025–2026 COVID-19 vaccine dose by up to 3 months following symptom onset or positive COVID-19 test (if asymptomatic). Studies have shown that a longer time between infection and vaccination may improve the immune response to vaccination. The likelihood of reinfection in the first few months following infection is low.\nA recipient’s individual risks for severe disease and current COVID-19 conditions in the community should be taken into account when deciding whether to delay vaccination up to 3 months after infection. As with all vaccines, vaccination should be deferred until after recovery from moderate to severe illness.\nLast reviewed: \n\t\t\t\tNovember 16, 2025\nAdults age 65 years and older have the highest rates of hospitalization and death from COVID-19 illness. Protection against severe COVID-19 disease wanes after a few months. Disease surveillance data from the United States shows that SARS-CoV-2 viruses circulate and cause illness at varying levels year-round, with waves of activity observed historically in winter and late summer. It is not known whether this pattern will continue. This pattern is not like influenza, which usually causes a single epidemic wave (sometimes with more than one peak) each winter.\nThe 2025 CDC adult immunization schedule shows that adults age 65 years and older who are vaccinated against COVID-19 are recommended to receive a second dose of any 2025–2026 Formula COVID-19 vaccine 6 months after their first 2025–2026 Formula COVID-19 vaccine dose (minimum interval of 2 months for Comirnaty, Spikevax, and Nuvaxovid; minimum interval of 3 months for mNexspike). The second dose does not have to be the same brand as the first.\nLast reviewed: \n\t\t\t\tNovember 16, 2025\nCDC recommends waiting a minimum of 8 weeks (2 months) since the last 2024–2025 Formula COVID-19 vaccine to receive an age-appropriate 2025–2026 Formula COVID-19 vaccine, if using Comirnaty (Pfizer-BioNTech), Nuvaxovid (Sanofi-Novavax), or Spikevax (Moderna). They recommend a 3-month minimum interval when using mNexspike (Moderna); however, a dose of mNexspike administered at least 2 months after the most recent dose does not need to be repeated.\nAny person who initiated a COVID-19 vaccination initial series (e.g., a child 6 months through 23 months of age or a person with moderate or severe immunocompromise) with a previous formulation should follow the age-appropriate recommended schedule for completion of their primary series with the current formulation of the same brand, if feasible. For the 2025–26 season, Spikevax is the only licensed and recommended option for children age 6 through 59 months, regardless of their vaccination history.\nLast reviewed: \n\t\t\t\tNovember 16, 2025\nUnder section 564 of the Federal Food, Drug, and Cosmetic Act (FD&C Act), the FDA Commissioner may allow unapproved medical products or unapproved uses of approved medical products to be used in an emergency to diagnose, treat, or prevent serious or life-threatening diseases or conditions caused by chemical, biological, radiological or nuclear threat agents when there are no adequate, approved, and available alternatives. Vaccines that receive an EUA may later be fully licensed by the FDA.\nAll available COVID-19 vaccines were initially administered under EUA. All available 2025–2026 Formula COVID-19 vaccines are fully licensed by FDA and no longer administered under EUA.\nLast reviewed: \n\t\t\t\tNovember 16, 2025\nBoth the Pfizer-BioNTech COVID-19 Vaccine (Comirnaty) and the Moderna COVID-19 vaccines (Spikevax, mNexspike) are lipid nanoparticle-formulated, nucleoside-modified mRNA vaccines encoding the prefusion spike glycoprotein of SARS-CoV-2, the virus that causes COVID-19. The 2025–2026 formula mRNA vaccines target the Omicron JN.1 variant LP.8.1 strain. Moderna’s mNexspike was first licensed in 2025 for ages 12 years and older. It is designed to reduce the amount of mRNA required to elicit the same or slightly better immune response compared to Spikevax (10 mcg of mRNA versus 50 mcg of mRNA for an adult dose). Spikevax and mNexspike may be used interchangeably when both are age appropriate. Visit this CDC website for more details about how mRNA vaccines work:\nwww.cdc.gov\/covid\/vaccines\/how-they-work.html\n.\nLast reviewed: \n\t\t\t\tNovember 16, 2025\nSpikevax and mNexspike are both mRNA vaccines targeting the same strain of COVID-19. Spikevax is the original vaccine now licensed down to age 6 months. The mNexspike product is a newer mRNA vaccine licensed for ages 12 years and older with an advanced design that achieves the same or slightly better immune response with less mRNA in each dose (10 mcg in mNexspike compared to 50 mcg in adult doses of Spikevax). The two products may be used interchangeably when age appropriate.\nIn adults 65 years and older (and moderately or severely immunocompromised adults) who are recommended to receive a second dose 6 months after their first 2025–2026 formula dose, the minimum interval between the two recommended 2025–26 season doses is 3 months for mNexspike, but only 2 months for the other COVID-19 vaccine products. If mNexspike is inadvertently administered after only 2 months, the dose counts as valid and does not need to be repeated.\nLast reviewed: \n\t\t\t\tNovember 16, 2025\nLast reviewed: \n\t\t\t\tJanuary 9, 2026\nIt is estimated that for every million doses administered, about one (~0.0001%) will result in an anaphylactic reaction following vaccination. The estimate for mRNA COVID-19 vaccines is slightly higher, at 2 to 5 anaphylactic reactions per million vaccinations given. With proper screening, most providers who administer thousands of vaccines in their lifetimes will never see an anaphylactic reaction.\nLast reviewed: \n\t\t\t\tNovember 16, 2025\nThe original COVID-19 vaccines all targeted the spike protein of the original SARS-CoV-2 virus. The 2025–2026 formulation vaccines target the spike proteins of more recently circulating strains, known as the Omicron JN.1 lineage LP.8.1 strain (mRNA vaccines) or the JN.1 strain (Nuvaxovid adjuvanted protein subunit vaccine). The update is intended to boost production of antibodies that protect more effectively against disease caused by currently circulating Omicron subvariants.\nThe process of updating the strain without changing anything else is similar to the seasonal strain changes made for influenza vaccinations each year. Vaccine safety, side effects, and risk of allergic reactions are expected to be comparable to earlier formulations of vaccines of the same brand and dose. As with seasonal influenza vaccines, future COVID-19 vaccines can continue to be updated when needed, as the circulating viruses evolve.\nLast reviewed: \n\t\t\t\tNovember 16, 2025\nNo. The last U.S. doses of Janssen COVID-19 Vaccine expired May 7, 2023.\nLast reviewed: \n\t\t\t\tNovember 16, 2025\nNuvaxovid is the brand name of the adjuvanted protein subunit COVID-19 vaccine developed by Novavax and commercialized by Sanofi beginning in the 2025–26 season. It contains the Omicron JN.1 subvariant SARS-CoV-2 spike protein and Matrix-M adjuvant. The saponin-based adjuvant is made from extracts of the bark of the Soapbark tree native to Chile. It is added to enhance the immune response of the vaccine recipient. The spike protein is produced in insect cells.\nThe 2025–2026 formulation of Nuvaxovid is FDA-licensed for use in people age 12 years or older. It is recommended as a single dose for people age 12 years through 64 years, given at least 8 weeks after the most recent dose of COVID-19 vaccine, regardless of the recipient’s vaccination history. People age 65 years or older and those age 12 years and older who are moderately or severely immunocompromised are recommended to receive 2 doses of 2025–2026 Formula COVID-19 vaccines, 6 months apart (with a minimum interval of 2 months between doses if using Nuvaxovid for both doses).\nA 2-dose initial series is recommended for previously unvaccinated recipients who are moderately or severely immunocompromised, with the doses given at least 3 weeks apart. A third dose of any COVID-19 vaccine is recommended 6 months after the initial series is completed (with a minimum interval of 2 months between doses if using Nuvaxovid).\nLast reviewed: \n\t\t\t\tNovember 16, 2025\nThe benefit of COVID-19 vaccination to an individual patient varies depending on the health status of the patient, their history of vaccination and COVID-19 infection, and the circulating COVID-19 strains. However, despite these variables, observational studies consistently show vaccination in all age groups provides measurable additional protection against hospitalization or death compared to those who are unvaccinated.\nCDC published “Interim Estimates of 2024–2025 COVID-19 Vaccine Effectiveness Among Adults Aged ≥18 Years — VISION and IVY Networks, September 2024–January 2025” in MMWR on February 27, 2025 (\nwww.cdc.gov\/mmwr\/volumes\/74\/wr\/mm7406a1.htm\n). They concluded vaccine effectiveness (VE) of 2024–2025 COVID-19 vaccine was 33% against COVID-19–associated emergency department (ED) or urgent care (UC) visits among adults age18 years or older and 45%–46% against hospitalizations among immunocompetent adults age 65 years or older, compared with not receiving a 2024–2025 vaccine dose. VE against hospitalizations in immunocompromised adults age 65 years or older was 40%.\nLast reviewed: \n\t\t\t\tNovember 16, 2025\nCDC and ACIP recommend vaccination of all people age 6 months through 64 years based on individual decision-making (also known as shared clinical decision-making), with an emphasis that the risk-benefit of vaccination is most favorable for individuals who are at an increased risk for severe COVID-19 disease and lowest for individuals who are not at an increased risk, according to the CDC list of COVID-19 risk factors. Refer to CDC’s interim clinical considerations for COVID-19 vaccination for the specific dosing schedule:\nwww.cdc.gov\/covid\/hcp\/vaccine-considerations\/routine-guidance.html#cdc_clinical_guidance_recomm_key-table-1-2025–2026-covid-19-vaccination-schedule-november-4-2025\n.\nThe American Academy of Pediatrics (AAP) has issued separate COVID-19 vaccination recommendations for children during the 2025–26 season. Refer to the full statement for details of their recommendations:\nhttps:\/\/doi.org\/10.1542\/peds.2025-073924\n. In summary, AAP recommends age-appropriate COVID-19 vaccination of the following groups of children:\nAll children age 6 months through 23 months\nResidents of long-term care facilities or other congregate settings\nChildren who have never been vaccinated against COVID-19\nInfants and children with household contacts who are at high risk for severe COVID-19\nAll children who are at risk of severe COVID-19 due to underlying conditions or treatments, including: chronic pulmonary disease, cardiovascular disease, gastrointestinal disorders, hepatic disease, hematologic disease, metabolic disorders, obesity, neurologic and neurodevelopmental conditions, immunosuppressive conditions, and rheumatologic or autoimmune disease\nChildren age 2 through 18 years not in the above categories whose parent or guardian desires their protection from COVID-19\nLast reviewed: \n\t\t\t\tNovember 16, 2025\nThis child should receive one dose recommended for his age at the time of the vaccination visit. At age 11 years, an age-appropriate single dose of either Comirnaty (Pfizer-BioNTech) or Spikevax (Moderna) mRNA vaccine is recommended. If the patient arrives in your clinic after turning 12 years old, the 2025–2026 Formula Nuvaxovid (Sanofi-Novavax) protein subunit vaccine and the mNexspike (Moderna) mRNA vaccine are also options.\nLast reviewed: \n\t\t\t\tNovember 16, 2025\nCDC states that a person who moves to an older age group before completing the initial series recommended for the younger age group should follow the schedule for the older age group and receive the vaccine product and dosage for the older age group. In this case, the child should receive one dose of 2025–2026 Formula Spikevax (Moderna) at least 8 weeks after the most recent dose of COVID-19 vaccine.\nAn initial series of COVID-19 vaccine is recommended for children 6 months through 23 months of age. Children 24 months through 59 months of age are recommended to receive only one dose of 2025–2026 Formula Spikevax regardless of their COVID-19 vaccination history.\nLast reviewed: \n\t\t\t\tNovember 16, 2025\nModerately or severely immunocompromised children who transition from age 11 years to age 12 years during the initial vaccination series should complete the 3-dose series using the dosage for people ages 12 years and older for all doses received once they are age 12 years.\nSee\nwww.cdc.gov\/covid\/hcp\/vaccine-considerations\/immunocompromised.html\nfor additional details.\nLast reviewed: \n\t\t\t\tNovember 16, 2025\nBoth vaccines have been demonstrated to be safe, with side effects typical of those in older age groups. The most common local reaction in this age group is pain at the injection site; the most common systemic symptom in older children was fatigue and in younger children (6 through 23 months) irritability\/crying and sleepiness were most common. Fever may occur after either vaccination. Febrile seizures can occur in infants and young children ages 6 months through 5 years as a result of any condition that causes a fever (most common with high fevers). Febrile seizures are uncommon after vaccination. Febrile seizures were rare after mRNA COVID-19 vaccine clinical trials in this age group, and CDC continues to monitor for this adverse event following vaccination in infants and young children.\nNo cases of myocarditis were reported during the clinical trials for either vaccine. To date, post-authorization surveillance has not detected an increased risk for myocarditis and pericarditis following mRNA COVID-19 vaccination in children ages 6 months–4 years (Pfizer-BioNTech) and ages 6 months–5 years (Moderna).\nLast reviewed: \n\t\t\t\tNovember 16, 2025\nLast reviewed: \n\t\t\t\tNovember 16, 2025\nComirnaty\n(Pfizer-BioNTech) mRNA COVID-19 vaccine is FDA-licensed for use in ages 5 years through 64 years with at least one underlying condition that puts them at risk for severe COVID-19 infection and individuals 65 years and older\nmNexspike\n(Moderna) is FDA-licensed for use in ages 12 through 64 years with at least one underlying condition that puts them at risk for severe COVID-19 infection and individuals 65 years and older\nNuvaxovid\n(Sanofi-Novavax) is FDA-licensed for use in ages 12 through 64 years with at least one underlying condition that puts them at risk for severe COVID-19 infection and individuals 65 years and older\nSpikevax\n(Moderna) mRNA COVID-19 vaccine is FDA-licensed for use in ages 6 months through 64 years with at least one underlying condition that puts them at risk for severe COVID-19 infection and individuals 65 years and older\nAlthough the FDA licenses are limited in the age group younger than 65 years to those with underlying conditions that put them at risk for severe COVID-19 infection, the ACIP has recommended use based on individual decision-making (i.e., shared clinical decision-making) for all people age 6 months and older. This means that it is acceptable standard of care to offer COVID-19 vaccination to people in this age group without a high-risk condition when vaccination is desired.\nLast reviewed: \n\t\t\t\tNovember 16, 2025\nClinical trial results for the original monovalent Pfizer-BioNTech COVID-19 Vaccine (administered as a two-dose primary series) demonstrated that among vaccine recipients age 12–15 years, side effects during the 7 days after vaccination were commonly reported (90.9% of vaccine recipients reported a local reaction and 90.7% reported a systemic reaction). Most reactions were mild to moderate. Pain at the injection site was the most common local reaction. One in 10 reported a side effect that interfered with daily activities. Side effects usually resolved after 1–2 days. Systemic side effects (e.g., fever, fatigue, headache, muscle pain) were more commonly reported after the second dose than after the first dose. No specific safety concerns were identified among adolescent vaccine recipients.\nThe safety and side effects of the 2025–2026 formula are expected to be consistent with the previous formulations of the product.\nLast reviewed: \n\t\t\t\tNovember 16, 2025\nThe 2025–2026 formula Nuvaxovid (Sanofi-Novavax) vaccine is an option for any person age 12 years or older who is due for a 2025–2026 updated vaccination. Below are listed the 2025–26 season dosing schedules (if using Nuvaxovid for all doses) for different ages and health conditions:\nAge 12 through 64 years, not moderately or severely immunocompromised: one 2025–2026 formula dose, at least 8 weeks after most recent dose from a previous season\nAge 65 years and older, not moderately or severely immunocompromised: two 2025–2026 formula doses 6 months apart (minimum interval 2 months)\nAge 12 years or older, moderately or severely immunocompromised:\nPreviously unvaccinated: give 2 doses at least 3 weeks apart as an initial series, followed by a third dose about 6 months after dose 2 (minimum interval 2 months)\nPreviously completed an initial series of any COVID-19 vaccine (2 doses of Novavax protein subunit vaccine or 3 doses of an mRNA vaccine): give first 2025–2026 formula dose at least 8 weeks after most recent COVID-19 vaccine from the previous season, then give a second dose about 6 months later (minimum interval, 2 months)\nSee Immunize.org’s standing orders template for administration of 2025–2026 formula adjuvanted protein subunit vaccine to individuals age 12 years and older for details:\nwww.immunize.org\/wp-content\/uploads\/catg.d\/p3141.pdf\n.\nLast reviewed: \n\t\t\t\tNovember 16, 2025\nYes. Evidence continues to demonstrate that COVID-19 vaccination is safe and effective during any stage of pregnancy; the benefits of vaccination clearly outweigh any known or potential risks of COVID-19 vaccination during pregnancy. The currently licensed COVID-19 vaccines are nonreplicating vaccines and cannot cause infection in either the mother or the fetus. No evidence exists of risk to the fetus from vaccinating during pregnancy with nonreplicating vaccines in general.\nData from the Vaccine Adverse Events Reporting System (VAERS), the V-safe surveillance system, and the V-safe pregnancy registry have not signaled any safety concerns related to vaccination during pregnancy for mother or infant.\nPregnant women have historically been at an increased risk of severe disease, adverse pregnancy outcomes, and maternal death from COVID-19 infections. ACIP recommends the use of 2025–2026 COVID-19 vaccine during pregnancy based upon individual decision-making (i.e., shared clinical decision-making).\nThe American College of Obstetricians and Gynecologists (ACOG) recommends all pregnant women receive any age-appropriate 2025–2026 Formula COVID-19 vaccine if they have not already received one. Current ACOG recommendations are available here:\nwww.acog.org\/clinical\/clinical-guidance\/practice-advisory\/articles\/2020\/12\/covid-19-vaccination-considerations-for-obstetric-gynecologic-care\n.\nLast reviewed: \n\t\t\t\tNovember 16, 2025\nPregnant women have historically been at an increased risk of severe disease, adverse pregnancy outcomes, and maternal death from COVID-19 infections. Studies have shown that antibodies produced after COVID-19 vaccination during pregnancy are transferred to the newborn, and COVID-19 vaccination during pregnancy reduces the risk of COVID-19 hospitalization in infants younger than 6 months.\nACIP recommends the use of 2025–2026 COVID-19 vaccine during pregnancy based upon individual decision-making (i.e., shared clinical decision-making) after a discussion with a nurse, doctor, or pharmacist.\nThe American College of Obstetricians and Gynecologists (ACOG) recommends all pregnant women receive any age-appropriate 2025–2026 Formula COVID-19 vaccine if they have not already received one. A person who is up to date on COVID-19 vaccination and becomes pregnant is not recommended to get an additional dose. Current ACOG recommendations are available here:\nwww.acog.org\/clinical\/clinical-guidance\/practice-advisory\/articles\/2020\/12\/covid-19-vaccination-considerations-for-obstetric-gynecologic-care\n.\nLast reviewed: \n\t\t\t\tNovember 16, 2025\nLast reviewed: \n\t\t\t\tJanuary 9, 2026\nYes. COVID-19 vaccination may be given during lactation.\nLast reviewed: \n\t\t\t\tNovember 16, 2025\nPlease see CDC’s Interim Clinical Considerations for the Use of COVID-19 Vaccines for dosage guidance for detailed tables, including dosing intervals and options (\nwww.cdc.gov\/covid\/hcp\/vaccine-considerations\/immunocompromised.html\n). You will also find the vaccination schedules for people who are moderately or severely immunocompromised in the Immunize.org standing orders templates for administration of COVID-19 vaccines:\nFor ages 6 months through 11 years:\nwww.immunize.org\/wp-content\/uploads\/catg.d\/p3140a.pdf\nmRNA vaccines for ages 12 years and older:\nwww.immunize.org\/wp-content\/uploads\/catg.d\/p3140.pdf\nProtein subunit vaccine for ages 12 years and older:\nwww.immunize.org\/wp-content\/uploads\/catg.d\/p3141.pdf\nIn general, people who are moderately or severely immunocompromised and previously unvaccinated are recommended to receive a 2-dose (protein subunit) or 3-dose (mRNA) initial series of COVID-19 vaccine, with an additional dose 6 months later of any age-appropriate COVID-19 brand (minimum interval of 2 months for Nuvaxovid, Spikevax, or Comirnaty; 3-month minimum interval for mNexspike). CDC recommends use of the same manufacturer for all doses of the initial series when feasible. Spikevax and mNexspike are both made by Moderna and are interchangeable in ages 12 years and older.\nThose who completed an initial series before the 2025–2026 formula vaccines were available should receive 2 doses of 2025–2026 Formula COVID-19 vaccine (any age-appropriate brand) about 6 months apart (minimum interval of 2 months for Nuvaxovid, Spikevax, or Comirnaty; 3-month minimum interval for mNexspike).\nImmunocompromised people should be counseled that they may have a reduced immune response to COVID-19 vaccination. Continuing other infection prevention measures, such as wearing a face mask and avoiding crowds, can help limit their risk of exposure to the SARS-CoV-2 virus.\nPemivibart (Pemgarda, Invyvid) is a monoclonal antibody for COVID-19 pre-exposure prophylaxis in people who are moderately or severely immunocompromised and unlikely to mount an adequate immune response to COVID-19 vaccination and who meet the \nFDA-authorized conditions for use\n. See additional information from CDC at the immunocompromised link in the first paragraph.\nLast reviewed: \n\t\t\t\tNovember 16, 2025\nThe conditions and treatments that CDC specifies may result in moderate or severe immunocompromise include\nbut are not limited to\n:\nActive treatment for solid tumor and hematologic malignancies\nHematologic malignancies associated with poor responses to COVID-19 vaccines regardless of current treatment status (e.g., chronic lymphocytic leukemia, non-Hodgkin lymphoma, multiple myeloma, acute leukemia)\nReceipt of solid-organ transplant or an islet transplant and taking immunosuppressive therapy\nReceipt of chimeric antigen receptor (CAR)-T-cell therapy or hematopoietic cell transplant (HCT) (within 2 years of transplantation or taking immunosuppressive therapy)\nModerate or severe primary immunodeficiency (e.g., common variable immunodeficiency disease, severe combined immunodeficiency, DiGeorge syndrome, Wiskott-Aldrich syndrome)\nAdvanced HIV infection (people with HIV and CD4 cell counts less than 200\/mm³, history of an AIDS-defining illness without immune reconstitution, or clinical manifestations of symptomatic HIV) or untreated HIV infection\nActive treatment with high-dose corticosteroids (i.e., 20 mg or more of prednisone or equivalent per day when administered for 2 or more weeks), alkylating agents, antimetabolites, transplant-related immunosuppressive drugs, cancer chemotherapeutic agents classified as severely immunosuppressive, tumor necrosis factor (TNF) blockers, and other biologic agents that are immunosuppressive or immunomodulatory (e.g., B-cell-depleting agents)\nAdditional factors to consider in assessing the general level of immune competence in a patient include disease severity, duration, clinical stability, complications, comorbidities, and any potentially immune-suppressing treatment. A patient’s clinical care team is in the best position to evaluate the degree of immunocompromise and timing of vaccination.\nSee CDC’s interim clinical considerations for this population:\nwww.cdc.gov\/covid\/hcp\/vaccine-considerations\/immunocompromised.html\n.\nLast reviewed: \n\t\t\t\tNovember 16, 2025\nYes. See revaccination considerations at \nwww.cdc.gov\/covid\/hcp\/vaccine-considerations\/immunocompromised.html\n. This is the most current statement from CDC on COVID-19 revaccination:\nRecipients of chimeric antigen receptor (CAR)-T-cell therapy or hematopoietic cell transplant (HCT) who received 1 or more doses of COVID-19 vaccine prior to or during treatment should be revaccinated. Revaccination should start at least 3 months (12 weeks) after transplant or CAR-T-cell therapy and should follow the currently recommended schedule for people who are unvaccinated.\nRevaccination may also be considered for patients who received 1 or more doses of COVID-19 vaccine during treatment with B-cell-depleting therapies (e.g., rituximab, ocrelizumab) that were administered over a limited period (e.g., as part of a treatment regimen for certain malignancies) according to the currently recommended schedule for people who are unvaccinated. The suggested interval to start revaccination is about 6 months after completion of the B-cell-depleting therapy. Timing of vaccination for patients who receive B-cell-depleting therapies on a continuing basis (e.g., for treatment of certain autoimmune conditions such as rheumatoid arthritis or multiple sclerosis) is addressed in CDC’s\nconsiderations for timing of COVID-19 vaccination in relation to immunosuppressive therapies\n.\nCDC continues to recommend that a patient’s clinical team is best positioned to determine the degree of immune compromise, need for revaccination, and appropriate timing of revaccination.\nLast reviewed: \n\t\t\t\tNovember 16, 2025\nAccording to CDC’s interim clinical considerations for the use of COVID-19 vaccines, whenever possible, COVID-19 vaccines should be administered at least 2 weeks before initiation or resumption of immunosuppressive therapies. For patients who receive B-cell-depleting therapies on a continuing basis, COVID-19 vaccines should be administered approximately 4 weeks before the next scheduled therapy.\nCDC also notes that timing of COVID-19 vaccination should take into consideration current or planned immunosuppressive therapies, optimization of both the patient’s medical condition and response to vaccination, and individual benefits and risks. Review the CDC’s considerations for COVID-19 vaccination of those on immunosuppressive therapies here: \nwww.cdc.gov\/covid\/hcp\/vaccine-considerations\/immunocompromised.html#cdc_cg_special_populations_about-considerations-for-timing-of-covid-19-vaccination-in-relation-to-immunosuppressive-therapies\n.\nOn a case-by-case basis, providers caring for these patients may administer COVID-19 vaccines outside of the FDA and CDC dosing schedules based on their clinical judgment of what is most beneficial to the patient.\nLast reviewed: \n\t\t\t\tNovember 16, 2025\nCDC states that no additional medical documentation is required before administering COVID-19 vaccine. The patient’s self-attestation of a high-risk condition, including moderate or severe immunocompromise, is sufficient. Those who report moderate or severe immunocompromise should be offered the modified schedule for people with moderate or severe immunocompromise. Vaccinators should not deny COVID-19 vaccination to a person due to lack of documentation of a self-reported high-risk condition.\nLast reviewed: \n\t\t\t\tNovember 16, 2025\nLast reviewed: \n\t\t\t\tJanuary 9, 2026\nImmunocompromised people who need an initial series of 3 doses of mRNA COVID-19 vaccine or two doses of Nuvaxovid (Sanofi-Novavax) adjuvanted protein COVID-19 vaccine should receive the initial series using COVID-19 vaccines from the same manufacturer, unless it is not feasible. If the same manufacturer cannot be used for all primary series doses (e.g., the brand is unavailable at the time of the vaccination visit, the previous brand is unknown, or the patient would not be vaccinated with the previous brand due to a contraindication or other reason), then administer another age-appropriate brand. Spikevax (Moderna) is the only licensed 2025–2026 Formula COVID-19 vaccine option for children younger than age 5 years. If the immunocompromised recipient is age 5 years or older, once the initial series is complete, any appropriate brand may be used for all subsequent doses. Spikevax and mNexspike are interchangeable: both vaccines are made by Moderna.\nLast reviewed: \n\t\t\t\tNovember 16, 2025\nThe patient’s initial series is considered complete following a single dose of the Janssen COVID-19 Vaccine. People who are moderately or severely immunocompromised and have completed an initial series (no matter how long ago) should now receive 1 dose of an age-appropriate 2025–2026 Formula COVID-19 vaccine (at least 8 weeks after their most recent dose of a previous formulation). They should receive a second 2025–2026 Formula COVID-19 vaccine dose 6 months later (minimum interval 2 months for Comirnaty, Spikevax, and Nuvaxovid; minimum interval of 3 months if using mNexspike).\nLast reviewed: \n\t\t\t\tNovember 16, 2025\nThe patient should receive a 2025–2026 COVID-19 mRNA dose now, of the same manufacturer as the initial two doses (if feasible), in order to complete the 3-dose initial mRNA vaccine series recommended for people with moderate or severe immunocompromise. Advise the patient that he should receive an additional 2025–2026 Formula COVID-19 dose of any brand in 6 months (minimum interval 2 months if using Comirnaty, Spikevax, or Nuvaxovid; minimum interval 3 months if using mNexspike).\nLast reviewed: \n\t\t\t\tNovember 16, 2025\nAll COVID-19 vaccines are administered intramuscularly. Preparation details and dose volume vary by product. Most 2025-2026 formula products are now available in manufacturer-filled syringes.\nLast reviewed: \n\t\t\t\tNovember 16, 2025\nYes. CDC published an appendix to its interim clinical considerations for the use of COVID-19 vaccines to address a wide range of errors in vaccine administration. It includes a detailed table outlining actions to take after an error has occurred:\nwww.cdc.gov\/covid\/hcp\/vaccine-considerations\/appendices.html\n.\nCategories of errors covered in the CDC table include:\nSite\/route\nAge\nProduct and dosage\nStorage and handling\nIncorrect intervals\nInterchanging product types when not recommended\nAsk the Experts refers our readers to this CDC table for the most current and comprehensive guidance on COVID-19 vaccine administration errors and how to manage them. For all vaccine administration errors the following steps are recommended: inform the patient of the error, report the error to VAERS (\nhttps:\/\/vaers.hhs.gov\n) unless CDC’s guidance states that the error does not need to be reported, evaluate why the error occurred, and implement strategies to prevent future errors.\nLast reviewed: \n\t\t\t\tNovember 16, 2025\nNo. CDC does not recommend repeating the dose of any COVID-19 vaccine in circumstances where the dose is administered in an incorrect route or an incorrect site (i.e., not in the deltoid or anterolateral thigh). In the case of a subcutaneous injection, the patient should be advised of the possibility of self-limited local or systemic side effects.\nLast reviewed: \n\t\t\t\tNovember 16, 2025\nProviding a vaccine recipient with a COVID-19 vaccine VIS is recommended by CDC but not required. The requirement to provide the VIS to a patient is present only when a vaccine is included in the federal Vaccine Injury Compensation Program (VICP). COVID-19 vaccines are not included in the VICP at this time. The current official VIS and all available translations are available from Immunize.org:\nwww.immunize.org\/vaccines\/vis\/covid-19\/\n.\nLast reviewed: \n\t\t\t\tNovember 16, 2025\nLast reviewed: \n\t\t\t\tJanuary 9, 2026\nPeriodically verify whether you are using the most current available documents by checking Immunize.org’s regularly updated Checklist of Current Versions of U.S. COVID-19 Vaccination Guidance and Clinic Support Tools:\nwww.immunize.org\/catg.d\/p3130.pdf\n. This resource is updated as needed with the dates of the most currently available materials from CDC and FDA.\nInformation from CDC is generally updated first on the CDC web page: Interim Clinical Considerations for Use of COVID-19 Vaccines in the United States: (\nwww.cdc.gov\/covid\/hcp\/vaccine-considerations\/index.html\n).\nLast reviewed: \n\t\t\t\tNovember 16, 2025\nNo. Simply administer the next dose that\nis currently recommended\n, using a vaccine from the same manufacturer, if\nfeasible\n, even if\nprevious\ndoses in the series were an earlier formulation\n.\nLast reviewed: \n\t\t\t\tNovember 16, 2025\nCDC guidance allows for doses given up to 4 days before the recommended interval to be counted as valid – such doses do not need to be repeated. However, people should not be routinely scheduled to receive a dose earlier than recommended. Schedulers should offer appointments beginning on the date of the recommended interval or later.\nLast reviewed: \n\t\t\t\tNovember 16, 2025\nBeginning with the 2025–2026 season, a single dose of 2025–2026 Formula Nuvaxovid adjuvanted protein COVID-19 vaccine is recommended for all recipients age 12 through 64 years who are not moderately or severely immunocompromised, regardless of their vaccination history. Those age 65 years or older are recommended to receive a second dose of any 2025–2026 Formula COVID-19 vaccine 6 months after the first 2025–2026 Formula dose (minimum interval 2 months if using Comirnaty, Spikevax, or Nuvaxovid; minimum interval 3 months if using mNexspike).\nLast reviewed: \n\t\t\t\tNovember 16, 2025\nAn asymptomatic person who is scheduled for COVID-19 vaccination and is exposed to SARS-CoV-2 virus may be vaccinated. COVID-19 vaccination after exposure is not recommended as post-exposure prophylaxis, so vaccination should not be expected to prevent illness caused by past exposure. A person who is currently sick with a respiratory virus should defer vaccination until at least the recovery from the acute illness, and consider additional measures to prevent infecting others, in accordance with current CDC guidance. Healthcare facilities may have specific policies in place to reduce the risk of spread of respiratory viruses to healthcare staff and other patients.\nPeople who recently had SARS-CoV-2 infection and are due for a COVID-19 vaccine may consider delaying the dose by up to 3 months from symptom onset or positive test (if infection was asymptomatic). According to CDC, increasing the time between infection and vaccination may result in an improved immune response to vaccination. There is a low risk of reinfection in the weeks following an infection. A recipient’s individual risks for severe disease and current COVID-19 conditions in the community should be taken into consideration when deciding whether to delay vaccination up to 3 months after infection.\nLast reviewed: \n\t\t\t\tNovember 16, 2025\nRoutine administration of all age-appropriate doses of vaccines at the same visit, also known as coadministration, is acceptable for children, adolescents, and adults if there are no contraindications at the time of the healthcare visit. COVID-19 vaccine may also be coadministered with nirsevimab or clesrovimab (RSV preventive antibody for infants), given in different syringes and at different anatomical sites. COVID-19 vaccines may also be given at any interval before or after any other vaccination.\nThere are special considerations for orthopoxvirus vaccination. There is no required minimum interval between receiving a dose of any COVID-19 vaccine and an orthopoxvirus vaccine, either Jynneos or ACAM2000 vaccine (e.g., for mpox prevention), regardless of which vaccine is administered first. However, use of Jynneos vaccine should be prioritized over ACAM2000 when co-administering a COVID-19 vaccine and an orthopoxvirus vaccine.\nPeople, particularly adolescent or young adult males, who are recommended to be vaccinated against both mpox and COVID-19 might consider waiting 4 weeks between vaccines. This is because of the observed risk for myocarditis and pericarditis after receipt of ACAM2000 orthopoxvirus vaccine and COVID-19 vaccines, and the hypothetical risk for myocarditis and pericarditis after Jynneos vaccine. However, if a patient’s risk for mpox or severe disease due to COVID-19 is increased, administration of mpox and COVID-19 vaccines should not be delayed.\nLast reviewed: \n\t\t\t\tNovember 16, 2025\nYour patient may choose to receive the vaccines at the same visit or separately, without regard to the timing interval.\nWhen multiple vaccines are administered at a single visit, administer each injection in a different syringe and at a different injection site. For adolescents and adults, the deltoid muscle may be used for more than one injection, though injection sites should be at least one inch apart. It is generally preferable to administer reactogenic vaccines such as Shingrix and COVID-19 vaccine in different arms. However, if the patient prefers both injections in the same deltoid, that is also acceptable.\nImmunize.org has developed a one-page guide to administering multiple intramuscular vaccinations to an adult at one visit:\nwww.immunize.org\/catg.d\/p2030.pdf\n.\nLast reviewed: \n\t\t\t\tNovember 16, 2025\nThe timing of CDC-recommended vaccination is unaffected by the receipt of COVID-19 monoclonal antibodies or convalescent plasma.\nLast reviewed: \n\t\t\t\tNovember 16, 2025\nThis page was updated on\nJanuary 9, 2026\n.","attrs_markdown":"[Skip to content](http:\/\/www.immunize.org\/ask-experts\/topic\/covid-19\/#primary)\n\n[![Immunize.org Logo](https:\/\/www.immunize.org\/wp-content\/uploads\/Immunize.svg)](https:\/\/www.immunize.org\/)\n\n- [*IZ Express*](https:\/\/www.immunize.org\/news\/iz-express\/about\/)\n- [Shop](https:\/\/shop.immunize.org\/)\n- [Donate](https:\/\/www.immunize.org\/donate\/)\n- [Guide](https:\/\/www.immunize.org\/guide\/)\n\n- [Vaccines & VISs]()\n  - [Vaccines A-ZOur immunization resources organized by vaccine]()\n    - - - [Adenovirus](https:\/\/www.immunize.org\/vaccines\/a-z\/adenovirus\/)\n        - [Anthrax](https:\/\/www.immunize.org\/vaccines\/a-z\/anthrax\/)\n        - [BCG](https:\/\/www.immunize.org\/vaccines\/a-z\/bcg\/)\n        - [Chikungunya](https:\/\/www.immunize.org\/vaccines\/a-z\/chikungunya\/)\n        - [Cholera](https:\/\/www.immunize.org\/vaccines\/a-z\/cholera\/)\n        - [COVID-19](https:\/\/www.immunize.org\/vaccines\/a-z\/covid-19\/)\n        - [Dengue](https:\/\/www.immunize.org\/vaccines\/a-z\/dengue\/)\n        - [Diphtheria](https:\/\/www.immunize.org\/vaccines\/a-z\/diphtheria\/)\n        - [Ebola](https:\/\/www.immunize.org\/vaccines\/a-z\/ebola\/)\n        - [Hepatitis A](https:\/\/www.immunize.org\/vaccines\/a-z\/hepa\/)\n        - [Hepatitis B](https:\/\/www.immunize.org\/vaccines\/a-z\/hepb\/)\n        - [Hib (*Haemophilus Influenzae* type b)](https:\/\/www.immunize.org\/vaccines\/a-z\/hib\/)\n      - - [HPV (Human Papillomavirus)](https:\/\/www.immunize.org\/vaccines\/a-z\/hpv\/)\n        - [Influenza](https:\/\/www.immunize.org\/vaccines\/a-z\/influenza\/)\n        - [Japanese Encephalitis](https:\/\/www.immunize.org\/vaccines\/a-z\/japanese-encephalitis\/)\n        - [Measles](https:\/\/www.immunize.org\/vaccines\/a-z\/measles\/)\n        - [Meningococcal ACWY](https:\/\/www.immunize.org\/vaccines\/a-z\/menacwy\/)\n        - [Meningococcal B](https:\/\/www.immunize.org\/vaccines\/a-z\/menb\/)\n        - [Mpox](https:\/\/www.immunize.org\/vaccines\/a-z\/mpox\/)\n        - [Mumps](https:\/\/www.immunize.org\/vaccines\/a-z\/mumps\/)\n        - [Pertussis](https:\/\/www.immunize.org\/vaccines\/a-z\/pertussis\/)\n        - [Pneumococcal](https:\/\/www.immunize.org\/vaccines\/a-z\/pneumococcal\/)\n        - [Polio](https:\/\/www.immunize.org\/vaccines\/a-z\/polio\/)\n      - - [Rabies](https:\/\/www.immunize.org\/vaccines\/a-z\/rabies\/)\n        - [Rotavirus](https:\/\/www.immunize.org\/vaccines\/a-z\/rotavirus\/)\n        - [RSV (Respiratory Syncytial Virus)](https:\/\/www.immunize.org\/vaccines\/a-z\/rsv\/)\n        - [Rubella](https:\/\/www.immunize.org\/vaccines\/a-z\/rubella\/)\n        - [Smallpox](https:\/\/www.immunize.org\/vaccines\/a-z\/smallpox\/)\n        - [TBE (Tick-borne Encephalitis)](https:\/\/www.immunize.org\/vaccines\/a-z\/tbe\/)\n        - [Tetanus](https:\/\/www.immunize.org\/vaccines\/a-z\/tetanus\/)\n        - [Typhoid](https:\/\/www.immunize.org\/vaccines\/a-z\/typhoid\/)\n        - [Varicella (Chickenpox)](https:\/\/www.immunize.org\/vaccines\/a-z\/varicella\/)\n        - [Yellow Fever](https:\/\/www.immunize.org\/vaccines\/a-z\/yellow-fever\/)\n        - [Zoster (Shingles)](https:\/\/www.immunize.org\/vaccines\/a-z\/zoster\/)\n  - [VISsAccess current Vaccine Information Statements from CDC]()\n    - - - [VISs Overview](https:\/\/www.immunize.org\/vaccines\/vis\/about-vis\/)\n        - [VIS-Related Resources](http:\/\/www.immunize.org\/clinical\/topic\/vis\/)\n        - [Translations](https:\/\/www.immunize.org\/translations\/)\n        - [Adenovirus](https:\/\/www.immunize.org\/vaccines\/vis\/adenovirus\/)\n        - [Anthrax](https:\/\/www.immunize.org\/vaccines\/vis\/anthrax\/)\n        - [Cholera](https:\/\/www.immunize.org\/vaccines\/vis\/cholera\/)\n        - [COVID-19](https:\/\/www.immunize.org\/vaccines\/vis\/covid-19\/)\n        - [Dengue](https:\/\/www.immunize.org\/vaccines\/vis\/dengue\/)\n        - [DTaP (Diphtheria, Tetanus, Pertussis)](https:\/\/www.immunize.org\/vaccines\/vis\/dtap\/)\n        - [Ebola](https:\/\/www.immunize.org\/vaccines\/vis\/ebola\/)\n        - [Hib (*Haemophilus Influenzae* type b)](https:\/\/www.immunize.org\/vaccines\/vis\/hib\/)\n        - [Hepatitis A](https:\/\/www.immunize.org\/vaccines\/vis\/hepa\/)\n        - [Hepatitis B](https:\/\/www.immunize.org\/vaccines\/vis\/hepb\/)\n      - - [HPV (Human Papillomavirus)](https:\/\/www.immunize.org\/vaccines\/vis\/hpv\/)\n        - [Influenza (Inactivated or Recombinant)](https:\/\/www.immunize.org\/vaccines\/vis\/influenza-inactivated\/)\n        - [Influenza (Live Intranasal)](https:\/\/www.immunize.org\/vaccines\/vis\/influenza-live\/)\n        - [Japanese Encephalitis](https:\/\/www.immunize.org\/vaccines\/vis\/japanese-encephalitis\/)\n        - [Meningococcal ACWY](https:\/\/www.immunize.org\/vaccines\/vis\/menacwy\/)\n        - [Meningococcal B](https:\/\/www.immunize.org\/vaccines\/vis\/menb\/)\n        - [MMR (Measles, Mumps, Rubella)](https:\/\/www.immunize.org\/vaccines\/vis\/mmr\/)\n        - [MMRV (Measles, Mumps, Rubella, Varicella)](https:\/\/www.immunize.org\/vaccines\/vis\/mmrv\/)\n        - [Multi-Vaccine](https:\/\/www.immunize.org\/vaccines\/vis\/multi-vaccine\/)\n        - [PCV (Pneumococcal Conjugate)](https:\/\/www.immunize.org\/vaccines\/vis\/pcv\/)\n        - [PPSV (Pneumococcal Polysaccharide)](https:\/\/www.immunize.org\/vaccines\/vis\/ppsv\/)\n        - [Polio](https:\/\/www.immunize.org\/vaccines\/vis\/polio\/)\n      - - [Rabies](https:\/\/www.immunize.org\/vaccines\/vis\/rabies\/)\n        - [Rotavirus](https:\/\/www.immunize.org\/vaccines\/vis\/rotavirus\/)\n        - [RSV (Respiratory Syncytial Virus)](https:\/\/www.immunize.org\/vaccines\/vis\/rsv\/)\n        - [RSV Preventive Antibody – IIS](https:\/\/www.immunize.org\/vaccines\/vis\/iis-rsv\/)\n        - [Smallpox\/Monkeypox](https:\/\/www.immunize.org\/vaccines\/vis\/smallpox-mpox\/)\n        - [TBE (Tick-borne Encephalitis)](https:\/\/www.immunize.org\/vaccines\/vis\/tbe\/)\n        - [Td (Tetanus, Diphtheria)](https:\/\/www.immunize.org\/vaccines\/vis\/td\/)\n        - [Tdap (Tetanus, Diphtheria, Pertussis)](https:\/\/www.immunize.org\/vaccines\/vis\/tdap\/)\n        - [Typhoid](https:\/\/www.immunize.org\/vaccines\/vis\/typhoid\/)\n        - [Varicella (Chickenpox)](https:\/\/www.immunize.org\/vaccines\/vis\/varicella\/)\n        - [Yellow Fever](https:\/\/www.immunize.org\/vaccines\/vis\/yellow-fever\/)\n        - [Zoster (Shingles)](https:\/\/www.immunize.org\/vaccines\/vis\/zoster\/)\n  - [VIS TranslationsVaccine-specific VISs translated into dozens of languages](https:\/\/www.immunize.org\/vaccines\/vis-translations\/)\n  - [Travel VaccinesInformation about travelers’ health and vaccination](https:\/\/www.immunize.org\/vaccines\/travel-vaccines\/)\n  - [Vaccine History TimelineNotable milestones in immunization going back to 400 BC](https:\/\/www.immunize.org\/vaccines\/vaccine-timeline\/)\n  - [CDC Recommended SchedulesCurrent immunization schedules from CDC](https:\/\/www.immunize.org\/vaccines\/rec-schedules\/)\n  - [ACIP Vaccine RecommendationsAs endorsed and published by CDC](https:\/\/www.immunize.org\/vaccines\/acip-recs\/)\n- [Clinical Resources]()\n  - [Clinical Resources A-ZOur printable resources designed to help healthcare professionals in all aspects of immunization practice]()\n    - - - [Search All Clinical Resources](https:\/\/www.immunize.org\/clinical\/a-z\/)\n        - [All Patient Handouts](http:\/\/www.immunize.org\/clinical\/a-z\/all-patient\/)\n        - [All Resources for Staff & Providers](http:\/\/www.immunize.org\/clinical\/a-z\/all-providers\/)\n        - [Translations](https:\/\/www.immunize.org\/translations\/)\n        - [Addressing Vaccination Anxiety](https:\/\/www.immunize.org\/clinical\/topic\/addressing-anxiety\/)\n        - [Administering Vaccines](https:\/\/www.immunize.org\/clinical\/topic\/admin-vaccines\/)\n        - [Adolescent Vaccination](https:\/\/www.immunize.org\/clinical\/topic\/adolescent-vaccination\/)\n        - [Adult Vaccination](https:\/\/www.immunize.org\/clinical\/topic\/adult-vaccination\/)\n        - [Contraindications & Precautions](https:\/\/www.immunize.org\/clinical\/topic\/contraindications\/)\n        - [Documenting Vaccination](https:\/\/www.immunize.org\/clinical\/topic\/documenting\/)\n        - [Healthcare Personnel](https:\/\/www.immunize.org\/clinical\/topic\/healthcare-personnel\/)\n      - - [Managing Vaccine Reactions](https:\/\/www.immunize.org\/clinical\/topic\/managing-vaccine-reactions\/)\n        - [Parent Handouts](https:\/\/www.immunize.org\/clinical\/topic\/parent-handouts\/)\n        - [Pregnancy and Vaccines](https:\/\/www.immunize.org\/clinical\/topic\/pregnancy-vaccines\/)\n        - [Q\\&As by Diseases and Vaccines](https:\/\/www.immunize.org\/clinical\/topic\/qas\/)\n        - [Schedules for Patients](https:\/\/www.immunize.org\/clinical\/topic\/patient-schedules\/)\n        - [Screening Checklists](https:\/\/www.immunize.org\/clinical\/topic\/screening-checklists\/)\n        - [Standing Orders Templates](https:\/\/www.immunize.org\/clinical\/topic\/standing-orders-templates\/)\n        - [Storage & Handling](https:\/\/www.immunize.org\/clinical\/topic\/storage-handling\/)\n        - [Strategies & Policies](https:\/\/www.immunize.org\/clinical\/topic\/strategies-policies\/)\n        - [Vaccine Confidence](https:\/\/www.immunize.org\/clinical\/topic\/vaccine-confidence\/)\n        - [VIS-Related Resources](https:\/\/www.immunize.org\/clinical\/topic\/vis\/)\n        - [Vaccine Recommendations](https:\/\/www.immunize.org\/clinical\/topic\/vaccine-recs\/)\n  - [Vaccine Confidence & Addressing ConcernsPractical resources to help providers respond to patient concerns]()\n    - - - [Vaccine Confidence Overview](https:\/\/www.immunize.org\/clinical\/vaccine-confidence\/)\n        - [Addressing Vaccination Anxiety](https:\/\/www.immunize.org\/clinical\/topic\/addressing-anxiety\/)\n        - [Adjuvants](https:\/\/www.immunize.org\/clinical\/vaccine-confidence\/topic\/adjuvants\/)\n        - [Alternative Schedules](https:\/\/www.immunize.org\/clinical\/vaccine-confidence\/topic\/alt-schedules\/)\n        - [Autism](https:\/\/www.immunize.org\/clinical\/vaccine-confidence\/topic\/autism\/)\n        - [Complementary and Alternative Medicine: Partner Resources](https:\/\/www.immunize.org\/clinical\/vaccine-confidence\/topic\/alt-medicine\/)\n        - [Importance of Vaccines](https:\/\/www.immunize.org\/clinical\/vaccine-confidence\/topic\/vaccine-importance\/)\n        - [Improving the Vaccination Experience](https:\/\/www.immunize.org\/clinical\/vaccine-confidence\/topic\/improving-vaccine-experience\/)\n      - - [MMR Vaccine](https:\/\/www.immunize.org\/clinical\/vaccine-confidence\/topic\/mmr-vaccine\/)\n        - [Religious Concerns](https:\/\/www.immunize.org\/clinical\/vaccine-confidence\/topic\/religious-concerns\/)\n        - [Responding to Parents](https:\/\/www.immunize.org\/clinical\/vaccine-confidence\/topic\/responding-parents\/)\n        - [Thimerosal](https:\/\/www.immunize.org\/clinical\/vaccine-confidence\/topic\/thimerosal\/)\n        - [Unprotected People Stories](https:\/\/www.immunize.org\/clinical\/vaccine-confidence\/unprotected-people\/)\n        - [Vaccine Hesitancy](https:\/\/www.immunize.org\/clinical\/vaccine-confidence\/topic\/vaccine-hesitancy\/)\n        - [Vaccine Safety](https:\/\/www.immunize.org\/clinical\/vaccine-confidence\/topic\/vaccine-safety\/)\n  - [Image LibraryPhotos related to vaccine-preventable diseases]()\n    - - - [Image Library Overview](https:\/\/www.immunize.org\/clinical\/image-library\/)\n        - [Anthrax](https:\/\/www.immunize.org\/clinical\/image-library\/anthrax\/)\n        - [Diphtheria](https:\/\/www.immunize.org\/clinical\/image-library\/diphtheria\/)\n        - [Hepatitis A](https:\/\/www.immunize.org\/clinical\/image-library\/hepa\/)\n        - [Hepatitis B](https:\/\/www.immunize.org\/clinical\/image-library\/hepb\/)\n        - [Hib (*Haemophilus Influenzae* type b)](https:\/\/www.immunize.org\/clinical\/image-library\/hib\/)\n        - [HPV (Human Papillomavirus)](https:\/\/www.immunize.org\/clinical\/image-library\/hpv\/)\n        - [Influenza](https:\/\/www.immunize.org\/clinical\/image-library\/influenza\/)\n      - - [Measles](https:\/\/www.immunize.org\/clinical\/image-library\/measles\/)\n        - [Meningococcal](https:\/\/www.immunize.org\/clinical\/image-library\/meningococcal\/)\n        - [Mpox](https:\/\/www.immunize.org\/clinical\/image-library\/mpox\/)\n        - [Mumps](https:\/\/www.immunize.org\/clinical\/image-library\/mumps\/)\n        - [Pertussis](https:\/\/www.immunize.org\/clinical\/image-library\/pertussis\/)\n        - [Pneumococcal](https:\/\/www.immunize.org\/clinical\/image-library\/pneumococcal\/)\n        - [Polio](https:\/\/www.immunize.org\/clinical\/image-library\/polio\/)\n        - [Rabies](https:\/\/www.immunize.org\/clinical\/image-library\/rabies\/)\n        - [Rotavirus](https:\/\/www.immunize.org\/clinical\/image-library\/rotavirus\/)\n      - - [Rubella](https:\/\/www.immunize.org\/clinical\/image-library\/rubella\/)\n        - [Smallpox](https:\/\/www.immunize.org\/clinical\/image-library\/smallpox\/)\n        - [Tetanus](https:\/\/www.immunize.org\/clinical\/image-library\/tetanus\/)\n        - [Vaccination](https:\/\/www.immunize.org\/clinical\/image-library\/vaccination\/)\n        - [Varicella (Chickenpox)](https:\/\/www.immunize.org\/clinical\/image-library\/varicella\/)\n        - [Zoster (Shingles)](https:\/\/www.immunize.org\/clinical\/image-library\/zoster\/)\n  - [External ResourcesContact information and resources for immunization providers]()\n    - - - [Vaccine Manufacturers](https:\/\/www.immunize.org\/clinical\/external\/manufacturers\/)\n        - [Vaccine Apps](https:\/\/www.immunize.org\/clinical\/external\/apps\/)\n        - [Email News Services](https:\/\/www.immunize.org\/clinical\/external\/news-services\/)\n        - [Immunize.org Partners](https:\/\/www.immunize.org\/clinical\/external\/immunize-org-partners\/)\n  - [Webinars & VideosOur library of educational videos and webinar recordings](https:\/\/www.immunize.org\/clinical\/webinar\/)\n- [Ask the Experts]()\n  - [Ask the ExpertsPractical answers to more than a thousand clinical questions about vaccines from our experts]()\n    - - - [Ask the Experts Overview](http:\/\/www.immunize.org\/ask-experts\/overview\/)\n        - [View All Questions](https:\/\/www.immunize.org\/ask-experts\/)\n        - [View All Video Questions](http:\/\/www.immunize.org\/ask-experts\/?q=%5Bvideo%5D)\n    - - - #### Vaccine Topics\n        - [COVID-19](https:\/\/www.immunize.org\/ask-experts\/topic\/covid-19\/)\n        - [Dengue](https:\/\/www.immunize.org\/ask-experts\/topic\/dengue\/)\n        - [Diphtheria](https:\/\/www.immunize.org\/ask-experts\/topic\/diphtheria\/)\n        - [Hepatitis A](https:\/\/www.immunize.org\/ask-experts\/topic\/hepa\/)\n        - [Hepatitis B](https:\/\/www.immunize.org\/ask-experts\/topic\/hepb\/)\n        - [Hib (*Haemophilus Influenzae* type b)](https:\/\/www.immunize.org\/ask-experts\/topic\/hib\/)\n        - [HPV (Human Papillomavirus)](https:\/\/www.immunize.org\/ask-experts\/topic\/hpv\/)\n        - [Influenza](https:\/\/www.immunize.org\/ask-experts\/topic\/influenza\/)\n        - [MMR (Measles, Mumps, and Rubella)](https:\/\/www.immunize.org\/ask-experts\/topic\/mmr\/)\n        - [Meningococcal ACWY](https:\/\/www.immunize.org\/ask-experts\/topic\/menacwy\/)\n      - - [Meningococcal B](https:\/\/www.immunize.org\/ask-experts\/topic\/menb\/)\n        - [Pertussis](https:\/\/www.immunize.org\/ask-experts\/topic\/pertussis\/)\n        - [Pneumococcal](https:\/\/www.immunize.org\/ask-experts\/topic\/pneumococcal\/)\n        - [Polio](https:\/\/www.immunize.org\/ask-experts\/topic\/polio\/)\n        - [Rabies](https:\/\/www.immunize.org\/ask-experts\/topic\/rabies\/)\n        - [Rotavirus](https:\/\/www.immunize.org\/ask-experts\/topic\/rotavirus\/)\n        - [RSV (Respiratory Syncytial Virus)](http:\/\/www.immunize.org\/ask-experts\/topic\/rsv\/)\n        - [Tetanus](https:\/\/www.immunize.org\/ask-experts\/topic\/tetanus\/)\n        - [Varicella (Chickenpox)](https:\/\/www.immunize.org\/ask-experts\/topic\/varicella\/)\n        - [Zoster (Shingles)](https:\/\/www.immunize.org\/ask-experts\/topic\/zoster\/)\n      - - #### General Topics\n        - [Administering Vaccines](https:\/\/www.immunize.org\/ask-experts\/topic\/admin-vaccines\/)\n        - [Billing & Reimbursement](https:\/\/www.immunize.org\/ask-experts\/topic\/billing-reimburse\/)\n        - [Combination Vaccines](https:\/\/www.immunize.org\/ask-experts\/topic\/combo-vaccines\/)\n        - [Contraindications & Precautions](https:\/\/www.immunize.org\/ask-experts\/topic\/contraindications-precautions\/)\n        - [Documenting Vaccination](https:\/\/www.immunize.org\/ask-experts\/topic\/documenting-vaccination\/)\n        - [Scheduling Vaccines](https:\/\/www.immunize.org\/ask-experts\/topic\/scheduling-vaccines\/)\n        - [Storage & Handling](https:\/\/www.immunize.org\/ask-experts\/topic\/storage-handling\/)\n        - [Travel Vaccines](https:\/\/www.immunize.org\/ask-experts\/topic\/travel-vaccines\/)\n        - [Vaccine Recommendations](https:\/\/www.immunize.org\/ask-experts\/topic\/vaccine-recs\/)\n        - [Vaccine Safety](https:\/\/www.immunize.org\/ask-experts\/topic\/vaccine-safety\/)\n- [Official Guidance]()\n  - [CDCKey CDC resources for immunization providers]()\n    - - - [CDC Recommended Schedules](https:\/\/www.immunize.org\/official-guidance\/cdc\/rec-schedules\/)\n        - [ACIP Vaccine Recommendations](https:\/\/www.immunize.org\/official-guidance\/cdc\/acip-recs\/vaccines\/)\n        - [Additional CDC Resources](https:\/\/www.immunize.org\/official-guidance\/cdc\/resources\/)\n  - [FDAFDA vaccine package inserts and related content](http:\/\/www.immunize.org\/ask-experts\/topic\/covid-19\/)\n    - - - [Package Inserts & EUAs](https:\/\/www.immunize.org\/official-guidance\/fda\/pkg-inserts\/)\n        - [Additional FDA Resources](https:\/\/www.immunize.org\/official-guidance\/fda\/fda-resources\/)\n  - [StatesState-specific recommendations, school requirements, related state websites and public health contact information]()\n    - - - [School and Childcare Vaccine-Specific Requirements](https:\/\/www.immunize.org\/official-guidance\/state-policies\/requirements\/)\n        - [School and Childcare Immunization Exemption Policies](https:\/\/www.immunize.org\/official-guidance\/state-policies\/exemptions\/)\n        - [State Immunization Websites](https:\/\/www.immunize.org\/official-guidance\/state-policies\/state-websites\/)\n        - [State Immunization Recommendations](https:\/\/www.immunize.org\/official-guidance\/state-policies\/state-vaccine-recommendations\/)\n        - [Additional State Resources](https:\/\/www.immunize.org\/official-guidance\/state-policies\/state-resources\/)\n  - [Healthcare Professional OrganizationsImmunization guidance from groups such as the American Academy of Pediatrics](https:\/\/www.immunize.org\/official-guidance\/hpo\/)\n    - - - [Recommended Schedules](http:\/\/www.immunize.org\/official-guidance\/hpo\/rec-schedules)\n        - [Vaccine Recommendations](http:\/\/www.immunize.org\/official-guidance\/hpo\/vax-recs\/vaccine\/)\n  - [WHOPosition papers on vaccines and other vaccine-related resources from the World Health Organization](https:\/\/www.immunize.org\/official-guidance\/who\/)\n- [News & Updates]()\n  - [IZ Express NewsletterWeekly digest of important immunization news and updates]()\n    - - - [About *IZ Express*](https:\/\/www.immunize.org\/news\/iz-express\/about\/)\n        - [Current Issue](http:\/\/www.immunize.org\/news\/iz-express\/current-issue\/)\n        - [Browse All Issues](https:\/\/www.immunize.org\/news\/iz-express\/all-issues\/)\n  - [What's New on Immunize.orgChronological listing of our website content updates](https:\/\/www.immunize.org\/news\/updates\/website\/)\n  - [Official Release RepositoryChronological listing of vaccine-related announcements from FDA, CDC, and ACIP](https:\/\/www.immunize.org\/news\/official-release-repository\/acip\/)\n  - [Calendar of EventsImmunization-related events, including national conferences and training programs, plus Immunize.org webinars](https:\/\/www.immunize.org\/events\/)\n  - [Publication ArchivesRepository of our publications since 1994, including IAC Express (now IZ Express), Needle Tips, and more](https:\/\/www.immunize.org\/about\/history\/overview\/)\n- [About]()\n  - [Our OrganizationLearn about our mission, our people, and our recognition and honors]()\n    - - - [Overview](https:\/\/www.immunize.org\/about\/org\/overview\/)\n        - [Our People](https:\/\/www.immunize.org\/about\/org\/people\/)\n        - [Board of Directors](https:\/\/www.immunize.org\/about\/org\/bod\/)\n        - [Recognition](https:\/\/www.immunize.org\/about\/org\/recognition\/)\n        - [Contact Us](https:\/\/www.immunize.org\/about\/org\/contact\/)\n  - [Our HistoryLearn about our history and our founder, Deborah L. Wexler, MD. Browse past publications in our archives]()\n    - - - [Our Founder](https:\/\/www.immunize.org\/about\/history\/founder\/)\n        - [Publication Archives](https:\/\/www.immunize.org\/about\/history\/overview\/)\n        - [Our History Through Film](https:\/\/www.immunize.org\/about\/history\/film-history\/)\n  - [Financial SupportView our supporters and learn how to join our corporate membership program]()\n    - - - [Funding](https:\/\/www.immunize.org\/about\/financial-support\/funding\/)\n        - [Corporate Membership Program](https:\/\/www.immunize.org\/about\/financial-support\/corp-membership\/)\n  - [Recognizing ExcellenceOur honor rolls for institutions with vaccination policies that protect lives, plus our Becky Payne Award recipients]()\n    - - - #### Patient Safety Honor Rolls\n        - [Influenza Vaccination Honor Roll](https:\/\/www.immunize.org\/about\/excellence\/honor-rolls\/influenza-vaccination\/)\n        - [Hepatitis B Birth Dose Honor Roll](https:\/\/www.immunize.org\/about\/excellence\/honor-rolls\/hepb-birth-dose\/)\n        - [MenB Vaccination Honor Roll](https:\/\/www.immunize.org\/about\/excellence\/honor-rolls\/menb-vaccination\/)\n        - [Honor Rolls Honorees](https:\/\/www.immunize.org\/about\/excellence\/honor-rolls\/honorees\/)\n      - - [The Immunize.org Becky Payne Award](https:\/\/www.immunize.org\/about\/excellence\/becky-payne-award\/)\n  - [MediaInformation for the media, including how to request an interview, past press mentions, and our press releases]()\n    - - - [Press Room](https:\/\/www.immunize.org\/about\/media\/press-room\/)\n        - [Press Releases](https:\/\/www.immunize.org\/about\/media\/press-room\/#Press-Releases)\n        - [Immunize.org In the News](https:\/\/www.immunize.org\/about\/media\/immunize-news\/)\n\nback\n\n- [Vaccines & VISs](https:\/\/www.immunize.org\/vaccines\/)\n- [Clinical Resources](http:\/\/www.immunize.org\/clinical\/a-z\/)\n- [Ask the Experts](http:\/\/www.immunize.org\/ask-experts\/topic\/covid-19\/)\n- [Official Guidance](http:\/\/www.immunize.org\/ask-experts\/topic\/covid-19\/)\n- [News & Updates](http:\/\/www.immunize.org\/ask-experts\/topic\/covid-19\/)\n- [About](https:\/\/www.immunize.org\/about\/)\n\n- [*IZ Express*](https:\/\/www.immunize.org\/news\/iz-express\/about\/)\n- [Shop](https:\/\/shop.immunize.org\/)\n- [Donate](https:\/\/www.immunize.org\/donate\/)\n- [Guide](https:\/\/www.immunize.org\/guide\/)\n\nVaccines\n\n- [Vaccines A-Z Our immunization resources organized by vaccine](https:\/\/www.immunize.org\/vaccines\/)\n  - [Adenovirus](https:\/\/www.immunize.org\/vaccines\/a-z\/adenovirus\/)\n  - [Anthrax](https:\/\/www.immunize.org\/vaccines\/a-z\/anthrax\/)\n  - [BCG](https:\/\/www.immunize.org\/vaccines\/a-z\/bcg\/)\n  - [Chikungunya](https:\/\/www.immunize.org\/vaccines\/a-z\/chikungunya\/)\n  - [Cholera](https:\/\/www.immunize.org\/vaccines\/a-z\/cholera\/)\n  - [COVID-19](https:\/\/www.immunize.org\/vaccines\/a-z\/covid-19\/)\n  - [Dengue](https:\/\/www.immunize.org\/vaccines\/a-z\/dengue\/)\n  - [Diphtheria](https:\/\/www.immunize.org\/vaccines\/a-z\/diphtheria\/)\n  - [Ebola](https:\/\/www.immunize.org\/vaccines\/a-z\/ebola\/)\n  - [Hepatitis A](https:\/\/www.immunize.org\/vaccines\/a-z\/hepa\/)\n  - [Hepatitis B](https:\/\/www.immunize.org\/vaccines\/a-z\/hepb\/)\n  - [Hib (*Haemophilus Influenzae* type b)](https:\/\/www.immunize.org\/vaccines\/a-z\/hib\/)\n  - [HPV (Human Papillomavirus)](https:\/\/www.immunize.org\/vaccines\/a-z\/hpv\/)\n  - [Influenza](https:\/\/www.immunize.org\/vaccines\/a-z\/influenza\/)\n  - [Japanese Encephalitis](https:\/\/www.immunize.org\/vaccines\/a-z\/japanese-encephalitis\/)\n  - [Measles](https:\/\/www.immunize.org\/vaccines\/a-z\/measles\/)\n  - [Meningococcal ACWY](https:\/\/www.immunize.org\/vaccines\/a-z\/menacwy\/)\n  - [Meningococcal B](https:\/\/www.immunize.org\/vaccines\/a-z\/menb\/)\n  - [Mpox](https:\/\/www.immunize.org\/vaccines\/a-z\/mpox\/)\n  - [Mumps](https:\/\/www.immunize.org\/vaccines\/a-z\/mumps\/)\n  - [Pertussis](https:\/\/www.immunize.org\/vaccines\/a-z\/pertussis\/)\n  - [Pneumococcal](https:\/\/www.immunize.org\/vaccines\/a-z\/pneumococcal\/)\n  - [Polio](https:\/\/www.immunize.org\/vaccines\/a-z\/polio\/)\n  - [Rabies](https:\/\/www.immunize.org\/vaccines\/a-z\/rabies\/)\n  - [RSV (Respiratory Syncytial Virus)](https:\/\/www.immunize.org\/vaccines\/a-z\/rsv\/)\n  - [Rotavirus](https:\/\/www.immunize.org\/vaccines\/a-z\/rotavirus\/)\n  - [Rubella](https:\/\/www.immunize.org\/vaccines\/a-z\/rubella\/)\n  - [Smallpox](https:\/\/www.immunize.org\/vaccines\/a-z\/smallpox\/)\n  - [Tetanus](https:\/\/www.immunize.org\/vaccines\/a-z\/tetanus\/)\n  - [TBE (Tick-borne Encephalitis)](https:\/\/www.immunize.org\/vaccines\/a-z\/tbe\/)\n  - [Typhoid](https:\/\/www.immunize.org\/vaccines\/a-z\/typhoid\/)\n  - [Varicella (Chickenpox)](https:\/\/www.immunize.org\/vaccines\/a-z\/varicella\/)\n  - [Yellow Fever](https:\/\/www.immunize.org\/vaccines\/a-z\/yellow-fever\/)\n  - [Zoster (Shingles)](https:\/\/www.immunize.org\/vaccines\/a-z\/zoster\/)\n- [VISs Access current Vaccine Information Statements from CDC](https:\/\/www.immunize.org\/vaccines\/vis\/about-vis\/)\n  - [VISs Overview](https:\/\/www.immunize.org\/vaccines\/vis\/about-vis\/)\n  - [VIS-Related Resources](http:\/\/www.immunize.org\/clinical\/topic\/vis\/)\n  - [Translations](https:\/\/www.immunize.org\/translations\/)\n  - [Adenovirus](https:\/\/www.immunize.org\/vaccines\/vis\/adenovirus\/)\n  - [Anthrax](https:\/\/www.immunize.org\/vaccines\/vis\/anthrax\/)\n  - [Cholera](https:\/\/www.immunize.org\/vaccines\/vis\/cholera\/)\n  - [COVID-19](https:\/\/www.immunize.org\/vaccines\/vis\/covid-19\/)\n  - [Dengue](https:\/\/www.immunize.org\/vaccines\/vis\/dengue\/)\n  - [DTaP (Diphtheria, Tetanus, Pertussis)](https:\/\/www.immunize.org\/vaccines\/vis\/dtap\/)\n  - [Ebola](https:\/\/www.immunize.org\/vaccines\/vis\/ebola\/)\n  - [Hib (*Haemophilus Influenzae* type b)](https:\/\/www.immunize.org\/vaccines\/vis\/hib\/)\n  - [Hepatitis A](https:\/\/www.immunize.org\/vaccines\/vis\/hepa\/)\n  - [Hepatitis B](https:\/\/www.immunize.org\/vaccines\/vis\/hepb\/)\n  - [HPV (Human Papillomavirus)](https:\/\/www.immunize.org\/vaccines\/vis\/hpv\/)\n  - [Influenza (Inactivated or Recombinant)](https:\/\/www.immunize.org\/vaccines\/vis\/influenza-inactivated\/)\n  - [Influenza (Live Intranasal)](https:\/\/www.immunize.org\/vaccines\/vis\/influenza-live\/)\n  - [Japanese Encephalitis](https:\/\/www.immunize.org\/vaccines\/vis\/japanese-encephalitis\/)\n  - [Meningococcal ACWY](https:\/\/www.immunize.org\/vaccines\/vis\/menacwy\/)\n  - [Meningococcal B](https:\/\/www.immunize.org\/vaccines\/vis\/menb\/)\n  - [MMR (Measles, Mumps, Rubella)](https:\/\/www.immunize.org\/vaccines\/vis\/mmr\/)\n  - [MMRV (Measles, Mumps, Rubella, Varicella)](https:\/\/www.immunize.org\/vaccines\/vis\/mmrv\/)\n  - [Multi-Vaccine](https:\/\/www.immunize.org\/vaccines\/vis\/multi-vaccine\/)\n  - [PCV (Pneumococcal Conjugate)](https:\/\/www.immunize.org\/vaccines\/vis\/pcv\/)\n  - [PPSV (Pneumococcal Polysaccharide)](https:\/\/www.immunize.org\/vaccines\/vis\/ppsv\/)\n  - [Polio](https:\/\/www.immunize.org\/vaccines\/vis\/polio\/)\n  - [Rabies](https:\/\/www.immunize.org\/vaccines\/vis\/rabies\/)\n  - [Rotavirus](https:\/\/www.immunize.org\/vaccines\/vis\/rotavirus\/)\n  - [RSV (Respiratory Syncytial Virus)](https:\/\/www.immunize.org\/vaccines\/vis\/rsv\/)\n  - [RSV Preventive Antibody – IIS](https:\/\/www.immunize.org\/vaccines\/vis\/iis-rsv\/)\n  - [Smallpox\/Monkeypox](https:\/\/www.immunize.org\/vaccines\/vis\/smallpox-mpox\/)\n  - [TBE (Tick-borne Encephalitis)](https:\/\/www.immunize.org\/vaccines\/vis\/tbe\/)\n  - [Td (Tetanus, Diphtheria)](https:\/\/www.immunize.org\/vaccines\/vis\/td\/)\n  - [Tdap (Tetanus, Diphtheria, Pertussis)](https:\/\/www.immunize.org\/vaccines\/vis\/tdap\/)\n  - [Typhoid](https:\/\/www.immunize.org\/vaccines\/vis\/typhoid\/)\n  - [Varicella (Chickenpox)](https:\/\/www.immunize.org\/vaccines\/vis\/varicella\/)\n  - [Yellow Fever](https:\/\/www.immunize.org\/vaccines\/vis\/yellow-fever\/)\n  - [Zoster (Shingles)](https:\/\/www.immunize.org\/vaccines\/vis\/zoster\/)\n- [VIS Translations Vaccine-specific VISs translated into dozens of languages](https:\/\/www.immunize.org\/vaccines\/vis-translations\/)\n- [Travel Vaccines Information about travelers’ health and vaccination](https:\/\/www.immunize.org\/vaccines\/travel-vaccines\/)\n- [Vaccine History Timeline Notable milestones in immunization going back to 400 BC](https:\/\/www.immunize.org\/vaccines\/vaccine-timeline\/)\n- [CDC Recommended Schedules Current immunization schedules from CDC](https:\/\/www.immunize.org\/vaccines\/rec-schedules\/)\n- [ACIP Vaccine Recommendations As endorsed and published by CDC](https:\/\/www.immunize.org\/vaccines\/acip-recs\/)\n\nClinical Resources\n\n- [Clinical Resources A-Z Our printable resources designed to help healthcare professionals in all aspects of immunization practice](https:\/\/www.immunize.org\/clinical\/a-z\/)\n  - [Search All Clinical Resources](https:\/\/www.immunize.org\/clinical\/a-z\/)\n  - [All Patient Handouts](http:\/\/www.immunize.org\/clinical\/a-z\/all-patient\/)\n  - [All Resources for Staff & Providers](http:\/\/www.immunize.org\/clinical\/a-z\/all-providers\/)\n  - [Translations](https:\/\/www.immunize.org\/translations\/)\n  - [By Topic](http:\/\/www.immunize.org\/ask-experts\/topic\/covid-19\/)\n    - [Addressing Vaccination Anxiety](https:\/\/www.immunize.org\/clinical\/topic\/addressing-anxiety\/)\n    - [Administering Vaccines](https:\/\/www.immunize.org\/clinical\/topic\/admin-vaccines\/)\n    - [Adolescent Vaccination](https:\/\/www.immunize.org\/clinical\/topic\/adolescent-vaccination\/)\n    - [Adult Vaccination](https:\/\/www.immunize.org\/clinical\/topic\/adult-vaccination\/)\n    - [Contraindications & Precautions](https:\/\/www.immunize.org\/clinical\/topic\/contraindications\/)\n    - [Documenting Vaccination](https:\/\/www.immunize.org\/clinical\/topic\/documenting\/)\n    - [Healthcare Personnel](https:\/\/www.immunize.org\/clinical\/topic\/healthcare-personnel\/)\n    - [Managing Vaccine Reactions](https:\/\/www.immunize.org\/clinical\/topic\/managing-vaccine-reactions\/)\n    - [Parent Handouts](https:\/\/www.immunize.org\/clinical\/topic\/parent-handouts\/)\n    - [Pregnancy and Vaccines](https:\/\/www.immunize.org\/clinical\/topic\/pregnancy-vaccines\/)\n    - [Q\\&As by Diseases and Vaccines](https:\/\/www.immunize.org\/clinical\/topic\/qas\/)\n    - [Schedules for Patients](https:\/\/www.immunize.org\/clinical\/topic\/patient-schedules\/)\n    - [Screening Checklists](https:\/\/www.immunize.org\/clinical\/topic\/screening-checklists\/)\n    - [Standing Orders Templates](https:\/\/www.immunize.org\/clinical\/topic\/standing-orders-templates\/)\n    - [Storage & Handling](https:\/\/www.immunize.org\/clinical\/topic\/storage-handling\/)\n    - [Strategies & Policies](https:\/\/www.immunize.org\/clinical\/topic\/strategies-policies\/)\n    - [Vaccine Confidence](https:\/\/www.immunize.org\/clinical\/topic\/vaccine-confidence\/)\n    - [VIS-Related Resources](https:\/\/www.immunize.org\/clinical\/topic\/vis\/)\n    - [Vaccine Recommendations](https:\/\/www.immunize.org\/clinical\/topic\/vaccine-recs\/)\n- [Vaccine Confidence & Addressing Concerns Practical resources to help providers respond to patient concerns](http:\/\/www.immunize.org\/ask-experts\/topic\/covid-19\/)\n  - [Vaccine Confidence Overview](https:\/\/www.immunize.org\/clinical\/vaccine-confidence\/)\n  - [Adjuvants](https:\/\/www.immunize.org\/clinical\/vaccine-confidence\/topic\/adjuvants\/)\n  - [Alternative Schedules](https:\/\/www.immunize.org\/clinical\/vaccine-confidence\/topic\/alt-schedules\/)\n  - [Autism](https:\/\/www.immunize.org\/clinical\/vaccine-confidence\/topic\/autism\/)\n  - [Complementary and Alternative Medicine: Partner Resources](https:\/\/www.immunize.org\/clinical\/vaccine-confidence\/topic\/alt-medicine\/)\n  - [Importance of Vaccines](https:\/\/www.immunize.org\/clinical\/vaccine-confidence\/topic\/vaccine-importance\/)\n  - [Improving the Vaccination Experience](https:\/\/www.immunize.org\/clinical\/vaccine-confidence\/topic\/improving-vaccine-experience\/)\n  - [MMR Vaccine](https:\/\/www.immunize.org\/clinical\/vaccine-confidence\/topic\/mmr-vaccine\/)\n  - [Religious Concerns](https:\/\/www.immunize.org\/clinical\/vaccine-confidence\/topic\/religious-concerns\/)\n  - [Responding to Parents](https:\/\/www.immunize.org\/clinical\/vaccine-confidence\/topic\/responding-parents\/)\n  - [Thimerosal](https:\/\/www.immunize.org\/clinical\/vaccine-confidence\/topic\/thimerosal\/)\n  - [Unprotected People Stories](https:\/\/www.immunize.org\/clinical\/vaccine-confidence\/unprotected-people\/)\n  - [Vaccine Hesitancy](https:\/\/www.immunize.org\/clinical\/vaccine-confidence\/topic\/vaccine-hesitancy\/)\n  - [Vaccine Safety](https:\/\/www.immunize.org\/clinical\/vaccine-confidence\/topic\/vaccine-safety\/)\n- [Image Library Photos related to vaccine-preventable diseases](https:\/\/www.immunize.org\/clinical\/image-library\/)\n  - [Image Library Overview](https:\/\/www.immunize.org\/clinical\/image-library\/)\n  - [Anthrax](https:\/\/www.immunize.org\/clinical\/image-library\/anthrax\/)\n  - [Diphtheria](https:\/\/www.immunize.org\/clinical\/image-library\/diphtheria\/)\n  - [Hepatitis A](https:\/\/www.immunize.org\/clinical\/image-library\/hepa\/)\n  - [Hepatitis B](https:\/\/www.immunize.org\/clinical\/image-library\/hepb\/)\n  - [Hib (*Haemophilus Influenzae* type b)](https:\/\/www.immunize.org\/clinical\/image-library\/hib\/)\n  - [HPV (Human Papillomavirus)](https:\/\/www.immunize.org\/clinical\/image-library\/hpv\/)\n  - [Influenza](https:\/\/www.immunize.org\/clinical\/image-library\/influenza\/)\n  - [Measles](https:\/\/www.immunize.org\/clinical\/image-library\/measles\/)\n  - [Meningococcal](https:\/\/www.immunize.org\/clinical\/image-library\/meningococcal\/)\n  - [Mpox](https:\/\/www.immunize.org\/clinical\/image-library\/mpox\/)\n  - [Mumps](https:\/\/www.immunize.org\/clinical\/image-library\/mumps\/)\n  - [Pertussis](https:\/\/www.immunize.org\/clinical\/image-library\/pertussis\/)\n  - [Pneumococcal](https:\/\/www.immunize.org\/clinical\/image-library\/pneumococcal\/)\n  - [Polio](https:\/\/www.immunize.org\/clinical\/image-library\/polio\/)\n  - [Rabies](https:\/\/www.immunize.org\/clinical\/image-library\/rabies\/)\n  - [Rotavirus](https:\/\/www.immunize.org\/clinical\/image-library\/rotavirus\/)\n  - [Rubella](https:\/\/www.immunize.org\/clinical\/image-library\/rubella\/)\n  - [Smallpox](https:\/\/www.immunize.org\/clinical\/image-library\/smallpox\/)\n  - [Tetanus](https:\/\/www.immunize.org\/clinical\/image-library\/tetanus\/)\n  - [Vaccination](https:\/\/www.immunize.org\/clinical\/image-library\/vaccination\/)\n  - [Varicella (Chickenpox)](https:\/\/www.immunize.org\/clinical\/image-library\/varicella\/)\n  - [Zoster (Shingles)](https:\/\/www.immunize.org\/clinical\/image-library\/zoster\/)\n- [External Resources Contact information and resources for immunization providers](https:\/\/www.immunize.org\/clinical\/external\/)\n  - [Vaccine Manufacturers](https:\/\/www.immunize.org\/clinical\/external\/manufacturers\/)\n  - [Vaccine Apps](https:\/\/www.immunize.org\/clinical\/external\/apps\/)\n  - [Email News Services](https:\/\/www.immunize.org\/clinical\/external\/news-services\/)\n  - [Immunize.org Partners](https:\/\/www.immunize.org\/clinical\/external\/immunize-org-partners\/)\n- [Webinars & Videos Our library of educational videos and webinar recordings](https:\/\/www.immunize.org\/clinical\/webinar\/)\n\nAsk the Experts\n\n- [Ask the Experts Practical answers to more than a thousand clinical questions about vaccines from our experts](https:\/\/www.immunize.org\/ask-experts\/)\n  - [Ask the Experts Overview](http:\/\/www.immunize.org\/ask-experts\/overview\/)\n  - [View All Questions](https:\/\/www.immunize.org\/ask-experts\/)\n  - [View All Video Questions](http:\/\/www.immunize.org\/ask-experts\/?q=%5Bvideo%5D)\n  - [By Vaccine](http:\/\/www.immunize.org\/ask-experts\/topic\/covid-19\/)\n    - [COVID-19](https:\/\/www.immunize.org\/ask-experts\/topic\/covid-19\/)\n    - [Dengue](https:\/\/www.immunize.org\/ask-experts\/topic\/dengue\/)\n    - [Diphtheria](https:\/\/www.immunize.org\/ask-experts\/topic\/diphtheria\/)\n    - [Hepatitis A](https:\/\/www.immunize.org\/ask-experts\/topic\/hepa\/)\n    - [Hepatitis B](https:\/\/www.immunize.org\/ask-experts\/topic\/hepb\/)\n    - [Hib (*Haemophilus Influenzae* type b)](https:\/\/www.immunize.org\/ask-experts\/topic\/hib\/)\n    - [HPV (Human Papillomavirus)](https:\/\/www.immunize.org\/ask-experts\/topic\/hpv\/)\n    - [Influenza](https:\/\/www.immunize.org\/ask-experts\/topic\/influenza\/)\n    - [MMR (Measles, Mumps, and Rubella)](https:\/\/www.immunize.org\/ask-experts\/topic\/mmr\/)\n    - [Meningococcal ACWY](https:\/\/www.immunize.org\/ask-experts\/topic\/menacwy\/)\n    - [Meningococcal B](https:\/\/www.immunize.org\/ask-experts\/topic\/menb\/)\n    - [Pertussis](https:\/\/www.immunize.org\/ask-experts\/topic\/pertussis\/)\n    - [Pneumococcal](https:\/\/www.immunize.org\/ask-experts\/topic\/pneumococcal\/)\n    - [Polio](https:\/\/www.immunize.org\/ask-experts\/topic\/polio\/)\n    - [Rabies](https:\/\/www.immunize.org\/ask-experts\/topic\/rabies\/)\n    - [Rotavirus](https:\/\/www.immunize.org\/ask-experts\/topic\/rotavirus\/)\n    - [RSV (Respiratory Syncytial Virus)](http:\/\/www.immunize.org\/ask-experts\/topic\/rsv\/)\n    - [Tetanus](https:\/\/www.immunize.org\/ask-experts\/topic\/tetanus\/)\n    - [Typhoid](https:\/\/www.immunize.org\/ask-experts\/topic\/typhoid\/)\n    - [Varicella (Chickenpox)](https:\/\/www.immunize.org\/ask-experts\/topic\/varicella\/)\n    - [Yellow Fever](https:\/\/www.immunize.org\/ask-experts\/topic\/yellow-fever\/)\n    - [Zoster (Shingles)](https:\/\/www.immunize.org\/ask-experts\/topic\/zoster\/)\n  - [By Topic](http:\/\/www.immunize.org\/ask-experts\/topic\/covid-19\/)\n    - [Administering Vaccines](https:\/\/www.immunize.org\/ask-experts\/topic\/admin-vaccines\/)\n    - [Billing & Reimbursement](https:\/\/www.immunize.org\/ask-experts\/topic\/billing-reimburse\/)\n    - [Combination Vaccines](https:\/\/www.immunize.org\/ask-experts\/topic\/combo-vaccines\/)\n    - [Contraindications & Precautions](https:\/\/www.immunize.org\/ask-experts\/topic\/contraindications-precautions\/)\n    - [Documenting Vaccination](https:\/\/www.immunize.org\/ask-experts\/topic\/documenting-vaccination\/)\n    - [Scheduling Vaccines](https:\/\/www.immunize.org\/ask-experts\/topic\/scheduling-vaccines\/)\n    - [Storage & Handling](https:\/\/www.immunize.org\/ask-experts\/topic\/storage-handling\/)\n    - [Travel Vaccines](https:\/\/www.immunize.org\/ask-experts\/topic\/travel-vaccines\/)\n    - [Vaccine Recommendations](https:\/\/www.immunize.org\/ask-experts\/topic\/vaccine-recs\/)\n    - [Vaccine Safety](https:\/\/www.immunize.org\/ask-experts\/topic\/vaccine-safety\/)\n\nOfficial Guidance\n\n- [CDC Key CDC resources for immunization providers](https:\/\/www.immunize.org\/official-guidance\/cdc\/)\n  - [CDC Recommended Schedules](https:\/\/www.immunize.org\/official-guidance\/cdc\/rec-schedules\/)\n  - [ACIP Vaccine Recommendations](https:\/\/www.immunize.org\/official-guidance\/cdc\/acip-recs\/vaccines\/)\n  - [Additional CDC Resources](https:\/\/www.immunize.org\/official-guidance\/cdc\/resources\/)\n- [FDA FDA vaccine package inserts and related content](http:\/\/www.immunize.org\/ask-experts\/topic\/covid-19\/)\n  - [Package Inserts & EUAs](https:\/\/www.immunize.org\/official-guidance\/fda\/pkg-inserts\/)\n  - [Additional FDA Resources](https:\/\/www.immunize.org\/official-guidance\/fda\/fda-resources\/)\n- [States State-specific recommendations, school requirements, related state websites and public health contact information](http:\/\/www.immunize.org\/ask-experts\/topic\/covid-19\/)\n  - [School and Childcare Vaccine-Specific Requirements](https:\/\/www.immunize.org\/official-guidance\/state-policies\/requirements\/)\n  - [School and Childcare Immunization Exemption Policies](https:\/\/www.immunize.org\/official-guidance\/state-policies\/exemptions\/)\n  - [State Immunization Websites](https:\/\/www.immunize.org\/official-guidance\/state-policies\/state-websites\/)\n  - [State Immunization Recommendations](https:\/\/www.immunize.org\/official-guidance\/state-policies\/state-vaccine-recommendations\/)\n  - [Additional State Resources](https:\/\/www.immunize.org\/official-guidance\/state-policies\/state-resources\/)\n- [Healthcare Professional Organizations Immunization guidance from groups such as the American Academy of Pediatrics](https:\/\/www.immunize.org\/official-guidance\/hpo\/)\n  - [Recommended Schedules](http:\/\/www.immunize.org\/official-guidance\/hpo\/rec-schedules)\n  - [Vaccine Recommendations](http:\/\/www.immunize.org\/official-guidance\/hpo\/vax-recs\/vaccine\/)\n- [WHO Position papers on vaccines and other vaccine-related resources from the World Health Organization](https:\/\/www.immunize.org\/official-guidance\/who\/)\n\nNews & Updates\n\n- [IZ Express Newsletter Weekly digest of important immunization news and updates](https:\/\/www.immunize.org\/news\/iz-express\/all-issues\/)\n  - [About *IZ Express*](https:\/\/www.immunize.org\/news\/iz-express\/about\/)\n  - [Current Issue](http:\/\/www.immunize.org\/news\/iz-express\/current-issue\/)\n  - [Browse All Issues](https:\/\/www.immunize.org\/news\/iz-express\/all-issues\/)\n- [What’s New on Immunize.org Chronological listing of our website content updates](https:\/\/www.immunize.org\/news\/updates\/website\/)\n- [Official Release Repository Chronological listing of vaccine-related announcements from FDA, CDC, and ACIP](https:\/\/www.immunize.org\/news\/official-release-repository\/acip\/)\n- [Calendar of Events Immunization-related events, including national conferences and training programs, plus Immunize.org webinars](https:\/\/www.immunize.org\/events\/)\n- [Publication Archives Repository of our publications since 1994, including IAC Express (now IZ Express), Needle Tips, and more](https:\/\/www.immunize.org\/about\/history\/overview\/)\n\nAbout\n\n- [Our Organization Learn about our mission, our people, and our recognition and honors](https:\/\/www.immunize.org\/about\/org\/)\n  - [Overview](https:\/\/www.immunize.org\/about\/org\/overview\/)\n  - [Our People](https:\/\/www.immunize.org\/about\/org\/people\/)\n  - [Board of Directors](https:\/\/www.immunize.org\/about\/org\/bod\/)\n  - [Recognition](https:\/\/www.immunize.org\/about\/org\/recognition\/)\n  - [Contact Us](https:\/\/www.immunize.org\/about\/org\/contact\/)\n- [Our History Learn about our history and our founder, Deborah L. Wexler, MD. Browse past publications in our archives](https:\/\/www.immunize.org\/about\/history\/)\n  - [Our Founder](https:\/\/www.immunize.org\/about\/history\/founder\/)\n  - [All Publication Archives](https:\/\/www.immunize.org\/about\/history\/overview\/)\n  - [Our History Through Film](https:\/\/www.immunize.org\/about\/history\/film-history\/)\n- [Financial Support View our supporters and learn how to join our corporate membership program](https:\/\/www.immunize.org\/about\/financial-support\/)\n  - [Funding](https:\/\/www.immunize.org\/about\/financial-support\/funding\/)\n  - [Corporate Membership Program](https:\/\/www.immunize.org\/about\/financial-support\/corp-membership\/)\n- [Recognizing Excellence Our honor rolls for institutions with vaccination policies that protect lives, plus our Becky Payne Award recipients](https:\/\/www.immunize.org\/about\/excellence\/)\n  - [Patient Safety Honor Rolls](http:\/\/www.immunize.org\/ask-experts\/topic\/covid-19\/)\n    - [Influenza Vaccination Honor Roll](https:\/\/www.immunize.org\/about\/excellence\/honor-rolls\/influenza-vaccination\/)\n    - [Hepatitis B Birth Dose Honor Roll](https:\/\/www.immunize.org\/about\/excellence\/honor-rolls\/hepb-birth-dose\/)\n    - [MenB Vaccination Honor Roll](https:\/\/www.immunize.org\/about\/excellence\/honor-rolls\/menb-vaccination\/)\n    - [Honor Rolls Honorees](https:\/\/www.immunize.org\/about\/excellence\/honor-rolls\/honorees\/)\n  - [The Immunize.org Becky Payne Award](https:\/\/www.immunize.org\/about\/excellence\/becky-payne-award\/)\n- [Media Information for the media, including how to request an interview, past press mentions, and our press releases](https:\/\/www.immunize.org\/about\/media\/)\n  - [Press Room](https:\/\/www.immunize.org\/about\/media\/press-room\/)\n  - [Press Releases](https:\/\/www.immunize.org\/about\/media\/press-room\/#Press-Releases)\n  - [Immunize.org In the News](https:\/\/www.immunize.org\/about\/media\/immunize-news\/)\n\n[Home](https:\/\/www.immunize.org\/) \/ [Ask the Experts](https:\/\/www.immunize.org\/ask-experts\/) \/ COVID-19\n\n# Ask the Experts: COVID-19\nThe COVID-19 questions were last reviewed on November 16, 2025. See CDC’s [Use of COVID-19 Vaccines in the United States Interim Clinical Considerations](https:\/\/www.cdc.gov\/vaccines\/covid-19\/clinical-considerations\/covid-19-vaccines-us.html) for more information. To keep up with the current available COVID-19 resources from CDC, FDA, and Immunize.org, see Immunize.org’s [Checklist of Current Versions of U.S. COVID-19 Vaccine Guidance and Clinic Support Tools](https:\/\/www.immunize.org\/wp-content\/uploads\/catg.d\/p3130.pdf), updated at least monthly. For alerts about new Immunize.org or CDC COVID-19 resources, subscribe to our weekly e-newsletter, [*IZ Express*](https:\/\/www.immunize.org\/subscribe).\n\n##### Search & Filters\n### Keyword Search\n### Filters\n×  Reset all filters\n\nAll results\n\nVaccine or Disease Name\n\nPatient Age\n\nPatient Health Conditions\n\nPatient Population\n\nWork, School or Living Setting\n\nDisease\n\nAdverse Events\n\nReason for Vaccination\n\nSchedule\n\nVaccine Platform \/ Ig Type\n\nIM Admin Site\n\nVaccine Storage and Handling\n\nPatient Sex\n\nOther\n\nShow Filters   Hide Filters\n\nResults (89)\n\nSearch & Filters\n\nShow All Answers\n\nHide All Answers\n\nShow All Answers\n\nHide All Answers\n\nLink copied\n\n- COVID-19\n- Disease Issues\n## What is COVID-19?\n\nCOVID-19 is the name given to the disease caused by infection with the SARS-CoV-2 coronavirus. This virus was first detected as a cause of human illness in late 2019 in Wuhan, China, and triggered a global pandemic that began in 2020. The virus spreads mainly from person to person through respiratory droplets and small particles produced when an infected person coughs, sneezes, or talks. The virus spreads easily in crowded or poorly ventilated indoor settings. Some people who are infected have no symptoms of illness, while the severity of symptomatic illness ranges from mild to life-threatening. Older adults and people of any age with underlying medical conditions are at higher risk for severe illness.\n\nThe incubation period after exposure ranges from 2–14 days, with an average of about 5 days. People with COVID-19 are generally considered potentially infectious up to 48 hours before symptom onset and up to 10 days after onset, though people with severe illness may be infectious longer. Symptoms may include fever or chills, cough, shortness of breath or difficulty breathing, fatigue, muscle or body aches, headache, new loss of taste or smell, sore throat, congestion or runny nose, nausea or vomiting, and diarrhea.\n\nLast reviewed: November 16, 2025\n\nLink copied\n\n- COVID-19\n- Disease Issues\n## Where can I find conditions that have been shown to increase the risk of severe COVID-19 illness?\n\nThe list of underlying health conditions and other factors shown to increase the risk of severe COVID-19 illness is long. Advanced age remains the strongest risk factor. In addition to age, CDC states that data has shown that compared to non-Hispanic White people, people from racial and ethnic minority groups are more likely to be infected with SARS-CoV-2. Once infected, people from racial and ethnic minority groups are more likely to be hospitalized, be admitted to the ICU, and die from COVID-19 at younger ages. CDC provides a list of at-risk conditions at this website: [www.cdc.gov\/covid\/hcp\/clinical-care\/underlying-conditions.html](http:\/\/www.cdc.gov\/covid\/hcp\/clinical-care\/underlying-conditions.html). The conditions are stratified by strength of published evidence.\n\nImmunize.org provides an age-appropriate list of high-risk conditions with conclusive or suggestive published evidence as part of each of its standing orders templates for use of 2025-2026 COVID-19 vaccines, all of which may be found on the COVID-19 main page: [www.immunize.org\/vaccines\/a-z\/covid-19\/](http:\/\/www.immunize.org\/vaccines\/a-z\/covid-19\/).\n\nLast reviewed: November 16, 2025\n\nLink copied\n\n- COVID-19\n- Disease Issues\n## Where can I find answers to more clinical questions about COVID-19 disease, diagnosis, treatment and care of patients?\n\nThe CDC has assembled clinical information about COVID-19 at this site: [www.cdc.gov\/covid\/hcp](https:\/\/www.cdc.gov\/covid\/hcp\/).\n\nLast reviewed: November 16, 2025\n\nLink copied\n\n- COVID-19\n- Vaccine Recommendations\n## Where can I find current COVID-19 vaccine recommendations?\n\nCDC maintains a webpage with critical interim clinical considerations for vaccination of eligible recipients: [www.cdc.gov\/covid\/hcp\/vaccine-considerations\/index.html](http:\/\/www.cdc.gov\/covid\/hcp\/vaccine-considerations\/index.html). This covers important clinical details about COVID-19 vaccination. It is typically the first content to be updated after an announced change to CDC recommendations.\n\nAll of the CDC’s Advisory Committee on Immunization Practices (ACIP) vaccine recommendations published in MMWR can be accessed here: [www.cdc.gov\/acip-recs\/hcp\/vaccine-specific\/covid-19.html](https:\/\/www.cdc.gov\/acip-recs\/hcp\/vaccine-specific\/covid-19.html).\n\nCDC posts product-specific resources at this site: [www.cdc.gov\/vaccines\/covid-19\/info-by-product\/index.html](http:\/\/www.cdc.gov\/vaccines\/covid-19\/info-by-product\/index.html). At this writing, the website was last updated July 18, 2025.\n\nLast reviewed: November 16, 2025\n\nLink copied\n\n- COVID-19\n- Vaccine Recommendations\n## Who is recommended by CDC to receive COVID-19 vaccines?\n\nThe ACIP recommended on September 18, 2025, that all people age 6 months and older in the United States may receive one or more doses of an age-appropriate 2025–2026 Formula COVID-19 vaccination based on individual decision-making, following shared clinical decision-making discussion with a healthcare professional (e.g., a nurse, doctor, or pharmacist). The decision to vaccinate may be influenced by the presence of conditions that increase the risk of severe COVID-19 illness.\n\nProduct options include three FDA-licensed mRNA vaccines: Comirnaty (Pfizer-BioNTech, ages 5 years and older); Spikevax (Moderna, ages 6 months and older); mNexspike (Moderna, ages 12 years and older). There is one FDA-licensed adjuvanted protein subunit vaccine: Nuvaxovid (Sanofi-Novavax, ages 12 years and older). Schedules vary by age and immunocompromised status.\n\nAlthough the FDA licenses limit use of COVID-19 vaccines among recipients younger than age 64 to those with one or more conditions that increases the risk of severe COVID-19, the fact that ACIP did not include any restrictions in its shared clinical decision-making recommendation means that it is an acceptable standard of care for people younger than age 65 without a high risk condition to be vaccinated when desired.\n\nLast reviewed: November 16, 2025\n\nLink copied\n\n- COVID-19\n- Vaccine Recommendations\n## What are CDC and professional medical societies’ 2025–26 season COVID-19 vaccination recommendations for people age 6 months and older?\n\nCDC recommends individual decision-making (also known as shared clinical decision-making) for COVID-19 vaccination of all people age 6 months and older. Among people age 6 months through 64 years, ACIP emphasizes that the risk-benefit of vaccination is most favorable for individuals who are at an increased risk for severe COVID-19 disease and lowest for individuals who are not at an increased risk. Details of the vaccination schedule are available here: [www.cdc.gov\/covid\/hcp\/vaccine-considerations\/routine-guidance.html](http:\/\/www.cdc.gov\/covid\/hcp\/vaccine-considerations\/routine-guidance.html).\n\nOf note, among previously unvaccinated people who are not moderately or severely immunocompromised, an initial vaccination series is recommended only for young children age 6 through 23 months. All others younger than age 65 years are recommended to receive a single dose of an age-appropriate 2025–2026 formula COVID-19 vaccine. People age 65 years and older are recommended to receive a second 2025–2026 formula COVID-19 vaccine dose 6 months later (minimum interval 2 months if using Comirnaty, Spikevax, or Nuvaxovid; minimum interval 3 months if using mNexspike).\n\nMajor U.S. professional medical societies have issued their own recommendations for the 2025–26 COVID-19 season that differ from CDC, primarily in their stronger, routine recommendations for vaccination of people at risk of severe COVID-19 illness:\n\n- American Academy of Pediatrics (AAP) for children: <https:\/\/publications.aap.org\/pediatrics\/article\/156\/5\/e2025073924\/203222\/Recommendations-for-COVID-19-Vaccines-in-Infants>\n- American Academy of Family Physicians (AAFP) for healthy adults and elderly people: [www.aafp.org\/family-physician\/patient-care\/public-health-emergencies\/recent-outbreaks\/covid-19\/covid-19-vaccine.html](http:\/\/www.aafp.org\/family-physician\/patient-care\/public-health-emergencies\/recent-outbreaks\/covid-19\/covid-19-vaccine.html)\n- American College of Obstetricians and Gynecologists (ACOG) for pregnancy: [www.acog.org\/clinical\/clinical-guidance\/practice-advisory\/articles\/2020\/12\/covid-19-vaccination-considerations-for-obstetric-gynecologic-care](http:\/\/www.acog.org\/clinical\/clinical-guidance\/practice-advisory\/articles\/2020\/12\/covid-19-vaccination-considerations-for-obstetric-gynecologic-care)\n- Infectious Diseases Society of America (IDSA) for immunocompromised people and their close contacts: [www.idsociety.org\/Seasonal-RTI-Vaccinations-in-Immunocompromised-Patients\/](http:\/\/www.idsociety.org\/Seasonal-RTI-Vaccinations-in-Immunocompromised-Patients\/)\n\nLast reviewed: November 16, 2025\n\nLink copied\n\n- COVID-19\n- Vaccine Recommendations\n## What are CDC’s 2025–26 season COVID-19 vaccination recommendations for people age 6 months and older who are moderately or severely immunocompromised?\n\nPeople who are moderately or severely immunocompromised are at increased risk for severe COVID-19 illness. ACIP and CDC recommend individual decision-making (also known as shared clinical decision-making) after a discussion with a healthcare professional (nurse, doctor, or pharmacist) for people age 6 months and older who are moderately or severely immunocompromised. They are recommended to receive at least 2 doses during the season. The CDC vaccination schedule for people with moderate or severe immunocompromise is available here: [www.cdc.gov\/covid\/hcp\/vaccine-considerations\/immunocompromised.html](http:\/\/www.cdc.gov\/covid\/hcp\/vaccine-considerations\/immunocompromised.html).\n\nThe Infectious Diseases Society of America (IDSA) strongly recommends administration of age-appropriate 2025–2026 COVID-19 vaccinations to all adults and children with compromised immunity. They also recommend that household members and close contacts of immunocompromised people should be up to date with COVID-19 vaccination. See IDSA recommendations for full details: [www.idsociety.org\/Seasonal-RTI-Vaccinations-in-Immunocompromised-Patients\/](http:\/\/www.idsociety.org\/Seasonal-RTI-Vaccinations-in-Immunocompromised-Patients\/).\n\nLast reviewed: November 16, 2025\n\nLink copied\n\n- COVID-19\n- Vaccine Recommendations\n## What COVID-19 vaccine should we use in the 2025–26 season for children ages 6 through 59 months who received Pfizer-BioNTech COVID-19 vaccine in the past?\n\nIn past seasons, CDC recommended that all doses of COVID-19 vaccine given to children age 6 months through 4 years be from the same manufacturer. However, in the 2025–26 season, only Moderna’s Spikevax mRNA vaccine is licensed and recommended for use in children younger than age 5 years. All children in this age group who are vaccinated against COVID-19 should receive Spikevax, regardless of the brand they received in previous seasons. If the child is age 6 months through 23 months and received an incomplete (1- or 2-dose) initial COVID-19 vaccination series with Pfizer-BioNTech, a 3-dose initial series should be completed with Spikevax. It is not necessary to repeat the initial series.\n\nIn previously unvaccinated people age 5 years or older with moderate or severe immunocompromise, the same manufacturer is recommended for all initial COVID-19 vaccine series doses (either 2 doses of Nuvaxovid \\[if age 12 years or older\\] or 3 doses of an mRNA product). After completion of the initial series, any age-appropriate COVID-19 vaccine may be used in this age group.\n\nCDC sets out conditions when it is acceptable to use an age-appropriate COVID-19 vaccine from a different manufacturer in any situation where the same manufacturer is recommended:\n\n- Same vaccine not available at the time of the clinic visit\n- Previous dose unknown\n- Person would otherwise not receive a recommended vaccine dose\n- Person starts but unable to complete a vaccination series with the same COVID-19 vaccine due to a contraindication\n\nLast reviewed: November 16, 2025\n\nLink copied\n\n- COVID-19\n- Vaccine Recommendations\n## Before the 2025–26 season, CDC recommended the option of additional COVID-19 vaccine doses for people with moderate or severe immunocompromise. Did that change?\n\nIndividuals with moderate to severe immunocompromise who have completed an initial COVID-19 series should receive two dose of 2025–2026 Formula COVID-19 vaccine this season with the second dose given 6 months later (minimum interval 2 months for Comirnaty, Spikevax, and Nuvaxovid; minimum interval 3 months for mNexspike).\n\nIn previous seasons, CDC recommended that additional doses of COVID-19 vaccine may be administered (with a minimum two-month interval) based on the clinical judgment of the individual’s healthcare provider and the recipient’s personal preference and circumstances. For the 2025–26 season, CDC has removed this general statement from its interim clinical considerations document ([www.cdc.gov\/covid\/hcp\/vaccine-considerations\/immunocompromised.html](http:\/\/www.cdc.gov\/covid\/hcp\/vaccine-considerations\/immunocompromised.html)). The CDC clinical considerations document now states, “On a case-by-case basis, providers caring for these patients may administer Moderna, Novavax, and Pfizer-BioNTech COVID-19 vaccines outside of the FDA and CDC dosing intervals when, based on their clinical judgment, the benefits of vaccination are deemed to outweigh the potential and unknown risks for the recipient who is immunocompromised.”\n\nLast reviewed: November 16, 2025\n\nLink copied\n\n- COVID-19\n- Vaccine Recommendations\n## What is the recommended vaccination schedule for a person who received only the Janssen COVID-19 Vaccine?\n\nJanssen (Johnson & Johnson) COVID-19 vaccine is no longer produced. The last remaining doses expired May 7, 2023. The history of Janssen vaccine use is relevant only to evaluation of an adult with moderate or severe immunocompromise because such individuals are recommended to receive an initial series of COVID-19 vaccine. History of a single dose of Janssen COVID-19 vaccine constitutes a complete initial series. A person with this history should follow the vaccination schedule recommended for an immunocompromised person who has already completed an initial vaccination series.\n\nLast reviewed: November 16, 2025\n\nLink copied\n\n- COVID-19\n- Vaccine Recommendations\n## May people who have had COVID-19 illness be vaccinated?\n\nYes. Vaccination should be offered regardless of history of prior SARS-CoV-2 infection or long COVID.\n\nBecause COVID-19 illness temporarily boosts immunity, people who have recently had SARS-CoV-2 infection may consider delaying a 2025–2026 COVID-19 vaccine dose by up to 3 months following symptom onset or positive COVID-19 test (if asymptomatic). Studies have shown that a longer time between infection and vaccination may improve the immune response to vaccination. The likelihood of reinfection in the first few months following infection is low.\n\nA recipient’s individual risks for severe disease and current COVID-19 conditions in the community should be taken into account when deciding whether to delay vaccination up to 3 months after infection. As with all vaccines, vaccination should be deferred until after recovery from moderate to severe illness.\n\nLast reviewed: November 16, 2025\n\nLink copied\n\n- COVID-19\n- Vaccine Recommendations\n## Should adults age 65 years and older who are vaccinated against COVID-19 in the 2025–26 season receive one or two doses of COVID-19 vaccine during the season?\n\nAdults age 65 years and older have the highest rates of hospitalization and death from COVID-19 illness. Protection against severe COVID-19 disease wanes after a few months. Disease surveillance data from the United States shows that SARS-CoV-2 viruses circulate and cause illness at varying levels year-round, with waves of activity observed historically in winter and late summer. It is not known whether this pattern will continue. This pattern is not like influenza, which usually causes a single epidemic wave (sometimes with more than one peak) each winter.\n\nThe 2025 CDC adult immunization schedule shows that adults age 65 years and older who are vaccinated against COVID-19 are recommended to receive a second dose of any 2025–2026 Formula COVID-19 vaccine 6 months after their first 2025–2026 Formula COVID-19 vaccine dose (minimum interval of 2 months for Comirnaty, Spikevax, and Nuvaxovid; minimum interval of 3 months for mNexspike). The second dose does not have to be the same brand as the first.\n\nLast reviewed: November 16, 2025\n\nLink copied\n\n- COVID-19\n- Vaccine Recommendations\n## How long should people wait after their most recent dose of 2024–2025 Formula COVID-19 vaccine before getting a 2025–2026 Formula COVID-19 vaccine?\n\nCDC recommends waiting a minimum of 8 weeks (2 months) since the last 2024–2025 Formula COVID-19 vaccine to receive an age-appropriate 2025–2026 Formula COVID-19 vaccine, if using Comirnaty (Pfizer-BioNTech), Nuvaxovid (Sanofi-Novavax), or Spikevax (Moderna). They recommend a 3-month minimum interval when using mNexspike (Moderna); however, a dose of mNexspike administered at least 2 months after the most recent dose does not need to be repeated.\n\nAny person who initiated a COVID-19 vaccination initial series (e.g., a child 6 months through 23 months of age or a person with moderate or severe immunocompromise) with a previous formulation should follow the age-appropriate recommended schedule for completion of their primary series with the current formulation of the same brand, if feasible. For the 2025–26 season, Spikevax is the only licensed and recommended option for children age 6 through 59 months, regardless of their vaccination history.\n\nLast reviewed: November 16, 2025\n\nLink copied\n\n- COVID-19\n- Vaccine Products\n## What is an Emergency Use Authorization (EUA)?\n\nUnder section 564 of the Federal Food, Drug, and Cosmetic Act (FD\\&C Act), the FDA Commissioner may allow unapproved medical products or unapproved uses of approved medical products to be used in an emergency to diagnose, treat, or prevent serious or life-threatening diseases or conditions caused by chemical, biological, radiological or nuclear threat agents when there are no adequate, approved, and available alternatives. Vaccines that receive an EUA may later be fully licensed by the FDA.\n\nAll available COVID-19 vaccines were initially administered under EUA. All available 2025–2026 Formula COVID-19 vaccines are fully licensed by FDA and no longer administered under EUA.\n\nLast reviewed: November 16, 2025\n\nLink copied\n\n- COVID-19\n- Vaccine Products\n## What are mRNA vaccines?\n\nBoth the Pfizer-BioNTech COVID-19 Vaccine (Comirnaty) and the Moderna COVID-19 vaccines (Spikevax, mNexspike) are lipid nanoparticle-formulated, nucleoside-modified mRNA vaccines encoding the prefusion spike glycoprotein of SARS-CoV-2, the virus that causes COVID-19. The 2025–2026 formula mRNA vaccines target the Omicron JN.1 variant LP.8.1 strain. Moderna’s mNexspike was first licensed in 2025 for ages 12 years and older. It is designed to reduce the amount of mRNA required to elicit the same or slightly better immune response compared to Spikevax (10 mcg of mRNA versus 50 mcg of mRNA for an adult dose). Spikevax and mNexspike may be used interchangeably when both are age appropriate. Visit this CDC website for more details about how mRNA vaccines work: [www.cdc.gov\/covid\/vaccines\/how-they-work.html](https:\/\/www.cdc.gov\/covid\/vaccines\/how-they-work.html).\n\nLast reviewed: November 16, 2025\n\nLink copied\n\n- COVID-19\n- Vaccine Products\n## What is the difference between Spikevax and mNexspike by Moderna?\n\nSpikevax and mNexspike are both mRNA vaccines targeting the same strain of COVID-19. Spikevax is the original vaccine now licensed down to age 6 months. The mNexspike product is a newer mRNA vaccine licensed for ages 12 years and older with an advanced design that achieves the same or slightly better immune response with less mRNA in each dose (10 mcg in mNexspike compared to 50 mcg in adult doses of Spikevax). The two products may be used interchangeably when age appropriate.\n\nIn adults 65 years and older (and moderately or severely immunocompromised adults) who are recommended to receive a second dose 6 months after their first 2025–2026 formula dose, the minimum interval between the two recommended 2025–26 season doses is 3 months for mNexspike, but only 2 months for the other COVID-19 vaccine products. If mNexspike is inadvertently administered after only 2 months, the dose counts as valid and does not need to be repeated.\n\nLast reviewed: November 16, 2025\n\nLink copied\n\n- COVID-19\n- Vaccine Products\n## How are mRNA and protein-based COVID-19 vaccines different? \\[Video\\]\n\n[![](https:\/\/www.immunize.org\/wp-content\/uploads\/ask-experts\/COVID-19\/how-mrna-and-protein-based-covid-19-vaccines-different.jpg)](https:\/\/www.youtube.com\/watch?v=xGHs0u0VzoA)  \n  3:01\n\n[View All Video Questions](https:\/\/www.immunize.org\/clinical\/video\/?wpsolr_fq%5B0%5D=subject_str%3AAsk%20the%20Experts)\n\nLast reviewed: January 9, 2026\n\nLink copied\n\n- COVID-19\n- Contraindications & Precautions\n## What percentage of vaccine recipients will experience an anaphylactic reaction?\n\nIt is estimated that for every million doses administered, about one (~0.0001%) will result in an anaphylactic reaction following vaccination. The estimate for mRNA COVID-19 vaccines is slightly higher, at 2 to 5 anaphylactic reactions per million vaccinations given. With proper screening, most providers who administer thousands of vaccines in their lifetimes will never see an anaphylactic reaction.\n\nLast reviewed: November 16, 2025\n\nLink copied\n\n- COVID-19\n- Vaccine Products\n## What is the difference between the original COVID-19 vaccines and the currently recommended vaccines?\n\nThe original COVID-19 vaccines all targeted the spike protein of the original SARS-CoV-2 virus. The 2025–2026 formulation vaccines target the spike proteins of more recently circulating strains, known as the Omicron JN.1 lineage LP.8.1 strain (mRNA vaccines) or the JN.1 strain (Nuvaxovid adjuvanted protein subunit vaccine). The update is intended to boost production of antibodies that protect more effectively against disease caused by currently circulating Omicron subvariants.\n\nThe process of updating the strain without changing anything else is similar to the seasonal strain changes made for influenza vaccinations each year. Vaccine safety, side effects, and risk of allergic reactions are expected to be comparable to earlier formulations of vaccines of the same brand and dose. As with seasonal influenza vaccines, future COVID-19 vaccines can continue to be updated when needed, as the circulating viruses evolve.\n\nLast reviewed: November 16, 2025\n\nLink copied\n\n- COVID-19\n- Vaccine Products\n## Is the Janssen COVID-19 Vaccine (Johnson & Johnson) still available in the United States?\n\nNo. The last U.S. doses of Janssen COVID-19 Vaccine expired May 7, 2023.\n\nLast reviewed: November 16, 2025\n\nLink copied\n\n- COVID-19\n- Vaccine Products\n## What is the Nuvaxovid (Sanofi-Novavax) COVID-19 Vaccine?\n\nNuvaxovid is the brand name of the adjuvanted protein subunit COVID-19 vaccine developed by Novavax and commercialized by Sanofi beginning in the 2025–26 season. It contains the Omicron JN.1 subvariant SARS-CoV-2 spike protein and Matrix-M adjuvant. The saponin-based adjuvant is made from extracts of the bark of the Soapbark tree native to Chile. It is added to enhance the immune response of the vaccine recipient. The spike protein is produced in insect cells.\n\nThe 2025–2026 formulation of Nuvaxovid is FDA-licensed for use in people age 12 years or older. It is recommended as a single dose for people age 12 years through 64 years, given at least 8 weeks after the most recent dose of COVID-19 vaccine, regardless of the recipient’s vaccination history. People age 65 years or older and those age 12 years and older who are moderately or severely immunocompromised are recommended to receive 2 doses of 2025–2026 Formula COVID-19 vaccines, 6 months apart (with a minimum interval of 2 months between doses if using Nuvaxovid for both doses).\n\nA 2-dose initial series is recommended for previously unvaccinated recipients who are moderately or severely immunocompromised, with the doses given at least 3 weeks apart. A third dose of any COVID-19 vaccine is recommended 6 months after the initial series is completed (with a minimum interval of 2 months between doses if using Nuvaxovid).\n\nLast reviewed: November 16, 2025\n\nLink copied\n\n- COVID-19\n- Vaccine Products\n## How well do COVID-19 vaccines work?\n\nThe benefit of COVID-19 vaccination to an individual patient varies depending on the health status of the patient, their history of vaccination and COVID-19 infection, and the circulating COVID-19 strains. However, despite these variables, observational studies consistently show vaccination in all age groups provides measurable additional protection against hospitalization or death compared to those who are unvaccinated.\n\nCDC published “Interim Estimates of 2024–2025 COVID-19 Vaccine Effectiveness Among Adults Aged ≥18 Years — VISION and IVY Networks, September 2024–January 2025” in MMWR on February 27, 2025 ([www.cdc.gov\/mmwr\/volumes\/74\/wr\/mm7406a1.htm](http:\/\/www.cdc.gov\/mmwr\/volumes\/74\/wr\/mm7406a1.htm)). They concluded vaccine effectiveness (VE) of 2024–2025 COVID-19 vaccine was 33% against COVID-19–associated emergency department (ED) or urgent care (UC) visits among adults age18 years or older and 45%–46% against hospitalizations among immunocompetent adults age 65 years or older, compared with not receiving a 2024–2025 vaccine dose. VE against hospitalizations in immunocompromised adults age 65 years or older was 40%.\n\nLast reviewed: November 16, 2025\n\nLink copied\n\n- COVID-19\n- Vaccine Products\n## Where can I obtain detailed information about the COVID-19 vaccines?\n\nCDC has a product-specific webpage for each COVID-19 vaccine ([www.cdc.gov\/vaccines\/covid-19\/info-by-product\/index.html](http:\/\/www.cdc.gov\/vaccines\/covid-19\/info-by-product\/index.html)); however, at this writing the page has not been updated for the 2025–2026 Formula COVID-19 vaccines. You may access the package inserts for all four licensed 2025–26 COVID-19 vaccines on the Immunize.org COVID-19 main page: [www.immunize.org\/vaccines\/a-z\/covid-19\/](http:\/\/www.immunize.org\/vaccines\/a-z\/covid-19\/).\n\nLast reviewed: November 16, 2025\n\nLink copied\n\n- COVID-19\n- For Children under 12 Years\n## What are the differences between the 2025–26 season recommendations for COVID-19 vaccination of children from CDC and from the American Academy of Pediatrics (AAP)?\n\nCDC and ACIP recommend vaccination of all people age 6 months through 64 years based on individual decision-making (also known as shared clinical decision-making), with an emphasis that the risk-benefit of vaccination is most favorable for individuals who are at an increased risk for severe COVID-19 disease and lowest for individuals who are not at an increased risk, according to the CDC list of COVID-19 risk factors. Refer to CDC’s interim clinical considerations for COVID-19 vaccination for the specific dosing schedule: [www.cdc.gov\/covid\/hcp\/vaccine-considerations\/routine-guidance.html\\#cdc\\_clinical\\_guidance\\_recomm\\_key-table-1-2025–2026-covid-19-vaccination-schedule-november-4-2025](http:\/\/www.cdc.gov\/covid\/hcp\/vaccine-considerations\/routine-guidance.html#cdc_clinical_guidance_recomm_key-table-1-2025%E2%80%932026-covid-19-vaccination-schedule-november-4-2025).\n\nThe American Academy of Pediatrics (AAP) has issued separate COVID-19 vaccination recommendations for children during the 2025–26 season. Refer to the full statement for details of their recommendations: <https:\/\/doi.org\/10.1542\/peds.2025-073924>. In summary, AAP recommends age-appropriate COVID-19 vaccination of the following groups of children:\n\n- All children age 6 months through 23 months\n- Residents of long-term care facilities or other congregate settings\n- Children who have never been vaccinated against COVID-19\n- Infants and children with household contacts who are at high risk for severe COVID-19\n- All children who are at risk of severe COVID-19 due to underlying conditions or treatments, including: chronic pulmonary disease, cardiovascular disease, gastrointestinal disorders, hepatic disease, hematologic disease, metabolic disorders, obesity, neurologic and neurodevelopmental conditions, immunosuppressive conditions, and rheumatologic or autoimmune disease\n- Children age 2 through 18 years not in the above categories whose parent or guardian desires their protection from COVID-19\n\nLast reviewed: November 16, 2025\n\nLink copied\n\n- COVID-19\n- For Children under 12 Years\n## My patient turns 12 years old next week and has never had a COVID-19 vaccination. His parents want to vaccinate him. What options are available?\n\nThis child should receive one dose recommended for his age at the time of the vaccination visit. At age 11 years, an age-appropriate single dose of either Comirnaty (Pfizer-BioNTech) or Spikevax (Moderna) mRNA vaccine is recommended. If the patient arrives in your clinic after turning 12 years old, the 2025–2026 Formula Nuvaxovid (Sanofi-Novavax) protein subunit vaccine and the mNexspike (Moderna) mRNA vaccine are also options.\n\nLast reviewed: November 16, 2025\n\nLink copied\n\n- COVID-19\n- For Children under 12 Years\n## My patient had the first dose of the 3-dose primary series of Pfizer-BioNTech COVID-19 vaccine using a 2024-2025 Formula Pfizer-BioNTech vaccine at age 19 months, but she turned 2 years old before returning for a second dose. We have only the 2025–2026 Spikevax vaccine. What should she get now?\n\nCDC states that a person who moves to an older age group before completing the initial series recommended for the younger age group should follow the schedule for the older age group and receive the vaccine product and dosage for the older age group. In this case, the child should receive one dose of 2025–2026 Formula Spikevax (Moderna) at least 8 weeks after the most recent dose of COVID-19 vaccine.\n\nAn initial series of COVID-19 vaccine is recommended for children 6 months through 23 months of age. Children 24 months through 59 months of age are recommended to receive only one dose of 2025–2026 Formula Spikevax regardless of their COVID-19 vaccination history.\n\nLast reviewed: November 16, 2025\n\nLink copied\n\n- COVID-19\n- For Children under 12 Years\n## Immunocompromised patients who are given mRNA vaccine are recommended to receive an age-appropriate 3-dose initial series. What dose do I use for a severely immunocompromised patient that starts the initial series at age 11 years but turns 12 before completing the 3-dose primary series?\n\nModerately or severely immunocompromised children who transition from age 11 years to age 12 years during the initial vaccination series should complete the 3-dose series using the dosage for people ages 12 years and older for all doses received once they are age 12 years.\n\nSee [www.cdc.gov\/covid\/hcp\/vaccine-considerations\/immunocompromised.html](http:\/\/www.cdc.gov\/covid\/hcp\/vaccine-considerations\/immunocompromised.html) for additional details.\n\nLast reviewed: November 16, 2025\n\nLink copied\n\n- COVID-19\n- For Children under 12 Years\n## What do we know about the safety of Moderna and Pfizer-BioNTech mRNA COVID-19 vaccines in the youngest children?\n\nBoth vaccines have been demonstrated to be safe, with side effects typical of those in older age groups. The most common local reaction in this age group is pain at the injection site; the most common systemic symptom in older children was fatigue and in younger children (6 through 23 months) irritability\/crying and sleepiness were most common. Fever may occur after either vaccination. Febrile seizures can occur in infants and young children ages 6 months through 5 years as a result of any condition that causes a fever (most common with high fevers). Febrile seizures are uncommon after vaccination. Febrile seizures were rare after mRNA COVID-19 vaccine clinical trials in this age group, and CDC continues to monitor for this adverse event following vaccination in infants and young children.\n\nNo cases of myocarditis were reported during the clinical trials for either vaccine. To date, post-authorization surveillance has not detected an increased risk for myocarditis and pericarditis following mRNA COVID-19 vaccination in children ages 6 months–4 years (Pfizer-BioNTech) and ages 6 months–5 years (Moderna).\n\nLast reviewed: November 16, 2025\n\nLink copied\n\n- COVID-19\n- For Children under 12 Years\n## What do we know about the safety of Moderna and Pfizer-BioNTech mRNA COVID-19 vaccines in the youngest children? \\[Video\\]\n\n[![](https:\/\/www.immunize.org\/wp-content\/uploads\/ask-experts\/COVID-19\/What-do-we-know-about-the-safety-and-effectiveness-of-Moderna-and-Pfizer.jpg)](https:\/\/www.youtube.com\/watch?v=kXsLejc077A&list=PLqKEg4Y5HWfhjjcgcH7QZtk7sooXJC3wz&index=27)  \n  3:20\n\n[View All Video Questions](https:\/\/www.immunize.org\/clinical\/video\/?wpsolr_fq%5B0%5D=subject_str%3AAsk%20the%20Experts)\n\nLast reviewed: November 16, 2025\n\nLink copied\n\n- COVID-19\n- For Adolescents & Adults\n## What 2025–2026 Formula COVID-19 Vaccine options are available for adolescents age 12 years and older and adults?\n\n**Comirnaty** (Pfizer-BioNTech) mRNA COVID-19 vaccine is FDA-licensed for use in ages 5 years through 64 years with at least one underlying condition that puts them at risk for severe COVID-19 infection and individuals 65 years and older\n\n**mNexspike** (Moderna) is FDA-licensed for use in ages 12 through 64 years with at least one underlying condition that puts them at risk for severe COVID-19 infection and individuals 65 years and older\n\n**Nuvaxovid** (Sanofi-Novavax) is FDA-licensed for use in ages 12 through 64 years with at least one underlying condition that puts them at risk for severe COVID-19 infection and individuals 65 years and older\n\n**Spikevax** (Moderna) mRNA COVID-19 vaccine is FDA-licensed for use in ages 6 months through 64 years with at least one underlying condition that puts them at risk for severe COVID-19 infection and individuals 65 years and older\n\nAlthough the FDA licenses are limited in the age group younger than 65 years to those with underlying conditions that put them at risk for severe COVID-19 infection, the ACIP has recommended use based on individual decision-making (i.e., shared clinical decision-making) for all people age 6 months and older. This means that it is acceptable standard of care to offer COVID-19 vaccination to people in this age group without a high-risk condition when vaccination is desired.\n\nLast reviewed: November 16, 2025\n\nLink copied\n\n- COVID-19\n- For Adolescents & Adults\n## What do we know about the safety and side effects of the Pfizer-BioNTech COVID-19 Vaccine in children and young teens in the 12- to 15-year-old age group?\n\nClinical trial results for the original monovalent Pfizer-BioNTech COVID-19 Vaccine (administered as a two-dose primary series) demonstrated that among vaccine recipients age 12–15 years, side effects during the 7 days after vaccination were commonly reported (90.9% of vaccine recipients reported a local reaction and 90.7% reported a systemic reaction). Most reactions were mild to moderate. Pain at the injection site was the most common local reaction. One in 10 reported a side effect that interfered with daily activities. Side effects usually resolved after 1–2 days. Systemic side effects (e.g., fever, fatigue, headache, muscle pain) were more commonly reported after the second dose than after the first dose. No specific safety concerns were identified among adolescent vaccine recipients.\n\nThe safety and side effects of the 2025–2026 formula are expected to be consistent with the previous formulations of the product.\n\nLast reviewed: November 16, 2025\n\nLink copied\n\n- COVID-19\n- For Adolescents & Adults\n## How many doses of the 2025–2026 Formula COVID-19 adjuvanted protein subunit vaccine do recipients need this season?\n\nThe 2025–2026 formula Nuvaxovid (Sanofi-Novavax) vaccine is an option for any person age 12 years or older who is due for a 2025–2026 updated vaccination. Below are listed the 2025–26 season dosing schedules (if using Nuvaxovid for all doses) for different ages and health conditions:\n\n- Age 12 through 64 years, not moderately or severely immunocompromised: one 2025–2026 formula dose, at least 8 weeks after most recent dose from a previous season\n- Age 65 years and older, not moderately or severely immunocompromised: two 2025–2026 formula doses 6 months apart (minimum interval 2 months)\n- Age 12 years or older, moderately or severely immunocompromised:\n  - Previously unvaccinated: give 2 doses at least 3 weeks apart as an initial series, followed by a third dose about 6 months after dose 2 (minimum interval 2 months)\n  - Previously completed an initial series of any COVID-19 vaccine (2 doses of Novavax protein subunit vaccine or 3 doses of an mRNA vaccine): give first 2025–2026 formula dose at least 8 weeks after most recent COVID-19 vaccine from the previous season, then give a second dose about 6 months later (minimum interval, 2 months)\n\nSee Immunize.org’s standing orders template for administration of 2025–2026 formula adjuvanted protein subunit vaccine to individuals age 12 years and older for details: [www.immunize.org\/wp-content\/uploads\/catg.d\/p3141.pdf](http:\/\/www.immunize.org\/wp-content\/uploads\/catg.d\/p3141.pdf).\n\nLast reviewed: November 16, 2025\n\nLink copied\n\n- COVID-19\n- For Special Populations\n## Are COVID-19 vaccines safe during pregnancy?\n\nYes. Evidence continues to demonstrate that COVID-19 vaccination is safe and effective during any stage of pregnancy; the benefits of vaccination clearly outweigh any known or potential risks of COVID-19 vaccination during pregnancy. The currently licensed COVID-19 vaccines are nonreplicating vaccines and cannot cause infection in either the mother or the fetus. No evidence exists of risk to the fetus from vaccinating during pregnancy with nonreplicating vaccines in general.\n\nData from the Vaccine Adverse Events Reporting System (VAERS), the V-safe surveillance system, and the V-safe pregnancy registry have not signaled any safety concerns related to vaccination during pregnancy for mother or infant.\n\nPregnant women have historically been at an increased risk of severe disease, adverse pregnancy outcomes, and maternal death from COVID-19 infections. ACIP recommends the use of 2025–2026 COVID-19 vaccine during pregnancy based upon individual decision-making (i.e., shared clinical decision-making).\n\nThe American College of Obstetricians and Gynecologists (ACOG) recommends all pregnant women receive any age-appropriate 2025–2026 Formula COVID-19 vaccine if they have not already received one. Current ACOG recommendations are available here: [www.acog.org\/clinical\/clinical-guidance\/practice-advisory\/articles\/2020\/12\/covid-19-vaccination-considerations-for-obstetric-gynecologic-care](http:\/\/www.acog.org\/clinical\/clinical-guidance\/practice-advisory\/articles\/2020\/12\/covid-19-vaccination-considerations-for-obstetric-gynecologic-care).\n\nLast reviewed: November 16, 2025\n\nLink copied\n\n- COVID-19\n- For Special Populations\n## Are COVID-19 vaccines recommended during pregnancy?\n\nPregnant women have historically been at an increased risk of severe disease, adverse pregnancy outcomes, and maternal death from COVID-19 infections. Studies have shown that antibodies produced after COVID-19 vaccination during pregnancy are transferred to the newborn, and COVID-19 vaccination during pregnancy reduces the risk of COVID-19 hospitalization in infants younger than 6 months.\n\nACIP recommends the use of 2025–2026 COVID-19 vaccine during pregnancy based upon individual decision-making (i.e., shared clinical decision-making) after a discussion with a nurse, doctor, or pharmacist.\n\nThe American College of Obstetricians and Gynecologists (ACOG) recommends all pregnant women receive any age-appropriate 2025–2026 Formula COVID-19 vaccine if they have not already received one. A person who is up to date on COVID-19 vaccination and becomes pregnant is not recommended to get an additional dose. Current ACOG recommendations are available here: [www.acog.org\/clinical\/clinical-guidance\/practice-advisory\/articles\/2020\/12\/covid-19-vaccination-considerations-for-obstetric-gynecologic-care](http:\/\/www.acog.org\/clinical\/clinical-guidance\/practice-advisory\/articles\/2020\/12\/covid-19-vaccination-considerations-for-obstetric-gynecologic-care).\n\nLast reviewed: November 16, 2025\n\nLink copied\n\n- COVID-19\n- For Special Populations\n## Ask the Experts: Are COVID-19 vaccines helpful during pregnancy? \\[Video\\]\n\n[![](https:\/\/www.immunize.org\/wp-content\/uploads\/ask-experts\/COVID-19\/are-covid19-vaccines-helpful-during-pregnancy.jpg)](https:\/\/youtu.be\/ohhn6Nkkc0g;index=5)  \n  1:34\n\n[View All Video Questions](https:\/\/www.immunize.org\/clinical\/video\/?wpsolr_fq%5B0%5D=subject_str%3AAsk%20the%20Experts)\n\nLast reviewed: January 9, 2026\n\nLink copied\n\n- COVID-19\n- For Special Populations\n## May COVID-19 vaccines be given if the recipient is breastfeeding?\n\nYes. COVID-19 vaccination may be given during lactation.\n\nLast reviewed: November 16, 2025\n\nLink copied\n\n- COVID-19\n- For Special Populations\n## What is the 2025–2026 Formula COVID-19 vaccination schedule for moderately or severely immunocompromised people?\n\nPlease see CDC’s Interim Clinical Considerations for the Use of COVID-19 Vaccines for dosage guidance for detailed tables, including dosing intervals and options ([www.cdc.gov\/covid\/hcp\/vaccine-considerations\/immunocompromised.html](http:\/\/www.cdc.gov\/covid\/hcp\/vaccine-considerations\/immunocompromised.html)). You will also find the vaccination schedules for people who are moderately or severely immunocompromised in the Immunize.org standing orders templates for administration of COVID-19 vaccines:\n\n- For ages 6 months through 11 years: [www.immunize.org\/wp-content\/uploads\/catg.d\/p3140a.pdf](http:\/\/www.immunize.org\/wp-content\/uploads\/catg.d\/p3140a.pdf)\n- mRNA vaccines for ages 12 years and older: [www.immunize.org\/wp-content\/uploads\/catg.d\/p3140.pdf](http:\/\/www.immunize.org\/wp-content\/uploads\/catg.d\/p3140.pdf)\n- Protein subunit vaccine for ages 12 years and older: [www.immunize.org\/wp-content\/uploads\/catg.d\/p3141.pdf](http:\/\/www.immunize.org\/wp-content\/uploads\/catg.d\/p3141.pdf)\n\nIn general, people who are moderately or severely immunocompromised and previously unvaccinated are recommended to receive a 2-dose (protein subunit) or 3-dose (mRNA) initial series of COVID-19 vaccine, with an additional dose 6 months later of any age-appropriate COVID-19 brand (minimum interval of 2 months for Nuvaxovid, Spikevax, or Comirnaty; 3-month minimum interval for mNexspike). CDC recommends use of the same manufacturer for all doses of the initial series when feasible. Spikevax and mNexspike are both made by Moderna and are interchangeable in ages 12 years and older.\n\nThose who completed an initial series before the 2025–2026 formula vaccines were available should receive 2 doses of 2025–2026 Formula COVID-19 vaccine (any age-appropriate brand) about 6 months apart (minimum interval of 2 months for Nuvaxovid, Spikevax, or Comirnaty; 3-month minimum interval for mNexspike).\n\nImmunocompromised people should be counseled that they may have a reduced immune response to COVID-19 vaccination. Continuing other infection prevention measures, such as wearing a face mask and avoiding crowds, can help limit their risk of exposure to the SARS-CoV-2 virus.\n\nPemivibart (Pemgarda, Invyvid) is a monoclonal antibody for COVID-19 pre-exposure prophylaxis in people who are moderately or severely immunocompromised and unlikely to mount an adequate immune response to COVID-19 vaccination and who meet the [FDA-authorized conditions for use](https:\/\/www.fda.gov\/media\/177067\/download?attachment). See additional information from CDC at the immunocompromised link in the first paragraph.\n\nLast reviewed: November 16, 2025\n\nLink copied\n\n- COVID-19\n- For Special Populations\n## What conditions or treatments are considered to qualify a person as moderately or severely immunocompromised for the purposes of COVID-19 vaccination?\n\nThe conditions and treatments that CDC specifies may result in moderate or severe immunocompromise include *but are not limited to*:\n\n- Active treatment for solid tumor and hematologic malignancies\n- Hematologic malignancies associated with poor responses to COVID-19 vaccines regardless of current treatment status (e.g., chronic lymphocytic leukemia, non-Hodgkin lymphoma, multiple myeloma, acute leukemia)\n- Receipt of solid-organ transplant or an islet transplant and taking immunosuppressive therapy\n- Receipt of chimeric antigen receptor (CAR)-T-cell therapy or hematopoietic cell transplant (HCT) (within 2 years of transplantation or taking immunosuppressive therapy)\n- Moderate or severe primary immunodeficiency (e.g., common variable immunodeficiency disease, severe combined immunodeficiency, DiGeorge syndrome, Wiskott-Aldrich syndrome)\n- Advanced HIV infection (people with HIV and CD4 cell counts less than 200\/mm³, history of an AIDS-defining illness without immune reconstitution, or clinical manifestations of symptomatic HIV) or untreated HIV infection\n- Active treatment with high-dose corticosteroids (i.e., 20 mg or more of prednisone or equivalent per day when administered for 2 or more weeks), alkylating agents, antimetabolites, transplant-related immunosuppressive drugs, cancer chemotherapeutic agents classified as severely immunosuppressive, tumor necrosis factor (TNF) blockers, and other biologic agents that are immunosuppressive or immunomodulatory (e.g., B-cell-depleting agents)\n\nAdditional factors to consider in assessing the general level of immune competence in a patient include disease severity, duration, clinical stability, complications, comorbidities, and any potentially immune-suppressing treatment. A patient’s clinical care team is in the best position to evaluate the degree of immunocompromise and timing of vaccination.\n\nSee CDC’s interim clinical considerations for this population: [www.cdc.gov\/covid\/hcp\/vaccine-considerations\/immunocompromised.html](http:\/\/www.cdc.gov\/covid\/hcp\/vaccine-considerations\/immunocompromised.html).\n\nLast reviewed: November 16, 2025\n\nLink copied\n\n- COVID-19\n- For Special Populations\n## Are there any conditions when revaccination with a new initial series of COVID-19 vaccine may be indicated?\n\nYes. See revaccination considerations at [www.cdc.gov\/covid\/hcp\/vaccine-considerations\/immunocompromised.html](http:\/\/www.cdc.gov\/covid\/hcp\/vaccine-considerations\/immunocompromised.html). This is the most current statement from CDC on COVID-19 revaccination:\n\nRecipients of chimeric antigen receptor (CAR)-T-cell therapy or hematopoietic cell transplant (HCT) who received 1 or more doses of COVID-19 vaccine prior to or during treatment should be revaccinated. Revaccination should start at least 3 months (12 weeks) after transplant or CAR-T-cell therapy and should follow the currently recommended schedule for people who are unvaccinated.\n\nRevaccination may also be considered for patients who received 1 or more doses of COVID-19 vaccine during treatment with B-cell-depleting therapies (e.g., rituximab, ocrelizumab) that were administered over a limited period (e.g., as part of a treatment regimen for certain malignancies) according to the currently recommended schedule for people who are unvaccinated. The suggested interval to start revaccination is about 6 months after completion of the B-cell-depleting therapy. Timing of vaccination for patients who receive B-cell-depleting therapies on a continuing basis (e.g., for treatment of certain autoimmune conditions such as rheumatoid arthritis or multiple sclerosis) is addressed in CDC’s [considerations for timing of COVID-19 vaccination in relation to immunosuppressive therapies](https:\/\/www.cdc.gov\/covid\/hcp\/vaccine-considerations\/immunocompromised.html#cdc_cg_special_populations_about-considerations-for-timing-of-covid-19-vaccination-in-relation-to-immunosuppressive-therapies).\n\nCDC continues to recommend that a patient’s clinical team is best positioned to determine the degree of immune compromise, need for revaccination, and appropriate timing of revaccination.\n\nLast reviewed: November 16, 2025\n\nLink copied\n\n- COVID-19\n- For Special Populations\n## My patient receives periodic infusions of rituximab for immunosuppressive treatment of an immune system disorder. Should we try to coordinate the timing of his COVID-19 vaccinations around his infusion schedule?\n\nAccording to CDC’s interim clinical considerations for the use of COVID-19 vaccines, whenever possible, COVID-19 vaccines should be administered at least 2 weeks before initiation or resumption of immunosuppressive therapies. For patients who receive B-cell-depleting therapies on a continuing basis, COVID-19 vaccines should be administered approximately 4 weeks before the next scheduled therapy.\n\nCDC also notes that timing of COVID-19 vaccination should take into consideration current or planned immunosuppressive therapies, optimization of both the patient’s medical condition and response to vaccination, and individual benefits and risks. Review the CDC’s considerations for COVID-19 vaccination of those on immunosuppressive therapies here: [www.cdc.gov\/covid\/hcp\/vaccine-considerations\/immunocompromised.html\\#cdc\\_cg\\_special\\_populations\\_about-considerations-for-timing-of-covid-19-vaccination-in-relation-to-immunosuppressive-therapies](http:\/\/www.cdc.gov\/covid\/hcp\/vaccine-considerations\/immunocompromised.html#cdc_cg_special_populations_about-considerations-for-timing-of-covid-19-vaccination-in-relation-to-immunosuppressive-therapies).\n\nOn a case-by-case basis, providers caring for these patients may administer COVID-19 vaccines outside of the FDA and CDC dosing schedules based on their clinical judgment of what is most beneficial to the patient.\n\nLast reviewed: November 16, 2025\n\nLink copied\n\n- COVID-19\n- For Special Populations\n## What proof do I need before giving COVID-19 vaccine to a patient who says he has a high-risk condition?\n\nCDC states that no additional medical documentation is required before administering COVID-19 vaccine. The patient’s self-attestation of a high-risk condition, including moderate or severe immunocompromise, is sufficient. Those who report moderate or severe immunocompromise should be offered the modified schedule for people with moderate or severe immunocompromise. Vaccinators should not deny COVID-19 vaccination to a person due to lack of documentation of a self-reported high-risk condition.\n\nLast reviewed: November 16, 2025\n\nLink copied\n\n- COVID-19\n- For Special Populations\n## What proof do I need before giving COVID-19 vaccine to a person who says he is immunocompromised? \\[Video\\]\n\n[![](https:\/\/www.immunize.org\/wp-content\/uploads\/ask-experts\/COVID-19\/proof-before-giving-covid-19-vaccine-if-immunocompromised.jpg)](https:\/\/www.youtube.com\/watch?v=iVH0EOM03eI)  \n  1:12\n\n[View All Video Questions](https:\/\/www.immunize.org\/clinical\/video\/?wpsolr_fq%5B0%5D=subject_str%3AAsk%20the%20Experts)\n\nLast reviewed: January 9, 2026\n\nLink copied\n\n- COVID-19\n- For Special Populations\n## May different brands of 2025–2026 Formula COVID-19 vaccine be used for immunocompromised people who require multiple doses over time?\n\nImmunocompromised people who need an initial series of 3 doses of mRNA COVID-19 vaccine or two doses of Nuvaxovid (Sanofi-Novavax) adjuvanted protein COVID-19 vaccine should receive the initial series using COVID-19 vaccines from the same manufacturer, unless it is not feasible. If the same manufacturer cannot be used for all primary series doses (e.g., the brand is unavailable at the time of the vaccination visit, the previous brand is unknown, or the patient would not be vaccinated with the previous brand due to a contraindication or other reason), then administer another age-appropriate brand. Spikevax (Moderna) is the only licensed 2025–2026 Formula COVID-19 vaccine option for children younger than age 5 years. If the immunocompromised recipient is age 5 years or older, once the initial series is complete, any appropriate brand may be used for all subsequent doses. Spikevax and mNexspike are interchangeable: both vaccines are made by Moderna.\n\nLast reviewed: November 16, 2025\n\nLink copied\n\n- COVID-19\n- For Special Populations\n## My patient takes high dose steroids and received a single dose of Janssen COVID-19 Vaccine (Johnson & Johnson) in 2021. He has had no doses since. He fits the definition for moderate or severe immunocompromise. What do I do now?\n\nThe patient’s initial series is considered complete following a single dose of the Janssen COVID-19 Vaccine. People who are moderately or severely immunocompromised and have completed an initial series (no matter how long ago) should now receive 1 dose of an age-appropriate 2025–2026 Formula COVID-19 vaccine (at least 8 weeks after their most recent dose of a previous formulation). They should receive a second 2025–2026 Formula COVID-19 vaccine dose 6 months later (minimum interval 2 months for Comirnaty, Spikevax, and Nuvaxovid; minimum interval of 3 months if using mNexspike).\n\nLast reviewed: November 16, 2025\n\nLink copied\n\n- COVID-19\n- For Special Populations\n## My adult patient is immunocompromised and we agree he should be vaccinated. The schedule says he should receive a third dose of mRNA COVID-19 vaccine to complete his initial series, but his most recent dose was 3 years ago. What do I do now?\n\nThe patient should receive a 2025–2026 COVID-19 mRNA dose now, of the same manufacturer as the initial two doses (if feasible), in order to complete the 3-dose initial mRNA vaccine series recommended for people with moderate or severe immunocompromise. Advise the patient that he should receive an additional 2025–2026 Formula COVID-19 dose of any brand in 6 months (minimum interval 2 months if using Comirnaty, Spikevax, or Nuvaxovid; minimum interval 3 months if using mNexspike).\n\nLast reviewed: November 16, 2025\n\nLink copied\n\n- COVID-19\n- Administering Vaccines\n## How are COVID-19 vaccines administered?\n\nAll COVID-19 vaccines are administered intramuscularly. Preparation details and dose volume vary by product. Most 2025-2026 formula products are now available in manufacturer-filled syringes.\n\nLast reviewed: November 16, 2025\n\nLink copied\n\n- COVID-19\n- Administering Vaccines\n## Has CDC provided clinical guidance on what to do if an error occurs while administering COVID-19 vaccinations?\n\nYes. CDC published an appendix to its interim clinical considerations for the use of COVID-19 vaccines to address a wide range of errors in vaccine administration. It includes a detailed table outlining actions to take after an error has occurred: [www.cdc.gov\/covid\/hcp\/vaccine-considerations\/appendices.html](http:\/\/www.cdc.gov\/covid\/hcp\/vaccine-considerations\/appendices.html).\n\nCategories of errors covered in the CDC table include:\n\n- Site\/route\n- Age\n- Product and dosage\n- Storage and handling\n- Incorrect intervals\n- Interchanging product types when not recommended\n\nAsk the Experts refers our readers to this CDC table for the most current and comprehensive guidance on COVID-19 vaccine administration errors and how to manage them. For all vaccine administration errors the following steps are recommended: inform the patient of the error, report the error to VAERS (<https:\/\/vaers.hhs.gov>) unless CDC’s guidance states that the error does not need to be reported, evaluate why the error occurred, and implement strategies to prevent future errors.\n\nLast reviewed: November 16, 2025\n\nLink copied\n\n- COVID-19\n- Administering Vaccines\n## A dose of COVID-19 vaccine was administered subcutaneously instead of by the intramuscular route. Does the dose need to be repeated?\n\nNo. CDC does not recommend repeating the dose of any COVID-19 vaccine in circumstances where the dose is administered in an incorrect route or an incorrect site (i.e., not in the deltoid or anterolateral thigh). In the case of a subcutaneous injection, the patient should be advised of the possibility of self-limited local or systemic side effects.\n\nLast reviewed: November 16, 2025\n\nLink copied\n\n- COVID-19\n- Administering Vaccines\n## When giving COVID-19 vaccine, is use of a Vaccine Information Statement (VIS) required?\n\nProviding a vaccine recipient with a COVID-19 vaccine VIS is recommended by CDC but not required. The requirement to provide the VIS to a patient is present only when a vaccine is included in the federal Vaccine Injury Compensation Program (VICP). COVID-19 vaccines are not included in the VICP at this time. The current official VIS and all available translations are available from Immunize.org: [www.immunize.org\/vaccines\/vis\/covid-19\/](http:\/\/www.immunize.org\/vaccines\/vis\/covid-19\/).\n\nLast reviewed: November 16, 2025\n\nLink copied\n\n- COVID-19\n- Administering Vaccines\n## When giving COVID-19 vaccine is use of a VIS required? \\[Video\\]\n\n[![](https:\/\/www.immunize.org\/wp-content\/uploads\/ask-experts\/COVID-19\/when-giving-covid-19-vaccine-is-use-of-a-vis-required.jpg)](https:\/\/www.youtube.com\/watch?v=-DAT6-_3kJY)  \n  1:06\n\n[View All Video Questions](https:\/\/www.immunize.org\/clinical\/video\/?wpsolr_fq%5B0%5D=subject_str%3AAsk%20the%20Experts)\n\nLast reviewed: January 9, 2026\n\nLink copied\n\n- COVID-19\n- Scheduling Vaccines\n## How can I confirm if I am using the most up-to-date information on COVID-19 vaccines?\n\nPeriodically verify whether you are using the most current available documents by checking Immunize.org’s regularly updated Checklist of Current Versions of U.S. COVID-19 Vaccination Guidance and Clinic Support Tools: [www.immunize.org\/catg.d\/p3130.pdf](http:\/\/www.immunize.org\/catg.d\/p3130.pdf). This resource is updated as needed with the dates of the most currently available materials from CDC and FDA.\n\nInformation from CDC is generally updated first on the CDC web page: Interim Clinical Considerations for Use of COVID-19 Vaccines in the United States: ([www.cdc.gov\/covid\/hcp\/vaccine-considerations\/index.html](http:\/\/www.cdc.gov\/covid\/hcp\/vaccine-considerations\/index.html)).\n\nLast reviewed: November 16, 2025\n\nLink copied\n\n- COVID-19\n- Scheduling Vaccines\n## If a moderately or severely immunocompromised person has fallen far behind with recommended COVID-19 vaccination, do we ever need to re-start the initial vaccine series?\n\nNo. Simply administer the next dose that is currently recommended, using a vaccine from the same manufacturer, if feasible, even if previous doses in the series were an earlier formulation.\n\nLast reviewed: November 16, 2025\n\nLink copied\n\n- COVID-19\n- Scheduling Vaccines\n## My moderately immunocompromised patient is unvaccinated against COVID-19 and now wants to receive an initial series. I know there is a 4-day grace period that allows a dose to be valid if given up to 4 days before the minimum interval. Should we schedule her doses 4 days before the recommended intervals to get her vaccinated faster?\n\nCDC guidance allows for doses given up to 4 days before the recommended interval to be counted as valid – such doses do not need to be repeated. However, people should not be routinely scheduled to receive a dose earlier than recommended. Schedulers should offer appointments beginning on the date of the recommended interval or later.\n\nLast reviewed: November 16, 2025\n\nLink copied\n\n- COVID-19\n- Scheduling Vaccines\n## If an 18-month-old patient received her first and only Pfizer-BioNTech mRNA COVID-19 vaccine last season, what should the child receive now?\n\nIn this specific situation, a child age 6 months–23 months who received one 2024–2025 Formula Pfizer-BioNTech COVID-19 vaccine dose should receive 2 doses of Spikevax (Moderna) vaccine to complete the initial series.\n\nRefer to the schedule tables on the CDC website ([www.cdc.gov\/covid\/hcp\/vaccine-considerations\/routine-guidance.html\\#cdc\\_clinical\\_guidance\\_recomm\\_key-table-1-2025–2026-covid-19-vaccination-schedule-november-4-2025](http:\/\/www.cdc.gov\/covid\/hcp\/vaccine-considerations\/routine-guidance.html#cdc_clinical_guidance_recomm_key-table-1-2025%E2%80%932026-covid-19-vaccination-schedule-november-4-2025)) or on the Immunize.org standing orders template for children age 6 months through 11 years ([www.immunize.org\/wp-content\/uploads\/catg.d\/p3140a.pdf](http:\/\/www.immunize.org\/wp-content\/uploads\/catg.d\/p3140a.pdf)) for specific dosing intervals.\n\nLast reviewed: November 16, 2025\n\nLink copied\n\n- COVID-19\n- Scheduling Vaccines\n## Do previously unvaccinated patients who are not immunocompromised need two doses of Nuvaxovid (Sanofi-Novavax) COVID-19 vaccine in the 2025–2026 season?\n\nBeginning with the 2025–2026 season, a single dose of 2025–2026 Formula Nuvaxovid adjuvanted protein COVID-19 vaccine is recommended for all recipients age 12 through 64 years who are not moderately or severely immunocompromised, regardless of their vaccination history. Those age 65 years or older are recommended to receive a second dose of any 2025–2026 Formula COVID-19 vaccine 6 months after the first 2025–2026 Formula dose (minimum interval 2 months if using Comirnaty, Spikevax, or Nuvaxovid; minimum interval 3 months if using mNexspike).\n\nLast reviewed: November 16, 2025\n\nLink copied\n\n- COVID-19\n- Scheduling Vaccines\n## What should be done if a patient scheduled for vaccination is exposed to COVID-19 or is sick with suspected or confirmed SARS-CoV-2 infection?\n\nAn asymptomatic person who is scheduled for COVID-19 vaccination and is exposed to SARS-CoV-2 virus may be vaccinated. COVID-19 vaccination after exposure is not recommended as post-exposure prophylaxis, so vaccination should not be expected to prevent illness caused by past exposure. A person who is currently sick with a respiratory virus should defer vaccination until at least the recovery from the acute illness, and consider additional measures to prevent infecting others, in accordance with current CDC guidance. Healthcare facilities may have specific policies in place to reduce the risk of spread of respiratory viruses to healthcare staff and other patients.\n\nPeople who recently had SARS-CoV-2 infection and are due for a COVID-19 vaccine may consider delaying the dose by up to 3 months from symptom onset or positive test (if infection was asymptomatic). According to CDC, increasing the time between infection and vaccination may result in an improved immune response to vaccination. There is a low risk of reinfection in the weeks following an infection. A recipient’s individual risks for severe disease and current COVID-19 conditions in the community should be taken into consideration when deciding whether to delay vaccination up to 3 months after infection.\n\nLast reviewed: November 16, 2025\n\nLink copied\n\n- COVID-19\n- Scheduling Vaccines\n## Can COVID-19 vaccine recipients be given other vaccines at the same visit?\n\nRoutine administration of all age-appropriate doses of vaccines at the same visit, also known as coadministration, is acceptable for children, adolescents, and adults if there are no contraindications at the time of the healthcare visit. COVID-19 vaccine may also be coadministered with nirsevimab or clesrovimab (RSV preventive antibody for infants), given in different syringes and at different anatomical sites. COVID-19 vaccines may also be given at any interval before or after any other vaccination.\n\nThere are special considerations for orthopoxvirus vaccination. There is no required minimum interval between receiving a dose of any COVID-19 vaccine and an orthopoxvirus vaccine, either Jynneos or ACAM2000 vaccine (e.g., for mpox prevention), regardless of which vaccine is administered first. However, use of Jynneos vaccine should be prioritized over ACAM2000 when co-administering a COVID-19 vaccine and an orthopoxvirus vaccine.\n\nPeople, particularly adolescent or young adult males, who are recommended to be vaccinated against both mpox and COVID-19 might consider waiting 4 weeks between vaccines. This is because of the observed risk for myocarditis and pericarditis after receipt of ACAM2000 orthopoxvirus vaccine and COVID-19 vaccines, and the hypothetical risk for myocarditis and pericarditis after Jynneos vaccine. However, if a patient’s risk for mpox or severe disease due to COVID-19 is increased, administration of mpox and COVID-19 vaccines should not be delayed.\n\nLast reviewed: November 16, 2025\n\nLink copied\n\n- COVID-19\n- Scheduling Vaccines\n## My patient is age 70 and due for a second dose of recombinant zoster vaccine (Shingrix, GSK). The patient also is eligible for, and wants to receive, a COVID-19 vaccine dose. What should we advise our patient about scheduling these?\n\nYour patient may choose to receive the vaccines at the same visit or separately, without regard to the timing interval.\n\nWhen multiple vaccines are administered at a single visit, administer each injection in a different syringe and at a different injection site. For adolescents and adults, the deltoid muscle may be used for more than one injection, though injection sites should be at least one inch apart. It is generally preferable to administer reactogenic vaccines such as Shingrix and COVID-19 vaccine in different arms. However, if the patient prefers both injections in the same deltoid, that is also acceptable.\n\nImmunize.org has developed a one-page guide to administering multiple intramuscular vaccinations to an adult at one visit: [www.immunize.org\/catg.d\/p2030.pdf](http:\/\/www.immunize.org\/catg.d\/p2030.pdf).\n\nLast reviewed: November 16, 2025\n\nLink copied\n\n- COVID-19\n- Scheduling Vaccines\n## How does the use of monoclonal antibodies or convalescent plasma to treat or prevent COVID-19 affect the scheduling of COVID-19 vaccination?\n\nThe timing of CDC-recommended vaccination is unaffected by the receipt of COVID-19 monoclonal antibodies or convalescent plasma.\n\nLast reviewed: November 16, 2025\n\nLink copied\n\n- COVID-19\n- Contraindications & Precautions\n## Please describe the contraindications for COVID-19 vaccination.\n\nWe refer our readers to CDC’s updated set of contraindications and precautions to vaccination with COVID-19 vaccines, located in its interim clinical considerations for the use of COVID-19 vaccines in the United States: [www.cdc.gov\/covid\/hcp\/vaccine-considerations\/contraindications-precautions.html](http:\/\/www.cdc.gov\/covid\/hcp\/vaccine-considerations\/contraindications-precautions.html).\n\nLast reviewed: November 16, 2025\n\nLink copied\n\n- COVID-19\n- Contraindications & Precautions\n## What are the precautions to COVID-19 vaccination?\n\nWe refer our readers to CDC’s updated set of contraindications and precautions to COVID-19 vaccination, located in its interim clinical considerations for the use of COVID-19 vaccines: [www.cdc.gov\/covid\/hcp\/vaccine-considerations\/contraindications-precautions.html](http:\/\/www.cdc.gov\/covid\/hcp\/vaccine-considerations\/contraindications-precautions.html).\n\nLast reviewed: November 16, 2025\n\n## Posts pagination\n1 [2](https:\/\/www.immunize.org\/ask-experts\/topic\/covid-19\/page\/2\/) [Next](https:\/\/www.immunize.org\/ask-experts\/topic\/covid-19\/page\/2\/)\n\nThis page was updated on January 9, 2026 .\n\n- [Ask the Experts](https:\/\/www.immunize.org\/ask-experts\/)\n  - [Ask the Experts Overview](http:\/\/www.immunize.org\/ask-experts\/overview\/)\n  - [View All Questions](https:\/\/www.immunize.org\/ask-experts\/)\n  - [View All Video Questions](http:\/\/www.immunize.org\/ask-experts\/?q=%5Bvideo%5D)\n  - [Vaccine Topics](http:\/\/www.immunize.org\/ask-experts\/topic\/covid-19\/)\n    - [COVID-19](http:\/\/www.immunize.org\/ask-experts\/topic\/covid-19\/)\n      - [All COVID-19](https:\/\/www.immunize.org\/ask-experts\/topic\/covid-19\/)\n      - [Disease Issues](https:\/\/www.immunize.org\/ask-experts\/topic\/covid-19\/disease-issues\/)\n      - [Vaccine Recommendations](https:\/\/www.immunize.org\/ask-experts\/topic\/covid-19\/vaccine-recommendations-covid-19\/)\n      - [Vaccine Products](https:\/\/www.immunize.org\/ask-experts\/topic\/covid-19\/vaccine-products-covid-19\/)\n      - [For Children Under 12](https:\/\/www.immunize.org\/ask-experts\/topic\/covid-19\/children-under-12-covid-19\/)\n      - [For Adolescents & Adults](https:\/\/www.immunize.org\/ask-experts\/topic\/covid-19\/adolescents-adults-covid-19\/)\n      - [For Special Populations](https:\/\/www.immunize.org\/ask-experts\/topic\/covid-19\/special-populations-covid-19\/)\n      - [Administering Vaccines](https:\/\/www.immunize.org\/ask-experts\/topic\/covid-19\/admin-vaccines-covid-19\/)\n      - [Scheduling Vaccines](https:\/\/www.immunize.org\/ask-experts\/topic\/covid-19\/scheduling-vaccines-covid-19\/)\n      - [Contraindications & Precautions](https:\/\/www.immunize.org\/ask-experts\/topic\/covid-19\/contraindications-precautions-covid-19\/)\n      - [Storage & Handling](https:\/\/www.immunize.org\/ask-experts\/topic\/covid-19\/storage-handling-covid-19\/)\n    - [Dengue](http:\/\/www.immunize.org\/ask-experts\/topic\/covid-19\/)\n      - [All Dengue](https:\/\/www.immunize.org\/ask-experts\/topic\/dengue\/)\n      - [Disease Issues](https:\/\/www.immunize.org\/ask-experts\/topic\/dengue\/disease-issues-dengue\/)\n      - [Vaccine Products](https:\/\/www.immunize.org\/ask-experts\/topic\/dengue\/vaccine-products-dengue\/)\n      - [Vaccine Recommendations](https:\/\/www.immunize.org\/ask-experts\/topic\/dengue\/vaccine-recommendations-dengue\/)\n      - [Prevaccination Testing](https:\/\/www.immunize.org\/ask-experts\/topic\/dengue\/prevaccination-testing\/)\n      - [Scheduling & Administration](https:\/\/www.immunize.org\/ask-experts\/topic\/dengue\/scheduling-administration-dengue\/)\n      - [Contraindications & Precautions](https:\/\/www.immunize.org\/ask-experts\/topic\/dengue\/contraindications-precautions-dengue\/)\n      - [Vaccine Safety](https:\/\/www.immunize.org\/ask-experts\/topic\/dengue\/vaccine-safety-dengue\/)\n      - [Storage & Handling](https:\/\/www.immunize.org\/ask-experts\/topic\/dengue\/storage-handling-dengue\/)\n    - [Diphtheria](http:\/\/www.immunize.org\/ask-experts\/topic\/covid-19\/)\n      - [All Diphtheria](https:\/\/www.immunize.org\/ask-experts\/topic\/diphtheria\/)\n      - [Disease Issues](https:\/\/www.immunize.org\/ask-experts\/topic\/diphtheria\/disease-issues-diphtheria\/)\n      - [Vaccine Recommendations](https:\/\/www.immunize.org\/ask-experts\/topic\/diphtheria\/vaccine-recommendations-diphtheria\/)\n      - [Vaccine Products](https:\/\/www.immunize.org\/ask-experts\/topic\/diphtheria\/vaccine-products-diphtheria\/)\n      - [Tdap for Adolescents & Adults](https:\/\/www.immunize.org\/ask-experts\/topic\/diphtheria\/tdap-adolescents-adults-diphtheria\/)\n      - [Tdap & Pregnancy](https:\/\/www.immunize.org\/ask-experts\/topic\/diphtheria\/tdap-pregnancy-diphtheria\/)\n      - [Scheduling Vaccines](https:\/\/www.immunize.org\/ask-experts\/topic\/diphtheria\/scheduling-vaccines-diphtheria\/)\n      - [Contraindications & Precautions](https:\/\/www.immunize.org\/ask-experts\/topic\/diphtheria\/contraindications-precautions-diphtheria\/)\n      - [Tetanus & Wound Management](https:\/\/www.immunize.org\/ask-experts\/topic\/diphtheria\/tetanus-wound-management-diphtheria\/)\n      - [Storage & Handling](https:\/\/www.immunize.org\/ask-experts\/topic\/diphtheria\/storage-handling-diphtheria\/)\n    - [Hepatitis A](http:\/\/www.immunize.org\/ask-experts\/topic\/covid-19\/)\n      - [All Hep A](https:\/\/www.immunize.org\/ask-experts\/topic\/hepa\/)\n      - [Disease Issues](https:\/\/www.immunize.org\/ask-experts\/topic\/hepa\/disease-issues-hepa\/)\n      - [Vaccine Recommendations](https:\/\/www.immunize.org\/ask-experts\/topic\/hepa\/vaccine-recommendations-hepa\/)\n      - [For Special Populations](https:\/\/www.immunize.org\/ask-experts\/topic\/hepa\/special-populations-hepa\/)\n      - [Administering Vaccines](https:\/\/www.immunize.org\/ask-experts\/topic\/hepa\/admin-vaccines-hepa\/)\n      - [Twinrix](https:\/\/www.immunize.org\/ask-experts\/topic\/hepa\/twinrix\/)\n      - [Immune Globulin](https:\/\/www.immunize.org\/ask-experts\/topic\/hepa\/immune-globulin\/)\n      - [Intʼl Travel](https:\/\/www.immunize.org\/ask-experts\/topic\/hepa\/international-travel\/)\n      - [Vaccine Safety](https:\/\/www.immunize.org\/ask-experts\/topic\/hepa\/vaccine-safety-hepa\/)\n      - [Contraindications & Precautions](https:\/\/www.immunize.org\/ask-experts\/topic\/hepa\/contraindications-precautions-hepa\/)\n      - [Storage & Handling](https:\/\/www.immunize.org\/ask-experts\/topic\/hepa\/storage-handling-hepa\/)\n    - [Hepatitis B](http:\/\/www.immunize.org\/ask-experts\/topic\/covid-19\/)\n      - [All Hep B](https:\/\/www.immunize.org\/ask-experts\/topic\/hepb\/)\n      - [Disease Issues](https:\/\/www.immunize.org\/ask-experts\/topic\/hepb\/disease-issues-hepb\/)\n      - [Tests & Interpretation](https:\/\/www.immunize.org\/ask-experts\/topic\/hepb\/tests-interpretation\/)\n      - [Vaccine Recommendations](https:\/\/www.immunize.org\/ask-experts\/topic\/hepb\/vaccine-recommendations-hepb\/)\n      - [Pregnancy, Perinatal & Infants](https:\/\/www.immunize.org\/ask-experts\/topic\/hepb\/pregnancy-perinatal-infants\/)\n      - [For Children & Teens](https:\/\/www.immunize.org\/ask-experts\/topic\/hepb\/children-teens\/)\n      - [For Adults (includes HBV Screening)](https:\/\/www.immunize.org\/ask-experts\/topic\/hepb\/adults\/)\n      - [For Healthcare Personnel](https:\/\/www.immunize.org\/ask-experts\/topic\/hepb\/healthcare-personnel\/)\n      - [Vaccine Safety](https:\/\/www.immunize.org\/ask-experts\/topic\/hepb\/vaccine-safety-hepb\/)\n      - [Contraindications & Precautions](https:\/\/www.immunize.org\/ask-experts\/topic\/hepb\/contraindications-precautions-hepb\/)\n      - [Storage & Handling](https:\/\/www.immunize.org\/ask-experts\/topic\/hepb\/storage-handling-hepb\/)\n    - [Hib (*Haemophilus Influenzae* type b)](http:\/\/www.immunize.org\/ask-experts\/topic\/covid-19\/)\n      - [All Hib](https:\/\/www.immunize.org\/ask-experts\/topic\/hib\/)\n      - [Disease Issues](https:\/\/www.immunize.org\/ask-experts\/topic\/hib\/disease-issues-hib\/)\n      - [Vaccine Recommendations](https:\/\/www.immunize.org\/ask-experts\/topic\/hib\/vaccine-recommendations-hib\/)\n      - [Scheduling & Administration](https:\/\/www.immunize.org\/ask-experts\/topic\/hib\/scheduling-administration-hib\/)\n      - [Contraindications & Precautions](https:\/\/www.immunize.org\/ask-experts\/topic\/hib\/contraindications-precautions-hib\/)\n      - [Vaccine Safety](https:\/\/www.immunize.org\/ask-experts\/topic\/hib\/vaccine-safety-hib\/)\n      - [Storage & Handling](https:\/\/www.immunize.org\/ask-experts\/topic\/hib\/storage-handling-hib\/)\n      - [Chemoprophylaxis](https:\/\/www.immunize.org\/ask-experts\/topic\/hib\/chemoprophylaxis\/)\n    - [HPV (Human Papillomavirus)](http:\/\/www.immunize.org\/ask-experts\/topic\/covid-19\/)\n      - [All HPV](https:\/\/www.immunize.org\/ask-experts\/topic\/hpv\/)\n      - [Disease Issues](https:\/\/www.immunize.org\/ask-experts\/topic\/hpv\/disease-issues-hpv\/)\n      - [Vaccine Recommendations](https:\/\/www.immunize.org\/ask-experts\/topic\/hpv\/vaccine-recommendations-hpv\/)\n      - [Scheduling & Administration](https:\/\/www.immunize.org\/ask-experts\/topic\/hpv\/scheduling-administration-hpv\/)\n      - [Contraindications & Precautions](https:\/\/www.immunize.org\/ask-experts\/topic\/hpv\/contraindications-precautions-hpv\/)\n      - [Vaccine Safety](https:\/\/www.immunize.org\/ask-experts\/topic\/hpv\/vaccine-safety-hpv\/)\n      - [Storage & Handling](https:\/\/www.immunize.org\/ask-experts\/topic\/hpv\/storage-handling-hpv\/)\n    - [Influenza](http:\/\/www.immunize.org\/ask-experts\/topic\/covid-19\/)\n      - [All Influenza](https:\/\/www.immunize.org\/ask-experts\/topic\/influenza\/)\n      - [Disease Issues](https:\/\/www.immunize.org\/ask-experts\/topic\/influenza\/disease-issues-influenza\/)\n      - [Vaccine Recommendations](https:\/\/www.immunize.org\/ask-experts\/topic\/influenza\/vaccine-recommendations-influenza\/)\n      - [For Children](https:\/\/www.immunize.org\/ask-experts\/topic\/influenza\/children\/)\n      - [For Special Populations](https:\/\/www.immunize.org\/ask-experts\/topic\/influenza\/special-populations-influenza\/)\n      - [For Healthcare Personnel](https:\/\/www.immunize.org\/ask-experts\/topic\/influenza\/healthcare-personnel-influenza\/)\n      - [Contraindications & Precautions](https:\/\/www.immunize.org\/ask-experts\/topic\/influenza\/contraindications-precautions-influenza\/)\n      - [LAIV Issues](https:\/\/www.immunize.org\/ask-experts\/topic\/influenza\/laiv-issues\/)\n      - [Administering Vaccines](https:\/\/www.immunize.org\/ask-experts\/topic\/influenza\/admin-vaccines-influenza\/)\n      - [Storage & Handling](https:\/\/www.immunize.org\/ask-experts\/topic\/influenza\/storage-handling-influenza\/)\n    - [MMR (Measles, Mumps, and Rubella)](http:\/\/www.immunize.org\/ask-experts\/topic\/covid-19\/)\n      - [All MMR](https:\/\/www.immunize.org\/ask-experts\/topic\/mmr\/)\n      - [Disease Issues](https:\/\/www.immunize.org\/ask-experts\/topic\/mmr\/disease-issues-mmr\/)\n      - [Vaccine Recommendations](https:\/\/www.immunize.org\/ask-experts\/topic\/mmr\/vaccine-recommendations-mmr\/)\n      - [Administering Vaccines](https:\/\/www.immunize.org\/ask-experts\/topic\/mmr\/admin-vaccines-mmr\/)\n      - [Scheduling Vaccines](https:\/\/www.immunize.org\/ask-experts\/topic\/mmr\/scheduling-vaccines-mmr\/)\n      - [For Healthcare Personnel](https:\/\/www.immunize.org\/ask-experts\/topic\/mmr\/for-healthcare-personnel-mmr\/)\n      - [Contraindications & Precautions](https:\/\/www.immunize.org\/ask-experts\/topic\/mmr\/contraindications-precautions-mmr\/)\n      - [Pregnancy & Postpartum](https:\/\/www.immunize.org\/ask-experts\/topic\/mmr\/pregnancy-postpartum-considerations\/)\n      - [Vaccine Safety](https:\/\/www.immunize.org\/ask-experts\/topic\/mmr\/vaccine-safety-mmr\/)\n      - [Storage & Handling](https:\/\/www.immunize.org\/ask-experts\/topic\/mmr\/storage-handling-mmr\/)\n    - [Meningococcal ACWY](http:\/\/www.immunize.org\/ask-experts\/topic\/covid-19\/)\n      - [All MenACWY](https:\/\/www.immunize.org\/ask-experts\/topic\/menacwy\/)\n      - [Disease Issues](https:\/\/www.immunize.org\/ask-experts\/topic\/menacwy\/disease-issues-menacwy\/)\n      - [Vaccine Recommendations](https:\/\/www.immunize.org\/ask-experts\/topic\/menacwy\/vaccine-recommendations-menacwy\/)\n      - [For People with Risk Factors](https:\/\/www.immunize.org\/ask-experts\/topic\/menacwy\/risk-factors\/)\n      - [Booster Doses](https:\/\/www.immunize.org\/ask-experts\/topic\/menacwy\/booster-doses\/)\n      - [Administering Vaccines](https:\/\/www.immunize.org\/ask-experts\/topic\/menacwy\/admin-vaccines-menacwy\/)\n      - [Vaccine Safety](https:\/\/www.immunize.org\/ask-experts\/topic\/menacwy\/vaccine-safety-menacwy\/)\n      - [Contraindications & Precautions](https:\/\/www.immunize.org\/ask-experts\/topic\/menacwy\/contraindications-precautions-menacwy\/)\n      - [Storage & Handling](https:\/\/www.immunize.org\/ask-experts\/topic\/menacwy\/storage-handling-menacwy\/)\n    - [Meningococcal B](http:\/\/www.immunize.org\/ask-experts\/topic\/covid-19\/)\n      - [All Men B](https:\/\/www.immunize.org\/ask-experts\/topic\/menb\/)\n      - [Disease Issues](https:\/\/www.immunize.org\/ask-experts\/topic\/menb\/disease-issues-menb\/)\n      - [Vaccine Recommendations](https:\/\/www.immunize.org\/ask-experts\/topic\/menb\/vaccine-recommendations-menb\/)\n      - [For People with Risk Factors](https:\/\/www.immunize.org\/ask-experts\/topic\/menb\/risk-factors-menb\/)\n      - [Booster Doses](https:\/\/www.immunize.org\/ask-experts\/topic\/menb\/booster-doses-menb\/)\n      - [Administering Vaccines](https:\/\/www.immunize.org\/ask-experts\/topic\/menb\/admin-vaccines-menb\/)\n      - [Vaccine Safety](https:\/\/www.immunize.org\/ask-experts\/topic\/menb\/vaccine-safety-menb\/)\n      - [Contraindications & Precautions](https:\/\/www.immunize.org\/ask-experts\/topic\/menb\/contraindications-precautions-menb\/)\n      - [Storage & Handling](https:\/\/www.immunize.org\/ask-experts\/topic\/menb\/storage-handling-menb\/)\n    - [Pertussis](http:\/\/www.immunize.org\/ask-experts\/topic\/covid-19\/)\n      - [All Pertussis](https:\/\/www.immunize.org\/ask-experts\/topic\/pertussis\/)\n      - [Disease Issues](https:\/\/www.immunize.org\/ask-experts\/topic\/pertussis\/disease-issues-pertussis\/)\n      - [Vaccine Recommendations](https:\/\/www.immunize.org\/ask-experts\/topic\/pertussis\/vaccine-recommendations-pertussis\/)\n      - [Vaccine Products](https:\/\/www.immunize.org\/ask-experts\/topic\/pertussis\/vaccine-products-pertussis\/)\n      - [Tdap for Adolescents & Adults](https:\/\/www.immunize.org\/ask-experts\/topic\/pertussis\/tdap-adolescents-adults-pertussis\/)\n      - [Tdap & Pregnancy](https:\/\/www.immunize.org\/ask-experts\/topic\/pertussis\/tdap-pregnancy-pertussis\/)\n      - [Scheduling Vaccines](https:\/\/www.immunize.org\/ask-experts\/topic\/pertussis\/scheduling-vaccines-pertussis\/)\n      - [Contraindications & Precautions](https:\/\/www.immunize.org\/ask-experts\/topic\/pertussis\/contraindications-precautions-pertussis\/)\n      - [Tetanus & Wound Management](https:\/\/www.immunize.org\/ask-experts\/topic\/pertussis\/tetanus-wound-management-pertussis\/)\n      - [Storage & Handling](https:\/\/www.immunize.org\/ask-experts\/topic\/pertussis\/storage-handling-pertussis\/)\n    - [Pneumococcal](http:\/\/www.immunize.org\/ask-experts\/topic\/covid-19\/)\n      - [All Pneumococcal](https:\/\/www.immunize.org\/ask-experts\/topic\/pneumococcal\/)\n      - [Disease Issues](https:\/\/www.immunize.org\/ask-experts\/topic\/pneumococcal\/disease-issues-pneumococcal\/)\n      - [Vaccine Products](https:\/\/www.immunize.org\/ask-experts\/topic\/pneumococcal\/vaccine-products-pneumococcal\/)\n      - [Recommendations for Children](https:\/\/www.immunize.org\/ask-experts\/topic\/pneumococcal\/recommendations-children\/)\n      - [Recommendations for Adults](https:\/\/www.immunize.org\/ask-experts\/topic\/pneumococcal\/recommendations-adults\/)\n      - [Adults and PCV13](https:\/\/www.immunize.org\/ask-experts\/topic\/pneumococcal\/adults-pcv13\/)\n      - [Miscellaneous Vaccine Issues](https:\/\/www.immunize.org\/ask-experts\/topic\/pneumococcal\/miscellaneous\/)\n      - [Scheduling & Documentation](https:\/\/www.immunize.org\/ask-experts\/topic\/pneumococcal\/scheduling-documentation\/)\n      - [Administering Vaccines](https:\/\/www.immunize.org\/ask-experts\/topic\/pneumococcal\/admin-vaccines-pneumococcal\/)\n      - [Storage & Handling](https:\/\/www.immunize.org\/ask-experts\/topic\/pneumococcal\/storage-handling-pneumococcal\/)\n    - [Polio](https:\/\/www.immunize.org\/ask-experts\/topic\/polio\/)\n    - [Rabies](https:\/\/www.immunize.org\/ask-experts\/topic\/rabies\/)\n    - [Rotavirus](http:\/\/www.immunize.org\/ask-experts\/topic\/covid-19\/)\n      - [All Rotavirus](https:\/\/www.immunize.org\/ask-experts\/topic\/rotavirus\/)\n      - [Disease Issues](https:\/\/www.immunize.org\/ask-experts\/topic\/rotavirus\/disease-issues-rotavirus\/)\n      - [Vaccine Recommendations](https:\/\/www.immunize.org\/ask-experts\/topic\/rotavirus\/vaccine-recommendations-rotavirus\/)\n      - [Scheduling & Administration](https:\/\/www.immunize.org\/ask-experts\/topic\/rotavirus\/scheduling-administration-rotavirus\/)\n      - [Contraindications & Precautions](https:\/\/www.immunize.org\/ask-experts\/topic\/rotavirus\/contraindications-precautions-rotavirus\/)\n      - [Vaccine Safety](https:\/\/www.immunize.org\/ask-experts\/topic\/rotavirus\/vaccine-safety-rotavirus\/)\n      - [Storage & Handling](https:\/\/www.immunize.org\/ask-experts\/topic\/rotavirus\/storage-handling-rotavirus\/)\n    - [RSV (Respiratory Syncytial Virus)](http:\/\/www.immunize.org\/ask-experts\/topic\/covid-19\/)\n      - [All RSV](http:\/\/www.immunize.org\/ask-experts\/topic\/rsv)\n      - [Disease Issues](http:\/\/www.immunize.org\/ask-experts\/topic\/disease-issues-rsv)\n      - [Vaccine Products](http:\/\/www.immunize.org\/ask-experts\/topic\/vaccine-products-rsv)\n      - [Vaccine Recommendations for Older Adults](http:\/\/www.immunize.org\/ask-experts\/topic\/vaccine-recs-adults-rsv)\n      - [Vaccine Recommendations during Pregnancy](http:\/\/www.immunize.org\/ask-experts\/topic\/vaccine-recs-pregnancy-rsv)\n      - [Vaccine Administration](http:\/\/www.immunize.org\/ask-experts\/topic\/vaccine-admin-rsv)\n      - [RSV Preventive Antibody Products](https:\/\/www.immunize.org\/ask-experts\/topic\/rsv\/rsv-preventive-antibody\/)\n      - [RSV mAb Recommendations for Infants](https:\/\/www.immunize.org\/ask-experts\/topic\/rsv\/rsv-preventive-antibody-infants\/)\n      - [RSV mAb Administration](https:\/\/www.immunize.org\/ask-experts\/topic\/rsv\/rsv-preventive-antibody-admin\/)\n      - [Scheduling & Documentation (Vaccines and mAb)](https:\/\/www.immunize.org\/ask-experts\/topic\/rsv\/scheduling-documentation-rsv\/)\n      - [Safety (Vaccines and mAb)](https:\/\/www.immunize.org\/ask-experts\/topic\/rsv\/safety-rsv\/)\n      - [Contraindications & Precautions (Vaccines and mAb)](https:\/\/www.immunize.org\/ask-experts\/topic\/rsv\/contraindication-precautions-rsv\/)\n      - [Storage & Handling (Vaccines and mAb)](https:\/\/www.immunize.org\/ask-experts\/topic\/rsv\/storage-handling-rsv\/)\n    - [Tetanus](http:\/\/www.immunize.org\/ask-experts\/topic\/covid-19\/)\n      - [All Tetanus](https:\/\/www.immunize.org\/ask-experts\/topic\/tetanus\/)\n      - [Disease Issues](https:\/\/www.immunize.org\/ask-experts\/topic\/tetanus\/disease-issues-tetanus\/)\n      - [Vaccine Recommendations](https:\/\/www.immunize.org\/ask-experts\/topic\/tetanus\/vaccine-recommendations-tetanus\/)\n      - [Vaccine Products](https:\/\/www.immunize.org\/ask-experts\/topic\/tetanus\/vaccine-products-tetanus\/)\n      - [Tdap for Adolescents & Adults](https:\/\/www.immunize.org\/ask-experts\/topic\/tetanus\/tdap-adolescents-adults\/)\n      - [Tdap & Pregnancy](https:\/\/www.immunize.org\/ask-experts\/topic\/tetanus\/tdap-pregnancy\/)\n      - [Scheduling Vaccines](https:\/\/www.immunize.org\/ask-experts\/topic\/tetanus\/scheduling-vaccines-tetanus\/)\n      - [Contraindications & Precautions](https:\/\/www.immunize.org\/ask-experts\/topic\/tetanus\/contraindications-precautions-tetanus\/)\n      - [Wound Management](https:\/\/www.immunize.org\/ask-experts\/topic\/tetanus\/wound-management\/)\n      - [Storage & Handling](https:\/\/www.immunize.org\/ask-experts\/topic\/tetanus\/storage-handling-tetanus\/)\n    - [Varicella (Chickenpox)](http:\/\/www.immunize.org\/ask-experts\/topic\/covid-19\/)\n      - [All Varicella](https:\/\/www.immunize.org\/ask-experts\/topic\/varicella\/)\n      - [Disease Issues](https:\/\/www.immunize.org\/ask-experts\/topic\/varicella\/disease-issues-varicella\/)\n      - [Vaccine Recommendations](https:\/\/www.immunize.org\/ask-experts\/topic\/varicella\/vaccine-recommendations-varicella\/)\n      - [Scheduling Vaccines](https:\/\/www.immunize.org\/ask-experts\/topic\/varicella\/scheduling-vaccines-varicella\/)\n      - [Contraindications & Precautions](https:\/\/www.immunize.org\/ask-experts\/topic\/varicella\/contraindications-precautions-varicella\/)\n      - [Vaccine Safety](https:\/\/www.immunize.org\/ask-experts\/topic\/varicella\/vaccine-safety-varicella\/)\n      - [Varicella Zoster Immune Globulin](https:\/\/www.immunize.org\/ask-experts\/topic\/varicella\/varicella-zoster-immune-globulin\/)\n      - [Storage & Handling](https:\/\/www.immunize.org\/ask-experts\/topic\/varicella\/storage-handling-varicella\/)\n    - [Zoster (Shingles)](http:\/\/www.immunize.org\/ask-experts\/topic\/covid-19\/)\n      - [All Zoster](https:\/\/www.immunize.org\/ask-experts\/topic\/zoster\/)\n      - [Disease Issues](https:\/\/www.immunize.org\/ask-experts\/topic\/zoster\/disease-issues-zoster-shingles\/)\n      - [Vaccine Recommendations](https:\/\/www.immunize.org\/ask-experts\/topic\/zoster\/vaccine-recommendations-zoster-shingles\/)\n      - [Immunocompromised Adults](https:\/\/www.immunize.org\/ask-experts\/topic\/zoster\/immunocompromised-adults\/)\n      - [Vaccine Safety](https:\/\/www.immunize.org\/ask-experts\/topic\/zoster\/vaccine-safety-zoster-shingles\/)\n      - [Contraindications & Precautions](https:\/\/www.immunize.org\/ask-experts\/topic\/zoster\/contraindications-precautions-zoster-shingles\/)\n      - [Administering Vaccines](https:\/\/www.immunize.org\/ask-experts\/topic\/zoster\/admin-vaccines-zoster\/)\n      - [Storage & Handling](https:\/\/www.immunize.org\/ask-experts\/topic\/zoster\/storage-handling-zoster-shingles\/)\n  - [General Topics](http:\/\/www.immunize.org\/ask-experts\/topic\/covid-19\/)\n    - [Administering Vaccines](http:\/\/www.immunize.org\/ask-experts\/topic\/covid-19\/)\n      - [All Administering Vaccines](https:\/\/www.immunize.org\/ask-experts\/topic\/admin-vaccines\/)\n      - [General Issues](https:\/\/www.immunize.org\/ask-experts\/topic\/admin-vaccines\/general-issues\/)\n      - [Administration Errors](https:\/\/www.immunize.org\/ask-experts\/topic\/admin-vaccines\/vaccine-admin-errors\/)\n    - [Billing & Reimbursement](https:\/\/www.immunize.org\/ask-experts\/topic\/billing-reimburse\/)\n    - [Combination Vaccines](http:\/\/www.immunize.org\/ask-experts\/topic\/covid-19\/)\n      - [All Combo Vaccines](https:\/\/www.immunize.org\/ask-experts\/topic\/combo-vaccines\/)\n      - [General Issues](https:\/\/www.immunize.org\/ask-experts\/topic\/combo-vaccines\/combo-general\/)\n      - [DTaP-IPV-HepB](https:\/\/www.immunize.org\/ask-experts\/topic\/combo-vaccines\/dtap-ipv-hepb\/)\n      - [DTaP-IPV\/Hib](https:\/\/www.immunize.org\/ask-experts\/topic\/combo-vaccines\/dtap-ipv-hib\/)\n      - [DTaP-IPV-Hib-HepB](https:\/\/www.immunize.org\/ask-experts\/topic\/combo-vaccines\/dtap-ipv-hib-hepb\/)\n      - [DTaP-IPV](https:\/\/www.immunize.org\/ask-experts\/topic\/combo-vaccines\/dtap-ipv\/)\n      - [HepA-HepB](https:\/\/www.immunize.org\/ask-experts\/topic\/combo-vaccines\/hepa-hepb\/)\n      - [MMRV](https:\/\/www.immunize.org\/ask-experts\/topic\/combo-vaccines\/mmrv\/)\n    - [Contraindications & Precautions](https:\/\/www.immunize.org\/ask-experts\/topic\/contraindications-precautions\/)\n    - [Documenting Vaccination](https:\/\/www.immunize.org\/ask-experts\/topic\/documenting-vaccination\/)\n    - [Scheduling Vaccines](https:\/\/www.immunize.org\/ask-experts\/topic\/scheduling-vaccines\/)\n    - [Storage & Handling](http:\/\/www.immunize.org\/ask-experts\/topic\/covid-19\/)\n      - [All Storage & Handling](https:\/\/www.immunize.org\/ask-experts\/topic\/storage-handling\/)\n      - [Vaccine Storage Units](https:\/\/www.immunize.org\/ask-experts\/topic\/storage-handling\/vaccine-storage-units\/)\n      - [Temperature Monitoring & Controls](https:\/\/www.immunize.org\/ask-experts\/topic\/storage-handling\/temperature-monitoring-controls\/)\n      - [Troubleshooting & Follow-Up](https:\/\/www.immunize.org\/ask-experts\/topic\/storage-handling\/troubleshooting-follow-up\/)\n      - [Vaccine Viability & Expiration](https:\/\/www.immunize.org\/ask-experts\/topic\/storage-handling\/vaccine-viability-expiration\/)\n      - [Resources](https:\/\/www.immunize.org\/ask-experts\/topic\/storage-handling\/resources\/)\n    - [Travel Vaccines](https:\/\/www.immunize.org\/ask-experts\/topic\/travel-vaccines\/)\n    - [Vaccine Recommendations](https:\/\/www.immunize.org\/ask-experts\/topic\/vaccine-recs\/)\n    - [Vaccine Safety](https:\/\/www.immunize.org\/ask-experts\/topic\/vaccine-safety\/)\n\n#### On This Page\n- [Search & Filter](http:\/\/www.immunize.org\/ask-experts\/topic\/covid-19\/#offcanvasResponsive)\n- [Back to Top](http:\/\/www.immunize.org\/ask-experts\/topic\/covid-19\/#page)\n\n### Our Affiliated Sites\n[**For the Public:** VaccineInformation.org](https:\/\/vaccineinformation.org\/)\n\n[**For Coalitions:** ImmunizationCoalitions.org](https:\/\/immunizationcoalitions.org\/)\n\n[Let's Get Real Information about pediatric vaccines for parents and providers.](https:\/\/www.letsgetrealaboutvaccines.org\/)\n\n[65+ Flu Defense Protect vulnerable, older adult patients from influenza.](https:\/\/www.influenza-defense.org\/)\n\n[Give2MenACWY.org Improve protection from meningococcal serogroups ACWY.](https:\/\/www.give2menacwy.org\/)\n\n[NAIIS Home of the National Adult and Influenza Immunization Summit.](https:\/\/www.izsummitpartners.org\/)\n\n![](https:\/\/www.immunize.org\/wp-content\/uploads\/icons\/immunize.org-logo-white.svg)\n\nSave Lives. Immunize.\n\n- [“Facebook](https:\/\/facebook.com\/ImmunizeOrg)\n- [“Instagram](https:\/\/instagram.com\/immunizeorg\/)\n- [“YouTube](https:\/\/youtube.com\/user\/ImmunizationAction\/)\n\n#### About\n- [Our Mission](https:\/\/www.immunize.org\/about\/org\/overview\/)\n- [Our People](https:\/\/www.immunize.org\/about\/org\/people\/)\n- [Press Room](https:\/\/www.immunize.org\/about\/media\/press-room\/)\n- [Review Process](https:\/\/www.immunize.org\/content-review\/)\n- [Legal Disclaimer](https:\/\/www.immunize.org\/disclaimer\/)\n- [Privacy Policy](https:\/\/www.immunize.org\/privacy-policy\/)\n\n#### Support Our Work\n- [Shop](https:\/\/shop.immunize.org\/)\n- [Donate](http:\/\/www.immunize.org\/donate\/)\n\n#### Contact\n[Contact us online](http:\/\/www.immunize.org\/about\/org\/contact\/)\n\n2136 Ford Parkway  \n Suite 5011  \n Saint Paul, Minnesota, 55116\n\n**T:** 651-647-9009\n\n**F:** 651-647-9131\n\n#### Subscribe to *IZ Express*\nWeekly news from Immunize.org delivered free to your inbox\n\nThis website is supported in part by a cooperative agreement from the National Center for Immunization and Respiratory Diseases (Grant No. NH23IP922654) at the Centers for Disease Control and Prevention (CDC) in Atlanta, GA. The website content is the sole responsibility of Immunize.org and does not necessarily represent the official views of CDC.\n\nCopyright © 2026 Immunize.org","attrs_readable_markdown":"The COVID-19 questions were last reviewed on November 16, 2025. See CDC’s [Use of COVID-19 Vaccines in the United States Interim Clinical Considerations](https:\/\/www.cdc.gov\/vaccines\/covid-19\/clinical-considerations\/covid-19-vaccines-us.html) for more information. To keep up with the current available COVID-19 resources from CDC, FDA, and Immunize.org, see Immunize.org’s [Checklist of Current Versions of U.S. COVID-19 Vaccine Guidance and Clinic Support Tools](https:\/\/www.immunize.org\/wp-content\/uploads\/catg.d\/p3130.pdf), updated at least monthly. For alerts about new Immunize.org or CDC COVID-19 resources, subscribe to our weekly e-newsletter, [*IZ Express*](https:\/\/www.immunize.org\/subscribe).\n\nResults (89)\n\nCOVID-19 is the name given to the disease caused by infection with the SARS-CoV-2 coronavirus. This virus was first detected as a cause of human illness in late 2019 in Wuhan, China, and triggered a global pandemic that began in 2020. The virus spreads mainly from person to person through respiratory droplets and small particles produced when an infected person coughs, sneezes, or talks. The virus spreads easily in crowded or poorly ventilated indoor settings. Some people who are infected have no symptoms of illness, while the severity of symptomatic illness ranges from mild to life-threatening. Older adults and people of any age with underlying medical conditions are at higher risk for severe illness.\n\nThe incubation period after exposure ranges from 2–14 days, with an average of about 5 days. People with COVID-19 are generally considered potentially infectious up to 48 hours before symptom onset and up to 10 days after onset, though people with severe illness may be infectious longer. Symptoms may include fever or chills, cough, shortness of breath or difficulty breathing, fatigue, muscle or body aches, headache, new loss of taste or smell, sore throat, congestion or runny nose, nausea or vomiting, and diarrhea.\n\nLast reviewed: November 16, 2025\n\nThe list of underlying health conditions and other factors shown to increase the risk of severe COVID-19 illness is long. Advanced age remains the strongest risk factor. In addition to age, CDC states that data has shown that compared to non-Hispanic White people, people from racial and ethnic minority groups are more likely to be infected with SARS-CoV-2. Once infected, people from racial and ethnic minority groups are more likely to be hospitalized, be admitted to the ICU, and die from COVID-19 at younger ages. CDC provides a list of at-risk conditions at this website: [www.cdc.gov\/covid\/hcp\/clinical-care\/underlying-conditions.html](http:\/\/www.cdc.gov\/covid\/hcp\/clinical-care\/underlying-conditions.html). The conditions are stratified by strength of published evidence.\n\nImmunize.org provides an age-appropriate list of high-risk conditions with conclusive or suggestive published evidence as part of each of its standing orders templates for use of 2025-2026 COVID-19 vaccines, all of which may be found on the COVID-19 main page: [www.immunize.org\/vaccines\/a-z\/covid-19\/](http:\/\/www.immunize.org\/vaccines\/a-z\/covid-19\/).\n\nLast reviewed: November 16, 2025\n\nThe CDC has assembled clinical information about COVID-19 at this site: [www.cdc.gov\/covid\/hcp](https:\/\/www.cdc.gov\/covid\/hcp\/).\n\nLast reviewed: November 16, 2025\n\nThe ACIP recommended on September 18, 2025, that all people age 6 months and older in the United States may receive one or more doses of an age-appropriate 2025–2026 Formula COVID-19 vaccination based on individual decision-making, following shared clinical decision-making discussion with a healthcare professional (e.g., a nurse, doctor, or pharmacist). The decision to vaccinate may be influenced by the presence of conditions that increase the risk of severe COVID-19 illness.\n\nProduct options include three FDA-licensed mRNA vaccines: Comirnaty (Pfizer-BioNTech, ages 5 years and older); Spikevax (Moderna, ages 6 months and older); mNexspike (Moderna, ages 12 years and older). There is one FDA-licensed adjuvanted protein subunit vaccine: Nuvaxovid (Sanofi-Novavax, ages 12 years and older). Schedules vary by age and immunocompromised status.\n\nAlthough the FDA licenses limit use of COVID-19 vaccines among recipients younger than age 64 to those with one or more conditions that increases the risk of severe COVID-19, the fact that ACIP did not include any restrictions in its shared clinical decision-making recommendation means that it is an acceptable standard of care for people younger than age 65 without a high risk condition to be vaccinated when desired.\n\nLast reviewed: November 16, 2025\n\nPeople who are moderately or severely immunocompromised are at increased risk for severe COVID-19 illness. ACIP and CDC recommend individual decision-making (also known as shared clinical decision-making) after a discussion with a healthcare professional (nurse, doctor, or pharmacist) for people age 6 months and older who are moderately or severely immunocompromised. They are recommended to receive at least 2 doses during the season. The CDC vaccination schedule for people with moderate or severe immunocompromise is available here: [www.cdc.gov\/covid\/hcp\/vaccine-considerations\/immunocompromised.html](http:\/\/www.cdc.gov\/covid\/hcp\/vaccine-considerations\/immunocompromised.html).\n\nThe Infectious Diseases Society of America (IDSA) strongly recommends administration of age-appropriate 2025–2026 COVID-19 vaccinations to all adults and children with compromised immunity. They also recommend that household members and close contacts of immunocompromised people should be up to date with COVID-19 vaccination. See IDSA recommendations for full details: [www.idsociety.org\/Seasonal-RTI-Vaccinations-in-Immunocompromised-Patients\/](http:\/\/www.idsociety.org\/Seasonal-RTI-Vaccinations-in-Immunocompromised-Patients\/).\n\nLast reviewed: November 16, 2025\n\nIn past seasons, CDC recommended that all doses of COVID-19 vaccine given to children age 6 months through 4 years be from the same manufacturer. However, in the 2025–26 season, only Moderna’s Spikevax mRNA vaccine is licensed and recommended for use in children younger than age 5 years. All children in this age group who are vaccinated against COVID-19 should receive Spikevax, regardless of the brand they received in previous seasons. If the child is age 6 months through 23 months and received an incomplete (1- or 2-dose) initial COVID-19 vaccination series with Pfizer-BioNTech, a 3-dose initial series should be completed with Spikevax. It is not necessary to repeat the initial series.\n\nIn previously unvaccinated people age 5 years or older with moderate or severe immunocompromise, the same manufacturer is recommended for all initial COVID-19 vaccine series doses (either 2 doses of Nuvaxovid \\[if age 12 years or older\\] or 3 doses of an mRNA product). After completion of the initial series, any age-appropriate COVID-19 vaccine may be used in this age group.\n\nCDC sets out conditions when it is acceptable to use an age-appropriate COVID-19 vaccine from a different manufacturer in any situation where the same manufacturer is recommended:\n\n- Same vaccine not available at the time of the clinic visit\n- Previous dose unknown\n- Person would otherwise not receive a recommended vaccine dose\n- Person starts but unable to complete a vaccination series with the same COVID-19 vaccine due to a contraindication\n\nLast reviewed: November 16, 2025\n\nIndividuals with moderate to severe immunocompromise who have completed an initial COVID-19 series should receive two dose of 2025–2026 Formula COVID-19 vaccine this season with the second dose given 6 months later (minimum interval 2 months for Comirnaty, Spikevax, and Nuvaxovid; minimum interval 3 months for mNexspike).\n\nIn previous seasons, CDC recommended that additional doses of COVID-19 vaccine may be administered (with a minimum two-month interval) based on the clinical judgment of the individual’s healthcare provider and the recipient’s personal preference and circumstances. For the 2025–26 season, CDC has removed this general statement from its interim clinical considerations document ([www.cdc.gov\/covid\/hcp\/vaccine-considerations\/immunocompromised.html](http:\/\/www.cdc.gov\/covid\/hcp\/vaccine-considerations\/immunocompromised.html)). The CDC clinical considerations document now states, “On a case-by-case basis, providers caring for these patients may administer Moderna, Novavax, and Pfizer-BioNTech COVID-19 vaccines outside of the FDA and CDC dosing intervals when, based on their clinical judgment, the benefits of vaccination are deemed to outweigh the potential and unknown risks for the recipient who is immunocompromised.”\n\nLast reviewed: November 16, 2025\n\nJanssen (Johnson & Johnson) COVID-19 vaccine is no longer produced. The last remaining doses expired May 7, 2023. The history of Janssen vaccine use is relevant only to evaluation of an adult with moderate or severe immunocompromise because such individuals are recommended to receive an initial series of COVID-19 vaccine. History of a single dose of Janssen COVID-19 vaccine constitutes a complete initial series. A person with this history should follow the vaccination schedule recommended for an immunocompromised person who has already completed an initial vaccination series.\n\nLast reviewed: November 16, 2025\n\nYes. Vaccination should be offered regardless of history of prior SARS-CoV-2 infection or long COVID.\n\nBecause COVID-19 illness temporarily boosts immunity, people who have recently had SARS-CoV-2 infection may consider delaying a 2025–2026 COVID-19 vaccine dose by up to 3 months following symptom onset or positive COVID-19 test (if asymptomatic). Studies have shown that a longer time between infection and vaccination may improve the immune response to vaccination. The likelihood of reinfection in the first few months following infection is low.\n\nA recipient’s individual risks for severe disease and current COVID-19 conditions in the community should be taken into account when deciding whether to delay vaccination up to 3 months after infection. As with all vaccines, vaccination should be deferred until after recovery from moderate to severe illness.\n\nLast reviewed: November 16, 2025\n\nAdults age 65 years and older have the highest rates of hospitalization and death from COVID-19 illness. Protection against severe COVID-19 disease wanes after a few months. Disease surveillance data from the United States shows that SARS-CoV-2 viruses circulate and cause illness at varying levels year-round, with waves of activity observed historically in winter and late summer. It is not known whether this pattern will continue. This pattern is not like influenza, which usually causes a single epidemic wave (sometimes with more than one peak) each winter.\n\nThe 2025 CDC adult immunization schedule shows that adults age 65 years and older who are vaccinated against COVID-19 are recommended to receive a second dose of any 2025–2026 Formula COVID-19 vaccine 6 months after their first 2025–2026 Formula COVID-19 vaccine dose (minimum interval of 2 months for Comirnaty, Spikevax, and Nuvaxovid; minimum interval of 3 months for mNexspike). The second dose does not have to be the same brand as the first.\n\nLast reviewed: November 16, 2025\n\nCDC recommends waiting a minimum of 8 weeks (2 months) since the last 2024–2025 Formula COVID-19 vaccine to receive an age-appropriate 2025–2026 Formula COVID-19 vaccine, if using Comirnaty (Pfizer-BioNTech), Nuvaxovid (Sanofi-Novavax), or Spikevax (Moderna). They recommend a 3-month minimum interval when using mNexspike (Moderna); however, a dose of mNexspike administered at least 2 months after the most recent dose does not need to be repeated.\n\nAny person who initiated a COVID-19 vaccination initial series (e.g., a child 6 months through 23 months of age or a person with moderate or severe immunocompromise) with a previous formulation should follow the age-appropriate recommended schedule for completion of their primary series with the current formulation of the same brand, if feasible. For the 2025–26 season, Spikevax is the only licensed and recommended option for children age 6 through 59 months, regardless of their vaccination history.\n\nLast reviewed: November 16, 2025\n\nUnder section 564 of the Federal Food, Drug, and Cosmetic Act (FD\\&C Act), the FDA Commissioner may allow unapproved medical products or unapproved uses of approved medical products to be used in an emergency to diagnose, treat, or prevent serious or life-threatening diseases or conditions caused by chemical, biological, radiological or nuclear threat agents when there are no adequate, approved, and available alternatives. Vaccines that receive an EUA may later be fully licensed by the FDA.\n\nAll available COVID-19 vaccines were initially administered under EUA. All available 2025–2026 Formula COVID-19 vaccines are fully licensed by FDA and no longer administered under EUA.\n\nLast reviewed: November 16, 2025\n\nBoth the Pfizer-BioNTech COVID-19 Vaccine (Comirnaty) and the Moderna COVID-19 vaccines (Spikevax, mNexspike) are lipid nanoparticle-formulated, nucleoside-modified mRNA vaccines encoding the prefusion spike glycoprotein of SARS-CoV-2, the virus that causes COVID-19. The 2025–2026 formula mRNA vaccines target the Omicron JN.1 variant LP.8.1 strain. Moderna’s mNexspike was first licensed in 2025 for ages 12 years and older. It is designed to reduce the amount of mRNA required to elicit the same or slightly better immune response compared to Spikevax (10 mcg of mRNA versus 50 mcg of mRNA for an adult dose). Spikevax and mNexspike may be used interchangeably when both are age appropriate. Visit this CDC website for more details about how mRNA vaccines work: [www.cdc.gov\/covid\/vaccines\/how-they-work.html](https:\/\/www.cdc.gov\/covid\/vaccines\/how-they-work.html).\n\nLast reviewed: November 16, 2025\n\nSpikevax and mNexspike are both mRNA vaccines targeting the same strain of COVID-19. Spikevax is the original vaccine now licensed down to age 6 months. The mNexspike product is a newer mRNA vaccine licensed for ages 12 years and older with an advanced design that achieves the same or slightly better immune response with less mRNA in each dose (10 mcg in mNexspike compared to 50 mcg in adult doses of Spikevax). The two products may be used interchangeably when age appropriate.\n\nIn adults 65 years and older (and moderately or severely immunocompromised adults) who are recommended to receive a second dose 6 months after their first 2025–2026 formula dose, the minimum interval between the two recommended 2025–26 season doses is 3 months for mNexspike, but only 2 months for the other COVID-19 vaccine products. If mNexspike is inadvertently administered after only 2 months, the dose counts as valid and does not need to be repeated.\n\nLast reviewed: November 16, 2025\n\nLast reviewed: January 9, 2026\n\nIt is estimated that for every million doses administered, about one (~0.0001%) will result in an anaphylactic reaction following vaccination. The estimate for mRNA COVID-19 vaccines is slightly higher, at 2 to 5 anaphylactic reactions per million vaccinations given. With proper screening, most providers who administer thousands of vaccines in their lifetimes will never see an anaphylactic reaction.\n\nLast reviewed: November 16, 2025\n\nThe original COVID-19 vaccines all targeted the spike protein of the original SARS-CoV-2 virus. The 2025–2026 formulation vaccines target the spike proteins of more recently circulating strains, known as the Omicron JN.1 lineage LP.8.1 strain (mRNA vaccines) or the JN.1 strain (Nuvaxovid adjuvanted protein subunit vaccine). The update is intended to boost production of antibodies that protect more effectively against disease caused by currently circulating Omicron subvariants.\n\nThe process of updating the strain without changing anything else is similar to the seasonal strain changes made for influenza vaccinations each year. Vaccine safety, side effects, and risk of allergic reactions are expected to be comparable to earlier formulations of vaccines of the same brand and dose. As with seasonal influenza vaccines, future COVID-19 vaccines can continue to be updated when needed, as the circulating viruses evolve.\n\nLast reviewed: November 16, 2025\n\nNo. The last U.S. doses of Janssen COVID-19 Vaccine expired May 7, 2023.\n\nLast reviewed: November 16, 2025\n\nNuvaxovid is the brand name of the adjuvanted protein subunit COVID-19 vaccine developed by Novavax and commercialized by Sanofi beginning in the 2025–26 season. It contains the Omicron JN.1 subvariant SARS-CoV-2 spike protein and Matrix-M adjuvant. The saponin-based adjuvant is made from extracts of the bark of the Soapbark tree native to Chile. It is added to enhance the immune response of the vaccine recipient. The spike protein is produced in insect cells.\n\nThe 2025–2026 formulation of Nuvaxovid is FDA-licensed for use in people age 12 years or older. It is recommended as a single dose for people age 12 years through 64 years, given at least 8 weeks after the most recent dose of COVID-19 vaccine, regardless of the recipient’s vaccination history. People age 65 years or older and those age 12 years and older who are moderately or severely immunocompromised are recommended to receive 2 doses of 2025–2026 Formula COVID-19 vaccines, 6 months apart (with a minimum interval of 2 months between doses if using Nuvaxovid for both doses).\n\nA 2-dose initial series is recommended for previously unvaccinated recipients who are moderately or severely immunocompromised, with the doses given at least 3 weeks apart. A third dose of any COVID-19 vaccine is recommended 6 months after the initial series is completed (with a minimum interval of 2 months between doses if using Nuvaxovid).\n\nLast reviewed: November 16, 2025\n\nThe benefit of COVID-19 vaccination to an individual patient varies depending on the health status of the patient, their history of vaccination and COVID-19 infection, and the circulating COVID-19 strains. However, despite these variables, observational studies consistently show vaccination in all age groups provides measurable additional protection against hospitalization or death compared to those who are unvaccinated.\n\nCDC published “Interim Estimates of 2024–2025 COVID-19 Vaccine Effectiveness Among Adults Aged ≥18 Years — VISION and IVY Networks, September 2024–January 2025” in MMWR on February 27, 2025 ([www.cdc.gov\/mmwr\/volumes\/74\/wr\/mm7406a1.htm](http:\/\/www.cdc.gov\/mmwr\/volumes\/74\/wr\/mm7406a1.htm)). They concluded vaccine effectiveness (VE) of 2024–2025 COVID-19 vaccine was 33% against COVID-19–associated emergency department (ED) or urgent care (UC) visits among adults age18 years or older and 45%–46% against hospitalizations among immunocompetent adults age 65 years or older, compared with not receiving a 2024–2025 vaccine dose. VE against hospitalizations in immunocompromised adults age 65 years or older was 40%.\n\nLast reviewed: November 16, 2025\n\nCDC and ACIP recommend vaccination of all people age 6 months through 64 years based on individual decision-making (also known as shared clinical decision-making), with an emphasis that the risk-benefit of vaccination is most favorable for individuals who are at an increased risk for severe COVID-19 disease and lowest for individuals who are not at an increased risk, according to the CDC list of COVID-19 risk factors. Refer to CDC’s interim clinical considerations for COVID-19 vaccination for the specific dosing schedule: [www.cdc.gov\/covid\/hcp\/vaccine-considerations\/routine-guidance.html\\#cdc\\_clinical\\_guidance\\_recomm\\_key-table-1-2025–2026-covid-19-vaccination-schedule-november-4-2025](http:\/\/www.cdc.gov\/covid\/hcp\/vaccine-considerations\/routine-guidance.html#cdc_clinical_guidance_recomm_key-table-1-2025%E2%80%932026-covid-19-vaccination-schedule-november-4-2025).\n\nThe American Academy of Pediatrics (AAP) has issued separate COVID-19 vaccination recommendations for children during the 2025–26 season. Refer to the full statement for details of their recommendations: <https:\/\/doi.org\/10.1542\/peds.2025-073924>. In summary, AAP recommends age-appropriate COVID-19 vaccination of the following groups of children:\n\n- All children age 6 months through 23 months\n- Residents of long-term care facilities or other congregate settings\n- Children who have never been vaccinated against COVID-19\n- Infants and children with household contacts who are at high risk for severe COVID-19\n- All children who are at risk of severe COVID-19 due to underlying conditions or treatments, including: chronic pulmonary disease, cardiovascular disease, gastrointestinal disorders, hepatic disease, hematologic disease, metabolic disorders, obesity, neurologic and neurodevelopmental conditions, immunosuppressive conditions, and rheumatologic or autoimmune disease\n- Children age 2 through 18 years not in the above categories whose parent or guardian desires their protection from COVID-19\n\nLast reviewed: November 16, 2025\n\nThis child should receive one dose recommended for his age at the time of the vaccination visit. At age 11 years, an age-appropriate single dose of either Comirnaty (Pfizer-BioNTech) or Spikevax (Moderna) mRNA vaccine is recommended. If the patient arrives in your clinic after turning 12 years old, the 2025–2026 Formula Nuvaxovid (Sanofi-Novavax) protein subunit vaccine and the mNexspike (Moderna) mRNA vaccine are also options.\n\nLast reviewed: November 16, 2025\n\nCDC states that a person who moves to an older age group before completing the initial series recommended for the younger age group should follow the schedule for the older age group and receive the vaccine product and dosage for the older age group. In this case, the child should receive one dose of 2025–2026 Formula Spikevax (Moderna) at least 8 weeks after the most recent dose of COVID-19 vaccine.\n\nAn initial series of COVID-19 vaccine is recommended for children 6 months through 23 months of age. Children 24 months through 59 months of age are recommended to receive only one dose of 2025–2026 Formula Spikevax regardless of their COVID-19 vaccination history.\n\nLast reviewed: November 16, 2025\n\nModerately or severely immunocompromised children who transition from age 11 years to age 12 years during the initial vaccination series should complete the 3-dose series using the dosage for people ages 12 years and older for all doses received once they are age 12 years.\n\nSee [www.cdc.gov\/covid\/hcp\/vaccine-considerations\/immunocompromised.html](http:\/\/www.cdc.gov\/covid\/hcp\/vaccine-considerations\/immunocompromised.html) for additional details.\n\nLast reviewed: November 16, 2025\n\nBoth vaccines have been demonstrated to be safe, with side effects typical of those in older age groups. The most common local reaction in this age group is pain at the injection site; the most common systemic symptom in older children was fatigue and in younger children (6 through 23 months) irritability\/crying and sleepiness were most common. Fever may occur after either vaccination. Febrile seizures can occur in infants and young children ages 6 months through 5 years as a result of any condition that causes a fever (most common with high fevers). Febrile seizures are uncommon after vaccination. Febrile seizures were rare after mRNA COVID-19 vaccine clinical trials in this age group, and CDC continues to monitor for this adverse event following vaccination in infants and young children.\n\nNo cases of myocarditis were reported during the clinical trials for either vaccine. To date, post-authorization surveillance has not detected an increased risk for myocarditis and pericarditis following mRNA COVID-19 vaccination in children ages 6 months–4 years (Pfizer-BioNTech) and ages 6 months–5 years (Moderna).\n\nLast reviewed: November 16, 2025\n\nLast reviewed: November 16, 2025\n\n**Comirnaty** (Pfizer-BioNTech) mRNA COVID-19 vaccine is FDA-licensed for use in ages 5 years through 64 years with at least one underlying condition that puts them at risk for severe COVID-19 infection and individuals 65 years and older\n\n**mNexspike** (Moderna) is FDA-licensed for use in ages 12 through 64 years with at least one underlying condition that puts them at risk for severe COVID-19 infection and individuals 65 years and older\n\n**Nuvaxovid** (Sanofi-Novavax) is FDA-licensed for use in ages 12 through 64 years with at least one underlying condition that puts them at risk for severe COVID-19 infection and individuals 65 years and older\n\n**Spikevax** (Moderna) mRNA COVID-19 vaccine is FDA-licensed for use in ages 6 months through 64 years with at least one underlying condition that puts them at risk for severe COVID-19 infection and individuals 65 years and older\n\nAlthough the FDA licenses are limited in the age group younger than 65 years to those with underlying conditions that put them at risk for severe COVID-19 infection, the ACIP has recommended use based on individual decision-making (i.e., shared clinical decision-making) for all people age 6 months and older. This means that it is acceptable standard of care to offer COVID-19 vaccination to people in this age group without a high-risk condition when vaccination is desired.\n\nLast reviewed: November 16, 2025\n\nClinical trial results for the original monovalent Pfizer-BioNTech COVID-19 Vaccine (administered as a two-dose primary series) demonstrated that among vaccine recipients age 12–15 years, side effects during the 7 days after vaccination were commonly reported (90.9% of vaccine recipients reported a local reaction and 90.7% reported a systemic reaction). Most reactions were mild to moderate. Pain at the injection site was the most common local reaction. One in 10 reported a side effect that interfered with daily activities. Side effects usually resolved after 1–2 days. Systemic side effects (e.g., fever, fatigue, headache, muscle pain) were more commonly reported after the second dose than after the first dose. No specific safety concerns were identified among adolescent vaccine recipients.\n\nThe safety and side effects of the 2025–2026 formula are expected to be consistent with the previous formulations of the product.\n\nLast reviewed: November 16, 2025\n\nThe 2025–2026 formula Nuvaxovid (Sanofi-Novavax) vaccine is an option for any person age 12 years or older who is due for a 2025–2026 updated vaccination. Below are listed the 2025–26 season dosing schedules (if using Nuvaxovid for all doses) for different ages and health conditions:\n\n- Age 12 through 64 years, not moderately or severely immunocompromised: one 2025–2026 formula dose, at least 8 weeks after most recent dose from a previous season\n- Age 65 years and older, not moderately or severely immunocompromised: two 2025–2026 formula doses 6 months apart (minimum interval 2 months)\n- Age 12 years or older, moderately or severely immunocompromised:\n  - Previously unvaccinated: give 2 doses at least 3 weeks apart as an initial series, followed by a third dose about 6 months after dose 2 (minimum interval 2 months)\n  - Previously completed an initial series of any COVID-19 vaccine (2 doses of Novavax protein subunit vaccine or 3 doses of an mRNA vaccine): give first 2025–2026 formula dose at least 8 weeks after most recent COVID-19 vaccine from the previous season, then give a second dose about 6 months later (minimum interval, 2 months)\n\nSee Immunize.org’s standing orders template for administration of 2025–2026 formula adjuvanted protein subunit vaccine to individuals age 12 years and older for details: [www.immunize.org\/wp-content\/uploads\/catg.d\/p3141.pdf](http:\/\/www.immunize.org\/wp-content\/uploads\/catg.d\/p3141.pdf).\n\nLast reviewed: November 16, 2025\n\nYes. Evidence continues to demonstrate that COVID-19 vaccination is safe and effective during any stage of pregnancy; the benefits of vaccination clearly outweigh any known or potential risks of COVID-19 vaccination during pregnancy. The currently licensed COVID-19 vaccines are nonreplicating vaccines and cannot cause infection in either the mother or the fetus. No evidence exists of risk to the fetus from vaccinating during pregnancy with nonreplicating vaccines in general.\n\nData from the Vaccine Adverse Events Reporting System (VAERS), the V-safe surveillance system, and the V-safe pregnancy registry have not signaled any safety concerns related to vaccination during pregnancy for mother or infant.\n\nPregnant women have historically been at an increased risk of severe disease, adverse pregnancy outcomes, and maternal death from COVID-19 infections. ACIP recommends the use of 2025–2026 COVID-19 vaccine during pregnancy based upon individual decision-making (i.e., shared clinical decision-making).\n\nThe American College of Obstetricians and Gynecologists (ACOG) recommends all pregnant women receive any age-appropriate 2025–2026 Formula COVID-19 vaccine if they have not already received one. Current ACOG recommendations are available here: [www.acog.org\/clinical\/clinical-guidance\/practice-advisory\/articles\/2020\/12\/covid-19-vaccination-considerations-for-obstetric-gynecologic-care](http:\/\/www.acog.org\/clinical\/clinical-guidance\/practice-advisory\/articles\/2020\/12\/covid-19-vaccination-considerations-for-obstetric-gynecologic-care).\n\nLast reviewed: November 16, 2025\n\nPregnant women have historically been at an increased risk of severe disease, adverse pregnancy outcomes, and maternal death from COVID-19 infections. Studies have shown that antibodies produced after COVID-19 vaccination during pregnancy are transferred to the newborn, and COVID-19 vaccination during pregnancy reduces the risk of COVID-19 hospitalization in infants younger than 6 months.\n\nACIP recommends the use of 2025–2026 COVID-19 vaccine during pregnancy based upon individual decision-making (i.e., shared clinical decision-making) after a discussion with a nurse, doctor, or pharmacist.\n\nThe American College of Obstetricians and Gynecologists (ACOG) recommends all pregnant women receive any age-appropriate 2025–2026 Formula COVID-19 vaccine if they have not already received one. A person who is up to date on COVID-19 vaccination and becomes pregnant is not recommended to get an additional dose. Current ACOG recommendations are available here: [www.acog.org\/clinical\/clinical-guidance\/practice-advisory\/articles\/2020\/12\/covid-19-vaccination-considerations-for-obstetric-gynecologic-care](http:\/\/www.acog.org\/clinical\/clinical-guidance\/practice-advisory\/articles\/2020\/12\/covid-19-vaccination-considerations-for-obstetric-gynecologic-care).\n\nLast reviewed: November 16, 2025\n\nLast reviewed: January 9, 2026\n\nYes. COVID-19 vaccination may be given during lactation.\n\nLast reviewed: November 16, 2025\n\nPlease see CDC’s Interim Clinical Considerations for the Use of COVID-19 Vaccines for dosage guidance for detailed tables, including dosing intervals and options ([www.cdc.gov\/covid\/hcp\/vaccine-considerations\/immunocompromised.html](http:\/\/www.cdc.gov\/covid\/hcp\/vaccine-considerations\/immunocompromised.html)). You will also find the vaccination schedules for people who are moderately or severely immunocompromised in the Immunize.org standing orders templates for administration of COVID-19 vaccines:\n\n- For ages 6 months through 11 years: [www.immunize.org\/wp-content\/uploads\/catg.d\/p3140a.pdf](http:\/\/www.immunize.org\/wp-content\/uploads\/catg.d\/p3140a.pdf)\n- mRNA vaccines for ages 12 years and older: [www.immunize.org\/wp-content\/uploads\/catg.d\/p3140.pdf](http:\/\/www.immunize.org\/wp-content\/uploads\/catg.d\/p3140.pdf)\n- Protein subunit vaccine for ages 12 years and older: [www.immunize.org\/wp-content\/uploads\/catg.d\/p3141.pdf](http:\/\/www.immunize.org\/wp-content\/uploads\/catg.d\/p3141.pdf)\n\nIn general, people who are moderately or severely immunocompromised and previously unvaccinated are recommended to receive a 2-dose (protein subunit) or 3-dose (mRNA) initial series of COVID-19 vaccine, with an additional dose 6 months later of any age-appropriate COVID-19 brand (minimum interval of 2 months for Nuvaxovid, Spikevax, or Comirnaty; 3-month minimum interval for mNexspike). CDC recommends use of the same manufacturer for all doses of the initial series when feasible. Spikevax and mNexspike are both made by Moderna and are interchangeable in ages 12 years and older.\n\nThose who completed an initial series before the 2025–2026 formula vaccines were available should receive 2 doses of 2025–2026 Formula COVID-19 vaccine (any age-appropriate brand) about 6 months apart (minimum interval of 2 months for Nuvaxovid, Spikevax, or Comirnaty; 3-month minimum interval for mNexspike).\n\nImmunocompromised people should be counseled that they may have a reduced immune response to COVID-19 vaccination. Continuing other infection prevention measures, such as wearing a face mask and avoiding crowds, can help limit their risk of exposure to the SARS-CoV-2 virus.\n\nPemivibart (Pemgarda, Invyvid) is a monoclonal antibody for COVID-19 pre-exposure prophylaxis in people who are moderately or severely immunocompromised and unlikely to mount an adequate immune response to COVID-19 vaccination and who meet the [FDA-authorized conditions for use](https:\/\/www.fda.gov\/media\/177067\/download?attachment). See additional information from CDC at the immunocompromised link in the first paragraph.\n\nLast reviewed: November 16, 2025\n\nThe conditions and treatments that CDC specifies may result in moderate or severe immunocompromise include *but are not limited to*:\n\n- Active treatment for solid tumor and hematologic malignancies\n- Hematologic malignancies associated with poor responses to COVID-19 vaccines regardless of current treatment status (e.g., chronic lymphocytic leukemia, non-Hodgkin lymphoma, multiple myeloma, acute leukemia)\n- Receipt of solid-organ transplant or an islet transplant and taking immunosuppressive therapy\n- Receipt of chimeric antigen receptor (CAR)-T-cell therapy or hematopoietic cell transplant (HCT) (within 2 years of transplantation or taking immunosuppressive therapy)\n- Moderate or severe primary immunodeficiency (e.g., common variable immunodeficiency disease, severe combined immunodeficiency, DiGeorge syndrome, Wiskott-Aldrich syndrome)\n- Advanced HIV infection (people with HIV and CD4 cell counts less than 200\/mm³, history of an AIDS-defining illness without immune reconstitution, or clinical manifestations of symptomatic HIV) or untreated HIV infection\n- Active treatment with high-dose corticosteroids (i.e., 20 mg or more of prednisone or equivalent per day when administered for 2 or more weeks), alkylating agents, antimetabolites, transplant-related immunosuppressive drugs, cancer chemotherapeutic agents classified as severely immunosuppressive, tumor necrosis factor (TNF) blockers, and other biologic agents that are immunosuppressive or immunomodulatory (e.g., B-cell-depleting agents)\n\nAdditional factors to consider in assessing the general level of immune competence in a patient include disease severity, duration, clinical stability, complications, comorbidities, and any potentially immune-suppressing treatment. A patient’s clinical care team is in the best position to evaluate the degree of immunocompromise and timing of vaccination.\n\nSee CDC’s interim clinical considerations for this population: [www.cdc.gov\/covid\/hcp\/vaccine-considerations\/immunocompromised.html](http:\/\/www.cdc.gov\/covid\/hcp\/vaccine-considerations\/immunocompromised.html).\n\nLast reviewed: November 16, 2025\n\nYes. See revaccination considerations at [www.cdc.gov\/covid\/hcp\/vaccine-considerations\/immunocompromised.html](http:\/\/www.cdc.gov\/covid\/hcp\/vaccine-considerations\/immunocompromised.html). This is the most current statement from CDC on COVID-19 revaccination:\n\nRecipients of chimeric antigen receptor (CAR)-T-cell therapy or hematopoietic cell transplant (HCT) who received 1 or more doses of COVID-19 vaccine prior to or during treatment should be revaccinated. Revaccination should start at least 3 months (12 weeks) after transplant or CAR-T-cell therapy and should follow the currently recommended schedule for people who are unvaccinated.\n\nRevaccination may also be considered for patients who received 1 or more doses of COVID-19 vaccine during treatment with B-cell-depleting therapies (e.g., rituximab, ocrelizumab) that were administered over a limited period (e.g., as part of a treatment regimen for certain malignancies) according to the currently recommended schedule for people who are unvaccinated. The suggested interval to start revaccination is about 6 months after completion of the B-cell-depleting therapy. Timing of vaccination for patients who receive B-cell-depleting therapies on a continuing basis (e.g., for treatment of certain autoimmune conditions such as rheumatoid arthritis or multiple sclerosis) is addressed in CDC’s [considerations for timing of COVID-19 vaccination in relation to immunosuppressive therapies](https:\/\/www.cdc.gov\/covid\/hcp\/vaccine-considerations\/immunocompromised.html#cdc_cg_special_populations_about-considerations-for-timing-of-covid-19-vaccination-in-relation-to-immunosuppressive-therapies).\n\nCDC continues to recommend that a patient’s clinical team is best positioned to determine the degree of immune compromise, need for revaccination, and appropriate timing of revaccination.\n\nLast reviewed: November 16, 2025\n\nAccording to CDC’s interim clinical considerations for the use of COVID-19 vaccines, whenever possible, COVID-19 vaccines should be administered at least 2 weeks before initiation or resumption of immunosuppressive therapies. For patients who receive B-cell-depleting therapies on a continuing basis, COVID-19 vaccines should be administered approximately 4 weeks before the next scheduled therapy.\n\nCDC also notes that timing of COVID-19 vaccination should take into consideration current or planned immunosuppressive therapies, optimization of both the patient’s medical condition and response to vaccination, and individual benefits and risks. Review the CDC’s considerations for COVID-19 vaccination of those on immunosuppressive therapies here: [www.cdc.gov\/covid\/hcp\/vaccine-considerations\/immunocompromised.html\\#cdc\\_cg\\_special\\_populations\\_about-considerations-for-timing-of-covid-19-vaccination-in-relation-to-immunosuppressive-therapies](http:\/\/www.cdc.gov\/covid\/hcp\/vaccine-considerations\/immunocompromised.html#cdc_cg_special_populations_about-considerations-for-timing-of-covid-19-vaccination-in-relation-to-immunosuppressive-therapies).\n\nOn a case-by-case basis, providers caring for these patients may administer COVID-19 vaccines outside of the FDA and CDC dosing schedules based on their clinical judgment of what is most beneficial to the patient.\n\nLast reviewed: November 16, 2025\n\nCDC states that no additional medical documentation is required before administering COVID-19 vaccine. The patient’s self-attestation of a high-risk condition, including moderate or severe immunocompromise, is sufficient. Those who report moderate or severe immunocompromise should be offered the modified schedule for people with moderate or severe immunocompromise. Vaccinators should not deny COVID-19 vaccination to a person due to lack of documentation of a self-reported high-risk condition.\n\nLast reviewed: November 16, 2025\n\nLast reviewed: January 9, 2026\n\nImmunocompromised people who need an initial series of 3 doses of mRNA COVID-19 vaccine or two doses of Nuvaxovid (Sanofi-Novavax) adjuvanted protein COVID-19 vaccine should receive the initial series using COVID-19 vaccines from the same manufacturer, unless it is not feasible. If the same manufacturer cannot be used for all primary series doses (e.g., the brand is unavailable at the time of the vaccination visit, the previous brand is unknown, or the patient would not be vaccinated with the previous brand due to a contraindication or other reason), then administer another age-appropriate brand. Spikevax (Moderna) is the only licensed 2025–2026 Formula COVID-19 vaccine option for children younger than age 5 years. If the immunocompromised recipient is age 5 years or older, once the initial series is complete, any appropriate brand may be used for all subsequent doses. Spikevax and mNexspike are interchangeable: both vaccines are made by Moderna.\n\nLast reviewed: November 16, 2025\n\nThe patient’s initial series is considered complete following a single dose of the Janssen COVID-19 Vaccine. People who are moderately or severely immunocompromised and have completed an initial series (no matter how long ago) should now receive 1 dose of an age-appropriate 2025–2026 Formula COVID-19 vaccine (at least 8 weeks after their most recent dose of a previous formulation). They should receive a second 2025–2026 Formula COVID-19 vaccine dose 6 months later (minimum interval 2 months for Comirnaty, Spikevax, and Nuvaxovid; minimum interval of 3 months if using mNexspike).\n\nLast reviewed: November 16, 2025\n\nThe patient should receive a 2025–2026 COVID-19 mRNA dose now, of the same manufacturer as the initial two doses (if feasible), in order to complete the 3-dose initial mRNA vaccine series recommended for people with moderate or severe immunocompromise. Advise the patient that he should receive an additional 2025–2026 Formula COVID-19 dose of any brand in 6 months (minimum interval 2 months if using Comirnaty, Spikevax, or Nuvaxovid; minimum interval 3 months if using mNexspike).\n\nLast reviewed: November 16, 2025\n\nAll COVID-19 vaccines are administered intramuscularly. Preparation details and dose volume vary by product. Most 2025-2026 formula products are now available in manufacturer-filled syringes.\n\nLast reviewed: November 16, 2025\n\nYes. CDC published an appendix to its interim clinical considerations for the use of COVID-19 vaccines to address a wide range of errors in vaccine administration. It includes a detailed table outlining actions to take after an error has occurred: [www.cdc.gov\/covid\/hcp\/vaccine-considerations\/appendices.html](http:\/\/www.cdc.gov\/covid\/hcp\/vaccine-considerations\/appendices.html).\n\nCategories of errors covered in the CDC table include:\n\n- Site\/route\n- Age\n- Product and dosage\n- Storage and handling\n- Incorrect intervals\n- Interchanging product types when not recommended\n\nAsk the Experts refers our readers to this CDC table for the most current and comprehensive guidance on COVID-19 vaccine administration errors and how to manage them. For all vaccine administration errors the following steps are recommended: inform the patient of the error, report the error to VAERS ([https:\/\/vaers.hhs.gov](https:\/\/vaers.hhs.gov\/)) unless CDC’s guidance states that the error does not need to be reported, evaluate why the error occurred, and implement strategies to prevent future errors.\n\nLast reviewed: November 16, 2025\n\nNo. CDC does not recommend repeating the dose of any COVID-19 vaccine in circumstances where the dose is administered in an incorrect route or an incorrect site (i.e., not in the deltoid or anterolateral thigh). In the case of a subcutaneous injection, the patient should be advised of the possibility of self-limited local or systemic side effects.\n\nLast reviewed: November 16, 2025\n\nProviding a vaccine recipient with a COVID-19 vaccine VIS is recommended by CDC but not required. The requirement to provide the VIS to a patient is present only when a vaccine is included in the federal Vaccine Injury Compensation Program (VICP). COVID-19 vaccines are not included in the VICP at this time. The current official VIS and all available translations are available from Immunize.org: [www.immunize.org\/vaccines\/vis\/covid-19\/](http:\/\/www.immunize.org\/vaccines\/vis\/covid-19\/).\n\nLast reviewed: November 16, 2025\n\nLast reviewed: January 9, 2026\n\nPeriodically verify whether you are using the most current available documents by checking Immunize.org’s regularly updated Checklist of Current Versions of U.S. COVID-19 Vaccination Guidance and Clinic Support Tools: [www.immunize.org\/catg.d\/p3130.pdf](http:\/\/www.immunize.org\/catg.d\/p3130.pdf). This resource is updated as needed with the dates of the most currently available materials from CDC and FDA.\n\nInformation from CDC is generally updated first on the CDC web page: Interim Clinical Considerations for Use of COVID-19 Vaccines in the United States: ([www.cdc.gov\/covid\/hcp\/vaccine-considerations\/index.html](http:\/\/www.cdc.gov\/covid\/hcp\/vaccine-considerations\/index.html)).\n\nLast reviewed: November 16, 2025\n\nNo. Simply administer the next dose that is currently recommended, using a vaccine from the same manufacturer, if feasible, even if previous doses in the series were an earlier formulation.\n\nLast reviewed: November 16, 2025\n\nCDC guidance allows for doses given up to 4 days before the recommended interval to be counted as valid – such doses do not need to be repeated. However, people should not be routinely scheduled to receive a dose earlier than recommended. Schedulers should offer appointments beginning on the date of the recommended interval or later.\n\nLast reviewed: November 16, 2025\n\nBeginning with the 2025–2026 season, a single dose of 2025–2026 Formula Nuvaxovid adjuvanted protein COVID-19 vaccine is recommended for all recipients age 12 through 64 years who are not moderately or severely immunocompromised, regardless of their vaccination history. Those age 65 years or older are recommended to receive a second dose of any 2025–2026 Formula COVID-19 vaccine 6 months after the first 2025–2026 Formula dose (minimum interval 2 months if using Comirnaty, Spikevax, or Nuvaxovid; minimum interval 3 months if using mNexspike).\n\nLast reviewed: November 16, 2025\n\nAn asymptomatic person who is scheduled for COVID-19 vaccination and is exposed to SARS-CoV-2 virus may be vaccinated. COVID-19 vaccination after exposure is not recommended as post-exposure prophylaxis, so vaccination should not be expected to prevent illness caused by past exposure. A person who is currently sick with a respiratory virus should defer vaccination until at least the recovery from the acute illness, and consider additional measures to prevent infecting others, in accordance with current CDC guidance. Healthcare facilities may have specific policies in place to reduce the risk of spread of respiratory viruses to healthcare staff and other patients.\n\nPeople who recently had SARS-CoV-2 infection and are due for a COVID-19 vaccine may consider delaying the dose by up to 3 months from symptom onset or positive test (if infection was asymptomatic). According to CDC, increasing the time between infection and vaccination may result in an improved immune response to vaccination. There is a low risk of reinfection in the weeks following an infection. A recipient’s individual risks for severe disease and current COVID-19 conditions in the community should be taken into consideration when deciding whether to delay vaccination up to 3 months after infection.\n\nLast reviewed: November 16, 2025\n\nRoutine administration of all age-appropriate doses of vaccines at the same visit, also known as coadministration, is acceptable for children, adolescents, and adults if there are no contraindications at the time of the healthcare visit. COVID-19 vaccine may also be coadministered with nirsevimab or clesrovimab (RSV preventive antibody for infants), given in different syringes and at different anatomical sites. COVID-19 vaccines may also be given at any interval before or after any other vaccination.\n\nThere are special considerations for orthopoxvirus vaccination. There is no required minimum interval between receiving a dose of any COVID-19 vaccine and an orthopoxvirus vaccine, either Jynneos or ACAM2000 vaccine (e.g., for mpox prevention), regardless of which vaccine is administered first. However, use of Jynneos vaccine should be prioritized over ACAM2000 when co-administering a COVID-19 vaccine and an orthopoxvirus vaccine.\n\nPeople, particularly adolescent or young adult males, who are recommended to be vaccinated against both mpox and COVID-19 might consider waiting 4 weeks between vaccines. This is because of the observed risk for myocarditis and pericarditis after receipt of ACAM2000 orthopoxvirus vaccine and COVID-19 vaccines, and the hypothetical risk for myocarditis and pericarditis after Jynneos vaccine. However, if a patient’s risk for mpox or severe disease due to COVID-19 is increased, administration of mpox and COVID-19 vaccines should not be delayed.\n\nLast reviewed: November 16, 2025\n\nYour patient may choose to receive the vaccines at the same visit or separately, without regard to the timing interval.\n\nWhen multiple vaccines are administered at a single visit, administer each injection in a different syringe and at a different injection site. For adolescents and adults, the deltoid muscle may be used for more than one injection, though injection sites should be at least one inch apart. It is generally preferable to administer reactogenic vaccines such as Shingrix and COVID-19 vaccine in different arms. However, if the patient prefers both injections in the same deltoid, that is also acceptable.\n\nImmunize.org has developed a one-page guide to administering multiple intramuscular vaccinations to an adult at one visit: [www.immunize.org\/catg.d\/p2030.pdf](http:\/\/www.immunize.org\/catg.d\/p2030.pdf).\n\nLast reviewed: November 16, 2025\n\nThe timing of CDC-recommended vaccination is unaffected by the receipt of COVID-19 monoclonal antibodies or convalescent plasma.\n\nLast reviewed: November 16, 2025\n\nThis page was updated on January 9, 2026 .","meta_canonical":null}

3. Robots.txt Check

Query:

Response:

4. Spam/Ban Check

Query:

Response:

5. Seen Status Check

ℹ️ Skipped - page is already crawled

📄

INDEXABLE

✅

CRAWLED

1 day ago

🤖

ROBOTS ALLOWED

Page Info Filters

Filter	Status	Condition	Details
HTTP status	PASS	`download_http_code = 200`	HTTP 200
Age cutoff	PASS	`download_stamp > now() - 6 MONTH`	0 months ago
History drop	PASS	`isNull(history_drop_reason)`	No drop reason
Spam/ban	PASS	`fh_dont_index != 1 AND ml_spam_score = 0`	ml_spam_score=0
Canonical	PASS	`meta_canonical IS NULL OR = '' OR = src_unparsed`	Not set

Page Details

Property	Value
URL	http://www.immunize.org/ask-experts/topic/covid-19/
Last Crawled	2026-04-17 12:09:56 (1 day ago)
First Indexed	2024-09-04 16:25:28 (1 year ago)
HTTP Status Code	200
Meta Title	Ask The Experts About Vaccines: COVID-19 \| Immunize.org
Meta Description	Read answers by medical experts to healthcare provider questions on vaccines and COVID-19.
Meta Canonical	null
Boilerpipe Text	The COVID-19 questions were last reviewed on November 16, 2025. See CDC’s Use of COVID-19 Vaccines in the United States Interim Clinical Considerations for more information. To keep up with the current available COVID-19 resources from CDC, FDA, and Immunize.org, see Immunize.org’s Checklist of Current Versions of U.S. COVID-19 Vaccine Guidance and Clinic Support Tools , updated at least monthly. For alerts about new Immunize.org or CDC COVID-19 resources, subscribe to our weekly e-newsletter, IZ Express . Results (89) COVID-19 is the name given to the disease caused by infection with the SARS-CoV-2 coronavirus. This virus was first detected as a cause of human illness in late 2019 in Wuhan, China, and triggered a global pandemic that began in 2020. The virus spreads mainly from person to person through respiratory droplets and small particles produced when an infected person coughs, sneezes, or talks. The virus spreads easily in crowded or poorly ventilated indoor settings. Some people who are infected have no symptoms of illness, while the severity of symptomatic illness ranges from mild to life-threatening. Older adults and people of any age with underlying medical conditions are at higher risk for severe illness. The incubation period after exposure ranges from 2–14 days, with an average of about 5 days. People with COVID-19 are generally considered potentially infectious up to 48 hours before symptom onset and up to 10 days after onset, though people with severe illness may be infectious longer. Symptoms may include fever or chills, cough, shortness of breath or difficulty breathing, fatigue, muscle or body aches, headache, new loss of taste or smell, sore throat, congestion or runny nose, nausea or vomiting, and diarrhea. Last reviewed: November 16, 2025 The list of underlying health conditions and other factors shown to increase the risk of severe COVID-19 illness is long. Advanced age remains the strongest risk factor. In addition to age, CDC states that data has shown that compared to non-Hispanic White people, people from racial and ethnic minority groups are more likely to be infected with SARS-CoV-2. Once infected, people from racial and ethnic minority groups are more likely to be hospitalized, be admitted to the ICU, and die from COVID-19 at younger ages. CDC provides a list of at-risk conditions at this website: www.cdc.gov/covid/hcp/clinical-care/underlying-conditions.html . The conditions are stratified by strength of published evidence. Immunize.org provides an age-appropriate list of high-risk conditions with conclusive or suggestive published evidence as part of each of its standing orders templates for use of 2025-2026 COVID-19 vaccines, all of which may be found on the COVID-19 main page: www.immunize.org/vaccines/a-z/covid-19/ . Last reviewed: November 16, 2025 The CDC has assembled clinical information about COVID-19 at this site: www.cdc.gov/covid/hcp . Last reviewed: November 16, 2025 The ACIP recommended on September 18, 2025, that all people age 6 months and older in the United States may receive one or more doses of an age-appropriate 2025–2026 Formula COVID-19 vaccination based on individual decision-making, following shared clinical decision-making discussion with a healthcare professional (e.g., a nurse, doctor, or pharmacist). The decision to vaccinate may be influenced by the presence of conditions that increase the risk of severe COVID-19 illness. Product options include three FDA-licensed mRNA vaccines: Comirnaty (Pfizer-BioNTech, ages 5 years and older); Spikevax (Moderna, ages 6 months and older); mNexspike (Moderna, ages 12 years and older). There is one FDA-licensed adjuvanted protein subunit vaccine: Nuvaxovid (Sanofi-Novavax, ages 12 years and older). Schedules vary by age and immunocompromised status. Although the FDA licenses limit use of COVID-19 vaccines among recipients younger than age 64 to those with one or more conditions that increases the risk of severe COVID-19, the fact that ACIP did not include any restrictions in its shared clinical decision-making recommendation means that it is an acceptable standard of care for people younger than age 65 without a high risk condition to be vaccinated when desired. Last reviewed: November 16, 2025 People who are moderately or severely immunocompromised are at increased risk for severe COVID-19 illness. ACIP and CDC recommend individual decision-making (also known as shared clinical decision-making) after a discussion with a healthcare professional (nurse, doctor, or pharmacist) for people age 6 months and older who are moderately or severely immunocompromised. They are recommended to receive at least 2 doses during the season. The CDC vaccination schedule for people with moderate or severe immunocompromise is available here: www.cdc.gov/covid/hcp/vaccine-considerations/immunocompromised.html . The Infectious Diseases Society of America (IDSA) strongly recommends administration of age-appropriate 2025–2026 COVID-19 vaccinations to all adults and children with compromised immunity. They also recommend that household members and close contacts of immunocompromised people should be up to date with COVID-19 vaccination. See IDSA recommendations for full details: www.idsociety.org/Seasonal-RTI-Vaccinations-in-Immunocompromised-Patients/ . Last reviewed: November 16, 2025 In past seasons, CDC recommended that all doses of COVID-19 vaccine given to children age 6 months through 4 years be from the same manufacturer. However, in the 2025–26 season, only Moderna’s Spikevax mRNA vaccine is licensed and recommended for use in children younger than age 5 years. All children in this age group who are vaccinated against COVID-19 should receive Spikevax, regardless of the brand they received in previous seasons. If the child is age 6 months through 23 months and received an incomplete (1- or 2-dose) initial COVID-19 vaccination series with Pfizer-BioNTech, a 3-dose initial series should be completed with Spikevax. It is not necessary to repeat the initial series. In previously unvaccinated people age 5 years or older with moderate or severe immunocompromise, the same manufacturer is recommended for all initial COVID-19 vaccine series doses (either 2 doses of Nuvaxovid [if age 12 years or older] or 3 doses of an mRNA product). After completion of the initial series, any age-appropriate COVID-19 vaccine may be used in this age group. CDC sets out conditions when it is acceptable to use an age-appropriate COVID-19 vaccine from a different manufacturer in any situation where the same manufacturer is recommended: Same vaccine not available at the time of the clinic visit Previous dose unknown Person would otherwise not receive a recommended vaccine dose Person starts but unable to complete a vaccination series with the same COVID-19 vaccine due to a contraindication Last reviewed: November 16, 2025 Individuals with moderate to severe immunocompromise who have completed an initial COVID-19 series should receive two dose of 2025–2026 Formula COVID-19 vaccine this season with the second dose given 6 months later (minimum interval 2 months for Comirnaty, Spikevax, and Nuvaxovid; minimum interval 3 months for mNexspike). In previous seasons, CDC recommended that additional doses of COVID-19 vaccine may be administered (with a minimum two-month interval) based on the clinical judgment of the individual’s healthcare provider and the recipient’s personal preference and circumstances. For the 2025–26 season, CDC has removed this general statement from its interim clinical considerations document ( www.cdc.gov/covid/hcp/vaccine-considerations/immunocompromised.html ). The CDC clinical considerations document now states, “On a case-by-case basis, providers caring for these patients may administer Moderna, Novavax, and Pfizer-BioNTech COVID-19 vaccines outside of the FDA and CDC dosing intervals when, based on their clinical judgment, the benefits of vaccination are deemed to outweigh the potential and unknown risks for the recipient who is immunocompromised.” Last reviewed: November 16, 2025 Janssen (Johnson & Johnson) COVID-19 vaccine is no longer produced. The last remaining doses expired May 7, 2023. The history of Janssen vaccine use is relevant only to evaluation of an adult with moderate or severe immunocompromise because such individuals are recommended to receive an initial series of COVID-19 vaccine. History of a single dose of Janssen COVID-19 vaccine constitutes a complete initial series. A person with this history should follow the vaccination schedule recommended for an immunocompromised person who has already completed an initial vaccination series. Last reviewed: November 16, 2025 Yes. Vaccination should be offered regardless of history of prior SARS-CoV-2 infection or long COVID. Because COVID-19 illness temporarily boosts immunity, people who have recently had SARS-CoV-2 infection may consider delaying a 2025–2026 COVID-19 vaccine dose by up to 3 months following symptom onset or positive COVID-19 test (if asymptomatic). Studies have shown that a longer time between infection and vaccination may improve the immune response to vaccination. The likelihood of reinfection in the first few months following infection is low. A recipient’s individual risks for severe disease and current COVID-19 conditions in the community should be taken into account when deciding whether to delay vaccination up to 3 months after infection. As with all vaccines, vaccination should be deferred until after recovery from moderate to severe illness. Last reviewed: November 16, 2025 Adults age 65 years and older have the highest rates of hospitalization and death from COVID-19 illness. Protection against severe COVID-19 disease wanes after a few months. Disease surveillance data from the United States shows that SARS-CoV-2 viruses circulate and cause illness at varying levels year-round, with waves of activity observed historically in winter and late summer. It is not known whether this pattern will continue. This pattern is not like influenza, which usually causes a single epidemic wave (sometimes with more than one peak) each winter. The 2025 CDC adult immunization schedule shows that adults age 65 years and older who are vaccinated against COVID-19 are recommended to receive a second dose of any 2025–2026 Formula COVID-19 vaccine 6 months after their first 2025–2026 Formula COVID-19 vaccine dose (minimum interval of 2 months for Comirnaty, Spikevax, and Nuvaxovid; minimum interval of 3 months for mNexspike). The second dose does not have to be the same brand as the first. Last reviewed: November 16, 2025 CDC recommends waiting a minimum of 8 weeks (2 months) since the last 2024–2025 Formula COVID-19 vaccine to receive an age-appropriate 2025–2026 Formula COVID-19 vaccine, if using Comirnaty (Pfizer-BioNTech), Nuvaxovid (Sanofi-Novavax), or Spikevax (Moderna). They recommend a 3-month minimum interval when using mNexspike (Moderna); however, a dose of mNexspike administered at least 2 months after the most recent dose does not need to be repeated. Any person who initiated a COVID-19 vaccination initial series (e.g., a child 6 months through 23 months of age or a person with moderate or severe immunocompromise) with a previous formulation should follow the age-appropriate recommended schedule for completion of their primary series with the current formulation of the same brand, if feasible. For the 2025–26 season, Spikevax is the only licensed and recommended option for children age 6 through 59 months, regardless of their vaccination history. Last reviewed: November 16, 2025 Under section 564 of the Federal Food, Drug, and Cosmetic Act (FD&C Act), the FDA Commissioner may allow unapproved medical products or unapproved uses of approved medical products to be used in an emergency to diagnose, treat, or prevent serious or life-threatening diseases or conditions caused by chemical, biological, radiological or nuclear threat agents when there are no adequate, approved, and available alternatives. Vaccines that receive an EUA may later be fully licensed by the FDA. All available COVID-19 vaccines were initially administered under EUA. All available 2025–2026 Formula COVID-19 vaccines are fully licensed by FDA and no longer administered under EUA. Last reviewed: November 16, 2025 Both the Pfizer-BioNTech COVID-19 Vaccine (Comirnaty) and the Moderna COVID-19 vaccines (Spikevax, mNexspike) are lipid nanoparticle-formulated, nucleoside-modified mRNA vaccines encoding the prefusion spike glycoprotein of SARS-CoV-2, the virus that causes COVID-19. The 2025–2026 formula mRNA vaccines target the Omicron JN.1 variant LP.8.1 strain. Moderna’s mNexspike was first licensed in 2025 for ages 12 years and older. It is designed to reduce the amount of mRNA required to elicit the same or slightly better immune response compared to Spikevax (10 mcg of mRNA versus 50 mcg of mRNA for an adult dose). Spikevax and mNexspike may be used interchangeably when both are age appropriate. Visit this CDC website for more details about how mRNA vaccines work: www.cdc.gov/covid/vaccines/how-they-work.html . Last reviewed: November 16, 2025 Spikevax and mNexspike are both mRNA vaccines targeting the same strain of COVID-19. Spikevax is the original vaccine now licensed down to age 6 months. The mNexspike product is a newer mRNA vaccine licensed for ages 12 years and older with an advanced design that achieves the same or slightly better immune response with less mRNA in each dose (10 mcg in mNexspike compared to 50 mcg in adult doses of Spikevax). The two products may be used interchangeably when age appropriate. In adults 65 years and older (and moderately or severely immunocompromised adults) who are recommended to receive a second dose 6 months after their first 2025–2026 formula dose, the minimum interval between the two recommended 2025–26 season doses is 3 months for mNexspike, but only 2 months for the other COVID-19 vaccine products. If mNexspike is inadvertently administered after only 2 months, the dose counts as valid and does not need to be repeated. Last reviewed: November 16, 2025 Last reviewed: January 9, 2026 It is estimated that for every million doses administered, about one (~0.0001%) will result in an anaphylactic reaction following vaccination. The estimate for mRNA COVID-19 vaccines is slightly higher, at 2 to 5 anaphylactic reactions per million vaccinations given. With proper screening, most providers who administer thousands of vaccines in their lifetimes will never see an anaphylactic reaction. Last reviewed: November 16, 2025 The original COVID-19 vaccines all targeted the spike protein of the original SARS-CoV-2 virus. The 2025–2026 formulation vaccines target the spike proteins of more recently circulating strains, known as the Omicron JN.1 lineage LP.8.1 strain (mRNA vaccines) or the JN.1 strain (Nuvaxovid adjuvanted protein subunit vaccine). The update is intended to boost production of antibodies that protect more effectively against disease caused by currently circulating Omicron subvariants. The process of updating the strain without changing anything else is similar to the seasonal strain changes made for influenza vaccinations each year. Vaccine safety, side effects, and risk of allergic reactions are expected to be comparable to earlier formulations of vaccines of the same brand and dose. As with seasonal influenza vaccines, future COVID-19 vaccines can continue to be updated when needed, as the circulating viruses evolve. Last reviewed: November 16, 2025 No. The last U.S. doses of Janssen COVID-19 Vaccine expired May 7, 2023. Last reviewed: November 16, 2025 Nuvaxovid is the brand name of the adjuvanted protein subunit COVID-19 vaccine developed by Novavax and commercialized by Sanofi beginning in the 2025–26 season. It contains the Omicron JN.1 subvariant SARS-CoV-2 spike protein and Matrix-M adjuvant. The saponin-based adjuvant is made from extracts of the bark of the Soapbark tree native to Chile. It is added to enhance the immune response of the vaccine recipient. The spike protein is produced in insect cells. The 2025–2026 formulation of Nuvaxovid is FDA-licensed for use in people age 12 years or older. It is recommended as a single dose for people age 12 years through 64 years, given at least 8 weeks after the most recent dose of COVID-19 vaccine, regardless of the recipient’s vaccination history. People age 65 years or older and those age 12 years and older who are moderately or severely immunocompromised are recommended to receive 2 doses of 2025–2026 Formula COVID-19 vaccines, 6 months apart (with a minimum interval of 2 months between doses if using Nuvaxovid for both doses). A 2-dose initial series is recommended for previously unvaccinated recipients who are moderately or severely immunocompromised, with the doses given at least 3 weeks apart. A third dose of any COVID-19 vaccine is recommended 6 months after the initial series is completed (with a minimum interval of 2 months between doses if using Nuvaxovid). Last reviewed: November 16, 2025 The benefit of COVID-19 vaccination to an individual patient varies depending on the health status of the patient, their history of vaccination and COVID-19 infection, and the circulating COVID-19 strains. However, despite these variables, observational studies consistently show vaccination in all age groups provides measurable additional protection against hospitalization or death compared to those who are unvaccinated. CDC published “Interim Estimates of 2024–2025 COVID-19 Vaccine Effectiveness Among Adults Aged ≥18 Years — VISION and IVY Networks, September 2024–January 2025” in MMWR on February 27, 2025 ( www.cdc.gov/mmwr/volumes/74/wr/mm7406a1.htm ). They concluded vaccine effectiveness (VE) of 2024–2025 COVID-19 vaccine was 33% against COVID-19–associated emergency department (ED) or urgent care (UC) visits among adults age18 years or older and 45%–46% against hospitalizations among immunocompetent adults age 65 years or older, compared with not receiving a 2024–2025 vaccine dose. VE against hospitalizations in immunocompromised adults age 65 years or older was 40%. Last reviewed: November 16, 2025 CDC and ACIP recommend vaccination of all people age 6 months through 64 years based on individual decision-making (also known as shared clinical decision-making), with an emphasis that the risk-benefit of vaccination is most favorable for individuals who are at an increased risk for severe COVID-19 disease and lowest for individuals who are not at an increased risk, according to the CDC list of COVID-19 risk factors. Refer to CDC’s interim clinical considerations for COVID-19 vaccination for the specific dosing schedule: www.cdc.gov/covid/hcp/vaccine-considerations/routine-guidance.html#cdc_clinical_guidance_recomm_key-table-1-2025–2026-covid-19-vaccination-schedule-november-4-2025 . The American Academy of Pediatrics (AAP) has issued separate COVID-19 vaccination recommendations for children during the 2025–26 season. Refer to the full statement for details of their recommendations: https://doi.org/10.1542/peds.2025-073924 . In summary, AAP recommends age-appropriate COVID-19 vaccination of the following groups of children: All children age 6 months through 23 months Residents of long-term care facilities or other congregate settings Children who have never been vaccinated against COVID-19 Infants and children with household contacts who are at high risk for severe COVID-19 All children who are at risk of severe COVID-19 due to underlying conditions or treatments, including: chronic pulmonary disease, cardiovascular disease, gastrointestinal disorders, hepatic disease, hematologic disease, metabolic disorders, obesity, neurologic and neurodevelopmental conditions, immunosuppressive conditions, and rheumatologic or autoimmune disease Children age 2 through 18 years not in the above categories whose parent or guardian desires their protection from COVID-19 Last reviewed: November 16, 2025 This child should receive one dose recommended for his age at the time of the vaccination visit. At age 11 years, an age-appropriate single dose of either Comirnaty (Pfizer-BioNTech) or Spikevax (Moderna) mRNA vaccine is recommended. If the patient arrives in your clinic after turning 12 years old, the 2025–2026 Formula Nuvaxovid (Sanofi-Novavax) protein subunit vaccine and the mNexspike (Moderna) mRNA vaccine are also options. Last reviewed: November 16, 2025 CDC states that a person who moves to an older age group before completing the initial series recommended for the younger age group should follow the schedule for the older age group and receive the vaccine product and dosage for the older age group. In this case, the child should receive one dose of 2025–2026 Formula Spikevax (Moderna) at least 8 weeks after the most recent dose of COVID-19 vaccine. An initial series of COVID-19 vaccine is recommended for children 6 months through 23 months of age. Children 24 months through 59 months of age are recommended to receive only one dose of 2025–2026 Formula Spikevax regardless of their COVID-19 vaccination history. Last reviewed: November 16, 2025 Moderately or severely immunocompromised children who transition from age 11 years to age 12 years during the initial vaccination series should complete the 3-dose series using the dosage for people ages 12 years and older for all doses received once they are age 12 years. See www.cdc.gov/covid/hcp/vaccine-considerations/immunocompromised.html for additional details. Last reviewed: November 16, 2025 Both vaccines have been demonstrated to be safe, with side effects typical of those in older age groups. The most common local reaction in this age group is pain at the injection site; the most common systemic symptom in older children was fatigue and in younger children (6 through 23 months) irritability/crying and sleepiness were most common. Fever may occur after either vaccination. Febrile seizures can occur in infants and young children ages 6 months through 5 years as a result of any condition that causes a fever (most common with high fevers). Febrile seizures are uncommon after vaccination. Febrile seizures were rare after mRNA COVID-19 vaccine clinical trials in this age group, and CDC continues to monitor for this adverse event following vaccination in infants and young children. No cases of myocarditis were reported during the clinical trials for either vaccine. To date, post-authorization surveillance has not detected an increased risk for myocarditis and pericarditis following mRNA COVID-19 vaccination in children ages 6 months–4 years (Pfizer-BioNTech) and ages 6 months–5 years (Moderna). Last reviewed: November 16, 2025 Last reviewed: November 16, 2025 Comirnaty (Pfizer-BioNTech) mRNA COVID-19 vaccine is FDA-licensed for use in ages 5 years through 64 years with at least one underlying condition that puts them at risk for severe COVID-19 infection and individuals 65 years and older mNexspike (Moderna) is FDA-licensed for use in ages 12 through 64 years with at least one underlying condition that puts them at risk for severe COVID-19 infection and individuals 65 years and older Nuvaxovid (Sanofi-Novavax) is FDA-licensed for use in ages 12 through 64 years with at least one underlying condition that puts them at risk for severe COVID-19 infection and individuals 65 years and older Spikevax (Moderna) mRNA COVID-19 vaccine is FDA-licensed for use in ages 6 months through 64 years with at least one underlying condition that puts them at risk for severe COVID-19 infection and individuals 65 years and older Although the FDA licenses are limited in the age group younger than 65 years to those with underlying conditions that put them at risk for severe COVID-19 infection, the ACIP has recommended use based on individual decision-making (i.e., shared clinical decision-making) for all people age 6 months and older. This means that it is acceptable standard of care to offer COVID-19 vaccination to people in this age group without a high-risk condition when vaccination is desired. Last reviewed: November 16, 2025 Clinical trial results for the original monovalent Pfizer-BioNTech COVID-19 Vaccine (administered as a two-dose primary series) demonstrated that among vaccine recipients age 12–15 years, side effects during the 7 days after vaccination were commonly reported (90.9% of vaccine recipients reported a local reaction and 90.7% reported a systemic reaction). Most reactions were mild to moderate. Pain at the injection site was the most common local reaction. One in 10 reported a side effect that interfered with daily activities. Side effects usually resolved after 1–2 days. Systemic side effects (e.g., fever, fatigue, headache, muscle pain) were more commonly reported after the second dose than after the first dose. No specific safety concerns were identified among adolescent vaccine recipients. The safety and side effects of the 2025–2026 formula are expected to be consistent with the previous formulations of the product. Last reviewed: November 16, 2025 The 2025–2026 formula Nuvaxovid (Sanofi-Novavax) vaccine is an option for any person age 12 years or older who is due for a 2025–2026 updated vaccination. Below are listed the 2025–26 season dosing schedules (if using Nuvaxovid for all doses) for different ages and health conditions: Age 12 through 64 years, not moderately or severely immunocompromised: one 2025–2026 formula dose, at least 8 weeks after most recent dose from a previous season Age 65 years and older, not moderately or severely immunocompromised: two 2025–2026 formula doses 6 months apart (minimum interval 2 months) Age 12 years or older, moderately or severely immunocompromised: Previously unvaccinated: give 2 doses at least 3 weeks apart as an initial series, followed by a third dose about 6 months after dose 2 (minimum interval 2 months) Previously completed an initial series of any COVID-19 vaccine (2 doses of Novavax protein subunit vaccine or 3 doses of an mRNA vaccine): give first 2025–2026 formula dose at least 8 weeks after most recent COVID-19 vaccine from the previous season, then give a second dose about 6 months later (minimum interval, 2 months) See Immunize.org’s standing orders template for administration of 2025–2026 formula adjuvanted protein subunit vaccine to individuals age 12 years and older for details: www.immunize.org/wp-content/uploads/catg.d/p3141.pdf . Last reviewed: November 16, 2025 Yes. Evidence continues to demonstrate that COVID-19 vaccination is safe and effective during any stage of pregnancy; the benefits of vaccination clearly outweigh any known or potential risks of COVID-19 vaccination during pregnancy. The currently licensed COVID-19 vaccines are nonreplicating vaccines and cannot cause infection in either the mother or the fetus. No evidence exists of risk to the fetus from vaccinating during pregnancy with nonreplicating vaccines in general. Data from the Vaccine Adverse Events Reporting System (VAERS), the V-safe surveillance system, and the V-safe pregnancy registry have not signaled any safety concerns related to vaccination during pregnancy for mother or infant. Pregnant women have historically been at an increased risk of severe disease, adverse pregnancy outcomes, and maternal death from COVID-19 infections. ACIP recommends the use of 2025–2026 COVID-19 vaccine during pregnancy based upon individual decision-making (i.e., shared clinical decision-making). The American College of Obstetricians and Gynecologists (ACOG) recommends all pregnant women receive any age-appropriate 2025–2026 Formula COVID-19 vaccine if they have not already received one. Current ACOG recommendations are available here: www.acog.org/clinical/clinical-guidance/practice-advisory/articles/2020/12/covid-19-vaccination-considerations-for-obstetric-gynecologic-care . Last reviewed: November 16, 2025 Pregnant women have historically been at an increased risk of severe disease, adverse pregnancy outcomes, and maternal death from COVID-19 infections. Studies have shown that antibodies produced after COVID-19 vaccination during pregnancy are transferred to the newborn, and COVID-19 vaccination during pregnancy reduces the risk of COVID-19 hospitalization in infants younger than 6 months. ACIP recommends the use of 2025–2026 COVID-19 vaccine during pregnancy based upon individual decision-making (i.e., shared clinical decision-making) after a discussion with a nurse, doctor, or pharmacist. The American College of Obstetricians and Gynecologists (ACOG) recommends all pregnant women receive any age-appropriate 2025–2026 Formula COVID-19 vaccine if they have not already received one. A person who is up to date on COVID-19 vaccination and becomes pregnant is not recommended to get an additional dose. Current ACOG recommendations are available here: www.acog.org/clinical/clinical-guidance/practice-advisory/articles/2020/12/covid-19-vaccination-considerations-for-obstetric-gynecologic-care . Last reviewed: November 16, 2025 Last reviewed: January 9, 2026 Yes. COVID-19 vaccination may be given during lactation. Last reviewed: November 16, 2025 Please see CDC’s Interim Clinical Considerations for the Use of COVID-19 Vaccines for dosage guidance for detailed tables, including dosing intervals and options ( www.cdc.gov/covid/hcp/vaccine-considerations/immunocompromised.html ). You will also find the vaccination schedules for people who are moderately or severely immunocompromised in the Immunize.org standing orders templates for administration of COVID-19 vaccines: For ages 6 months through 11 years: www.immunize.org/wp-content/uploads/catg.d/p3140a.pdf mRNA vaccines for ages 12 years and older: www.immunize.org/wp-content/uploads/catg.d/p3140.pdf Protein subunit vaccine for ages 12 years and older: www.immunize.org/wp-content/uploads/catg.d/p3141.pdf In general, people who are moderately or severely immunocompromised and previously unvaccinated are recommended to receive a 2-dose (protein subunit) or 3-dose (mRNA) initial series of COVID-19 vaccine, with an additional dose 6 months later of any age-appropriate COVID-19 brand (minimum interval of 2 months for Nuvaxovid, Spikevax, or Comirnaty; 3-month minimum interval for mNexspike). CDC recommends use of the same manufacturer for all doses of the initial series when feasible. Spikevax and mNexspike are both made by Moderna and are interchangeable in ages 12 years and older. Those who completed an initial series before the 2025–2026 formula vaccines were available should receive 2 doses of 2025–2026 Formula COVID-19 vaccine (any age-appropriate brand) about 6 months apart (minimum interval of 2 months for Nuvaxovid, Spikevax, or Comirnaty; 3-month minimum interval for mNexspike). Immunocompromised people should be counseled that they may have a reduced immune response to COVID-19 vaccination. Continuing other infection prevention measures, such as wearing a face mask and avoiding crowds, can help limit their risk of exposure to the SARS-CoV-2 virus. Pemivibart (Pemgarda, Invyvid) is a monoclonal antibody for COVID-19 pre-exposure prophylaxis in people who are moderately or severely immunocompromised and unlikely to mount an adequate immune response to COVID-19 vaccination and who meet the FDA-authorized conditions for use . See additional information from CDC at the immunocompromised link in the first paragraph. Last reviewed: November 16, 2025 The conditions and treatments that CDC specifies may result in moderate or severe immunocompromise include but are not limited to : Active treatment for solid tumor and hematologic malignancies Hematologic malignancies associated with poor responses to COVID-19 vaccines regardless of current treatment status (e.g., chronic lymphocytic leukemia, non-Hodgkin lymphoma, multiple myeloma, acute leukemia) Receipt of solid-organ transplant or an islet transplant and taking immunosuppressive therapy Receipt of chimeric antigen receptor (CAR)-T-cell therapy or hematopoietic cell transplant (HCT) (within 2 years of transplantation or taking immunosuppressive therapy) Moderate or severe primary immunodeficiency (e.g., common variable immunodeficiency disease, severe combined immunodeficiency, DiGeorge syndrome, Wiskott-Aldrich syndrome) Advanced HIV infection (people with HIV and CD4 cell counts less than 200/mm³, history of an AIDS-defining illness without immune reconstitution, or clinical manifestations of symptomatic HIV) or untreated HIV infection Active treatment with high-dose corticosteroids (i.e., 20 mg or more of prednisone or equivalent per day when administered for 2 or more weeks), alkylating agents, antimetabolites, transplant-related immunosuppressive drugs, cancer chemotherapeutic agents classified as severely immunosuppressive, tumor necrosis factor (TNF) blockers, and other biologic agents that are immunosuppressive or immunomodulatory (e.g., B-cell-depleting agents) Additional factors to consider in assessing the general level of immune competence in a patient include disease severity, duration, clinical stability, complications, comorbidities, and any potentially immune-suppressing treatment. A patient’s clinical care team is in the best position to evaluate the degree of immunocompromise and timing of vaccination. See CDC’s interim clinical considerations for this population: www.cdc.gov/covid/hcp/vaccine-considerations/immunocompromised.html . Last reviewed: November 16, 2025 Yes. See revaccination considerations at www.cdc.gov/covid/hcp/vaccine-considerations/immunocompromised.html . This is the most current statement from CDC on COVID-19 revaccination: Recipients of chimeric antigen receptor (CAR)-T-cell therapy or hematopoietic cell transplant (HCT) who received 1 or more doses of COVID-19 vaccine prior to or during treatment should be revaccinated. Revaccination should start at least 3 months (12 weeks) after transplant or CAR-T-cell therapy and should follow the currently recommended schedule for people who are unvaccinated. Revaccination may also be considered for patients who received 1 or more doses of COVID-19 vaccine during treatment with B-cell-depleting therapies (e.g., rituximab, ocrelizumab) that were administered over a limited period (e.g., as part of a treatment regimen for certain malignancies) according to the currently recommended schedule for people who are unvaccinated. The suggested interval to start revaccination is about 6 months after completion of the B-cell-depleting therapy. Timing of vaccination for patients who receive B-cell-depleting therapies on a continuing basis (e.g., for treatment of certain autoimmune conditions such as rheumatoid arthritis or multiple sclerosis) is addressed in CDC’s considerations for timing of COVID-19 vaccination in relation to immunosuppressive therapies . CDC continues to recommend that a patient’s clinical team is best positioned to determine the degree of immune compromise, need for revaccination, and appropriate timing of revaccination. Last reviewed: November 16, 2025 According to CDC’s interim clinical considerations for the use of COVID-19 vaccines, whenever possible, COVID-19 vaccines should be administered at least 2 weeks before initiation or resumption of immunosuppressive therapies. For patients who receive B-cell-depleting therapies on a continuing basis, COVID-19 vaccines should be administered approximately 4 weeks before the next scheduled therapy. CDC also notes that timing of COVID-19 vaccination should take into consideration current or planned immunosuppressive therapies, optimization of both the patient’s medical condition and response to vaccination, and individual benefits and risks. Review the CDC’s considerations for COVID-19 vaccination of those on immunosuppressive therapies here: www.cdc.gov/covid/hcp/vaccine-considerations/immunocompromised.html#cdc_cg_special_populations_about-considerations-for-timing-of-covid-19-vaccination-in-relation-to-immunosuppressive-therapies . On a case-by-case basis, providers caring for these patients may administer COVID-19 vaccines outside of the FDA and CDC dosing schedules based on their clinical judgment of what is most beneficial to the patient. Last reviewed: November 16, 2025 CDC states that no additional medical documentation is required before administering COVID-19 vaccine. The patient’s self-attestation of a high-risk condition, including moderate or severe immunocompromise, is sufficient. Those who report moderate or severe immunocompromise should be offered the modified schedule for people with moderate or severe immunocompromise. Vaccinators should not deny COVID-19 vaccination to a person due to lack of documentation of a self-reported high-risk condition. Last reviewed: November 16, 2025 Last reviewed: January 9, 2026 Immunocompromised people who need an initial series of 3 doses of mRNA COVID-19 vaccine or two doses of Nuvaxovid (Sanofi-Novavax) adjuvanted protein COVID-19 vaccine should receive the initial series using COVID-19 vaccines from the same manufacturer, unless it is not feasible. If the same manufacturer cannot be used for all primary series doses (e.g., the brand is unavailable at the time of the vaccination visit, the previous brand is unknown, or the patient would not be vaccinated with the previous brand due to a contraindication or other reason), then administer another age-appropriate brand. Spikevax (Moderna) is the only licensed 2025–2026 Formula COVID-19 vaccine option for children younger than age 5 years. If the immunocompromised recipient is age 5 years or older, once the initial series is complete, any appropriate brand may be used for all subsequent doses. Spikevax and mNexspike are interchangeable: both vaccines are made by Moderna. Last reviewed: November 16, 2025 The patient’s initial series is considered complete following a single dose of the Janssen COVID-19 Vaccine. People who are moderately or severely immunocompromised and have completed an initial series (no matter how long ago) should now receive 1 dose of an age-appropriate 2025–2026 Formula COVID-19 vaccine (at least 8 weeks after their most recent dose of a previous formulation). They should receive a second 2025–2026 Formula COVID-19 vaccine dose 6 months later (minimum interval 2 months for Comirnaty, Spikevax, and Nuvaxovid; minimum interval of 3 months if using mNexspike). Last reviewed: November 16, 2025 The patient should receive a 2025–2026 COVID-19 mRNA dose now, of the same manufacturer as the initial two doses (if feasible), in order to complete the 3-dose initial mRNA vaccine series recommended for people with moderate or severe immunocompromise. Advise the patient that he should receive an additional 2025–2026 Formula COVID-19 dose of any brand in 6 months (minimum interval 2 months if using Comirnaty, Spikevax, or Nuvaxovid; minimum interval 3 months if using mNexspike). Last reviewed: November 16, 2025 All COVID-19 vaccines are administered intramuscularly. Preparation details and dose volume vary by product. Most 2025-2026 formula products are now available in manufacturer-filled syringes. Last reviewed: November 16, 2025 Yes. CDC published an appendix to its interim clinical considerations for the use of COVID-19 vaccines to address a wide range of errors in vaccine administration. It includes a detailed table outlining actions to take after an error has occurred: www.cdc.gov/covid/hcp/vaccine-considerations/appendices.html . Categories of errors covered in the CDC table include: Site/route Age Product and dosage Storage and handling Incorrect intervals Interchanging product types when not recommended Ask the Experts refers our readers to this CDC table for the most current and comprehensive guidance on COVID-19 vaccine administration errors and how to manage them. For all vaccine administration errors the following steps are recommended: inform the patient of the error, report the error to VAERS ( https://vaers.hhs.gov ) unless CDC’s guidance states that the error does not need to be reported, evaluate why the error occurred, and implement strategies to prevent future errors. Last reviewed: November 16, 2025 No. CDC does not recommend repeating the dose of any COVID-19 vaccine in circumstances where the dose is administered in an incorrect route or an incorrect site (i.e., not in the deltoid or anterolateral thigh). In the case of a subcutaneous injection, the patient should be advised of the possibility of self-limited local or systemic side effects. Last reviewed: November 16, 2025 Providing a vaccine recipient with a COVID-19 vaccine VIS is recommended by CDC but not required. The requirement to provide the VIS to a patient is present only when a vaccine is included in the federal Vaccine Injury Compensation Program (VICP). COVID-19 vaccines are not included in the VICP at this time. The current official VIS and all available translations are available from Immunize.org: www.immunize.org/vaccines/vis/covid-19/ . Last reviewed: November 16, 2025 Last reviewed: January 9, 2026 Periodically verify whether you are using the most current available documents by checking Immunize.org’s regularly updated Checklist of Current Versions of U.S. COVID-19 Vaccination Guidance and Clinic Support Tools: www.immunize.org/catg.d/p3130.pdf . This resource is updated as needed with the dates of the most currently available materials from CDC and FDA. Information from CDC is generally updated first on the CDC web page: Interim Clinical Considerations for Use of COVID-19 Vaccines in the United States: ( www.cdc.gov/covid/hcp/vaccine-considerations/index.html ). Last reviewed: November 16, 2025 No. Simply administer the next dose that is currently recommended , using a vaccine from the same manufacturer, if feasible , even if previous doses in the series were an earlier formulation . Last reviewed: November 16, 2025 CDC guidance allows for doses given up to 4 days before the recommended interval to be counted as valid – such doses do not need to be repeated. However, people should not be routinely scheduled to receive a dose earlier than recommended. Schedulers should offer appointments beginning on the date of the recommended interval or later. Last reviewed: November 16, 2025 Beginning with the 2025–2026 season, a single dose of 2025–2026 Formula Nuvaxovid adjuvanted protein COVID-19 vaccine is recommended for all recipients age 12 through 64 years who are not moderately or severely immunocompromised, regardless of their vaccination history. Those age 65 years or older are recommended to receive a second dose of any 2025–2026 Formula COVID-19 vaccine 6 months after the first 2025–2026 Formula dose (minimum interval 2 months if using Comirnaty, Spikevax, or Nuvaxovid; minimum interval 3 months if using mNexspike). Last reviewed: November 16, 2025 An asymptomatic person who is scheduled for COVID-19 vaccination and is exposed to SARS-CoV-2 virus may be vaccinated. COVID-19 vaccination after exposure is not recommended as post-exposure prophylaxis, so vaccination should not be expected to prevent illness caused by past exposure. A person who is currently sick with a respiratory virus should defer vaccination until at least the recovery from the acute illness, and consider additional measures to prevent infecting others, in accordance with current CDC guidance. Healthcare facilities may have specific policies in place to reduce the risk of spread of respiratory viruses to healthcare staff and other patients. People who recently had SARS-CoV-2 infection and are due for a COVID-19 vaccine may consider delaying the dose by up to 3 months from symptom onset or positive test (if infection was asymptomatic). According to CDC, increasing the time between infection and vaccination may result in an improved immune response to vaccination. There is a low risk of reinfection in the weeks following an infection. A recipient’s individual risks for severe disease and current COVID-19 conditions in the community should be taken into consideration when deciding whether to delay vaccination up to 3 months after infection. Last reviewed: November 16, 2025 Routine administration of all age-appropriate doses of vaccines at the same visit, also known as coadministration, is acceptable for children, adolescents, and adults if there are no contraindications at the time of the healthcare visit. COVID-19 vaccine may also be coadministered with nirsevimab or clesrovimab (RSV preventive antibody for infants), given in different syringes and at different anatomical sites. COVID-19 vaccines may also be given at any interval before or after any other vaccination. There are special considerations for orthopoxvirus vaccination. There is no required minimum interval between receiving a dose of any COVID-19 vaccine and an orthopoxvirus vaccine, either Jynneos or ACAM2000 vaccine (e.g., for mpox prevention), regardless of which vaccine is administered first. However, use of Jynneos vaccine should be prioritized over ACAM2000 when co-administering a COVID-19 vaccine and an orthopoxvirus vaccine. People, particularly adolescent or young adult males, who are recommended to be vaccinated against both mpox and COVID-19 might consider waiting 4 weeks between vaccines. This is because of the observed risk for myocarditis and pericarditis after receipt of ACAM2000 orthopoxvirus vaccine and COVID-19 vaccines, and the hypothetical risk for myocarditis and pericarditis after Jynneos vaccine. However, if a patient’s risk for mpox or severe disease due to COVID-19 is increased, administration of mpox and COVID-19 vaccines should not be delayed. Last reviewed: November 16, 2025 Your patient may choose to receive the vaccines at the same visit or separately, without regard to the timing interval. When multiple vaccines are administered at a single visit, administer each injection in a different syringe and at a different injection site. For adolescents and adults, the deltoid muscle may be used for more than one injection, though injection sites should be at least one inch apart. It is generally preferable to administer reactogenic vaccines such as Shingrix and COVID-19 vaccine in different arms. However, if the patient prefers both injections in the same deltoid, that is also acceptable. Immunize.org has developed a one-page guide to administering multiple intramuscular vaccinations to an adult at one visit: www.immunize.org/catg.d/p2030.pdf . Last reviewed: November 16, 2025 The timing of CDC-recommended vaccination is unaffected by the receipt of COVID-19 monoclonal antibodies or convalescent plasma. Last reviewed: November 16, 2025 This page was updated on January 9, 2026 .
Markdown	[Skip to content](http://www.immunize.org/ask-experts/topic/covid-19/#primary) [![Immunize.org Logo](https://www.immunize.org/wp-content/uploads/Immunize.svg)](https://www.immunize.org/) - [IZ Express](https://www.immunize.org/news/iz-express/about/) - [Shop](https://shop.immunize.org/) - [Donate](https://www.immunize.org/donate/) - [Guide](https://www.immunize.org/guide/) - [Vaccines & VISs]() - [Vaccines A-ZOur immunization resources organized by vaccine]() - - - [Adenovirus](https://www.immunize.org/vaccines/a-z/adenovirus/) - [Anthrax](https://www.immunize.org/vaccines/a-z/anthrax/) - [BCG](https://www.immunize.org/vaccines/a-z/bcg/) - [Chikungunya](https://www.immunize.org/vaccines/a-z/chikungunya/) - [Cholera](https://www.immunize.org/vaccines/a-z/cholera/) - [COVID-19](https://www.immunize.org/vaccines/a-z/covid-19/) - [Dengue](https://www.immunize.org/vaccines/a-z/dengue/) - [Diphtheria](https://www.immunize.org/vaccines/a-z/diphtheria/) - [Ebola](https://www.immunize.org/vaccines/a-z/ebola/) - [Hepatitis A](https://www.immunize.org/vaccines/a-z/hepa/) - [Hepatitis B](https://www.immunize.org/vaccines/a-z/hepb/) - [Hib (Haemophilus Influenzae type b)](https://www.immunize.org/vaccines/a-z/hib/) - - [HPV (Human Papillomavirus)](https://www.immunize.org/vaccines/a-z/hpv/) - [Influenza](https://www.immunize.org/vaccines/a-z/influenza/) - [Japanese Encephalitis](https://www.immunize.org/vaccines/a-z/japanese-encephalitis/) - [Measles](https://www.immunize.org/vaccines/a-z/measles/) - [Meningococcal ACWY](https://www.immunize.org/vaccines/a-z/menacwy/) - [Meningococcal B](https://www.immunize.org/vaccines/a-z/menb/) - [Mpox](https://www.immunize.org/vaccines/a-z/mpox/) - [Mumps](https://www.immunize.org/vaccines/a-z/mumps/) - [Pertussis](https://www.immunize.org/vaccines/a-z/pertussis/) - [Pneumococcal](https://www.immunize.org/vaccines/a-z/pneumococcal/) - [Polio](https://www.immunize.org/vaccines/a-z/polio/) - - [Rabies](https://www.immunize.org/vaccines/a-z/rabies/) - [Rotavirus](https://www.immunize.org/vaccines/a-z/rotavirus/) - [RSV (Respiratory Syncytial Virus)](https://www.immunize.org/vaccines/a-z/rsv/) - [Rubella](https://www.immunize.org/vaccines/a-z/rubella/) - [Smallpox](https://www.immunize.org/vaccines/a-z/smallpox/) - [TBE (Tick-borne Encephalitis)](https://www.immunize.org/vaccines/a-z/tbe/) - [Tetanus](https://www.immunize.org/vaccines/a-z/tetanus/) - [Typhoid](https://www.immunize.org/vaccines/a-z/typhoid/) - [Varicella (Chickenpox)](https://www.immunize.org/vaccines/a-z/varicella/) - [Yellow Fever](https://www.immunize.org/vaccines/a-z/yellow-fever/) - [Zoster (Shingles)](https://www.immunize.org/vaccines/a-z/zoster/) - [VISsAccess current Vaccine Information Statements from CDC]() - - - [VISs Overview](https://www.immunize.org/vaccines/vis/about-vis/) - [VIS-Related Resources](http://www.immunize.org/clinical/topic/vis/) - [Translations](https://www.immunize.org/translations/) - [Adenovirus](https://www.immunize.org/vaccines/vis/adenovirus/) - [Anthrax](https://www.immunize.org/vaccines/vis/anthrax/) - [Cholera](https://www.immunize.org/vaccines/vis/cholera/) - [COVID-19](https://www.immunize.org/vaccines/vis/covid-19/) - [Dengue](https://www.immunize.org/vaccines/vis/dengue/) - [DTaP (Diphtheria, Tetanus, Pertussis)](https://www.immunize.org/vaccines/vis/dtap/) - [Ebola](https://www.immunize.org/vaccines/vis/ebola/) - [Hib (Haemophilus Influenzae type b)](https://www.immunize.org/vaccines/vis/hib/) - [Hepatitis A](https://www.immunize.org/vaccines/vis/hepa/) - [Hepatitis B](https://www.immunize.org/vaccines/vis/hepb/) - - [HPV (Human Papillomavirus)](https://www.immunize.org/vaccines/vis/hpv/) - [Influenza (Inactivated or Recombinant)](https://www.immunize.org/vaccines/vis/influenza-inactivated/) - [Influenza (Live Intranasal)](https://www.immunize.org/vaccines/vis/influenza-live/) - [Japanese Encephalitis](https://www.immunize.org/vaccines/vis/japanese-encephalitis/) - [Meningococcal ACWY](https://www.immunize.org/vaccines/vis/menacwy/) - [Meningococcal B](https://www.immunize.org/vaccines/vis/menb/) - [MMR (Measles, Mumps, Rubella)](https://www.immunize.org/vaccines/vis/mmr/) - [MMRV (Measles, Mumps, Rubella, Varicella)](https://www.immunize.org/vaccines/vis/mmrv/) - [Multi-Vaccine](https://www.immunize.org/vaccines/vis/multi-vaccine/) - [PCV (Pneumococcal Conjugate)](https://www.immunize.org/vaccines/vis/pcv/) - [PPSV (Pneumococcal Polysaccharide)](https://www.immunize.org/vaccines/vis/ppsv/) - [Polio](https://www.immunize.org/vaccines/vis/polio/) - - [Rabies](https://www.immunize.org/vaccines/vis/rabies/) - [Rotavirus](https://www.immunize.org/vaccines/vis/rotavirus/) - [RSV (Respiratory Syncytial Virus)](https://www.immunize.org/vaccines/vis/rsv/) - [RSV Preventive Antibody – IIS](https://www.immunize.org/vaccines/vis/iis-rsv/) - [Smallpox/Monkeypox](https://www.immunize.org/vaccines/vis/smallpox-mpox/) - [TBE (Tick-borne Encephalitis)](https://www.immunize.org/vaccines/vis/tbe/) - [Td (Tetanus, Diphtheria)](https://www.immunize.org/vaccines/vis/td/) - [Tdap (Tetanus, Diphtheria, Pertussis)](https://www.immunize.org/vaccines/vis/tdap/) - [Typhoid](https://www.immunize.org/vaccines/vis/typhoid/) - [Varicella (Chickenpox)](https://www.immunize.org/vaccines/vis/varicella/) - [Yellow Fever](https://www.immunize.org/vaccines/vis/yellow-fever/) - [Zoster (Shingles)](https://www.immunize.org/vaccines/vis/zoster/) - [VIS TranslationsVaccine-specific VISs translated into dozens of languages](https://www.immunize.org/vaccines/vis-translations/) - [Travel VaccinesInformation about travelers’ health and vaccination](https://www.immunize.org/vaccines/travel-vaccines/) - [Vaccine History TimelineNotable milestones in immunization going back to 400 BC](https://www.immunize.org/vaccines/vaccine-timeline/) - [CDC Recommended SchedulesCurrent immunization schedules from CDC](https://www.immunize.org/vaccines/rec-schedules/) - [ACIP Vaccine RecommendationsAs endorsed and published by CDC](https://www.immunize.org/vaccines/acip-recs/) - [Clinical Resources]() - [Clinical Resources A-ZOur printable resources designed to help healthcare professionals in all aspects of immunization practice]() - - - [Search All Clinical Resources](https://www.immunize.org/clinical/a-z/) - [All Patient Handouts](http://www.immunize.org/clinical/a-z/all-patient/) - [All Resources for Staff & Providers](http://www.immunize.org/clinical/a-z/all-providers/) - [Translations](https://www.immunize.org/translations/) - [Addressing Vaccination Anxiety](https://www.immunize.org/clinical/topic/addressing-anxiety/) - [Administering Vaccines](https://www.immunize.org/clinical/topic/admin-vaccines/) - [Adolescent Vaccination](https://www.immunize.org/clinical/topic/adolescent-vaccination/) - [Adult Vaccination](https://www.immunize.org/clinical/topic/adult-vaccination/) - [Contraindications & Precautions](https://www.immunize.org/clinical/topic/contraindications/) - [Documenting Vaccination](https://www.immunize.org/clinical/topic/documenting/) - [Healthcare Personnel](https://www.immunize.org/clinical/topic/healthcare-personnel/) - - [Managing Vaccine Reactions](https://www.immunize.org/clinical/topic/managing-vaccine-reactions/) - [Parent Handouts](https://www.immunize.org/clinical/topic/parent-handouts/) - [Pregnancy and Vaccines](https://www.immunize.org/clinical/topic/pregnancy-vaccines/) - [Q\&As by Diseases and Vaccines](https://www.immunize.org/clinical/topic/qas/) - [Schedules for Patients](https://www.immunize.org/clinical/topic/patient-schedules/) - [Screening Checklists](https://www.immunize.org/clinical/topic/screening-checklists/) - [Standing Orders Templates](https://www.immunize.org/clinical/topic/standing-orders-templates/) - [Storage & Handling](https://www.immunize.org/clinical/topic/storage-handling/) - [Strategies & Policies](https://www.immunize.org/clinical/topic/strategies-policies/) - [Vaccine Confidence](https://www.immunize.org/clinical/topic/vaccine-confidence/) - [VIS-Related Resources](https://www.immunize.org/clinical/topic/vis/) - [Vaccine Recommendations](https://www.immunize.org/clinical/topic/vaccine-recs/) - [Vaccine Confidence & Addressing ConcernsPractical resources to help providers respond to patient concerns]() - - - [Vaccine Confidence Overview](https://www.immunize.org/clinical/vaccine-confidence/) - [Addressing Vaccination Anxiety](https://www.immunize.org/clinical/topic/addressing-anxiety/) - [Adjuvants](https://www.immunize.org/clinical/vaccine-confidence/topic/adjuvants/) - [Alternative Schedules](https://www.immunize.org/clinical/vaccine-confidence/topic/alt-schedules/) - [Autism](https://www.immunize.org/clinical/vaccine-confidence/topic/autism/) - [Complementary and Alternative Medicine: Partner Resources](https://www.immunize.org/clinical/vaccine-confidence/topic/alt-medicine/) - [Importance of Vaccines](https://www.immunize.org/clinical/vaccine-confidence/topic/vaccine-importance/) - [Improving the Vaccination Experience](https://www.immunize.org/clinical/vaccine-confidence/topic/improving-vaccine-experience/) - - [MMR Vaccine](https://www.immunize.org/clinical/vaccine-confidence/topic/mmr-vaccine/) - [Religious Concerns](https://www.immunize.org/clinical/vaccine-confidence/topic/religious-concerns/) - [Responding to Parents](https://www.immunize.org/clinical/vaccine-confidence/topic/responding-parents/) - [Thimerosal](https://www.immunize.org/clinical/vaccine-confidence/topic/thimerosal/) - [Unprotected People Stories](https://www.immunize.org/clinical/vaccine-confidence/unprotected-people/) - [Vaccine Hesitancy](https://www.immunize.org/clinical/vaccine-confidence/topic/vaccine-hesitancy/) - [Vaccine Safety](https://www.immunize.org/clinical/vaccine-confidence/topic/vaccine-safety/) - [Image LibraryPhotos related to vaccine-preventable diseases]() - - - [Image Library Overview](https://www.immunize.org/clinical/image-library/) - [Anthrax](https://www.immunize.org/clinical/image-library/anthrax/) - [Diphtheria](https://www.immunize.org/clinical/image-library/diphtheria/) - [Hepatitis A](https://www.immunize.org/clinical/image-library/hepa/) - [Hepatitis B](https://www.immunize.org/clinical/image-library/hepb/) - [Hib (Haemophilus Influenzae type b)](https://www.immunize.org/clinical/image-library/hib/) - [HPV (Human Papillomavirus)](https://www.immunize.org/clinical/image-library/hpv/) - [Influenza](https://www.immunize.org/clinical/image-library/influenza/) - - [Measles](https://www.immunize.org/clinical/image-library/measles/) - [Meningococcal](https://www.immunize.org/clinical/image-library/meningococcal/) - [Mpox](https://www.immunize.org/clinical/image-library/mpox/) - [Mumps](https://www.immunize.org/clinical/image-library/mumps/) - [Pertussis](https://www.immunize.org/clinical/image-library/pertussis/) - [Pneumococcal](https://www.immunize.org/clinical/image-library/pneumococcal/) - [Polio](https://www.immunize.org/clinical/image-library/polio/) - [Rabies](https://www.immunize.org/clinical/image-library/rabies/) - [Rotavirus](https://www.immunize.org/clinical/image-library/rotavirus/) - - [Rubella](https://www.immunize.org/clinical/image-library/rubella/) - [Smallpox](https://www.immunize.org/clinical/image-library/smallpox/) - [Tetanus](https://www.immunize.org/clinical/image-library/tetanus/) - [Vaccination](https://www.immunize.org/clinical/image-library/vaccination/) - [Varicella (Chickenpox)](https://www.immunize.org/clinical/image-library/varicella/) - [Zoster (Shingles)](https://www.immunize.org/clinical/image-library/zoster/) - [External ResourcesContact information and resources for immunization providers]() - - - [Vaccine Manufacturers](https://www.immunize.org/clinical/external/manufacturers/) - [Vaccine Apps](https://www.immunize.org/clinical/external/apps/) - [Email News Services](https://www.immunize.org/clinical/external/news-services/) - [Immunize.org Partners](https://www.immunize.org/clinical/external/immunize-org-partners/) - [Webinars & VideosOur library of educational videos and webinar recordings](https://www.immunize.org/clinical/webinar/) - [Ask the Experts]() - [Ask the ExpertsPractical answers to more than a thousand clinical questions about vaccines from our experts]() - - - [Ask the Experts Overview](http://www.immunize.org/ask-experts/overview/) - [View All Questions](https://www.immunize.org/ask-experts/) - [View All Video Questions](http://www.immunize.org/ask-experts/?q=%5Bvideo%5D) - - - #### Vaccine Topics - [COVID-19](https://www.immunize.org/ask-experts/topic/covid-19/) - [Dengue](https://www.immunize.org/ask-experts/topic/dengue/) - [Diphtheria](https://www.immunize.org/ask-experts/topic/diphtheria/) - [Hepatitis A](https://www.immunize.org/ask-experts/topic/hepa/) - [Hepatitis B](https://www.immunize.org/ask-experts/topic/hepb/) - [Hib (Haemophilus Influenzae type b)](https://www.immunize.org/ask-experts/topic/hib/) - [HPV (Human Papillomavirus)](https://www.immunize.org/ask-experts/topic/hpv/) - [Influenza](https://www.immunize.org/ask-experts/topic/influenza/) - [MMR (Measles, Mumps, and Rubella)](https://www.immunize.org/ask-experts/topic/mmr/) - [Meningococcal ACWY](https://www.immunize.org/ask-experts/topic/menacwy/) - - [Meningococcal B](https://www.immunize.org/ask-experts/topic/menb/) - [Pertussis](https://www.immunize.org/ask-experts/topic/pertussis/) - [Pneumococcal](https://www.immunize.org/ask-experts/topic/pneumococcal/) - [Polio](https://www.immunize.org/ask-experts/topic/polio/) - [Rabies](https://www.immunize.org/ask-experts/topic/rabies/) - [Rotavirus](https://www.immunize.org/ask-experts/topic/rotavirus/) - [RSV (Respiratory Syncytial Virus)](http://www.immunize.org/ask-experts/topic/rsv/) - [Tetanus](https://www.immunize.org/ask-experts/topic/tetanus/) - [Varicella (Chickenpox)](https://www.immunize.org/ask-experts/topic/varicella/) - [Zoster (Shingles)](https://www.immunize.org/ask-experts/topic/zoster/) - - #### General Topics - [Administering Vaccines](https://www.immunize.org/ask-experts/topic/admin-vaccines/) - [Billing & Reimbursement](https://www.immunize.org/ask-experts/topic/billing-reimburse/) - [Combination Vaccines](https://www.immunize.org/ask-experts/topic/combo-vaccines/) - [Contraindications & Precautions](https://www.immunize.org/ask-experts/topic/contraindications-precautions/) - [Documenting Vaccination](https://www.immunize.org/ask-experts/topic/documenting-vaccination/) - [Scheduling Vaccines](https://www.immunize.org/ask-experts/topic/scheduling-vaccines/) - [Storage & Handling](https://www.immunize.org/ask-experts/topic/storage-handling/) - [Travel Vaccines](https://www.immunize.org/ask-experts/topic/travel-vaccines/) - [Vaccine Recommendations](https://www.immunize.org/ask-experts/topic/vaccine-recs/) - [Vaccine Safety](https://www.immunize.org/ask-experts/topic/vaccine-safety/) - [Official Guidance]() - [CDCKey CDC resources for immunization providers]() - - - [CDC Recommended Schedules](https://www.immunize.org/official-guidance/cdc/rec-schedules/) - [ACIP Vaccine Recommendations](https://www.immunize.org/official-guidance/cdc/acip-recs/vaccines/) - [Additional CDC Resources](https://www.immunize.org/official-guidance/cdc/resources/) - [FDAFDA vaccine package inserts and related content](http://www.immunize.org/ask-experts/topic/covid-19/) - - - [Package Inserts & EUAs](https://www.immunize.org/official-guidance/fda/pkg-inserts/) - [Additional FDA Resources](https://www.immunize.org/official-guidance/fda/fda-resources/) - [StatesState-specific recommendations, school requirements, related state websites and public health contact information]() - - - [School and Childcare Vaccine-Specific Requirements](https://www.immunize.org/official-guidance/state-policies/requirements/) - [School and Childcare Immunization Exemption Policies](https://www.immunize.org/official-guidance/state-policies/exemptions/) - [State Immunization Websites](https://www.immunize.org/official-guidance/state-policies/state-websites/) - [State Immunization Recommendations](https://www.immunize.org/official-guidance/state-policies/state-vaccine-recommendations/) - [Additional State Resources](https://www.immunize.org/official-guidance/state-policies/state-resources/) - [Healthcare Professional OrganizationsImmunization guidance from groups such as the American Academy of Pediatrics](https://www.immunize.org/official-guidance/hpo/) - - - [Recommended Schedules](http://www.immunize.org/official-guidance/hpo/rec-schedules) - [Vaccine Recommendations](http://www.immunize.org/official-guidance/hpo/vax-recs/vaccine/) - [WHOPosition papers on vaccines and other vaccine-related resources from the World Health Organization](https://www.immunize.org/official-guidance/who/) - [News & Updates]() - [IZ Express NewsletterWeekly digest of important immunization news and updates]() - - - [About IZ Express](https://www.immunize.org/news/iz-express/about/) - [Current Issue](http://www.immunize.org/news/iz-express/current-issue/) - [Browse All Issues](https://www.immunize.org/news/iz-express/all-issues/) - [What's New on Immunize.orgChronological listing of our website content updates](https://www.immunize.org/news/updates/website/) - [Official Release RepositoryChronological listing of vaccine-related announcements from FDA, CDC, and ACIP](https://www.immunize.org/news/official-release-repository/acip/) - [Calendar of EventsImmunization-related events, including national conferences and training programs, plus Immunize.org webinars](https://www.immunize.org/events/) - [Publication ArchivesRepository of our publications since 1994, including IAC Express (now IZ Express), Needle Tips, and more](https://www.immunize.org/about/history/overview/) - [About]() - [Our OrganizationLearn about our mission, our people, and our recognition and honors]() - - - [Overview](https://www.immunize.org/about/org/overview/) - [Our People](https://www.immunize.org/about/org/people/) - [Board of Directors](https://www.immunize.org/about/org/bod/) - [Recognition](https://www.immunize.org/about/org/recognition/) - [Contact Us](https://www.immunize.org/about/org/contact/) - [Our HistoryLearn about our history and our founder, Deborah L. Wexler, MD. Browse past publications in our archives]() - - - [Our Founder](https://www.immunize.org/about/history/founder/) - [Publication Archives](https://www.immunize.org/about/history/overview/) - [Our History Through Film](https://www.immunize.org/about/history/film-history/) - [Financial SupportView our supporters and learn how to join our corporate membership program]() - - - [Funding](https://www.immunize.org/about/financial-support/funding/) - [Corporate Membership Program](https://www.immunize.org/about/financial-support/corp-membership/) - [Recognizing ExcellenceOur honor rolls for institutions with vaccination policies that protect lives, plus our Becky Payne Award recipients]() - - - #### Patient Safety Honor Rolls - [Influenza Vaccination Honor Roll](https://www.immunize.org/about/excellence/honor-rolls/influenza-vaccination/) - [Hepatitis B Birth Dose Honor Roll](https://www.immunize.org/about/excellence/honor-rolls/hepb-birth-dose/) - [MenB Vaccination Honor Roll](https://www.immunize.org/about/excellence/honor-rolls/menb-vaccination/) - [Honor Rolls Honorees](https://www.immunize.org/about/excellence/honor-rolls/honorees/) - - [The Immunize.org Becky Payne Award](https://www.immunize.org/about/excellence/becky-payne-award/) - [MediaInformation for the media, including how to request an interview, past press mentions, and our press releases]() - - - [Press Room](https://www.immunize.org/about/media/press-room/) - [Press Releases](https://www.immunize.org/about/media/press-room/#Press-Releases) - [Immunize.org In the News](https://www.immunize.org/about/media/immunize-news/) back - [Vaccines & VISs](https://www.immunize.org/vaccines/) - [Clinical Resources](http://www.immunize.org/clinical/a-z/) - [Ask the Experts](http://www.immunize.org/ask-experts/topic/covid-19/) - [Official Guidance](http://www.immunize.org/ask-experts/topic/covid-19/) - [News & Updates](http://www.immunize.org/ask-experts/topic/covid-19/) - [About](https://www.immunize.org/about/) - [IZ Express](https://www.immunize.org/news/iz-express/about/) - [Shop](https://shop.immunize.org/) - [Donate](https://www.immunize.org/donate/) - [Guide](https://www.immunize.org/guide/) Vaccines - [Vaccines A-Z Our immunization resources organized by vaccine](https://www.immunize.org/vaccines/) - [Adenovirus](https://www.immunize.org/vaccines/a-z/adenovirus/) - [Anthrax](https://www.immunize.org/vaccines/a-z/anthrax/) - [BCG](https://www.immunize.org/vaccines/a-z/bcg/) - [Chikungunya](https://www.immunize.org/vaccines/a-z/chikungunya/) - [Cholera](https://www.immunize.org/vaccines/a-z/cholera/) - [COVID-19](https://www.immunize.org/vaccines/a-z/covid-19/) - [Dengue](https://www.immunize.org/vaccines/a-z/dengue/) - [Diphtheria](https://www.immunize.org/vaccines/a-z/diphtheria/) - [Ebola](https://www.immunize.org/vaccines/a-z/ebola/) - [Hepatitis A](https://www.immunize.org/vaccines/a-z/hepa/) - [Hepatitis B](https://www.immunize.org/vaccines/a-z/hepb/) - [Hib (Haemophilus Influenzae type b)](https://www.immunize.org/vaccines/a-z/hib/) - [HPV (Human Papillomavirus)](https://www.immunize.org/vaccines/a-z/hpv/) - [Influenza](https://www.immunize.org/vaccines/a-z/influenza/) - [Japanese Encephalitis](https://www.immunize.org/vaccines/a-z/japanese-encephalitis/) - [Measles](https://www.immunize.org/vaccines/a-z/measles/) - [Meningococcal ACWY](https://www.immunize.org/vaccines/a-z/menacwy/) - [Meningococcal B](https://www.immunize.org/vaccines/a-z/menb/) - [Mpox](https://www.immunize.org/vaccines/a-z/mpox/) - [Mumps](https://www.immunize.org/vaccines/a-z/mumps/) - [Pertussis](https://www.immunize.org/vaccines/a-z/pertussis/) - [Pneumococcal](https://www.immunize.org/vaccines/a-z/pneumococcal/) - [Polio](https://www.immunize.org/vaccines/a-z/polio/) - [Rabies](https://www.immunize.org/vaccines/a-z/rabies/) - [RSV (Respiratory Syncytial Virus)](https://www.immunize.org/vaccines/a-z/rsv/) - [Rotavirus](https://www.immunize.org/vaccines/a-z/rotavirus/) - [Rubella](https://www.immunize.org/vaccines/a-z/rubella/) - [Smallpox](https://www.immunize.org/vaccines/a-z/smallpox/) - [Tetanus](https://www.immunize.org/vaccines/a-z/tetanus/) - [TBE (Tick-borne Encephalitis)](https://www.immunize.org/vaccines/a-z/tbe/) - [Typhoid](https://www.immunize.org/vaccines/a-z/typhoid/) - [Varicella (Chickenpox)](https://www.immunize.org/vaccines/a-z/varicella/) - [Yellow Fever](https://www.immunize.org/vaccines/a-z/yellow-fever/) - [Zoster (Shingles)](https://www.immunize.org/vaccines/a-z/zoster/) - [VISs Access current Vaccine Information Statements from CDC](https://www.immunize.org/vaccines/vis/about-vis/) - [VISs Overview](https://www.immunize.org/vaccines/vis/about-vis/) - [VIS-Related Resources](http://www.immunize.org/clinical/topic/vis/) - [Translations](https://www.immunize.org/translations/) - [Adenovirus](https://www.immunize.org/vaccines/vis/adenovirus/) - [Anthrax](https://www.immunize.org/vaccines/vis/anthrax/) - [Cholera](https://www.immunize.org/vaccines/vis/cholera/) - [COVID-19](https://www.immunize.org/vaccines/vis/covid-19/) - [Dengue](https://www.immunize.org/vaccines/vis/dengue/) - [DTaP (Diphtheria, Tetanus, Pertussis)](https://www.immunize.org/vaccines/vis/dtap/) - [Ebola](https://www.immunize.org/vaccines/vis/ebola/) - [Hib (Haemophilus Influenzae type b)](https://www.immunize.org/vaccines/vis/hib/) - [Hepatitis A](https://www.immunize.org/vaccines/vis/hepa/) - [Hepatitis B](https://www.immunize.org/vaccines/vis/hepb/) - [HPV (Human Papillomavirus)](https://www.immunize.org/vaccines/vis/hpv/) - [Influenza (Inactivated or Recombinant)](https://www.immunize.org/vaccines/vis/influenza-inactivated/) - [Influenza (Live Intranasal)](https://www.immunize.org/vaccines/vis/influenza-live/) - [Japanese Encephalitis](https://www.immunize.org/vaccines/vis/japanese-encephalitis/) - [Meningococcal ACWY](https://www.immunize.org/vaccines/vis/menacwy/) - [Meningococcal B](https://www.immunize.org/vaccines/vis/menb/) - [MMR (Measles, Mumps, Rubella)](https://www.immunize.org/vaccines/vis/mmr/) - [MMRV (Measles, Mumps, Rubella, Varicella)](https://www.immunize.org/vaccines/vis/mmrv/) - [Multi-Vaccine](https://www.immunize.org/vaccines/vis/multi-vaccine/) - [PCV (Pneumococcal Conjugate)](https://www.immunize.org/vaccines/vis/pcv/) - [PPSV (Pneumococcal Polysaccharide)](https://www.immunize.org/vaccines/vis/ppsv/) - [Polio](https://www.immunize.org/vaccines/vis/polio/) - [Rabies](https://www.immunize.org/vaccines/vis/rabies/) - [Rotavirus](https://www.immunize.org/vaccines/vis/rotavirus/) - [RSV (Respiratory Syncytial Virus)](https://www.immunize.org/vaccines/vis/rsv/) - [RSV Preventive Antibody – IIS](https://www.immunize.org/vaccines/vis/iis-rsv/) - [Smallpox/Monkeypox](https://www.immunize.org/vaccines/vis/smallpox-mpox/) - [TBE (Tick-borne Encephalitis)](https://www.immunize.org/vaccines/vis/tbe/) - [Td (Tetanus, Diphtheria)](https://www.immunize.org/vaccines/vis/td/) - [Tdap (Tetanus, Diphtheria, Pertussis)](https://www.immunize.org/vaccines/vis/tdap/) - [Typhoid](https://www.immunize.org/vaccines/vis/typhoid/) - [Varicella (Chickenpox)](https://www.immunize.org/vaccines/vis/varicella/) - [Yellow Fever](https://www.immunize.org/vaccines/vis/yellow-fever/) - [Zoster (Shingles)](https://www.immunize.org/vaccines/vis/zoster/) - [VIS Translations Vaccine-specific VISs translated into dozens of languages](https://www.immunize.org/vaccines/vis-translations/) - [Travel Vaccines Information about travelers’ health and vaccination](https://www.immunize.org/vaccines/travel-vaccines/) - [Vaccine History Timeline Notable milestones in immunization going back to 400 BC](https://www.immunize.org/vaccines/vaccine-timeline/) - [CDC Recommended Schedules Current immunization schedules from CDC](https://www.immunize.org/vaccines/rec-schedules/) - [ACIP Vaccine Recommendations As endorsed and published by CDC](https://www.immunize.org/vaccines/acip-recs/) Clinical Resources - [Clinical Resources A-Z Our printable resources designed to help healthcare professionals in all aspects of immunization practice](https://www.immunize.org/clinical/a-z/) - [Search All Clinical Resources](https://www.immunize.org/clinical/a-z/) - [All Patient Handouts](http://www.immunize.org/clinical/a-z/all-patient/) - [All Resources for Staff & Providers](http://www.immunize.org/clinical/a-z/all-providers/) - [Translations](https://www.immunize.org/translations/) - [By Topic](http://www.immunize.org/ask-experts/topic/covid-19/) - [Addressing Vaccination Anxiety](https://www.immunize.org/clinical/topic/addressing-anxiety/) - [Administering Vaccines](https://www.immunize.org/clinical/topic/admin-vaccines/) - [Adolescent Vaccination](https://www.immunize.org/clinical/topic/adolescent-vaccination/) - [Adult Vaccination](https://www.immunize.org/clinical/topic/adult-vaccination/) - [Contraindications & Precautions](https://www.immunize.org/clinical/topic/contraindications/) - [Documenting Vaccination](https://www.immunize.org/clinical/topic/documenting/) - [Healthcare Personnel](https://www.immunize.org/clinical/topic/healthcare-personnel/) - [Managing Vaccine Reactions](https://www.immunize.org/clinical/topic/managing-vaccine-reactions/) - [Parent Handouts](https://www.immunize.org/clinical/topic/parent-handouts/) - [Pregnancy and Vaccines](https://www.immunize.org/clinical/topic/pregnancy-vaccines/) - [Q\&As by Diseases and Vaccines](https://www.immunize.org/clinical/topic/qas/) - [Schedules for Patients](https://www.immunize.org/clinical/topic/patient-schedules/) - [Screening Checklists](https://www.immunize.org/clinical/topic/screening-checklists/) - [Standing Orders Templates](https://www.immunize.org/clinical/topic/standing-orders-templates/) - [Storage & Handling](https://www.immunize.org/clinical/topic/storage-handling/) - [Strategies & Policies](https://www.immunize.org/clinical/topic/strategies-policies/) - [Vaccine Confidence](https://www.immunize.org/clinical/topic/vaccine-confidence/) - [VIS-Related Resources](https://www.immunize.org/clinical/topic/vis/) - [Vaccine Recommendations](https://www.immunize.org/clinical/topic/vaccine-recs/) - [Vaccine Confidence & Addressing Concerns Practical resources to help providers respond to patient concerns](http://www.immunize.org/ask-experts/topic/covid-19/) - [Vaccine Confidence Overview](https://www.immunize.org/clinical/vaccine-confidence/) - [Adjuvants](https://www.immunize.org/clinical/vaccine-confidence/topic/adjuvants/) - [Alternative Schedules](https://www.immunize.org/clinical/vaccine-confidence/topic/alt-schedules/) - [Autism](https://www.immunize.org/clinical/vaccine-confidence/topic/autism/) - [Complementary and Alternative Medicine: Partner Resources](https://www.immunize.org/clinical/vaccine-confidence/topic/alt-medicine/) - [Importance of Vaccines](https://www.immunize.org/clinical/vaccine-confidence/topic/vaccine-importance/) - [Improving the Vaccination Experience](https://www.immunize.org/clinical/vaccine-confidence/topic/improving-vaccine-experience/) - [MMR Vaccine](https://www.immunize.org/clinical/vaccine-confidence/topic/mmr-vaccine/) - [Religious Concerns](https://www.immunize.org/clinical/vaccine-confidence/topic/religious-concerns/) - [Responding to Parents](https://www.immunize.org/clinical/vaccine-confidence/topic/responding-parents/) - [Thimerosal](https://www.immunize.org/clinical/vaccine-confidence/topic/thimerosal/) - [Unprotected People Stories](https://www.immunize.org/clinical/vaccine-confidence/unprotected-people/) - [Vaccine Hesitancy](https://www.immunize.org/clinical/vaccine-confidence/topic/vaccine-hesitancy/) - [Vaccine Safety](https://www.immunize.org/clinical/vaccine-confidence/topic/vaccine-safety/) - [Image Library Photos related to vaccine-preventable diseases](https://www.immunize.org/clinical/image-library/) - [Image Library Overview](https://www.immunize.org/clinical/image-library/) - [Anthrax](https://www.immunize.org/clinical/image-library/anthrax/) - [Diphtheria](https://www.immunize.org/clinical/image-library/diphtheria/) - [Hepatitis A](https://www.immunize.org/clinical/image-library/hepa/) - [Hepatitis B](https://www.immunize.org/clinical/image-library/hepb/) - [Hib (Haemophilus Influenzae type b)](https://www.immunize.org/clinical/image-library/hib/) - [HPV (Human Papillomavirus)](https://www.immunize.org/clinical/image-library/hpv/) - [Influenza](https://www.immunize.org/clinical/image-library/influenza/) - [Measles](https://www.immunize.org/clinical/image-library/measles/) - [Meningococcal](https://www.immunize.org/clinical/image-library/meningococcal/) - [Mpox](https://www.immunize.org/clinical/image-library/mpox/) - [Mumps](https://www.immunize.org/clinical/image-library/mumps/) - [Pertussis](https://www.immunize.org/clinical/image-library/pertussis/) - [Pneumococcal](https://www.immunize.org/clinical/image-library/pneumococcal/) - [Polio](https://www.immunize.org/clinical/image-library/polio/) - [Rabies](https://www.immunize.org/clinical/image-library/rabies/) - [Rotavirus](https://www.immunize.org/clinical/image-library/rotavirus/) - [Rubella](https://www.immunize.org/clinical/image-library/rubella/) - [Smallpox](https://www.immunize.org/clinical/image-library/smallpox/) - [Tetanus](https://www.immunize.org/clinical/image-library/tetanus/) - [Vaccination](https://www.immunize.org/clinical/image-library/vaccination/) - [Varicella (Chickenpox)](https://www.immunize.org/clinical/image-library/varicella/) - [Zoster (Shingles)](https://www.immunize.org/clinical/image-library/zoster/) - [External Resources Contact information and resources for immunization providers](https://www.immunize.org/clinical/external/) - [Vaccine Manufacturers](https://www.immunize.org/clinical/external/manufacturers/) - [Vaccine Apps](https://www.immunize.org/clinical/external/apps/) - [Email News Services](https://www.immunize.org/clinical/external/news-services/) - [Immunize.org Partners](https://www.immunize.org/clinical/external/immunize-org-partners/) - [Webinars & Videos Our library of educational videos and webinar recordings](https://www.immunize.org/clinical/webinar/) Ask the Experts - [Ask the Experts Practical answers to more than a thousand clinical questions about vaccines from our experts](https://www.immunize.org/ask-experts/) - [Ask the Experts Overview](http://www.immunize.org/ask-experts/overview/) - [View All Questions](https://www.immunize.org/ask-experts/) - [View All Video Questions](http://www.immunize.org/ask-experts/?q=%5Bvideo%5D) - [By Vaccine](http://www.immunize.org/ask-experts/topic/covid-19/) - [COVID-19](https://www.immunize.org/ask-experts/topic/covid-19/) - [Dengue](https://www.immunize.org/ask-experts/topic/dengue/) - [Diphtheria](https://www.immunize.org/ask-experts/topic/diphtheria/) - [Hepatitis A](https://www.immunize.org/ask-experts/topic/hepa/) - [Hepatitis B](https://www.immunize.org/ask-experts/topic/hepb/) - [Hib (Haemophilus Influenzae type b)](https://www.immunize.org/ask-experts/topic/hib/) - [HPV (Human Papillomavirus)](https://www.immunize.org/ask-experts/topic/hpv/) - [Influenza](https://www.immunize.org/ask-experts/topic/influenza/) - [MMR (Measles, Mumps, and Rubella)](https://www.immunize.org/ask-experts/topic/mmr/) - [Meningococcal ACWY](https://www.immunize.org/ask-experts/topic/menacwy/) - [Meningococcal B](https://www.immunize.org/ask-experts/topic/menb/) - [Pertussis](https://www.immunize.org/ask-experts/topic/pertussis/) - [Pneumococcal](https://www.immunize.org/ask-experts/topic/pneumococcal/) - [Polio](https://www.immunize.org/ask-experts/topic/polio/) - [Rabies](https://www.immunize.org/ask-experts/topic/rabies/) - [Rotavirus](https://www.immunize.org/ask-experts/topic/rotavirus/) - [RSV (Respiratory Syncytial Virus)](http://www.immunize.org/ask-experts/topic/rsv/) - [Tetanus](https://www.immunize.org/ask-experts/topic/tetanus/) - [Typhoid](https://www.immunize.org/ask-experts/topic/typhoid/) - [Varicella (Chickenpox)](https://www.immunize.org/ask-experts/topic/varicella/) - [Yellow Fever](https://www.immunize.org/ask-experts/topic/yellow-fever/) - [Zoster (Shingles)](https://www.immunize.org/ask-experts/topic/zoster/) - [By Topic](http://www.immunize.org/ask-experts/topic/covid-19/) - [Administering Vaccines](https://www.immunize.org/ask-experts/topic/admin-vaccines/) - [Billing & Reimbursement](https://www.immunize.org/ask-experts/topic/billing-reimburse/) - [Combination Vaccines](https://www.immunize.org/ask-experts/topic/combo-vaccines/) - [Contraindications & Precautions](https://www.immunize.org/ask-experts/topic/contraindications-precautions/) - [Documenting Vaccination](https://www.immunize.org/ask-experts/topic/documenting-vaccination/) - [Scheduling Vaccines](https://www.immunize.org/ask-experts/topic/scheduling-vaccines/) - [Storage & Handling](https://www.immunize.org/ask-experts/topic/storage-handling/) - [Travel Vaccines](https://www.immunize.org/ask-experts/topic/travel-vaccines/) - [Vaccine Recommendations](https://www.immunize.org/ask-experts/topic/vaccine-recs/) - [Vaccine Safety](https://www.immunize.org/ask-experts/topic/vaccine-safety/) Official Guidance - [CDC Key CDC resources for immunization providers](https://www.immunize.org/official-guidance/cdc/) - [CDC Recommended Schedules](https://www.immunize.org/official-guidance/cdc/rec-schedules/) - [ACIP Vaccine Recommendations](https://www.immunize.org/official-guidance/cdc/acip-recs/vaccines/) - [Additional CDC Resources](https://www.immunize.org/official-guidance/cdc/resources/) - [FDA FDA vaccine package inserts and related content](http://www.immunize.org/ask-experts/topic/covid-19/) - [Package Inserts & EUAs](https://www.immunize.org/official-guidance/fda/pkg-inserts/) - [Additional FDA Resources](https://www.immunize.org/official-guidance/fda/fda-resources/) - [States State-specific recommendations, school requirements, related state websites and public health contact information](http://www.immunize.org/ask-experts/topic/covid-19/) - [School and Childcare Vaccine-Specific Requirements](https://www.immunize.org/official-guidance/state-policies/requirements/) - [School and Childcare Immunization Exemption Policies](https://www.immunize.org/official-guidance/state-policies/exemptions/) - [State Immunization Websites](https://www.immunize.org/official-guidance/state-policies/state-websites/) - [State Immunization Recommendations](https://www.immunize.org/official-guidance/state-policies/state-vaccine-recommendations/) - [Additional State Resources](https://www.immunize.org/official-guidance/state-policies/state-resources/) - [Healthcare Professional Organizations Immunization guidance from groups such as the American Academy of Pediatrics](https://www.immunize.org/official-guidance/hpo/) - [Recommended Schedules](http://www.immunize.org/official-guidance/hpo/rec-schedules) - [Vaccine Recommendations](http://www.immunize.org/official-guidance/hpo/vax-recs/vaccine/) - [WHO Position papers on vaccines and other vaccine-related resources from the World Health Organization](https://www.immunize.org/official-guidance/who/) News & Updates - [IZ Express Newsletter Weekly digest of important immunization news and updates](https://www.immunize.org/news/iz-express/all-issues/) - [About IZ Express](https://www.immunize.org/news/iz-express/about/) - [Current Issue](http://www.immunize.org/news/iz-express/current-issue/) - [Browse All Issues](https://www.immunize.org/news/iz-express/all-issues/) - [What’s New on Immunize.org Chronological listing of our website content updates](https://www.immunize.org/news/updates/website/) - [Official Release Repository Chronological listing of vaccine-related announcements from FDA, CDC, and ACIP](https://www.immunize.org/news/official-release-repository/acip/) - [Calendar of Events Immunization-related events, including national conferences and training programs, plus Immunize.org webinars](https://www.immunize.org/events/) - [Publication Archives Repository of our publications since 1994, including IAC Express (now IZ Express), Needle Tips, and more](https://www.immunize.org/about/history/overview/) About - [Our Organization Learn about our mission, our people, and our recognition and honors](https://www.immunize.org/about/org/) - [Overview](https://www.immunize.org/about/org/overview/) - [Our People](https://www.immunize.org/about/org/people/) - [Board of Directors](https://www.immunize.org/about/org/bod/) - [Recognition](https://www.immunize.org/about/org/recognition/) - [Contact Us](https://www.immunize.org/about/org/contact/) - [Our History Learn about our history and our founder, Deborah L. Wexler, MD. Browse past publications in our archives](https://www.immunize.org/about/history/) - [Our Founder](https://www.immunize.org/about/history/founder/) - [All Publication Archives](https://www.immunize.org/about/history/overview/) - [Our History Through Film](https://www.immunize.org/about/history/film-history/) - [Financial Support View our supporters and learn how to join our corporate membership program](https://www.immunize.org/about/financial-support/) - [Funding](https://www.immunize.org/about/financial-support/funding/) - [Corporate Membership Program](https://www.immunize.org/about/financial-support/corp-membership/) - [Recognizing Excellence Our honor rolls for institutions with vaccination policies that protect lives, plus our Becky Payne Award recipients](https://www.immunize.org/about/excellence/) - [Patient Safety Honor Rolls](http://www.immunize.org/ask-experts/topic/covid-19/) - [Influenza Vaccination Honor Roll](https://www.immunize.org/about/excellence/honor-rolls/influenza-vaccination/) - [Hepatitis B Birth Dose Honor Roll](https://www.immunize.org/about/excellence/honor-rolls/hepb-birth-dose/) - [MenB Vaccination Honor Roll](https://www.immunize.org/about/excellence/honor-rolls/menb-vaccination/) - [Honor Rolls Honorees](https://www.immunize.org/about/excellence/honor-rolls/honorees/) - [The Immunize.org Becky Payne Award](https://www.immunize.org/about/excellence/becky-payne-award/) - [Media Information for the media, including how to request an interview, past press mentions, and our press releases](https://www.immunize.org/about/media/) - [Press Room](https://www.immunize.org/about/media/press-room/) - [Press Releases](https://www.immunize.org/about/media/press-room/#Press-Releases) - [Immunize.org In the News](https://www.immunize.org/about/media/immunize-news/) [Home](https://www.immunize.org/) / [Ask the Experts](https://www.immunize.org/ask-experts/) / COVID-19 # Ask the Experts: COVID-19 The COVID-19 questions were last reviewed on November 16, 2025. See CDC’s [Use of COVID-19 Vaccines in the United States Interim Clinical Considerations](https://www.cdc.gov/vaccines/covid-19/clinical-considerations/covid-19-vaccines-us.html) for more information. To keep up with the current available COVID-19 resources from CDC, FDA, and Immunize.org, see Immunize.org’s [Checklist of Current Versions of U.S. COVID-19 Vaccine Guidance and Clinic Support Tools](https://www.immunize.org/wp-content/uploads/catg.d/p3130.pdf), updated at least monthly. For alerts about new Immunize.org or CDC COVID-19 resources, subscribe to our weekly e-newsletter, [IZ Express](https://www.immunize.org/subscribe). ##### Search & Filters ### Keyword Search ### Filters × Reset all filters All results Vaccine or Disease Name Patient Age Patient Health Conditions Patient Population Work, School or Living Setting Disease Adverse Events Reason for Vaccination Schedule Vaccine Platform / Ig Type IM Admin Site Vaccine Storage and Handling Patient Sex Other Show Filters Hide Filters Results (89) Search & Filters Show All Answers Hide All Answers Show All Answers Hide All Answers Link copied - COVID-19 - Disease Issues ## What is COVID-19? COVID-19 is the name given to the disease caused by infection with the SARS-CoV-2 coronavirus. This virus was first detected as a cause of human illness in late 2019 in Wuhan, China, and triggered a global pandemic that began in 2020. The virus spreads mainly from person to person through respiratory droplets and small particles produced when an infected person coughs, sneezes, or talks. The virus spreads easily in crowded or poorly ventilated indoor settings. Some people who are infected have no symptoms of illness, while the severity of symptomatic illness ranges from mild to life-threatening. Older adults and people of any age with underlying medical conditions are at higher risk for severe illness. The incubation period after exposure ranges from 2–14 days, with an average of about 5 days. People with COVID-19 are generally considered potentially infectious up to 48 hours before symptom onset and up to 10 days after onset, though people with severe illness may be infectious longer. Symptoms may include fever or chills, cough, shortness of breath or difficulty breathing, fatigue, muscle or body aches, headache, new loss of taste or smell, sore throat, congestion or runny nose, nausea or vomiting, and diarrhea. Last reviewed: November 16, 2025 Link copied - COVID-19 - Disease Issues ## Where can I find conditions that have been shown to increase the risk of severe COVID-19 illness? The list of underlying health conditions and other factors shown to increase the risk of severe COVID-19 illness is long. Advanced age remains the strongest risk factor. In addition to age, CDC states that data has shown that compared to non-Hispanic White people, people from racial and ethnic minority groups are more likely to be infected with SARS-CoV-2. Once infected, people from racial and ethnic minority groups are more likely to be hospitalized, be admitted to the ICU, and die from COVID-19 at younger ages. CDC provides a list of at-risk conditions at this website: [www.cdc.gov/covid/hcp/clinical-care/underlying-conditions.html](http://www.cdc.gov/covid/hcp/clinical-care/underlying-conditions.html). The conditions are stratified by strength of published evidence. Immunize.org provides an age-appropriate list of high-risk conditions with conclusive or suggestive published evidence as part of each of its standing orders templates for use of 2025-2026 COVID-19 vaccines, all of which may be found on the COVID-19 main page: [www.immunize.org/vaccines/a-z/covid-19/](http://www.immunize.org/vaccines/a-z/covid-19/). Last reviewed: November 16, 2025 Link copied - COVID-19 - Disease Issues ## Where can I find answers to more clinical questions about COVID-19 disease, diagnosis, treatment and care of patients? The CDC has assembled clinical information about COVID-19 at this site: [www.cdc.gov/covid/hcp](https://www.cdc.gov/covid/hcp/). Last reviewed: November 16, 2025 Link copied - COVID-19 - Vaccine Recommendations ## Where can I find current COVID-19 vaccine recommendations? CDC maintains a webpage with critical interim clinical considerations for vaccination of eligible recipients: [www.cdc.gov/covid/hcp/vaccine-considerations/index.html](http://www.cdc.gov/covid/hcp/vaccine-considerations/index.html). This covers important clinical details about COVID-19 vaccination. It is typically the first content to be updated after an announced change to CDC recommendations. All of the CDC’s Advisory Committee on Immunization Practices (ACIP) vaccine recommendations published in MMWR can be accessed here: [www.cdc.gov/acip-recs/hcp/vaccine-specific/covid-19.html](https://www.cdc.gov/acip-recs/hcp/vaccine-specific/covid-19.html). CDC posts product-specific resources at this site: [www.cdc.gov/vaccines/covid-19/info-by-product/index.html](http://www.cdc.gov/vaccines/covid-19/info-by-product/index.html). At this writing, the website was last updated July 18, 2025. Last reviewed: November 16, 2025 Link copied - COVID-19 - Vaccine Recommendations ## Who is recommended by CDC to receive COVID-19 vaccines? The ACIP recommended on September 18, 2025, that all people age 6 months and older in the United States may receive one or more doses of an age-appropriate 2025–2026 Formula COVID-19 vaccination based on individual decision-making, following shared clinical decision-making discussion with a healthcare professional (e.g., a nurse, doctor, or pharmacist). The decision to vaccinate may be influenced by the presence of conditions that increase the risk of severe COVID-19 illness. Product options include three FDA-licensed mRNA vaccines: Comirnaty (Pfizer-BioNTech, ages 5 years and older); Spikevax (Moderna, ages 6 months and older); mNexspike (Moderna, ages 12 years and older). There is one FDA-licensed adjuvanted protein subunit vaccine: Nuvaxovid (Sanofi-Novavax, ages 12 years and older). Schedules vary by age and immunocompromised status. Although the FDA licenses limit use of COVID-19 vaccines among recipients younger than age 64 to those with one or more conditions that increases the risk of severe COVID-19, the fact that ACIP did not include any restrictions in its shared clinical decision-making recommendation means that it is an acceptable standard of care for people younger than age 65 without a high risk condition to be vaccinated when desired. Last reviewed: November 16, 2025 Link copied - COVID-19 - Vaccine Recommendations ## What are CDC and professional medical societies’ 2025–26 season COVID-19 vaccination recommendations for people age 6 months and older? CDC recommends individual decision-making (also known as shared clinical decision-making) for COVID-19 vaccination of all people age 6 months and older. Among people age 6 months through 64 years, ACIP emphasizes that the risk-benefit of vaccination is most favorable for individuals who are at an increased risk for severe COVID-19 disease and lowest for individuals who are not at an increased risk. Details of the vaccination schedule are available here: [www.cdc.gov/covid/hcp/vaccine-considerations/routine-guidance.html](http://www.cdc.gov/covid/hcp/vaccine-considerations/routine-guidance.html). Of note, among previously unvaccinated people who are not moderately or severely immunocompromised, an initial vaccination series is recommended only for young children age 6 through 23 months. All others younger than age 65 years are recommended to receive a single dose of an age-appropriate 2025–2026 formula COVID-19 vaccine. People age 65 years and older are recommended to receive a second 2025–2026 formula COVID-19 vaccine dose 6 months later (minimum interval 2 months if using Comirnaty, Spikevax, or Nuvaxovid; minimum interval 3 months if using mNexspike). Major U.S. professional medical societies have issued their own recommendations for the 2025–26 COVID-19 season that differ from CDC, primarily in their stronger, routine recommendations for vaccination of people at risk of severe COVID-19 illness: - American Academy of Pediatrics (AAP) for children: <https://publications.aap.org/pediatrics/article/156/5/e2025073924/203222/Recommendations-for-COVID-19-Vaccines-in-Infants> - American Academy of Family Physicians (AAFP) for healthy adults and elderly people: [www.aafp.org/family-physician/patient-care/public-health-emergencies/recent-outbreaks/covid-19/covid-19-vaccine.html](http://www.aafp.org/family-physician/patient-care/public-health-emergencies/recent-outbreaks/covid-19/covid-19-vaccine.html) - American College of Obstetricians and Gynecologists (ACOG) for pregnancy: [www.acog.org/clinical/clinical-guidance/practice-advisory/articles/2020/12/covid-19-vaccination-considerations-for-obstetric-gynecologic-care](http://www.acog.org/clinical/clinical-guidance/practice-advisory/articles/2020/12/covid-19-vaccination-considerations-for-obstetric-gynecologic-care) - Infectious Diseases Society of America (IDSA) for immunocompromised people and their close contacts: [www.idsociety.org/Seasonal-RTI-Vaccinations-in-Immunocompromised-Patients/](http://www.idsociety.org/Seasonal-RTI-Vaccinations-in-Immunocompromised-Patients/) Last reviewed: November 16, 2025 Link copied - COVID-19 - Vaccine Recommendations ## What are CDC’s 2025–26 season COVID-19 vaccination recommendations for people age 6 months and older who are moderately or severely immunocompromised? People who are moderately or severely immunocompromised are at increased risk for severe COVID-19 illness. ACIP and CDC recommend individual decision-making (also known as shared clinical decision-making) after a discussion with a healthcare professional (nurse, doctor, or pharmacist) for people age 6 months and older who are moderately or severely immunocompromised. They are recommended to receive at least 2 doses during the season. The CDC vaccination schedule for people with moderate or severe immunocompromise is available here: [www.cdc.gov/covid/hcp/vaccine-considerations/immunocompromised.html](http://www.cdc.gov/covid/hcp/vaccine-considerations/immunocompromised.html). The Infectious Diseases Society of America (IDSA) strongly recommends administration of age-appropriate 2025–2026 COVID-19 vaccinations to all adults and children with compromised immunity. They also recommend that household members and close contacts of immunocompromised people should be up to date with COVID-19 vaccination. See IDSA recommendations for full details: [www.idsociety.org/Seasonal-RTI-Vaccinations-in-Immunocompromised-Patients/](http://www.idsociety.org/Seasonal-RTI-Vaccinations-in-Immunocompromised-Patients/). Last reviewed: November 16, 2025 Link copied - COVID-19 - Vaccine Recommendations ## What COVID-19 vaccine should we use in the 2025–26 season for children ages 6 through 59 months who received Pfizer-BioNTech COVID-19 vaccine in the past? In past seasons, CDC recommended that all doses of COVID-19 vaccine given to children age 6 months through 4 years be from the same manufacturer. However, in the 2025–26 season, only Moderna’s Spikevax mRNA vaccine is licensed and recommended for use in children younger than age 5 years. All children in this age group who are vaccinated against COVID-19 should receive Spikevax, regardless of the brand they received in previous seasons. If the child is age 6 months through 23 months and received an incomplete (1- or 2-dose) initial COVID-19 vaccination series with Pfizer-BioNTech, a 3-dose initial series should be completed with Spikevax. It is not necessary to repeat the initial series. In previously unvaccinated people age 5 years or older with moderate or severe immunocompromise, the same manufacturer is recommended for all initial COVID-19 vaccine series doses (either 2 doses of Nuvaxovid \[if age 12 years or older\] or 3 doses of an mRNA product). After completion of the initial series, any age-appropriate COVID-19 vaccine may be used in this age group. CDC sets out conditions when it is acceptable to use an age-appropriate COVID-19 vaccine from a different manufacturer in any situation where the same manufacturer is recommended: - Same vaccine not available at the time of the clinic visit - Previous dose unknown - Person would otherwise not receive a recommended vaccine dose - Person starts but unable to complete a vaccination series with the same COVID-19 vaccine due to a contraindication Last reviewed: November 16, 2025 Link copied - COVID-19 - Vaccine Recommendations ## Before the 2025–26 season, CDC recommended the option of additional COVID-19 vaccine doses for people with moderate or severe immunocompromise. Did that change? Individuals with moderate to severe immunocompromise who have completed an initial COVID-19 series should receive two dose of 2025–2026 Formula COVID-19 vaccine this season with the second dose given 6 months later (minimum interval 2 months for Comirnaty, Spikevax, and Nuvaxovid; minimum interval 3 months for mNexspike). In previous seasons, CDC recommended that additional doses of COVID-19 vaccine may be administered (with a minimum two-month interval) based on the clinical judgment of the individual’s healthcare provider and the recipient’s personal preference and circumstances. For the 2025–26 season, CDC has removed this general statement from its interim clinical considerations document ([www.cdc.gov/covid/hcp/vaccine-considerations/immunocompromised.html](http://www.cdc.gov/covid/hcp/vaccine-considerations/immunocompromised.html)). The CDC clinical considerations document now states, “On a case-by-case basis, providers caring for these patients may administer Moderna, Novavax, and Pfizer-BioNTech COVID-19 vaccines outside of the FDA and CDC dosing intervals when, based on their clinical judgment, the benefits of vaccination are deemed to outweigh the potential and unknown risks for the recipient who is immunocompromised.” Last reviewed: November 16, 2025 Link copied - COVID-19 - Vaccine Recommendations ## What is the recommended vaccination schedule for a person who received only the Janssen COVID-19 Vaccine? Janssen (Johnson & Johnson) COVID-19 vaccine is no longer produced. The last remaining doses expired May 7, 2023. The history of Janssen vaccine use is relevant only to evaluation of an adult with moderate or severe immunocompromise because such individuals are recommended to receive an initial series of COVID-19 vaccine. History of a single dose of Janssen COVID-19 vaccine constitutes a complete initial series. A person with this history should follow the vaccination schedule recommended for an immunocompromised person who has already completed an initial vaccination series. Last reviewed: November 16, 2025 Link copied - COVID-19 - Vaccine Recommendations ## May people who have had COVID-19 illness be vaccinated? Yes. Vaccination should be offered regardless of history of prior SARS-CoV-2 infection or long COVID. Because COVID-19 illness temporarily boosts immunity, people who have recently had SARS-CoV-2 infection may consider delaying a 2025–2026 COVID-19 vaccine dose by up to 3 months following symptom onset or positive COVID-19 test (if asymptomatic). Studies have shown that a longer time between infection and vaccination may improve the immune response to vaccination. The likelihood of reinfection in the first few months following infection is low. A recipient’s individual risks for severe disease and current COVID-19 conditions in the community should be taken into account when deciding whether to delay vaccination up to 3 months after infection. As with all vaccines, vaccination should be deferred until after recovery from moderate to severe illness. Last reviewed: November 16, 2025 Link copied - COVID-19 - Vaccine Recommendations ## Should adults age 65 years and older who are vaccinated against COVID-19 in the 2025–26 season receive one or two doses of COVID-19 vaccine during the season? Adults age 65 years and older have the highest rates of hospitalization and death from COVID-19 illness. Protection against severe COVID-19 disease wanes after a few months. Disease surveillance data from the United States shows that SARS-CoV-2 viruses circulate and cause illness at varying levels year-round, with waves of activity observed historically in winter and late summer. It is not known whether this pattern will continue. This pattern is not like influenza, which usually causes a single epidemic wave (sometimes with more than one peak) each winter. The 2025 CDC adult immunization schedule shows that adults age 65 years and older who are vaccinated against COVID-19 are recommended to receive a second dose of any 2025–2026 Formula COVID-19 vaccine 6 months after their first 2025–2026 Formula COVID-19 vaccine dose (minimum interval of 2 months for Comirnaty, Spikevax, and Nuvaxovid; minimum interval of 3 months for mNexspike). The second dose does not have to be the same brand as the first. Last reviewed: November 16, 2025 Link copied - COVID-19 - Vaccine Recommendations ## How long should people wait after their most recent dose of 2024–2025 Formula COVID-19 vaccine before getting a 2025–2026 Formula COVID-19 vaccine? CDC recommends waiting a minimum of 8 weeks (2 months) since the last 2024–2025 Formula COVID-19 vaccine to receive an age-appropriate 2025–2026 Formula COVID-19 vaccine, if using Comirnaty (Pfizer-BioNTech), Nuvaxovid (Sanofi-Novavax), or Spikevax (Moderna). They recommend a 3-month minimum interval when using mNexspike (Moderna); however, a dose of mNexspike administered at least 2 months after the most recent dose does not need to be repeated. Any person who initiated a COVID-19 vaccination initial series (e.g., a child 6 months through 23 months of age or a person with moderate or severe immunocompromise) with a previous formulation should follow the age-appropriate recommended schedule for completion of their primary series with the current formulation of the same brand, if feasible. For the 2025–26 season, Spikevax is the only licensed and recommended option for children age 6 through 59 months, regardless of their vaccination history. Last reviewed: November 16, 2025 Link copied - COVID-19 - Vaccine Products ## What is an Emergency Use Authorization (EUA)? Under section 564 of the Federal Food, Drug, and Cosmetic Act (FD\&C Act), the FDA Commissioner may allow unapproved medical products or unapproved uses of approved medical products to be used in an emergency to diagnose, treat, or prevent serious or life-threatening diseases or conditions caused by chemical, biological, radiological or nuclear threat agents when there are no adequate, approved, and available alternatives. Vaccines that receive an EUA may later be fully licensed by the FDA. All available COVID-19 vaccines were initially administered under EUA. All available 2025–2026 Formula COVID-19 vaccines are fully licensed by FDA and no longer administered under EUA. Last reviewed: November 16, 2025 Link copied - COVID-19 - Vaccine Products ## What are mRNA vaccines? Both the Pfizer-BioNTech COVID-19 Vaccine (Comirnaty) and the Moderna COVID-19 vaccines (Spikevax, mNexspike) are lipid nanoparticle-formulated, nucleoside-modified mRNA vaccines encoding the prefusion spike glycoprotein of SARS-CoV-2, the virus that causes COVID-19. The 2025–2026 formula mRNA vaccines target the Omicron JN.1 variant LP.8.1 strain. Moderna’s mNexspike was first licensed in 2025 for ages 12 years and older. It is designed to reduce the amount of mRNA required to elicit the same or slightly better immune response compared to Spikevax (10 mcg of mRNA versus 50 mcg of mRNA for an adult dose). Spikevax and mNexspike may be used interchangeably when both are age appropriate. Visit this CDC website for more details about how mRNA vaccines work: [www.cdc.gov/covid/vaccines/how-they-work.html](https://www.cdc.gov/covid/vaccines/how-they-work.html). Last reviewed: November 16, 2025 Link copied - COVID-19 - Vaccine Products ## What is the difference between Spikevax and mNexspike by Moderna? Spikevax and mNexspike are both mRNA vaccines targeting the same strain of COVID-19. Spikevax is the original vaccine now licensed down to age 6 months. The mNexspike product is a newer mRNA vaccine licensed for ages 12 years and older with an advanced design that achieves the same or slightly better immune response with less mRNA in each dose (10 mcg in mNexspike compared to 50 mcg in adult doses of Spikevax). The two products may be used interchangeably when age appropriate. In adults 65 years and older (and moderately or severely immunocompromised adults) who are recommended to receive a second dose 6 months after their first 2025–2026 formula dose, the minimum interval between the two recommended 2025–26 season doses is 3 months for mNexspike, but only 2 months for the other COVID-19 vaccine products. If mNexspike is inadvertently administered after only 2 months, the dose counts as valid and does not need to be repeated. Last reviewed: November 16, 2025 Link copied - COVID-19 - Vaccine Products ## How are mRNA and protein-based COVID-19 vaccines different? \[Video\] [![](https://www.immunize.org/wp-content/uploads/ask-experts/COVID-19/how-mrna-and-protein-based-covid-19-vaccines-different.jpg)](https://www.youtube.com/watch?v=xGHs0u0VzoA) 3:01 [View All Video Questions](https://www.immunize.org/clinical/video/?wpsolr_fq%5B0%5D=subject_str%3AAsk%20the%20Experts) Last reviewed: January 9, 2026 Link copied - COVID-19 - Contraindications & Precautions ## What percentage of vaccine recipients will experience an anaphylactic reaction? It is estimated that for every million doses administered, about one (~0.0001%) will result in an anaphylactic reaction following vaccination. The estimate for mRNA COVID-19 vaccines is slightly higher, at 2 to 5 anaphylactic reactions per million vaccinations given. With proper screening, most providers who administer thousands of vaccines in their lifetimes will never see an anaphylactic reaction. Last reviewed: November 16, 2025 Link copied - COVID-19 - Vaccine Products ## What is the difference between the original COVID-19 vaccines and the currently recommended vaccines? The original COVID-19 vaccines all targeted the spike protein of the original SARS-CoV-2 virus. The 2025–2026 formulation vaccines target the spike proteins of more recently circulating strains, known as the Omicron JN.1 lineage LP.8.1 strain (mRNA vaccines) or the JN.1 strain (Nuvaxovid adjuvanted protein subunit vaccine). The update is intended to boost production of antibodies that protect more effectively against disease caused by currently circulating Omicron subvariants. The process of updating the strain without changing anything else is similar to the seasonal strain changes made for influenza vaccinations each year. Vaccine safety, side effects, and risk of allergic reactions are expected to be comparable to earlier formulations of vaccines of the same brand and dose. As with seasonal influenza vaccines, future COVID-19 vaccines can continue to be updated when needed, as the circulating viruses evolve. Last reviewed: November 16, 2025 Link copied - COVID-19 - Vaccine Products ## Is the Janssen COVID-19 Vaccine (Johnson & Johnson) still available in the United States? No. The last U.S. doses of Janssen COVID-19 Vaccine expired May 7, 2023. Last reviewed: November 16, 2025 Link copied - COVID-19 - Vaccine Products ## What is the Nuvaxovid (Sanofi-Novavax) COVID-19 Vaccine? Nuvaxovid is the brand name of the adjuvanted protein subunit COVID-19 vaccine developed by Novavax and commercialized by Sanofi beginning in the 2025–26 season. It contains the Omicron JN.1 subvariant SARS-CoV-2 spike protein and Matrix-M adjuvant. The saponin-based adjuvant is made from extracts of the bark of the Soapbark tree native to Chile. It is added to enhance the immune response of the vaccine recipient. The spike protein is produced in insect cells. The 2025–2026 formulation of Nuvaxovid is FDA-licensed for use in people age 12 years or older. It is recommended as a single dose for people age 12 years through 64 years, given at least 8 weeks after the most recent dose of COVID-19 vaccine, regardless of the recipient’s vaccination history. People age 65 years or older and those age 12 years and older who are moderately or severely immunocompromised are recommended to receive 2 doses of 2025–2026 Formula COVID-19 vaccines, 6 months apart (with a minimum interval of 2 months between doses if using Nuvaxovid for both doses). A 2-dose initial series is recommended for previously unvaccinated recipients who are moderately or severely immunocompromised, with the doses given at least 3 weeks apart. A third dose of any COVID-19 vaccine is recommended 6 months after the initial series is completed (with a minimum interval of 2 months between doses if using Nuvaxovid). Last reviewed: November 16, 2025 Link copied - COVID-19 - Vaccine Products ## How well do COVID-19 vaccines work? The benefit of COVID-19 vaccination to an individual patient varies depending on the health status of the patient, their history of vaccination and COVID-19 infection, and the circulating COVID-19 strains. However, despite these variables, observational studies consistently show vaccination in all age groups provides measurable additional protection against hospitalization or death compared to those who are unvaccinated. CDC published “Interim Estimates of 2024–2025 COVID-19 Vaccine Effectiveness Among Adults Aged ≥18 Years — VISION and IVY Networks, September 2024–January 2025” in MMWR on February 27, 2025 ([www.cdc.gov/mmwr/volumes/74/wr/mm7406a1.htm](http://www.cdc.gov/mmwr/volumes/74/wr/mm7406a1.htm)). They concluded vaccine effectiveness (VE) of 2024–2025 COVID-19 vaccine was 33% against COVID-19–associated emergency department (ED) or urgent care (UC) visits among adults age18 years or older and 45%–46% against hospitalizations among immunocompetent adults age 65 years or older, compared with not receiving a 2024–2025 vaccine dose. VE against hospitalizations in immunocompromised adults age 65 years or older was 40%. Last reviewed: November 16, 2025 Link copied - COVID-19 - Vaccine Products ## Where can I obtain detailed information about the COVID-19 vaccines? CDC has a product-specific webpage for each COVID-19 vaccine ([www.cdc.gov/vaccines/covid-19/info-by-product/index.html](http://www.cdc.gov/vaccines/covid-19/info-by-product/index.html)); however, at this writing the page has not been updated for the 2025–2026 Formula COVID-19 vaccines. You may access the package inserts for all four licensed 2025–26 COVID-19 vaccines on the Immunize.org COVID-19 main page: [www.immunize.org/vaccines/a-z/covid-19/](http://www.immunize.org/vaccines/a-z/covid-19/). Last reviewed: November 16, 2025 Link copied - COVID-19 - For Children under 12 Years ## What are the differences between the 2025–26 season recommendations for COVID-19 vaccination of children from CDC and from the American Academy of Pediatrics (AAP)? CDC and ACIP recommend vaccination of all people age 6 months through 64 years based on individual decision-making (also known as shared clinical decision-making), with an emphasis that the risk-benefit of vaccination is most favorable for individuals who are at an increased risk for severe COVID-19 disease and lowest for individuals who are not at an increased risk, according to the CDC list of COVID-19 risk factors. Refer to CDC’s interim clinical considerations for COVID-19 vaccination for the specific dosing schedule: [www.cdc.gov/covid/hcp/vaccine-considerations/routine-guidance.html\#cdc\_clinical\_guidance\_recomm\_key-table-1-2025–2026-covid-19-vaccination-schedule-november-4-2025](http://www.cdc.gov/covid/hcp/vaccine-considerations/routine-guidance.html#cdc_clinical_guidance_recomm_key-table-1-2025%E2%80%932026-covid-19-vaccination-schedule-november-4-2025). The American Academy of Pediatrics (AAP) has issued separate COVID-19 vaccination recommendations for children during the 2025–26 season. Refer to the full statement for details of their recommendations: <https://doi.org/10.1542/peds.2025-073924>. In summary, AAP recommends age-appropriate COVID-19 vaccination of the following groups of children: - All children age 6 months through 23 months - Residents of long-term care facilities or other congregate settings - Children who have never been vaccinated against COVID-19 - Infants and children with household contacts who are at high risk for severe COVID-19 - All children who are at risk of severe COVID-19 due to underlying conditions or treatments, including: chronic pulmonary disease, cardiovascular disease, gastrointestinal disorders, hepatic disease, hematologic disease, metabolic disorders, obesity, neurologic and neurodevelopmental conditions, immunosuppressive conditions, and rheumatologic or autoimmune disease - Children age 2 through 18 years not in the above categories whose parent or guardian desires their protection from COVID-19 Last reviewed: November 16, 2025 Link copied - COVID-19 - For Children under 12 Years ## My patient turns 12 years old next week and has never had a COVID-19 vaccination. His parents want to vaccinate him. What options are available? This child should receive one dose recommended for his age at the time of the vaccination visit. At age 11 years, an age-appropriate single dose of either Comirnaty (Pfizer-BioNTech) or Spikevax (Moderna) mRNA vaccine is recommended. If the patient arrives in your clinic after turning 12 years old, the 2025–2026 Formula Nuvaxovid (Sanofi-Novavax) protein subunit vaccine and the mNexspike (Moderna) mRNA vaccine are also options. Last reviewed: November 16, 2025 Link copied - COVID-19 - For Children under 12 Years ## My patient had the first dose of the 3-dose primary series of Pfizer-BioNTech COVID-19 vaccine using a 2024-2025 Formula Pfizer-BioNTech vaccine at age 19 months, but she turned 2 years old before returning for a second dose. We have only the 2025–2026 Spikevax vaccine. What should she get now? CDC states that a person who moves to an older age group before completing the initial series recommended for the younger age group should follow the schedule for the older age group and receive the vaccine product and dosage for the older age group. In this case, the child should receive one dose of 2025–2026 Formula Spikevax (Moderna) at least 8 weeks after the most recent dose of COVID-19 vaccine. An initial series of COVID-19 vaccine is recommended for children 6 months through 23 months of age. Children 24 months through 59 months of age are recommended to receive only one dose of 2025–2026 Formula Spikevax regardless of their COVID-19 vaccination history. Last reviewed: November 16, 2025 Link copied - COVID-19 - For Children under 12 Years ## Immunocompromised patients who are given mRNA vaccine are recommended to receive an age-appropriate 3-dose initial series. What dose do I use for a severely immunocompromised patient that starts the initial series at age 11 years but turns 12 before completing the 3-dose primary series? Moderately or severely immunocompromised children who transition from age 11 years to age 12 years during the initial vaccination series should complete the 3-dose series using the dosage for people ages 12 years and older for all doses received once they are age 12 years. See [www.cdc.gov/covid/hcp/vaccine-considerations/immunocompromised.html](http://www.cdc.gov/covid/hcp/vaccine-considerations/immunocompromised.html) for additional details. Last reviewed: November 16, 2025 Link copied - COVID-19 - For Children under 12 Years ## What do we know about the safety of Moderna and Pfizer-BioNTech mRNA COVID-19 vaccines in the youngest children? Both vaccines have been demonstrated to be safe, with side effects typical of those in older age groups. The most common local reaction in this age group is pain at the injection site; the most common systemic symptom in older children was fatigue and in younger children (6 through 23 months) irritability/crying and sleepiness were most common. Fever may occur after either vaccination. Febrile seizures can occur in infants and young children ages 6 months through 5 years as a result of any condition that causes a fever (most common with high fevers). Febrile seizures are uncommon after vaccination. Febrile seizures were rare after mRNA COVID-19 vaccine clinical trials in this age group, and CDC continues to monitor for this adverse event following vaccination in infants and young children. No cases of myocarditis were reported during the clinical trials for either vaccine. To date, post-authorization surveillance has not detected an increased risk for myocarditis and pericarditis following mRNA COVID-19 vaccination in children ages 6 months–4 years (Pfizer-BioNTech) and ages 6 months–5 years (Moderna). Last reviewed: November 16, 2025 Link copied - COVID-19 - For Children under 12 Years ## What do we know about the safety of Moderna and Pfizer-BioNTech mRNA COVID-19 vaccines in the youngest children? \[Video\] [![](https://www.immunize.org/wp-content/uploads/ask-experts/COVID-19/What-do-we-know-about-the-safety-and-effectiveness-of-Moderna-and-Pfizer.jpg)](https://www.youtube.com/watch?v=kXsLejc077A&list=PLqKEg4Y5HWfhjjcgcH7QZtk7sooXJC3wz&index=27) 3:20 [View All Video Questions](https://www.immunize.org/clinical/video/?wpsolr_fq%5B0%5D=subject_str%3AAsk%20the%20Experts) Last reviewed: November 16, 2025 Link copied - COVID-19 - For Adolescents & Adults ## What 2025–2026 Formula COVID-19 Vaccine options are available for adolescents age 12 years and older and adults? Comirnaty (Pfizer-BioNTech) mRNA COVID-19 vaccine is FDA-licensed for use in ages 5 years through 64 years with at least one underlying condition that puts them at risk for severe COVID-19 infection and individuals 65 years and older mNexspike (Moderna) is FDA-licensed for use in ages 12 through 64 years with at least one underlying condition that puts them at risk for severe COVID-19 infection and individuals 65 years and older Nuvaxovid (Sanofi-Novavax) is FDA-licensed for use in ages 12 through 64 years with at least one underlying condition that puts them at risk for severe COVID-19 infection and individuals 65 years and older Spikevax (Moderna) mRNA COVID-19 vaccine is FDA-licensed for use in ages 6 months through 64 years with at least one underlying condition that puts them at risk for severe COVID-19 infection and individuals 65 years and older Although the FDA licenses are limited in the age group younger than 65 years to those with underlying conditions that put them at risk for severe COVID-19 infection, the ACIP has recommended use based on individual decision-making (i.e., shared clinical decision-making) for all people age 6 months and older. This means that it is acceptable standard of care to offer COVID-19 vaccination to people in this age group without a high-risk condition when vaccination is desired. Last reviewed: November 16, 2025 Link copied - COVID-19 - For Adolescents & Adults ## What do we know about the safety and side effects of the Pfizer-BioNTech COVID-19 Vaccine in children and young teens in the 12- to 15-year-old age group? Clinical trial results for the original monovalent Pfizer-BioNTech COVID-19 Vaccine (administered as a two-dose primary series) demonstrated that among vaccine recipients age 12–15 years, side effects during the 7 days after vaccination were commonly reported (90.9% of vaccine recipients reported a local reaction and 90.7% reported a systemic reaction). Most reactions were mild to moderate. Pain at the injection site was the most common local reaction. One in 10 reported a side effect that interfered with daily activities. Side effects usually resolved after 1–2 days. Systemic side effects (e.g., fever, fatigue, headache, muscle pain) were more commonly reported after the second dose than after the first dose. No specific safety concerns were identified among adolescent vaccine recipients. The safety and side effects of the 2025–2026 formula are expected to be consistent with the previous formulations of the product. Last reviewed: November 16, 2025 Link copied - COVID-19 - For Adolescents & Adults ## How many doses of the 2025–2026 Formula COVID-19 adjuvanted protein subunit vaccine do recipients need this season? The 2025–2026 formula Nuvaxovid (Sanofi-Novavax) vaccine is an option for any person age 12 years or older who is due for a 2025–2026 updated vaccination. Below are listed the 2025–26 season dosing schedules (if using Nuvaxovid for all doses) for different ages and health conditions: - Age 12 through 64 years, not moderately or severely immunocompromised: one 2025–2026 formula dose, at least 8 weeks after most recent dose from a previous season - Age 65 years and older, not moderately or severely immunocompromised: two 2025–2026 formula doses 6 months apart (minimum interval 2 months) - Age 12 years or older, moderately or severely immunocompromised: - Previously unvaccinated: give 2 doses at least 3 weeks apart as an initial series, followed by a third dose about 6 months after dose 2 (minimum interval 2 months) - Previously completed an initial series of any COVID-19 vaccine (2 doses of Novavax protein subunit vaccine or 3 doses of an mRNA vaccine): give first 2025–2026 formula dose at least 8 weeks after most recent COVID-19 vaccine from the previous season, then give a second dose about 6 months later (minimum interval, 2 months) See Immunize.org’s standing orders template for administration of 2025–2026 formula adjuvanted protein subunit vaccine to individuals age 12 years and older for details: [www.immunize.org/wp-content/uploads/catg.d/p3141.pdf](http://www.immunize.org/wp-content/uploads/catg.d/p3141.pdf). Last reviewed: November 16, 2025 Link copied - COVID-19 - For Special Populations ## Are COVID-19 vaccines safe during pregnancy? Yes. Evidence continues to demonstrate that COVID-19 vaccination is safe and effective during any stage of pregnancy; the benefits of vaccination clearly outweigh any known or potential risks of COVID-19 vaccination during pregnancy. The currently licensed COVID-19 vaccines are nonreplicating vaccines and cannot cause infection in either the mother or the fetus. No evidence exists of risk to the fetus from vaccinating during pregnancy with nonreplicating vaccines in general. Data from the Vaccine Adverse Events Reporting System (VAERS), the V-safe surveillance system, and the V-safe pregnancy registry have not signaled any safety concerns related to vaccination during pregnancy for mother or infant. Pregnant women have historically been at an increased risk of severe disease, adverse pregnancy outcomes, and maternal death from COVID-19 infections. ACIP recommends the use of 2025–2026 COVID-19 vaccine during pregnancy based upon individual decision-making (i.e., shared clinical decision-making). The American College of Obstetricians and Gynecologists (ACOG) recommends all pregnant women receive any age-appropriate 2025–2026 Formula COVID-19 vaccine if they have not already received one. Current ACOG recommendations are available here: [www.acog.org/clinical/clinical-guidance/practice-advisory/articles/2020/12/covid-19-vaccination-considerations-for-obstetric-gynecologic-care](http://www.acog.org/clinical/clinical-guidance/practice-advisory/articles/2020/12/covid-19-vaccination-considerations-for-obstetric-gynecologic-care). Last reviewed: November 16, 2025 Link copied - COVID-19 - For Special Populations ## Are COVID-19 vaccines recommended during pregnancy? Pregnant women have historically been at an increased risk of severe disease, adverse pregnancy outcomes, and maternal death from COVID-19 infections. Studies have shown that antibodies produced after COVID-19 vaccination during pregnancy are transferred to the newborn, and COVID-19 vaccination during pregnancy reduces the risk of COVID-19 hospitalization in infants younger than 6 months. ACIP recommends the use of 2025–2026 COVID-19 vaccine during pregnancy based upon individual decision-making (i.e., shared clinical decision-making) after a discussion with a nurse, doctor, or pharmacist. The American College of Obstetricians and Gynecologists (ACOG) recommends all pregnant women receive any age-appropriate 2025–2026 Formula COVID-19 vaccine if they have not already received one. A person who is up to date on COVID-19 vaccination and becomes pregnant is not recommended to get an additional dose. Current ACOG recommendations are available here: [www.acog.org/clinical/clinical-guidance/practice-advisory/articles/2020/12/covid-19-vaccination-considerations-for-obstetric-gynecologic-care](http://www.acog.org/clinical/clinical-guidance/practice-advisory/articles/2020/12/covid-19-vaccination-considerations-for-obstetric-gynecologic-care). Last reviewed: November 16, 2025 Link copied - COVID-19 - For Special Populations ## Ask the Experts: Are COVID-19 vaccines helpful during pregnancy? \[Video\] [![](https://www.immunize.org/wp-content/uploads/ask-experts/COVID-19/are-covid19-vaccines-helpful-during-pregnancy.jpg)](https://youtu.be/ohhn6Nkkc0g;index=5) 1:34 [View All Video Questions](https://www.immunize.org/clinical/video/?wpsolr_fq%5B0%5D=subject_str%3AAsk%20the%20Experts) Last reviewed: January 9, 2026 Link copied - COVID-19 - For Special Populations ## May COVID-19 vaccines be given if the recipient is breastfeeding? Yes. COVID-19 vaccination may be given during lactation. Last reviewed: November 16, 2025 Link copied - COVID-19 - For Special Populations ## What is the 2025–2026 Formula COVID-19 vaccination schedule for moderately or severely immunocompromised people? Please see CDC’s Interim Clinical Considerations for the Use of COVID-19 Vaccines for dosage guidance for detailed tables, including dosing intervals and options ([www.cdc.gov/covid/hcp/vaccine-considerations/immunocompromised.html](http://www.cdc.gov/covid/hcp/vaccine-considerations/immunocompromised.html)). You will also find the vaccination schedules for people who are moderately or severely immunocompromised in the Immunize.org standing orders templates for administration of COVID-19 vaccines: - For ages 6 months through 11 years: [www.immunize.org/wp-content/uploads/catg.d/p3140a.pdf](http://www.immunize.org/wp-content/uploads/catg.d/p3140a.pdf) - mRNA vaccines for ages 12 years and older: [www.immunize.org/wp-content/uploads/catg.d/p3140.pdf](http://www.immunize.org/wp-content/uploads/catg.d/p3140.pdf) - Protein subunit vaccine for ages 12 years and older: [www.immunize.org/wp-content/uploads/catg.d/p3141.pdf](http://www.immunize.org/wp-content/uploads/catg.d/p3141.pdf) In general, people who are moderately or severely immunocompromised and previously unvaccinated are recommended to receive a 2-dose (protein subunit) or 3-dose (mRNA) initial series of COVID-19 vaccine, with an additional dose 6 months later of any age-appropriate COVID-19 brand (minimum interval of 2 months for Nuvaxovid, Spikevax, or Comirnaty; 3-month minimum interval for mNexspike). CDC recommends use of the same manufacturer for all doses of the initial series when feasible. Spikevax and mNexspike are both made by Moderna and are interchangeable in ages 12 years and older. Those who completed an initial series before the 2025–2026 formula vaccines were available should receive 2 doses of 2025–2026 Formula COVID-19 vaccine (any age-appropriate brand) about 6 months apart (minimum interval of 2 months for Nuvaxovid, Spikevax, or Comirnaty; 3-month minimum interval for mNexspike). Immunocompromised people should be counseled that they may have a reduced immune response to COVID-19 vaccination. Continuing other infection prevention measures, such as wearing a face mask and avoiding crowds, can help limit their risk of exposure to the SARS-CoV-2 virus. Pemivibart (Pemgarda, Invyvid) is a monoclonal antibody for COVID-19 pre-exposure prophylaxis in people who are moderately or severely immunocompromised and unlikely to mount an adequate immune response to COVID-19 vaccination and who meet the [FDA-authorized conditions for use](https://www.fda.gov/media/177067/download?attachment). See additional information from CDC at the immunocompromised link in the first paragraph. Last reviewed: November 16, 2025 Link copied - COVID-19 - For Special Populations ## What conditions or treatments are considered to qualify a person as moderately or severely immunocompromised for the purposes of COVID-19 vaccination? The conditions and treatments that CDC specifies may result in moderate or severe immunocompromise include but are not limited to: - Active treatment for solid tumor and hematologic malignancies - Hematologic malignancies associated with poor responses to COVID-19 vaccines regardless of current treatment status (e.g., chronic lymphocytic leukemia, non-Hodgkin lymphoma, multiple myeloma, acute leukemia) - Receipt of solid-organ transplant or an islet transplant and taking immunosuppressive therapy - Receipt of chimeric antigen receptor (CAR)-T-cell therapy or hematopoietic cell transplant (HCT) (within 2 years of transplantation or taking immunosuppressive therapy) - Moderate or severe primary immunodeficiency (e.g., common variable immunodeficiency disease, severe combined immunodeficiency, DiGeorge syndrome, Wiskott-Aldrich syndrome) - Advanced HIV infection (people with HIV and CD4 cell counts less than 200/mm³, history of an AIDS-defining illness without immune reconstitution, or clinical manifestations of symptomatic HIV) or untreated HIV infection - Active treatment with high-dose corticosteroids (i.e., 20 mg or more of prednisone or equivalent per day when administered for 2 or more weeks), alkylating agents, antimetabolites, transplant-related immunosuppressive drugs, cancer chemotherapeutic agents classified as severely immunosuppressive, tumor necrosis factor (TNF) blockers, and other biologic agents that are immunosuppressive or immunomodulatory (e.g., B-cell-depleting agents) Additional factors to consider in assessing the general level of immune competence in a patient include disease severity, duration, clinical stability, complications, comorbidities, and any potentially immune-suppressing treatment. A patient’s clinical care team is in the best position to evaluate the degree of immunocompromise and timing of vaccination. See CDC’s interim clinical considerations for this population: [www.cdc.gov/covid/hcp/vaccine-considerations/immunocompromised.html](http://www.cdc.gov/covid/hcp/vaccine-considerations/immunocompromised.html). Last reviewed: November 16, 2025 Link copied - COVID-19 - For Special Populations ## Are there any conditions when revaccination with a new initial series of COVID-19 vaccine may be indicated? Yes. See revaccination considerations at [www.cdc.gov/covid/hcp/vaccine-considerations/immunocompromised.html](http://www.cdc.gov/covid/hcp/vaccine-considerations/immunocompromised.html). This is the most current statement from CDC on COVID-19 revaccination: Recipients of chimeric antigen receptor (CAR)-T-cell therapy or hematopoietic cell transplant (HCT) who received 1 or more doses of COVID-19 vaccine prior to or during treatment should be revaccinated. Revaccination should start at least 3 months (12 weeks) after transplant or CAR-T-cell therapy and should follow the currently recommended schedule for people who are unvaccinated. Revaccination may also be considered for patients who received 1 or more doses of COVID-19 vaccine during treatment with B-cell-depleting therapies (e.g., rituximab, ocrelizumab) that were administered over a limited period (e.g., as part of a treatment regimen for certain malignancies) according to the currently recommended schedule for people who are unvaccinated. The suggested interval to start revaccination is about 6 months after completion of the B-cell-depleting therapy. Timing of vaccination for patients who receive B-cell-depleting therapies on a continuing basis (e.g., for treatment of certain autoimmune conditions such as rheumatoid arthritis or multiple sclerosis) is addressed in CDC’s [considerations for timing of COVID-19 vaccination in relation to immunosuppressive therapies](https://www.cdc.gov/covid/hcp/vaccine-considerations/immunocompromised.html#cdc_cg_special_populations_about-considerations-for-timing-of-covid-19-vaccination-in-relation-to-immunosuppressive-therapies). CDC continues to recommend that a patient’s clinical team is best positioned to determine the degree of immune compromise, need for revaccination, and appropriate timing of revaccination. Last reviewed: November 16, 2025 Link copied - COVID-19 - For Special Populations ## My patient receives periodic infusions of rituximab for immunosuppressive treatment of an immune system disorder. Should we try to coordinate the timing of his COVID-19 vaccinations around his infusion schedule? According to CDC’s interim clinical considerations for the use of COVID-19 vaccines, whenever possible, COVID-19 vaccines should be administered at least 2 weeks before initiation or resumption of immunosuppressive therapies. For patients who receive B-cell-depleting therapies on a continuing basis, COVID-19 vaccines should be administered approximately 4 weeks before the next scheduled therapy. CDC also notes that timing of COVID-19 vaccination should take into consideration current or planned immunosuppressive therapies, optimization of both the patient’s medical condition and response to vaccination, and individual benefits and risks. Review the CDC’s considerations for COVID-19 vaccination of those on immunosuppressive therapies here: [www.cdc.gov/covid/hcp/vaccine-considerations/immunocompromised.html\#cdc\_cg\_special\_populations\_about-considerations-for-timing-of-covid-19-vaccination-in-relation-to-immunosuppressive-therapies](http://www.cdc.gov/covid/hcp/vaccine-considerations/immunocompromised.html#cdc_cg_special_populations_about-considerations-for-timing-of-covid-19-vaccination-in-relation-to-immunosuppressive-therapies). On a case-by-case basis, providers caring for these patients may administer COVID-19 vaccines outside of the FDA and CDC dosing schedules based on their clinical judgment of what is most beneficial to the patient. Last reviewed: November 16, 2025 Link copied - COVID-19 - For Special Populations ## What proof do I need before giving COVID-19 vaccine to a patient who says he has a high-risk condition? CDC states that no additional medical documentation is required before administering COVID-19 vaccine. The patient’s self-attestation of a high-risk condition, including moderate or severe immunocompromise, is sufficient. Those who report moderate or severe immunocompromise should be offered the modified schedule for people with moderate or severe immunocompromise. Vaccinators should not deny COVID-19 vaccination to a person due to lack of documentation of a self-reported high-risk condition. Last reviewed: November 16, 2025 Link copied - COVID-19 - For Special Populations ## What proof do I need before giving COVID-19 vaccine to a person who says he is immunocompromised? \[Video\] [![](https://www.immunize.org/wp-content/uploads/ask-experts/COVID-19/proof-before-giving-covid-19-vaccine-if-immunocompromised.jpg)](https://www.youtube.com/watch?v=iVH0EOM03eI) 1:12 [View All Video Questions](https://www.immunize.org/clinical/video/?wpsolr_fq%5B0%5D=subject_str%3AAsk%20the%20Experts) Last reviewed: January 9, 2026 Link copied - COVID-19 - For Special Populations ## May different brands of 2025–2026 Formula COVID-19 vaccine be used for immunocompromised people who require multiple doses over time? Immunocompromised people who need an initial series of 3 doses of mRNA COVID-19 vaccine or two doses of Nuvaxovid (Sanofi-Novavax) adjuvanted protein COVID-19 vaccine should receive the initial series using COVID-19 vaccines from the same manufacturer, unless it is not feasible. If the same manufacturer cannot be used for all primary series doses (e.g., the brand is unavailable at the time of the vaccination visit, the previous brand is unknown, or the patient would not be vaccinated with the previous brand due to a contraindication or other reason), then administer another age-appropriate brand. Spikevax (Moderna) is the only licensed 2025–2026 Formula COVID-19 vaccine option for children younger than age 5 years. If the immunocompromised recipient is age 5 years or older, once the initial series is complete, any appropriate brand may be used for all subsequent doses. Spikevax and mNexspike are interchangeable: both vaccines are made by Moderna. Last reviewed: November 16, 2025 Link copied - COVID-19 - For Special Populations ## My patient takes high dose steroids and received a single dose of Janssen COVID-19 Vaccine (Johnson & Johnson) in 2021. He has had no doses since. He fits the definition for moderate or severe immunocompromise. What do I do now? The patient’s initial series is considered complete following a single dose of the Janssen COVID-19 Vaccine. People who are moderately or severely immunocompromised and have completed an initial series (no matter how long ago) should now receive 1 dose of an age-appropriate 2025–2026 Formula COVID-19 vaccine (at least 8 weeks after their most recent dose of a previous formulation). They should receive a second 2025–2026 Formula COVID-19 vaccine dose 6 months later (minimum interval 2 months for Comirnaty, Spikevax, and Nuvaxovid; minimum interval of 3 months if using mNexspike). Last reviewed: November 16, 2025 Link copied - COVID-19 - For Special Populations ## My adult patient is immunocompromised and we agree he should be vaccinated. The schedule says he should receive a third dose of mRNA COVID-19 vaccine to complete his initial series, but his most recent dose was 3 years ago. What do I do now? The patient should receive a 2025–2026 COVID-19 mRNA dose now, of the same manufacturer as the initial two doses (if feasible), in order to complete the 3-dose initial mRNA vaccine series recommended for people with moderate or severe immunocompromise. Advise the patient that he should receive an additional 2025–2026 Formula COVID-19 dose of any brand in 6 months (minimum interval 2 months if using Comirnaty, Spikevax, or Nuvaxovid; minimum interval 3 months if using mNexspike). Last reviewed: November 16, 2025 Link copied - COVID-19 - Administering Vaccines ## How are COVID-19 vaccines administered? All COVID-19 vaccines are administered intramuscularly. Preparation details and dose volume vary by product. Most 2025-2026 formula products are now available in manufacturer-filled syringes. Last reviewed: November 16, 2025 Link copied - COVID-19 - Administering Vaccines ## Has CDC provided clinical guidance on what to do if an error occurs while administering COVID-19 vaccinations? Yes. CDC published an appendix to its interim clinical considerations for the use of COVID-19 vaccines to address a wide range of errors in vaccine administration. It includes a detailed table outlining actions to take after an error has occurred: [www.cdc.gov/covid/hcp/vaccine-considerations/appendices.html](http://www.cdc.gov/covid/hcp/vaccine-considerations/appendices.html). Categories of errors covered in the CDC table include: - Site/route - Age - Product and dosage - Storage and handling - Incorrect intervals - Interchanging product types when not recommended Ask the Experts refers our readers to this CDC table for the most current and comprehensive guidance on COVID-19 vaccine administration errors and how to manage them. For all vaccine administration errors the following steps are recommended: inform the patient of the error, report the error to VAERS (<https://vaers.hhs.gov>) unless CDC’s guidance states that the error does not need to be reported, evaluate why the error occurred, and implement strategies to prevent future errors. Last reviewed: November 16, 2025 Link copied - COVID-19 - Administering Vaccines ## A dose of COVID-19 vaccine was administered subcutaneously instead of by the intramuscular route. Does the dose need to be repeated? No. CDC does not recommend repeating the dose of any COVID-19 vaccine in circumstances where the dose is administered in an incorrect route or an incorrect site (i.e., not in the deltoid or anterolateral thigh). In the case of a subcutaneous injection, the patient should be advised of the possibility of self-limited local or systemic side effects. Last reviewed: November 16, 2025 Link copied - COVID-19 - Administering Vaccines ## When giving COVID-19 vaccine, is use of a Vaccine Information Statement (VIS) required? Providing a vaccine recipient with a COVID-19 vaccine VIS is recommended by CDC but not required. The requirement to provide the VIS to a patient is present only when a vaccine is included in the federal Vaccine Injury Compensation Program (VICP). COVID-19 vaccines are not included in the VICP at this time. The current official VIS and all available translations are available from Immunize.org: [www.immunize.org/vaccines/vis/covid-19/](http://www.immunize.org/vaccines/vis/covid-19/). Last reviewed: November 16, 2025 Link copied - COVID-19 - Administering Vaccines ## When giving COVID-19 vaccine is use of a VIS required? \[Video\] [![](https://www.immunize.org/wp-content/uploads/ask-experts/COVID-19/when-giving-covid-19-vaccine-is-use-of-a-vis-required.jpg)](https://www.youtube.com/watch?v=-DAT6-_3kJY) 1:06 [View All Video Questions](https://www.immunize.org/clinical/video/?wpsolr_fq%5B0%5D=subject_str%3AAsk%20the%20Experts) Last reviewed: January 9, 2026 Link copied - COVID-19 - Scheduling Vaccines ## How can I confirm if I am using the most up-to-date information on COVID-19 vaccines? Periodically verify whether you are using the most current available documents by checking Immunize.org’s regularly updated Checklist of Current Versions of U.S. COVID-19 Vaccination Guidance and Clinic Support Tools: [www.immunize.org/catg.d/p3130.pdf](http://www.immunize.org/catg.d/p3130.pdf). This resource is updated as needed with the dates of the most currently available materials from CDC and FDA. Information from CDC is generally updated first on the CDC web page: Interim Clinical Considerations for Use of COVID-19 Vaccines in the United States: ([www.cdc.gov/covid/hcp/vaccine-considerations/index.html](http://www.cdc.gov/covid/hcp/vaccine-considerations/index.html)). Last reviewed: November 16, 2025 Link copied - COVID-19 - Scheduling Vaccines ## If a moderately or severely immunocompromised person has fallen far behind with recommended COVID-19 vaccination, do we ever need to re-start the initial vaccine series? No. Simply administer the next dose that is currently recommended, using a vaccine from the same manufacturer, if feasible, even if previous doses in the series were an earlier formulation. Last reviewed: November 16, 2025 Link copied - COVID-19 - Scheduling Vaccines ## My moderately immunocompromised patient is unvaccinated against COVID-19 and now wants to receive an initial series. I know there is a 4-day grace period that allows a dose to be valid if given up to 4 days before the minimum interval. Should we schedule her doses 4 days before the recommended intervals to get her vaccinated faster? CDC guidance allows for doses given up to 4 days before the recommended interval to be counted as valid – such doses do not need to be repeated. However, people should not be routinely scheduled to receive a dose earlier than recommended. Schedulers should offer appointments beginning on the date of the recommended interval or later. Last reviewed: November 16, 2025 Link copied - COVID-19 - Scheduling Vaccines ## If an 18-month-old patient received her first and only Pfizer-BioNTech mRNA COVID-19 vaccine last season, what should the child receive now? In this specific situation, a child age 6 months–23 months who received one 2024–2025 Formula Pfizer-BioNTech COVID-19 vaccine dose should receive 2 doses of Spikevax (Moderna) vaccine to complete the initial series. Refer to the schedule tables on the CDC website ([www.cdc.gov/covid/hcp/vaccine-considerations/routine-guidance.html\#cdc\_clinical\_guidance\_recomm\_key-table-1-2025–2026-covid-19-vaccination-schedule-november-4-2025](http://www.cdc.gov/covid/hcp/vaccine-considerations/routine-guidance.html#cdc_clinical_guidance_recomm_key-table-1-2025%E2%80%932026-covid-19-vaccination-schedule-november-4-2025)) or on the Immunize.org standing orders template for children age 6 months through 11 years ([www.immunize.org/wp-content/uploads/catg.d/p3140a.pdf](http://www.immunize.org/wp-content/uploads/catg.d/p3140a.pdf)) for specific dosing intervals. Last reviewed: November 16, 2025 Link copied - COVID-19 - Scheduling Vaccines ## Do previously unvaccinated patients who are not immunocompromised need two doses of Nuvaxovid (Sanofi-Novavax) COVID-19 vaccine in the 2025–2026 season? Beginning with the 2025–2026 season, a single dose of 2025–2026 Formula Nuvaxovid adjuvanted protein COVID-19 vaccine is recommended for all recipients age 12 through 64 years who are not moderately or severely immunocompromised, regardless of their vaccination history. Those age 65 years or older are recommended to receive a second dose of any 2025–2026 Formula COVID-19 vaccine 6 months after the first 2025–2026 Formula dose (minimum interval 2 months if using Comirnaty, Spikevax, or Nuvaxovid; minimum interval 3 months if using mNexspike). Last reviewed: November 16, 2025 Link copied - COVID-19 - Scheduling Vaccines ## What should be done if a patient scheduled for vaccination is exposed to COVID-19 or is sick with suspected or confirmed SARS-CoV-2 infection? An asymptomatic person who is scheduled for COVID-19 vaccination and is exposed to SARS-CoV-2 virus may be vaccinated. COVID-19 vaccination after exposure is not recommended as post-exposure prophylaxis, so vaccination should not be expected to prevent illness caused by past exposure. A person who is currently sick with a respiratory virus should defer vaccination until at least the recovery from the acute illness, and consider additional measures to prevent infecting others, in accordance with current CDC guidance. Healthcare facilities may have specific policies in place to reduce the risk of spread of respiratory viruses to healthcare staff and other patients. People who recently had SARS-CoV-2 infection and are due for a COVID-19 vaccine may consider delaying the dose by up to 3 months from symptom onset or positive test (if infection was asymptomatic). According to CDC, increasing the time between infection and vaccination may result in an improved immune response to vaccination. There is a low risk of reinfection in the weeks following an infection. A recipient’s individual risks for severe disease and current COVID-19 conditions in the community should be taken into consideration when deciding whether to delay vaccination up to 3 months after infection. Last reviewed: November 16, 2025 Link copied - COVID-19 - Scheduling Vaccines ## Can COVID-19 vaccine recipients be given other vaccines at the same visit? Routine administration of all age-appropriate doses of vaccines at the same visit, also known as coadministration, is acceptable for children, adolescents, and adults if there are no contraindications at the time of the healthcare visit. COVID-19 vaccine may also be coadministered with nirsevimab or clesrovimab (RSV preventive antibody for infants), given in different syringes and at different anatomical sites. COVID-19 vaccines may also be given at any interval before or after any other vaccination. There are special considerations for orthopoxvirus vaccination. There is no required minimum interval between receiving a dose of any COVID-19 vaccine and an orthopoxvirus vaccine, either Jynneos or ACAM2000 vaccine (e.g., for mpox prevention), regardless of which vaccine is administered first. However, use of Jynneos vaccine should be prioritized over ACAM2000 when co-administering a COVID-19 vaccine and an orthopoxvirus vaccine. People, particularly adolescent or young adult males, who are recommended to be vaccinated against both mpox and COVID-19 might consider waiting 4 weeks between vaccines. This is because of the observed risk for myocarditis and pericarditis after receipt of ACAM2000 orthopoxvirus vaccine and COVID-19 vaccines, and the hypothetical risk for myocarditis and pericarditis after Jynneos vaccine. However, if a patient’s risk for mpox or severe disease due to COVID-19 is increased, administration of mpox and COVID-19 vaccines should not be delayed. Last reviewed: November 16, 2025 Link copied - COVID-19 - Scheduling Vaccines ## My patient is age 70 and due for a second dose of recombinant zoster vaccine (Shingrix, GSK). The patient also is eligible for, and wants to receive, a COVID-19 vaccine dose. What should we advise our patient about scheduling these? Your patient may choose to receive the vaccines at the same visit or separately, without regard to the timing interval. When multiple vaccines are administered at a single visit, administer each injection in a different syringe and at a different injection site. For adolescents and adults, the deltoid muscle may be used for more than one injection, though injection sites should be at least one inch apart. It is generally preferable to administer reactogenic vaccines such as Shingrix and COVID-19 vaccine in different arms. However, if the patient prefers both injections in the same deltoid, that is also acceptable. Immunize.org has developed a one-page guide to administering multiple intramuscular vaccinations to an adult at one visit: [www.immunize.org/catg.d/p2030.pdf](http://www.immunize.org/catg.d/p2030.pdf). Last reviewed: November 16, 2025 Link copied - COVID-19 - Scheduling Vaccines ## How does the use of monoclonal antibodies or convalescent plasma to treat or prevent COVID-19 affect the scheduling of COVID-19 vaccination? The timing of CDC-recommended vaccination is unaffected by the receipt of COVID-19 monoclonal antibodies or convalescent plasma. Last reviewed: November 16, 2025 Link copied - COVID-19 - Contraindications & Precautions ## Please describe the contraindications for COVID-19 vaccination. We refer our readers to CDC’s updated set of contraindications and precautions to vaccination with COVID-19 vaccines, located in its interim clinical considerations for the use of COVID-19 vaccines in the United States: [www.cdc.gov/covid/hcp/vaccine-considerations/contraindications-precautions.html](http://www.cdc.gov/covid/hcp/vaccine-considerations/contraindications-precautions.html). Last reviewed: November 16, 2025 Link copied - COVID-19 - Contraindications & Precautions ## What are the precautions to COVID-19 vaccination? We refer our readers to CDC’s updated set of contraindications and precautions to COVID-19 vaccination, located in its interim clinical considerations for the use of COVID-19 vaccines: [www.cdc.gov/covid/hcp/vaccine-considerations/contraindications-precautions.html](http://www.cdc.gov/covid/hcp/vaccine-considerations/contraindications-precautions.html). Last reviewed: November 16, 2025 ## Posts pagination 1 [2](https://www.immunize.org/ask-experts/topic/covid-19/page/2/) [Next](https://www.immunize.org/ask-experts/topic/covid-19/page/2/) This page was updated on January 9, 2026 . - [Ask the Experts](https://www.immunize.org/ask-experts/) - [Ask the Experts Overview](http://www.immunize.org/ask-experts/overview/) - [View All Questions](https://www.immunize.org/ask-experts/) - [View All Video Questions](http://www.immunize.org/ask-experts/?q=%5Bvideo%5D) - [Vaccine Topics](http://www.immunize.org/ask-experts/topic/covid-19/) - [COVID-19](http://www.immunize.org/ask-experts/topic/covid-19/) - [All COVID-19](https://www.immunize.org/ask-experts/topic/covid-19/) - [Disease Issues](https://www.immunize.org/ask-experts/topic/covid-19/disease-issues/) - [Vaccine Recommendations](https://www.immunize.org/ask-experts/topic/covid-19/vaccine-recommendations-covid-19/) - [Vaccine Products](https://www.immunize.org/ask-experts/topic/covid-19/vaccine-products-covid-19/) - [For Children Under 12](https://www.immunize.org/ask-experts/topic/covid-19/children-under-12-covid-19/) - [For Adolescents & Adults](https://www.immunize.org/ask-experts/topic/covid-19/adolescents-adults-covid-19/) - [For Special Populations](https://www.immunize.org/ask-experts/topic/covid-19/special-populations-covid-19/) - [Administering Vaccines](https://www.immunize.org/ask-experts/topic/covid-19/admin-vaccines-covid-19/) - [Scheduling Vaccines](https://www.immunize.org/ask-experts/topic/covid-19/scheduling-vaccines-covid-19/) - [Contraindications & Precautions](https://www.immunize.org/ask-experts/topic/covid-19/contraindications-precautions-covid-19/) - [Storage & Handling](https://www.immunize.org/ask-experts/topic/covid-19/storage-handling-covid-19/) - [Dengue](http://www.immunize.org/ask-experts/topic/covid-19/) - [All Dengue](https://www.immunize.org/ask-experts/topic/dengue/) - [Disease Issues](https://www.immunize.org/ask-experts/topic/dengue/disease-issues-dengue/) - [Vaccine Products](https://www.immunize.org/ask-experts/topic/dengue/vaccine-products-dengue/) - [Vaccine Recommendations](https://www.immunize.org/ask-experts/topic/dengue/vaccine-recommendations-dengue/) - [Prevaccination Testing](https://www.immunize.org/ask-experts/topic/dengue/prevaccination-testing/) - [Scheduling & Administration](https://www.immunize.org/ask-experts/topic/dengue/scheduling-administration-dengue/) - [Contraindications & Precautions](https://www.immunize.org/ask-experts/topic/dengue/contraindications-precautions-dengue/) - [Vaccine Safety](https://www.immunize.org/ask-experts/topic/dengue/vaccine-safety-dengue/) - [Storage & Handling](https://www.immunize.org/ask-experts/topic/dengue/storage-handling-dengue/) - [Diphtheria](http://www.immunize.org/ask-experts/topic/covid-19/) - [All Diphtheria](https://www.immunize.org/ask-experts/topic/diphtheria/) - [Disease Issues](https://www.immunize.org/ask-experts/topic/diphtheria/disease-issues-diphtheria/) - [Vaccine Recommendations](https://www.immunize.org/ask-experts/topic/diphtheria/vaccine-recommendations-diphtheria/) - [Vaccine Products](https://www.immunize.org/ask-experts/topic/diphtheria/vaccine-products-diphtheria/) - [Tdap for Adolescents & Adults](https://www.immunize.org/ask-experts/topic/diphtheria/tdap-adolescents-adults-diphtheria/) - [Tdap & Pregnancy](https://www.immunize.org/ask-experts/topic/diphtheria/tdap-pregnancy-diphtheria/) - [Scheduling Vaccines](https://www.immunize.org/ask-experts/topic/diphtheria/scheduling-vaccines-diphtheria/) - [Contraindications & Precautions](https://www.immunize.org/ask-experts/topic/diphtheria/contraindications-precautions-diphtheria/) - [Tetanus & Wound Management](https://www.immunize.org/ask-experts/topic/diphtheria/tetanus-wound-management-diphtheria/) - [Storage & Handling](https://www.immunize.org/ask-experts/topic/diphtheria/storage-handling-diphtheria/) - [Hepatitis A](http://www.immunize.org/ask-experts/topic/covid-19/) - [All Hep A](https://www.immunize.org/ask-experts/topic/hepa/) - [Disease Issues](https://www.immunize.org/ask-experts/topic/hepa/disease-issues-hepa/) - [Vaccine Recommendations](https://www.immunize.org/ask-experts/topic/hepa/vaccine-recommendations-hepa/) - [For Special Populations](https://www.immunize.org/ask-experts/topic/hepa/special-populations-hepa/) - [Administering Vaccines](https://www.immunize.org/ask-experts/topic/hepa/admin-vaccines-hepa/) - [Twinrix](https://www.immunize.org/ask-experts/topic/hepa/twinrix/) - [Immune Globulin](https://www.immunize.org/ask-experts/topic/hepa/immune-globulin/) - [Intʼl Travel](https://www.immunize.org/ask-experts/topic/hepa/international-travel/) - [Vaccine Safety](https://www.immunize.org/ask-experts/topic/hepa/vaccine-safety-hepa/) - [Contraindications & Precautions](https://www.immunize.org/ask-experts/topic/hepa/contraindications-precautions-hepa/) - [Storage & Handling](https://www.immunize.org/ask-experts/topic/hepa/storage-handling-hepa/) - [Hepatitis B](http://www.immunize.org/ask-experts/topic/covid-19/) - [All Hep B](https://www.immunize.org/ask-experts/topic/hepb/) - [Disease Issues](https://www.immunize.org/ask-experts/topic/hepb/disease-issues-hepb/) - [Tests & Interpretation](https://www.immunize.org/ask-experts/topic/hepb/tests-interpretation/) - [Vaccine Recommendations](https://www.immunize.org/ask-experts/topic/hepb/vaccine-recommendations-hepb/) - [Pregnancy, Perinatal & Infants](https://www.immunize.org/ask-experts/topic/hepb/pregnancy-perinatal-infants/) - [For Children & Teens](https://www.immunize.org/ask-experts/topic/hepb/children-teens/) - [For Adults (includes HBV Screening)](https://www.immunize.org/ask-experts/topic/hepb/adults/) - [For Healthcare Personnel](https://www.immunize.org/ask-experts/topic/hepb/healthcare-personnel/) - [Vaccine Safety](https://www.immunize.org/ask-experts/topic/hepb/vaccine-safety-hepb/) - [Contraindications & Precautions](https://www.immunize.org/ask-experts/topic/hepb/contraindications-precautions-hepb/) - [Storage & Handling](https://www.immunize.org/ask-experts/topic/hepb/storage-handling-hepb/) - [Hib (Haemophilus Influenzae type b)](http://www.immunize.org/ask-experts/topic/covid-19/) - [All Hib](https://www.immunize.org/ask-experts/topic/hib/) - [Disease Issues](https://www.immunize.org/ask-experts/topic/hib/disease-issues-hib/) - [Vaccine Recommendations](https://www.immunize.org/ask-experts/topic/hib/vaccine-recommendations-hib/) - [Scheduling & Administration](https://www.immunize.org/ask-experts/topic/hib/scheduling-administration-hib/) - [Contraindications & Precautions](https://www.immunize.org/ask-experts/topic/hib/contraindications-precautions-hib/) - [Vaccine Safety](https://www.immunize.org/ask-experts/topic/hib/vaccine-safety-hib/) - [Storage & Handling](https://www.immunize.org/ask-experts/topic/hib/storage-handling-hib/) - [Chemoprophylaxis](https://www.immunize.org/ask-experts/topic/hib/chemoprophylaxis/) - [HPV (Human Papillomavirus)](http://www.immunize.org/ask-experts/topic/covid-19/) - [All HPV](https://www.immunize.org/ask-experts/topic/hpv/) - [Disease Issues](https://www.immunize.org/ask-experts/topic/hpv/disease-issues-hpv/) - [Vaccine Recommendations](https://www.immunize.org/ask-experts/topic/hpv/vaccine-recommendations-hpv/) - [Scheduling & Administration](https://www.immunize.org/ask-experts/topic/hpv/scheduling-administration-hpv/) - [Contraindications & Precautions](https://www.immunize.org/ask-experts/topic/hpv/contraindications-precautions-hpv/) - [Vaccine Safety](https://www.immunize.org/ask-experts/topic/hpv/vaccine-safety-hpv/) - [Storage & Handling](https://www.immunize.org/ask-experts/topic/hpv/storage-handling-hpv/) - [Influenza](http://www.immunize.org/ask-experts/topic/covid-19/) - [All Influenza](https://www.immunize.org/ask-experts/topic/influenza/) - [Disease Issues](https://www.immunize.org/ask-experts/topic/influenza/disease-issues-influenza/) - [Vaccine Recommendations](https://www.immunize.org/ask-experts/topic/influenza/vaccine-recommendations-influenza/) - [For Children](https://www.immunize.org/ask-experts/topic/influenza/children/) - [For Special Populations](https://www.immunize.org/ask-experts/topic/influenza/special-populations-influenza/) - [For Healthcare Personnel](https://www.immunize.org/ask-experts/topic/influenza/healthcare-personnel-influenza/) - [Contraindications & Precautions](https://www.immunize.org/ask-experts/topic/influenza/contraindications-precautions-influenza/) - [LAIV Issues](https://www.immunize.org/ask-experts/topic/influenza/laiv-issues/) - [Administering Vaccines](https://www.immunize.org/ask-experts/topic/influenza/admin-vaccines-influenza/) - [Storage & Handling](https://www.immunize.org/ask-experts/topic/influenza/storage-handling-influenza/) - [MMR (Measles, Mumps, and Rubella)](http://www.immunize.org/ask-experts/topic/covid-19/) - [All MMR](https://www.immunize.org/ask-experts/topic/mmr/) - [Disease Issues](https://www.immunize.org/ask-experts/topic/mmr/disease-issues-mmr/) - [Vaccine Recommendations](https://www.immunize.org/ask-experts/topic/mmr/vaccine-recommendations-mmr/) - [Administering Vaccines](https://www.immunize.org/ask-experts/topic/mmr/admin-vaccines-mmr/) - [Scheduling Vaccines](https://www.immunize.org/ask-experts/topic/mmr/scheduling-vaccines-mmr/) - [For Healthcare Personnel](https://www.immunize.org/ask-experts/topic/mmr/for-healthcare-personnel-mmr/) - [Contraindications & Precautions](https://www.immunize.org/ask-experts/topic/mmr/contraindications-precautions-mmr/) - [Pregnancy & Postpartum](https://www.immunize.org/ask-experts/topic/mmr/pregnancy-postpartum-considerations/) - [Vaccine Safety](https://www.immunize.org/ask-experts/topic/mmr/vaccine-safety-mmr/) - [Storage & Handling](https://www.immunize.org/ask-experts/topic/mmr/storage-handling-mmr/) - [Meningococcal ACWY](http://www.immunize.org/ask-experts/topic/covid-19/) - [All MenACWY](https://www.immunize.org/ask-experts/topic/menacwy/) - [Disease Issues](https://www.immunize.org/ask-experts/topic/menacwy/disease-issues-menacwy/) - [Vaccine Recommendations](https://www.immunize.org/ask-experts/topic/menacwy/vaccine-recommendations-menacwy/) - [For People with Risk Factors](https://www.immunize.org/ask-experts/topic/menacwy/risk-factors/) - [Booster Doses](https://www.immunize.org/ask-experts/topic/menacwy/booster-doses/) - [Administering Vaccines](https://www.immunize.org/ask-experts/topic/menacwy/admin-vaccines-menacwy/) - [Vaccine Safety](https://www.immunize.org/ask-experts/topic/menacwy/vaccine-safety-menacwy/) - [Contraindications & Precautions](https://www.immunize.org/ask-experts/topic/menacwy/contraindications-precautions-menacwy/) - [Storage & Handling](https://www.immunize.org/ask-experts/topic/menacwy/storage-handling-menacwy/) - [Meningococcal B](http://www.immunize.org/ask-experts/topic/covid-19/) - [All Men B](https://www.immunize.org/ask-experts/topic/menb/) - [Disease Issues](https://www.immunize.org/ask-experts/topic/menb/disease-issues-menb/) - [Vaccine Recommendations](https://www.immunize.org/ask-experts/topic/menb/vaccine-recommendations-menb/) - [For People with Risk Factors](https://www.immunize.org/ask-experts/topic/menb/risk-factors-menb/) - [Booster Doses](https://www.immunize.org/ask-experts/topic/menb/booster-doses-menb/) - [Administering Vaccines](https://www.immunize.org/ask-experts/topic/menb/admin-vaccines-menb/) - [Vaccine Safety](https://www.immunize.org/ask-experts/topic/menb/vaccine-safety-menb/) - [Contraindications & Precautions](https://www.immunize.org/ask-experts/topic/menb/contraindications-precautions-menb/) - [Storage & Handling](https://www.immunize.org/ask-experts/topic/menb/storage-handling-menb/) - [Pertussis](http://www.immunize.org/ask-experts/topic/covid-19/) - [All Pertussis](https://www.immunize.org/ask-experts/topic/pertussis/) - [Disease Issues](https://www.immunize.org/ask-experts/topic/pertussis/disease-issues-pertussis/) - [Vaccine Recommendations](https://www.immunize.org/ask-experts/topic/pertussis/vaccine-recommendations-pertussis/) - [Vaccine Products](https://www.immunize.org/ask-experts/topic/pertussis/vaccine-products-pertussis/) - [Tdap for Adolescents & Adults](https://www.immunize.org/ask-experts/topic/pertussis/tdap-adolescents-adults-pertussis/) - [Tdap & Pregnancy](https://www.immunize.org/ask-experts/topic/pertussis/tdap-pregnancy-pertussis/) - [Scheduling Vaccines](https://www.immunize.org/ask-experts/topic/pertussis/scheduling-vaccines-pertussis/) - [Contraindications & Precautions](https://www.immunize.org/ask-experts/topic/pertussis/contraindications-precautions-pertussis/) - [Tetanus & Wound Management](https://www.immunize.org/ask-experts/topic/pertussis/tetanus-wound-management-pertussis/) - [Storage & Handling](https://www.immunize.org/ask-experts/topic/pertussis/storage-handling-pertussis/) - [Pneumococcal](http://www.immunize.org/ask-experts/topic/covid-19/) - [All Pneumococcal](https://www.immunize.org/ask-experts/topic/pneumococcal/) - [Disease Issues](https://www.immunize.org/ask-experts/topic/pneumococcal/disease-issues-pneumococcal/) - [Vaccine Products](https://www.immunize.org/ask-experts/topic/pneumococcal/vaccine-products-pneumococcal/) - [Recommendations for Children](https://www.immunize.org/ask-experts/topic/pneumococcal/recommendations-children/) - [Recommendations for Adults](https://www.immunize.org/ask-experts/topic/pneumococcal/recommendations-adults/) - [Adults and PCV13](https://www.immunize.org/ask-experts/topic/pneumococcal/adults-pcv13/) - [Miscellaneous Vaccine Issues](https://www.immunize.org/ask-experts/topic/pneumococcal/miscellaneous/) - [Scheduling & Documentation](https://www.immunize.org/ask-experts/topic/pneumococcal/scheduling-documentation/) - [Administering Vaccines](https://www.immunize.org/ask-experts/topic/pneumococcal/admin-vaccines-pneumococcal/) - [Storage & Handling](https://www.immunize.org/ask-experts/topic/pneumococcal/storage-handling-pneumococcal/) - [Polio](https://www.immunize.org/ask-experts/topic/polio/) - [Rabies](https://www.immunize.org/ask-experts/topic/rabies/) - [Rotavirus](http://www.immunize.org/ask-experts/topic/covid-19/) - [All Rotavirus](https://www.immunize.org/ask-experts/topic/rotavirus/) - [Disease Issues](https://www.immunize.org/ask-experts/topic/rotavirus/disease-issues-rotavirus/) - [Vaccine Recommendations](https://www.immunize.org/ask-experts/topic/rotavirus/vaccine-recommendations-rotavirus/) - [Scheduling & Administration](https://www.immunize.org/ask-experts/topic/rotavirus/scheduling-administration-rotavirus/) - [Contraindications & Precautions](https://www.immunize.org/ask-experts/topic/rotavirus/contraindications-precautions-rotavirus/) - [Vaccine Safety](https://www.immunize.org/ask-experts/topic/rotavirus/vaccine-safety-rotavirus/) - [Storage & Handling](https://www.immunize.org/ask-experts/topic/rotavirus/storage-handling-rotavirus/) - [RSV (Respiratory Syncytial Virus)](http://www.immunize.org/ask-experts/topic/covid-19/) - [All RSV](http://www.immunize.org/ask-experts/topic/rsv) - [Disease Issues](http://www.immunize.org/ask-experts/topic/disease-issues-rsv) - [Vaccine Products](http://www.immunize.org/ask-experts/topic/vaccine-products-rsv) - [Vaccine Recommendations for Older Adults](http://www.immunize.org/ask-experts/topic/vaccine-recs-adults-rsv) - [Vaccine Recommendations during Pregnancy](http://www.immunize.org/ask-experts/topic/vaccine-recs-pregnancy-rsv) - [Vaccine Administration](http://www.immunize.org/ask-experts/topic/vaccine-admin-rsv) - [RSV Preventive Antibody Products](https://www.immunize.org/ask-experts/topic/rsv/rsv-preventive-antibody/) - [RSV mAb Recommendations for Infants](https://www.immunize.org/ask-experts/topic/rsv/rsv-preventive-antibody-infants/) - [RSV mAb Administration](https://www.immunize.org/ask-experts/topic/rsv/rsv-preventive-antibody-admin/) - [Scheduling & Documentation (Vaccines and mAb)](https://www.immunize.org/ask-experts/topic/rsv/scheduling-documentation-rsv/) - [Safety (Vaccines and mAb)](https://www.immunize.org/ask-experts/topic/rsv/safety-rsv/) - [Contraindications & Precautions (Vaccines and mAb)](https://www.immunize.org/ask-experts/topic/rsv/contraindication-precautions-rsv/) - [Storage & Handling (Vaccines and mAb)](https://www.immunize.org/ask-experts/topic/rsv/storage-handling-rsv/) - [Tetanus](http://www.immunize.org/ask-experts/topic/covid-19/) - [All Tetanus](https://www.immunize.org/ask-experts/topic/tetanus/) - [Disease Issues](https://www.immunize.org/ask-experts/topic/tetanus/disease-issues-tetanus/) - [Vaccine Recommendations](https://www.immunize.org/ask-experts/topic/tetanus/vaccine-recommendations-tetanus/) - [Vaccine Products](https://www.immunize.org/ask-experts/topic/tetanus/vaccine-products-tetanus/) - [Tdap for Adolescents & Adults](https://www.immunize.org/ask-experts/topic/tetanus/tdap-adolescents-adults/) - [Tdap & Pregnancy](https://www.immunize.org/ask-experts/topic/tetanus/tdap-pregnancy/) - [Scheduling Vaccines](https://www.immunize.org/ask-experts/topic/tetanus/scheduling-vaccines-tetanus/) - [Contraindications & Precautions](https://www.immunize.org/ask-experts/topic/tetanus/contraindications-precautions-tetanus/) - [Wound Management](https://www.immunize.org/ask-experts/topic/tetanus/wound-management/) - [Storage & Handling](https://www.immunize.org/ask-experts/topic/tetanus/storage-handling-tetanus/) - [Varicella (Chickenpox)](http://www.immunize.org/ask-experts/topic/covid-19/) - [All Varicella](https://www.immunize.org/ask-experts/topic/varicella/) - [Disease Issues](https://www.immunize.org/ask-experts/topic/varicella/disease-issues-varicella/) - [Vaccine Recommendations](https://www.immunize.org/ask-experts/topic/varicella/vaccine-recommendations-varicella/) - [Scheduling Vaccines](https://www.immunize.org/ask-experts/topic/varicella/scheduling-vaccines-varicella/) - [Contraindications & Precautions](https://www.immunize.org/ask-experts/topic/varicella/contraindications-precautions-varicella/) - [Vaccine Safety](https://www.immunize.org/ask-experts/topic/varicella/vaccine-safety-varicella/) - [Varicella Zoster Immune Globulin](https://www.immunize.org/ask-experts/topic/varicella/varicella-zoster-immune-globulin/) - [Storage & Handling](https://www.immunize.org/ask-experts/topic/varicella/storage-handling-varicella/) - [Zoster (Shingles)](http://www.immunize.org/ask-experts/topic/covid-19/) - [All Zoster](https://www.immunize.org/ask-experts/topic/zoster/) - [Disease Issues](https://www.immunize.org/ask-experts/topic/zoster/disease-issues-zoster-shingles/) - [Vaccine Recommendations](https://www.immunize.org/ask-experts/topic/zoster/vaccine-recommendations-zoster-shingles/) - [Immunocompromised Adults](https://www.immunize.org/ask-experts/topic/zoster/immunocompromised-adults/) - [Vaccine Safety](https://www.immunize.org/ask-experts/topic/zoster/vaccine-safety-zoster-shingles/) - [Contraindications & Precautions](https://www.immunize.org/ask-experts/topic/zoster/contraindications-precautions-zoster-shingles/) - [Administering Vaccines](https://www.immunize.org/ask-experts/topic/zoster/admin-vaccines-zoster/) - [Storage & Handling](https://www.immunize.org/ask-experts/topic/zoster/storage-handling-zoster-shingles/) - [General Topics](http://www.immunize.org/ask-experts/topic/covid-19/) - [Administering Vaccines](http://www.immunize.org/ask-experts/topic/covid-19/) - [All Administering Vaccines](https://www.immunize.org/ask-experts/topic/admin-vaccines/) - [General Issues](https://www.immunize.org/ask-experts/topic/admin-vaccines/general-issues/) - [Administration Errors](https://www.immunize.org/ask-experts/topic/admin-vaccines/vaccine-admin-errors/) - [Billing & Reimbursement](https://www.immunize.org/ask-experts/topic/billing-reimburse/) - [Combination Vaccines](http://www.immunize.org/ask-experts/topic/covid-19/) - [All Combo Vaccines](https://www.immunize.org/ask-experts/topic/combo-vaccines/) - [General Issues](https://www.immunize.org/ask-experts/topic/combo-vaccines/combo-general/) - [DTaP-IPV-HepB](https://www.immunize.org/ask-experts/topic/combo-vaccines/dtap-ipv-hepb/) - [DTaP-IPV/Hib](https://www.immunize.org/ask-experts/topic/combo-vaccines/dtap-ipv-hib/) - [DTaP-IPV-Hib-HepB](https://www.immunize.org/ask-experts/topic/combo-vaccines/dtap-ipv-hib-hepb/) - [DTaP-IPV](https://www.immunize.org/ask-experts/topic/combo-vaccines/dtap-ipv/) - [HepA-HepB](https://www.immunize.org/ask-experts/topic/combo-vaccines/hepa-hepb/) - [MMRV](https://www.immunize.org/ask-experts/topic/combo-vaccines/mmrv/) - [Contraindications & Precautions](https://www.immunize.org/ask-experts/topic/contraindications-precautions/) - [Documenting Vaccination](https://www.immunize.org/ask-experts/topic/documenting-vaccination/) - [Scheduling Vaccines](https://www.immunize.org/ask-experts/topic/scheduling-vaccines/) - [Storage & Handling](http://www.immunize.org/ask-experts/topic/covid-19/) - [All Storage & Handling](https://www.immunize.org/ask-experts/topic/storage-handling/) - [Vaccine Storage Units](https://www.immunize.org/ask-experts/topic/storage-handling/vaccine-storage-units/) - [Temperature Monitoring & Controls](https://www.immunize.org/ask-experts/topic/storage-handling/temperature-monitoring-controls/) - [Troubleshooting & Follow-Up](https://www.immunize.org/ask-experts/topic/storage-handling/troubleshooting-follow-up/) - [Vaccine Viability & Expiration](https://www.immunize.org/ask-experts/topic/storage-handling/vaccine-viability-expiration/) - [Resources](https://www.immunize.org/ask-experts/topic/storage-handling/resources/) - [Travel Vaccines](https://www.immunize.org/ask-experts/topic/travel-vaccines/) - [Vaccine Recommendations](https://www.immunize.org/ask-experts/topic/vaccine-recs/) - [Vaccine Safety](https://www.immunize.org/ask-experts/topic/vaccine-safety/) #### On This Page - [Search & Filter](http://www.immunize.org/ask-experts/topic/covid-19/#offcanvasResponsive) - [Back to Top](http://www.immunize.org/ask-experts/topic/covid-19/#page) ### Our Affiliated Sites [For the Public: VaccineInformation.org](https://vaccineinformation.org/) [For Coalitions: ImmunizationCoalitions.org](https://immunizationcoalitions.org/) [Let's Get Real Information about pediatric vaccines for parents and providers.](https://www.letsgetrealaboutvaccines.org/) [65+ Flu Defense Protect vulnerable, older adult patients from influenza.](https://www.influenza-defense.org/) [Give2MenACWY.org Improve protection from meningococcal serogroups ACWY.](https://www.give2menacwy.org/) [NAIIS Home of the National Adult and Influenza Immunization Summit.](https://www.izsummitpartners.org/) ![](https://www.immunize.org/wp-content/uploads/icons/immunize.org-logo-white.svg) Save Lives. Immunize. - [“Facebook](https://facebook.com/ImmunizeOrg) - [“Instagram](https://instagram.com/immunizeorg/) - [“YouTube](https://youtube.com/user/ImmunizationAction/) #### About - [Our Mission](https://www.immunize.org/about/org/overview/) - [Our People](https://www.immunize.org/about/org/people/) - [Press Room](https://www.immunize.org/about/media/press-room/) - [Review Process](https://www.immunize.org/content-review/) - [Legal Disclaimer](https://www.immunize.org/disclaimer/) - [Privacy Policy](https://www.immunize.org/privacy-policy/) #### Support Our Work - [Shop](https://shop.immunize.org/) - [Donate](http://www.immunize.org/donate/) #### Contact [Contact us online](http://www.immunize.org/about/org/contact/) 2136 Ford Parkway Suite 5011 Saint Paul, Minnesota, 55116 T: 651-647-9009 F: 651-647-9131 #### Subscribe to IZ Express Weekly news from Immunize.org delivered free to your inbox This website is supported in part by a cooperative agreement from the National Center for Immunization and Respiratory Diseases (Grant No. NH23IP922654) at the Centers for Disease Control and Prevention (CDC) in Atlanta, GA. The website content is the sole responsibility of Immunize.org and does not necessarily represent the official views of CDC. Copyright © 2026 Immunize.org
Readable Markdown	The COVID-19 questions were last reviewed on November 16, 2025. See CDC’s [Use of COVID-19 Vaccines in the United States Interim Clinical Considerations](https://www.cdc.gov/vaccines/covid-19/clinical-considerations/covid-19-vaccines-us.html) for more information. To keep up with the current available COVID-19 resources from CDC, FDA, and Immunize.org, see Immunize.org’s [Checklist of Current Versions of U.S. COVID-19 Vaccine Guidance and Clinic Support Tools](https://www.immunize.org/wp-content/uploads/catg.d/p3130.pdf), updated at least monthly. For alerts about new Immunize.org or CDC COVID-19 resources, subscribe to our weekly e-newsletter, [IZ Express](https://www.immunize.org/subscribe). Results (89) COVID-19 is the name given to the disease caused by infection with the SARS-CoV-2 coronavirus. This virus was first detected as a cause of human illness in late 2019 in Wuhan, China, and triggered a global pandemic that began in 2020. The virus spreads mainly from person to person through respiratory droplets and small particles produced when an infected person coughs, sneezes, or talks. The virus spreads easily in crowded or poorly ventilated indoor settings. Some people who are infected have no symptoms of illness, while the severity of symptomatic illness ranges from mild to life-threatening. Older adults and people of any age with underlying medical conditions are at higher risk for severe illness. The incubation period after exposure ranges from 2–14 days, with an average of about 5 days. People with COVID-19 are generally considered potentially infectious up to 48 hours before symptom onset and up to 10 days after onset, though people with severe illness may be infectious longer. Symptoms may include fever or chills, cough, shortness of breath or difficulty breathing, fatigue, muscle or body aches, headache, new loss of taste or smell, sore throat, congestion or runny nose, nausea or vomiting, and diarrhea. Last reviewed: November 16, 2025 The list of underlying health conditions and other factors shown to increase the risk of severe COVID-19 illness is long. Advanced age remains the strongest risk factor. In addition to age, CDC states that data has shown that compared to non-Hispanic White people, people from racial and ethnic minority groups are more likely to be infected with SARS-CoV-2. Once infected, people from racial and ethnic minority groups are more likely to be hospitalized, be admitted to the ICU, and die from COVID-19 at younger ages. CDC provides a list of at-risk conditions at this website: [www.cdc.gov/covid/hcp/clinical-care/underlying-conditions.html](http://www.cdc.gov/covid/hcp/clinical-care/underlying-conditions.html). The conditions are stratified by strength of published evidence. Immunize.org provides an age-appropriate list of high-risk conditions with conclusive or suggestive published evidence as part of each of its standing orders templates for use of 2025-2026 COVID-19 vaccines, all of which may be found on the COVID-19 main page: [www.immunize.org/vaccines/a-z/covid-19/](http://www.immunize.org/vaccines/a-z/covid-19/). Last reviewed: November 16, 2025 The CDC has assembled clinical information about COVID-19 at this site: [www.cdc.gov/covid/hcp](https://www.cdc.gov/covid/hcp/). Last reviewed: November 16, 2025 The ACIP recommended on September 18, 2025, that all people age 6 months and older in the United States may receive one or more doses of an age-appropriate 2025–2026 Formula COVID-19 vaccination based on individual decision-making, following shared clinical decision-making discussion with a healthcare professional (e.g., a nurse, doctor, or pharmacist). The decision to vaccinate may be influenced by the presence of conditions that increase the risk of severe COVID-19 illness. Product options include three FDA-licensed mRNA vaccines: Comirnaty (Pfizer-BioNTech, ages 5 years and older); Spikevax (Moderna, ages 6 months and older); mNexspike (Moderna, ages 12 years and older). There is one FDA-licensed adjuvanted protein subunit vaccine: Nuvaxovid (Sanofi-Novavax, ages 12 years and older). Schedules vary by age and immunocompromised status. Although the FDA licenses limit use of COVID-19 vaccines among recipients younger than age 64 to those with one or more conditions that increases the risk of severe COVID-19, the fact that ACIP did not include any restrictions in its shared clinical decision-making recommendation means that it is an acceptable standard of care for people younger than age 65 without a high risk condition to be vaccinated when desired. Last reviewed: November 16, 2025 People who are moderately or severely immunocompromised are at increased risk for severe COVID-19 illness. ACIP and CDC recommend individual decision-making (also known as shared clinical decision-making) after a discussion with a healthcare professional (nurse, doctor, or pharmacist) for people age 6 months and older who are moderately or severely immunocompromised. They are recommended to receive at least 2 doses during the season. The CDC vaccination schedule for people with moderate or severe immunocompromise is available here: [www.cdc.gov/covid/hcp/vaccine-considerations/immunocompromised.html](http://www.cdc.gov/covid/hcp/vaccine-considerations/immunocompromised.html). The Infectious Diseases Society of America (IDSA) strongly recommends administration of age-appropriate 2025–2026 COVID-19 vaccinations to all adults and children with compromised immunity. They also recommend that household members and close contacts of immunocompromised people should be up to date with COVID-19 vaccination. See IDSA recommendations for full details: [www.idsociety.org/Seasonal-RTI-Vaccinations-in-Immunocompromised-Patients/](http://www.idsociety.org/Seasonal-RTI-Vaccinations-in-Immunocompromised-Patients/). Last reviewed: November 16, 2025 In past seasons, CDC recommended that all doses of COVID-19 vaccine given to children age 6 months through 4 years be from the same manufacturer. However, in the 2025–26 season, only Moderna’s Spikevax mRNA vaccine is licensed and recommended for use in children younger than age 5 years. All children in this age group who are vaccinated against COVID-19 should receive Spikevax, regardless of the brand they received in previous seasons. If the child is age 6 months through 23 months and received an incomplete (1- or 2-dose) initial COVID-19 vaccination series with Pfizer-BioNTech, a 3-dose initial series should be completed with Spikevax. It is not necessary to repeat the initial series. In previously unvaccinated people age 5 years or older with moderate or severe immunocompromise, the same manufacturer is recommended for all initial COVID-19 vaccine series doses (either 2 doses of Nuvaxovid \[if age 12 years or older\] or 3 doses of an mRNA product). After completion of the initial series, any age-appropriate COVID-19 vaccine may be used in this age group. CDC sets out conditions when it is acceptable to use an age-appropriate COVID-19 vaccine from a different manufacturer in any situation where the same manufacturer is recommended: - Same vaccine not available at the time of the clinic visit - Previous dose unknown - Person would otherwise not receive a recommended vaccine dose - Person starts but unable to complete a vaccination series with the same COVID-19 vaccine due to a contraindication Last reviewed: November 16, 2025 Individuals with moderate to severe immunocompromise who have completed an initial COVID-19 series should receive two dose of 2025–2026 Formula COVID-19 vaccine this season with the second dose given 6 months later (minimum interval 2 months for Comirnaty, Spikevax, and Nuvaxovid; minimum interval 3 months for mNexspike). In previous seasons, CDC recommended that additional doses of COVID-19 vaccine may be administered (with a minimum two-month interval) based on the clinical judgment of the individual’s healthcare provider and the recipient’s personal preference and circumstances. For the 2025–26 season, CDC has removed this general statement from its interim clinical considerations document ([www.cdc.gov/covid/hcp/vaccine-considerations/immunocompromised.html](http://www.cdc.gov/covid/hcp/vaccine-considerations/immunocompromised.html)). The CDC clinical considerations document now states, “On a case-by-case basis, providers caring for these patients may administer Moderna, Novavax, and Pfizer-BioNTech COVID-19 vaccines outside of the FDA and CDC dosing intervals when, based on their clinical judgment, the benefits of vaccination are deemed to outweigh the potential and unknown risks for the recipient who is immunocompromised.” Last reviewed: November 16, 2025 Janssen (Johnson & Johnson) COVID-19 vaccine is no longer produced. The last remaining doses expired May 7, 2023. The history of Janssen vaccine use is relevant only to evaluation of an adult with moderate or severe immunocompromise because such individuals are recommended to receive an initial series of COVID-19 vaccine. History of a single dose of Janssen COVID-19 vaccine constitutes a complete initial series. A person with this history should follow the vaccination schedule recommended for an immunocompromised person who has already completed an initial vaccination series. Last reviewed: November 16, 2025 Yes. Vaccination should be offered regardless of history of prior SARS-CoV-2 infection or long COVID. Because COVID-19 illness temporarily boosts immunity, people who have recently had SARS-CoV-2 infection may consider delaying a 2025–2026 COVID-19 vaccine dose by up to 3 months following symptom onset or positive COVID-19 test (if asymptomatic). Studies have shown that a longer time between infection and vaccination may improve the immune response to vaccination. The likelihood of reinfection in the first few months following infection is low. A recipient’s individual risks for severe disease and current COVID-19 conditions in the community should be taken into account when deciding whether to delay vaccination up to 3 months after infection. As with all vaccines, vaccination should be deferred until after recovery from moderate to severe illness. Last reviewed: November 16, 2025 Adults age 65 years and older have the highest rates of hospitalization and death from COVID-19 illness. Protection against severe COVID-19 disease wanes after a few months. Disease surveillance data from the United States shows that SARS-CoV-2 viruses circulate and cause illness at varying levels year-round, with waves of activity observed historically in winter and late summer. It is not known whether this pattern will continue. This pattern is not like influenza, which usually causes a single epidemic wave (sometimes with more than one peak) each winter. The 2025 CDC adult immunization schedule shows that adults age 65 years and older who are vaccinated against COVID-19 are recommended to receive a second dose of any 2025–2026 Formula COVID-19 vaccine 6 months after their first 2025–2026 Formula COVID-19 vaccine dose (minimum interval of 2 months for Comirnaty, Spikevax, and Nuvaxovid; minimum interval of 3 months for mNexspike). The second dose does not have to be the same brand as the first. Last reviewed: November 16, 2025 CDC recommends waiting a minimum of 8 weeks (2 months) since the last 2024–2025 Formula COVID-19 vaccine to receive an age-appropriate 2025–2026 Formula COVID-19 vaccine, if using Comirnaty (Pfizer-BioNTech), Nuvaxovid (Sanofi-Novavax), or Spikevax (Moderna). They recommend a 3-month minimum interval when using mNexspike (Moderna); however, a dose of mNexspike administered at least 2 months after the most recent dose does not need to be repeated. Any person who initiated a COVID-19 vaccination initial series (e.g., a child 6 months through 23 months of age or a person with moderate or severe immunocompromise) with a previous formulation should follow the age-appropriate recommended schedule for completion of their primary series with the current formulation of the same brand, if feasible. For the 2025–26 season, Spikevax is the only licensed and recommended option for children age 6 through 59 months, regardless of their vaccination history. Last reviewed: November 16, 2025 Under section 564 of the Federal Food, Drug, and Cosmetic Act (FD\&C Act), the FDA Commissioner may allow unapproved medical products or unapproved uses of approved medical products to be used in an emergency to diagnose, treat, or prevent serious or life-threatening diseases or conditions caused by chemical, biological, radiological or nuclear threat agents when there are no adequate, approved, and available alternatives. Vaccines that receive an EUA may later be fully licensed by the FDA. All available COVID-19 vaccines were initially administered under EUA. All available 2025–2026 Formula COVID-19 vaccines are fully licensed by FDA and no longer administered under EUA. Last reviewed: November 16, 2025 Both the Pfizer-BioNTech COVID-19 Vaccine (Comirnaty) and the Moderna COVID-19 vaccines (Spikevax, mNexspike) are lipid nanoparticle-formulated, nucleoside-modified mRNA vaccines encoding the prefusion spike glycoprotein of SARS-CoV-2, the virus that causes COVID-19. The 2025–2026 formula mRNA vaccines target the Omicron JN.1 variant LP.8.1 strain. Moderna’s mNexspike was first licensed in 2025 for ages 12 years and older. It is designed to reduce the amount of mRNA required to elicit the same or slightly better immune response compared to Spikevax (10 mcg of mRNA versus 50 mcg of mRNA for an adult dose). Spikevax and mNexspike may be used interchangeably when both are age appropriate. Visit this CDC website for more details about how mRNA vaccines work: [www.cdc.gov/covid/vaccines/how-they-work.html](https://www.cdc.gov/covid/vaccines/how-they-work.html). Last reviewed: November 16, 2025 Spikevax and mNexspike are both mRNA vaccines targeting the same strain of COVID-19. Spikevax is the original vaccine now licensed down to age 6 months. The mNexspike product is a newer mRNA vaccine licensed for ages 12 years and older with an advanced design that achieves the same or slightly better immune response with less mRNA in each dose (10 mcg in mNexspike compared to 50 mcg in adult doses of Spikevax). The two products may be used interchangeably when age appropriate. In adults 65 years and older (and moderately or severely immunocompromised adults) who are recommended to receive a second dose 6 months after their first 2025–2026 formula dose, the minimum interval between the two recommended 2025–26 season doses is 3 months for mNexspike, but only 2 months for the other COVID-19 vaccine products. If mNexspike is inadvertently administered after only 2 months, the dose counts as valid and does not need to be repeated. Last reviewed: November 16, 2025 Last reviewed: January 9, 2026 It is estimated that for every million doses administered, about one (~0.0001%) will result in an anaphylactic reaction following vaccination. The estimate for mRNA COVID-19 vaccines is slightly higher, at 2 to 5 anaphylactic reactions per million vaccinations given. With proper screening, most providers who administer thousands of vaccines in their lifetimes will never see an anaphylactic reaction. Last reviewed: November 16, 2025 The original COVID-19 vaccines all targeted the spike protein of the original SARS-CoV-2 virus. The 2025–2026 formulation vaccines target the spike proteins of more recently circulating strains, known as the Omicron JN.1 lineage LP.8.1 strain (mRNA vaccines) or the JN.1 strain (Nuvaxovid adjuvanted protein subunit vaccine). The update is intended to boost production of antibodies that protect more effectively against disease caused by currently circulating Omicron subvariants. The process of updating the strain without changing anything else is similar to the seasonal strain changes made for influenza vaccinations each year. Vaccine safety, side effects, and risk of allergic reactions are expected to be comparable to earlier formulations of vaccines of the same brand and dose. As with seasonal influenza vaccines, future COVID-19 vaccines can continue to be updated when needed, as the circulating viruses evolve. Last reviewed: November 16, 2025 No. The last U.S. doses of Janssen COVID-19 Vaccine expired May 7, 2023. Last reviewed: November 16, 2025 Nuvaxovid is the brand name of the adjuvanted protein subunit COVID-19 vaccine developed by Novavax and commercialized by Sanofi beginning in the 2025–26 season. It contains the Omicron JN.1 subvariant SARS-CoV-2 spike protein and Matrix-M adjuvant. The saponin-based adjuvant is made from extracts of the bark of the Soapbark tree native to Chile. It is added to enhance the immune response of the vaccine recipient. The spike protein is produced in insect cells. The 2025–2026 formulation of Nuvaxovid is FDA-licensed for use in people age 12 years or older. It is recommended as a single dose for people age 12 years through 64 years, given at least 8 weeks after the most recent dose of COVID-19 vaccine, regardless of the recipient’s vaccination history. People age 65 years or older and those age 12 years and older who are moderately or severely immunocompromised are recommended to receive 2 doses of 2025–2026 Formula COVID-19 vaccines, 6 months apart (with a minimum interval of 2 months between doses if using Nuvaxovid for both doses). A 2-dose initial series is recommended for previously unvaccinated recipients who are moderately or severely immunocompromised, with the doses given at least 3 weeks apart. A third dose of any COVID-19 vaccine is recommended 6 months after the initial series is completed (with a minimum interval of 2 months between doses if using Nuvaxovid). Last reviewed: November 16, 2025 The benefit of COVID-19 vaccination to an individual patient varies depending on the health status of the patient, their history of vaccination and COVID-19 infection, and the circulating COVID-19 strains. However, despite these variables, observational studies consistently show vaccination in all age groups provides measurable additional protection against hospitalization or death compared to those who are unvaccinated. CDC published “Interim Estimates of 2024–2025 COVID-19 Vaccine Effectiveness Among Adults Aged ≥18 Years — VISION and IVY Networks, September 2024–January 2025” in MMWR on February 27, 2025 ([www.cdc.gov/mmwr/volumes/74/wr/mm7406a1.htm](http://www.cdc.gov/mmwr/volumes/74/wr/mm7406a1.htm)). They concluded vaccine effectiveness (VE) of 2024–2025 COVID-19 vaccine was 33% against COVID-19–associated emergency department (ED) or urgent care (UC) visits among adults age18 years or older and 45%–46% against hospitalizations among immunocompetent adults age 65 years or older, compared with not receiving a 2024–2025 vaccine dose. VE against hospitalizations in immunocompromised adults age 65 years or older was 40%. Last reviewed: November 16, 2025 CDC and ACIP recommend vaccination of all people age 6 months through 64 years based on individual decision-making (also known as shared clinical decision-making), with an emphasis that the risk-benefit of vaccination is most favorable for individuals who are at an increased risk for severe COVID-19 disease and lowest for individuals who are not at an increased risk, according to the CDC list of COVID-19 risk factors. Refer to CDC’s interim clinical considerations for COVID-19 vaccination for the specific dosing schedule: [www.cdc.gov/covid/hcp/vaccine-considerations/routine-guidance.html\#cdc\_clinical\_guidance\_recomm\_key-table-1-2025–2026-covid-19-vaccination-schedule-november-4-2025](http://www.cdc.gov/covid/hcp/vaccine-considerations/routine-guidance.html#cdc_clinical_guidance_recomm_key-table-1-2025%E2%80%932026-covid-19-vaccination-schedule-november-4-2025). The American Academy of Pediatrics (AAP) has issued separate COVID-19 vaccination recommendations for children during the 2025–26 season. Refer to the full statement for details of their recommendations: <https://doi.org/10.1542/peds.2025-073924>. In summary, AAP recommends age-appropriate COVID-19 vaccination of the following groups of children: - All children age 6 months through 23 months - Residents of long-term care facilities or other congregate settings - Children who have never been vaccinated against COVID-19 - Infants and children with household contacts who are at high risk for severe COVID-19 - All children who are at risk of severe COVID-19 due to underlying conditions or treatments, including: chronic pulmonary disease, cardiovascular disease, gastrointestinal disorders, hepatic disease, hematologic disease, metabolic disorders, obesity, neurologic and neurodevelopmental conditions, immunosuppressive conditions, and rheumatologic or autoimmune disease - Children age 2 through 18 years not in the above categories whose parent or guardian desires their protection from COVID-19 Last reviewed: November 16, 2025 This child should receive one dose recommended for his age at the time of the vaccination visit. At age 11 years, an age-appropriate single dose of either Comirnaty (Pfizer-BioNTech) or Spikevax (Moderna) mRNA vaccine is recommended. If the patient arrives in your clinic after turning 12 years old, the 2025–2026 Formula Nuvaxovid (Sanofi-Novavax) protein subunit vaccine and the mNexspike (Moderna) mRNA vaccine are also options. Last reviewed: November 16, 2025 CDC states that a person who moves to an older age group before completing the initial series recommended for the younger age group should follow the schedule for the older age group and receive the vaccine product and dosage for the older age group. In this case, the child should receive one dose of 2025–2026 Formula Spikevax (Moderna) at least 8 weeks after the most recent dose of COVID-19 vaccine. An initial series of COVID-19 vaccine is recommended for children 6 months through 23 months of age. Children 24 months through 59 months of age are recommended to receive only one dose of 2025–2026 Formula Spikevax regardless of their COVID-19 vaccination history. Last reviewed: November 16, 2025 Moderately or severely immunocompromised children who transition from age 11 years to age 12 years during the initial vaccination series should complete the 3-dose series using the dosage for people ages 12 years and older for all doses received once they are age 12 years. See [www.cdc.gov/covid/hcp/vaccine-considerations/immunocompromised.html](http://www.cdc.gov/covid/hcp/vaccine-considerations/immunocompromised.html) for additional details. Last reviewed: November 16, 2025 Both vaccines have been demonstrated to be safe, with side effects typical of those in older age groups. The most common local reaction in this age group is pain at the injection site; the most common systemic symptom in older children was fatigue and in younger children (6 through 23 months) irritability/crying and sleepiness were most common. Fever may occur after either vaccination. Febrile seizures can occur in infants and young children ages 6 months through 5 years as a result of any condition that causes a fever (most common with high fevers). Febrile seizures are uncommon after vaccination. Febrile seizures were rare after mRNA COVID-19 vaccine clinical trials in this age group, and CDC continues to monitor for this adverse event following vaccination in infants and young children. No cases of myocarditis were reported during the clinical trials for either vaccine. To date, post-authorization surveillance has not detected an increased risk for myocarditis and pericarditis following mRNA COVID-19 vaccination in children ages 6 months–4 years (Pfizer-BioNTech) and ages 6 months–5 years (Moderna). Last reviewed: November 16, 2025 Last reviewed: November 16, 2025 Comirnaty (Pfizer-BioNTech) mRNA COVID-19 vaccine is FDA-licensed for use in ages 5 years through 64 years with at least one underlying condition that puts them at risk for severe COVID-19 infection and individuals 65 years and older mNexspike (Moderna) is FDA-licensed for use in ages 12 through 64 years with at least one underlying condition that puts them at risk for severe COVID-19 infection and individuals 65 years and older Nuvaxovid (Sanofi-Novavax) is FDA-licensed for use in ages 12 through 64 years with at least one underlying condition that puts them at risk for severe COVID-19 infection and individuals 65 years and older Spikevax (Moderna) mRNA COVID-19 vaccine is FDA-licensed for use in ages 6 months through 64 years with at least one underlying condition that puts them at risk for severe COVID-19 infection and individuals 65 years and older Although the FDA licenses are limited in the age group younger than 65 years to those with underlying conditions that put them at risk for severe COVID-19 infection, the ACIP has recommended use based on individual decision-making (i.e., shared clinical decision-making) for all people age 6 months and older. This means that it is acceptable standard of care to offer COVID-19 vaccination to people in this age group without a high-risk condition when vaccination is desired. Last reviewed: November 16, 2025 Clinical trial results for the original monovalent Pfizer-BioNTech COVID-19 Vaccine (administered as a two-dose primary series) demonstrated that among vaccine recipients age 12–15 years, side effects during the 7 days after vaccination were commonly reported (90.9% of vaccine recipients reported a local reaction and 90.7% reported a systemic reaction). Most reactions were mild to moderate. Pain at the injection site was the most common local reaction. One in 10 reported a side effect that interfered with daily activities. Side effects usually resolved after 1–2 days. Systemic side effects (e.g., fever, fatigue, headache, muscle pain) were more commonly reported after the second dose than after the first dose. No specific safety concerns were identified among adolescent vaccine recipients. The safety and side effects of the 2025–2026 formula are expected to be consistent with the previous formulations of the product. Last reviewed: November 16, 2025 The 2025–2026 formula Nuvaxovid (Sanofi-Novavax) vaccine is an option for any person age 12 years or older who is due for a 2025–2026 updated vaccination. Below are listed the 2025–26 season dosing schedules (if using Nuvaxovid for all doses) for different ages and health conditions: - Age 12 through 64 years, not moderately or severely immunocompromised: one 2025–2026 formula dose, at least 8 weeks after most recent dose from a previous season - Age 65 years and older, not moderately or severely immunocompromised: two 2025–2026 formula doses 6 months apart (minimum interval 2 months) - Age 12 years or older, moderately or severely immunocompromised: - Previously unvaccinated: give 2 doses at least 3 weeks apart as an initial series, followed by a third dose about 6 months after dose 2 (minimum interval 2 months) - Previously completed an initial series of any COVID-19 vaccine (2 doses of Novavax protein subunit vaccine or 3 doses of an mRNA vaccine): give first 2025–2026 formula dose at least 8 weeks after most recent COVID-19 vaccine from the previous season, then give a second dose about 6 months later (minimum interval, 2 months) See Immunize.org’s standing orders template for administration of 2025–2026 formula adjuvanted protein subunit vaccine to individuals age 12 years and older for details: [www.immunize.org/wp-content/uploads/catg.d/p3141.pdf](http://www.immunize.org/wp-content/uploads/catg.d/p3141.pdf). Last reviewed: November 16, 2025 Yes. Evidence continues to demonstrate that COVID-19 vaccination is safe and effective during any stage of pregnancy; the benefits of vaccination clearly outweigh any known or potential risks of COVID-19 vaccination during pregnancy. The currently licensed COVID-19 vaccines are nonreplicating vaccines and cannot cause infection in either the mother or the fetus. No evidence exists of risk to the fetus from vaccinating during pregnancy with nonreplicating vaccines in general. Data from the Vaccine Adverse Events Reporting System (VAERS), the V-safe surveillance system, and the V-safe pregnancy registry have not signaled any safety concerns related to vaccination during pregnancy for mother or infant. Pregnant women have historically been at an increased risk of severe disease, adverse pregnancy outcomes, and maternal death from COVID-19 infections. ACIP recommends the use of 2025–2026 COVID-19 vaccine during pregnancy based upon individual decision-making (i.e., shared clinical decision-making). The American College of Obstetricians and Gynecologists (ACOG) recommends all pregnant women receive any age-appropriate 2025–2026 Formula COVID-19 vaccine if they have not already received one. Current ACOG recommendations are available here: [www.acog.org/clinical/clinical-guidance/practice-advisory/articles/2020/12/covid-19-vaccination-considerations-for-obstetric-gynecologic-care](http://www.acog.org/clinical/clinical-guidance/practice-advisory/articles/2020/12/covid-19-vaccination-considerations-for-obstetric-gynecologic-care). Last reviewed: November 16, 2025 Pregnant women have historically been at an increased risk of severe disease, adverse pregnancy outcomes, and maternal death from COVID-19 infections. Studies have shown that antibodies produced after COVID-19 vaccination during pregnancy are transferred to the newborn, and COVID-19 vaccination during pregnancy reduces the risk of COVID-19 hospitalization in infants younger than 6 months. ACIP recommends the use of 2025–2026 COVID-19 vaccine during pregnancy based upon individual decision-making (i.e., shared clinical decision-making) after a discussion with a nurse, doctor, or pharmacist. The American College of Obstetricians and Gynecologists (ACOG) recommends all pregnant women receive any age-appropriate 2025–2026 Formula COVID-19 vaccine if they have not already received one. A person who is up to date on COVID-19 vaccination and becomes pregnant is not recommended to get an additional dose. Current ACOG recommendations are available here: [www.acog.org/clinical/clinical-guidance/practice-advisory/articles/2020/12/covid-19-vaccination-considerations-for-obstetric-gynecologic-care](http://www.acog.org/clinical/clinical-guidance/practice-advisory/articles/2020/12/covid-19-vaccination-considerations-for-obstetric-gynecologic-care). Last reviewed: November 16, 2025 Last reviewed: January 9, 2026 Yes. COVID-19 vaccination may be given during lactation. Last reviewed: November 16, 2025 Please see CDC’s Interim Clinical Considerations for the Use of COVID-19 Vaccines for dosage guidance for detailed tables, including dosing intervals and options ([www.cdc.gov/covid/hcp/vaccine-considerations/immunocompromised.html](http://www.cdc.gov/covid/hcp/vaccine-considerations/immunocompromised.html)). You will also find the vaccination schedules for people who are moderately or severely immunocompromised in the Immunize.org standing orders templates for administration of COVID-19 vaccines: - For ages 6 months through 11 years: [www.immunize.org/wp-content/uploads/catg.d/p3140a.pdf](http://www.immunize.org/wp-content/uploads/catg.d/p3140a.pdf) - mRNA vaccines for ages 12 years and older: [www.immunize.org/wp-content/uploads/catg.d/p3140.pdf](http://www.immunize.org/wp-content/uploads/catg.d/p3140.pdf) - Protein subunit vaccine for ages 12 years and older: [www.immunize.org/wp-content/uploads/catg.d/p3141.pdf](http://www.immunize.org/wp-content/uploads/catg.d/p3141.pdf) In general, people who are moderately or severely immunocompromised and previously unvaccinated are recommended to receive a 2-dose (protein subunit) or 3-dose (mRNA) initial series of COVID-19 vaccine, with an additional dose 6 months later of any age-appropriate COVID-19 brand (minimum interval of 2 months for Nuvaxovid, Spikevax, or Comirnaty; 3-month minimum interval for mNexspike). CDC recommends use of the same manufacturer for all doses of the initial series when feasible. Spikevax and mNexspike are both made by Moderna and are interchangeable in ages 12 years and older. Those who completed an initial series before the 2025–2026 formula vaccines were available should receive 2 doses of 2025–2026 Formula COVID-19 vaccine (any age-appropriate brand) about 6 months apart (minimum interval of 2 months for Nuvaxovid, Spikevax, or Comirnaty; 3-month minimum interval for mNexspike). Immunocompromised people should be counseled that they may have a reduced immune response to COVID-19 vaccination. Continuing other infection prevention measures, such as wearing a face mask and avoiding crowds, can help limit their risk of exposure to the SARS-CoV-2 virus. Pemivibart (Pemgarda, Invyvid) is a monoclonal antibody for COVID-19 pre-exposure prophylaxis in people who are moderately or severely immunocompromised and unlikely to mount an adequate immune response to COVID-19 vaccination and who meet the [FDA-authorized conditions for use](https://www.fda.gov/media/177067/download?attachment). See additional information from CDC at the immunocompromised link in the first paragraph. Last reviewed: November 16, 2025 The conditions and treatments that CDC specifies may result in moderate or severe immunocompromise include but are not limited to: - Active treatment for solid tumor and hematologic malignancies - Hematologic malignancies associated with poor responses to COVID-19 vaccines regardless of current treatment status (e.g., chronic lymphocytic leukemia, non-Hodgkin lymphoma, multiple myeloma, acute leukemia) - Receipt of solid-organ transplant or an islet transplant and taking immunosuppressive therapy - Receipt of chimeric antigen receptor (CAR)-T-cell therapy or hematopoietic cell transplant (HCT) (within 2 years of transplantation or taking immunosuppressive therapy) - Moderate or severe primary immunodeficiency (e.g., common variable immunodeficiency disease, severe combined immunodeficiency, DiGeorge syndrome, Wiskott-Aldrich syndrome) - Advanced HIV infection (people with HIV and CD4 cell counts less than 200/mm³, history of an AIDS-defining illness without immune reconstitution, or clinical manifestations of symptomatic HIV) or untreated HIV infection - Active treatment with high-dose corticosteroids (i.e., 20 mg or more of prednisone or equivalent per day when administered for 2 or more weeks), alkylating agents, antimetabolites, transplant-related immunosuppressive drugs, cancer chemotherapeutic agents classified as severely immunosuppressive, tumor necrosis factor (TNF) blockers, and other biologic agents that are immunosuppressive or immunomodulatory (e.g., B-cell-depleting agents) Additional factors to consider in assessing the general level of immune competence in a patient include disease severity, duration, clinical stability, complications, comorbidities, and any potentially immune-suppressing treatment. A patient’s clinical care team is in the best position to evaluate the degree of immunocompromise and timing of vaccination. See CDC’s interim clinical considerations for this population: [www.cdc.gov/covid/hcp/vaccine-considerations/immunocompromised.html](http://www.cdc.gov/covid/hcp/vaccine-considerations/immunocompromised.html). Last reviewed: November 16, 2025 Yes. See revaccination considerations at [www.cdc.gov/covid/hcp/vaccine-considerations/immunocompromised.html](http://www.cdc.gov/covid/hcp/vaccine-considerations/immunocompromised.html). This is the most current statement from CDC on COVID-19 revaccination: Recipients of chimeric antigen receptor (CAR)-T-cell therapy or hematopoietic cell transplant (HCT) who received 1 or more doses of COVID-19 vaccine prior to or during treatment should be revaccinated. Revaccination should start at least 3 months (12 weeks) after transplant or CAR-T-cell therapy and should follow the currently recommended schedule for people who are unvaccinated. Revaccination may also be considered for patients who received 1 or more doses of COVID-19 vaccine during treatment with B-cell-depleting therapies (e.g., rituximab, ocrelizumab) that were administered over a limited period (e.g., as part of a treatment regimen for certain malignancies) according to the currently recommended schedule for people who are unvaccinated. The suggested interval to start revaccination is about 6 months after completion of the B-cell-depleting therapy. Timing of vaccination for patients who receive B-cell-depleting therapies on a continuing basis (e.g., for treatment of certain autoimmune conditions such as rheumatoid arthritis or multiple sclerosis) is addressed in CDC’s [considerations for timing of COVID-19 vaccination in relation to immunosuppressive therapies](https://www.cdc.gov/covid/hcp/vaccine-considerations/immunocompromised.html#cdc_cg_special_populations_about-considerations-for-timing-of-covid-19-vaccination-in-relation-to-immunosuppressive-therapies). CDC continues to recommend that a patient’s clinical team is best positioned to determine the degree of immune compromise, need for revaccination, and appropriate timing of revaccination. Last reviewed: November 16, 2025 According to CDC’s interim clinical considerations for the use of COVID-19 vaccines, whenever possible, COVID-19 vaccines should be administered at least 2 weeks before initiation or resumption of immunosuppressive therapies. For patients who receive B-cell-depleting therapies on a continuing basis, COVID-19 vaccines should be administered approximately 4 weeks before the next scheduled therapy. CDC also notes that timing of COVID-19 vaccination should take into consideration current or planned immunosuppressive therapies, optimization of both the patient’s medical condition and response to vaccination, and individual benefits and risks. Review the CDC’s considerations for COVID-19 vaccination of those on immunosuppressive therapies here: [www.cdc.gov/covid/hcp/vaccine-considerations/immunocompromised.html\#cdc\_cg\_special\_populations\_about-considerations-for-timing-of-covid-19-vaccination-in-relation-to-immunosuppressive-therapies](http://www.cdc.gov/covid/hcp/vaccine-considerations/immunocompromised.html#cdc_cg_special_populations_about-considerations-for-timing-of-covid-19-vaccination-in-relation-to-immunosuppressive-therapies). On a case-by-case basis, providers caring for these patients may administer COVID-19 vaccines outside of the FDA and CDC dosing schedules based on their clinical judgment of what is most beneficial to the patient. Last reviewed: November 16, 2025 CDC states that no additional medical documentation is required before administering COVID-19 vaccine. The patient’s self-attestation of a high-risk condition, including moderate or severe immunocompromise, is sufficient. Those who report moderate or severe immunocompromise should be offered the modified schedule for people with moderate or severe immunocompromise. Vaccinators should not deny COVID-19 vaccination to a person due to lack of documentation of a self-reported high-risk condition. Last reviewed: November 16, 2025 Last reviewed: January 9, 2026 Immunocompromised people who need an initial series of 3 doses of mRNA COVID-19 vaccine or two doses of Nuvaxovid (Sanofi-Novavax) adjuvanted protein COVID-19 vaccine should receive the initial series using COVID-19 vaccines from the same manufacturer, unless it is not feasible. If the same manufacturer cannot be used for all primary series doses (e.g., the brand is unavailable at the time of the vaccination visit, the previous brand is unknown, or the patient would not be vaccinated with the previous brand due to a contraindication or other reason), then administer another age-appropriate brand. Spikevax (Moderna) is the only licensed 2025–2026 Formula COVID-19 vaccine option for children younger than age 5 years. If the immunocompromised recipient is age 5 years or older, once the initial series is complete, any appropriate brand may be used for all subsequent doses. Spikevax and mNexspike are interchangeable: both vaccines are made by Moderna. Last reviewed: November 16, 2025 The patient’s initial series is considered complete following a single dose of the Janssen COVID-19 Vaccine. People who are moderately or severely immunocompromised and have completed an initial series (no matter how long ago) should now receive 1 dose of an age-appropriate 2025–2026 Formula COVID-19 vaccine (at least 8 weeks after their most recent dose of a previous formulation). They should receive a second 2025–2026 Formula COVID-19 vaccine dose 6 months later (minimum interval 2 months for Comirnaty, Spikevax, and Nuvaxovid; minimum interval of 3 months if using mNexspike). Last reviewed: November 16, 2025 The patient should receive a 2025–2026 COVID-19 mRNA dose now, of the same manufacturer as the initial two doses (if feasible), in order to complete the 3-dose initial mRNA vaccine series recommended for people with moderate or severe immunocompromise. Advise the patient that he should receive an additional 2025–2026 Formula COVID-19 dose of any brand in 6 months (minimum interval 2 months if using Comirnaty, Spikevax, or Nuvaxovid; minimum interval 3 months if using mNexspike). Last reviewed: November 16, 2025 All COVID-19 vaccines are administered intramuscularly. Preparation details and dose volume vary by product. Most 2025-2026 formula products are now available in manufacturer-filled syringes. Last reviewed: November 16, 2025 Yes. CDC published an appendix to its interim clinical considerations for the use of COVID-19 vaccines to address a wide range of errors in vaccine administration. It includes a detailed table outlining actions to take after an error has occurred: [www.cdc.gov/covid/hcp/vaccine-considerations/appendices.html](http://www.cdc.gov/covid/hcp/vaccine-considerations/appendices.html). Categories of errors covered in the CDC table include: - Site/route - Age - Product and dosage - Storage and handling - Incorrect intervals - Interchanging product types when not recommended Ask the Experts refers our readers to this CDC table for the most current and comprehensive guidance on COVID-19 vaccine administration errors and how to manage them. For all vaccine administration errors the following steps are recommended: inform the patient of the error, report the error to VAERS ([https://vaers.hhs.gov](https://vaers.hhs.gov/)) unless CDC’s guidance states that the error does not need to be reported, evaluate why the error occurred, and implement strategies to prevent future errors. Last reviewed: November 16, 2025 No. CDC does not recommend repeating the dose of any COVID-19 vaccine in circumstances where the dose is administered in an incorrect route or an incorrect site (i.e., not in the deltoid or anterolateral thigh). In the case of a subcutaneous injection, the patient should be advised of the possibility of self-limited local or systemic side effects. Last reviewed: November 16, 2025 Providing a vaccine recipient with a COVID-19 vaccine VIS is recommended by CDC but not required. The requirement to provide the VIS to a patient is present only when a vaccine is included in the federal Vaccine Injury Compensation Program (VICP). COVID-19 vaccines are not included in the VICP at this time. The current official VIS and all available translations are available from Immunize.org: [www.immunize.org/vaccines/vis/covid-19/](http://www.immunize.org/vaccines/vis/covid-19/). Last reviewed: November 16, 2025 Last reviewed: January 9, 2026 Periodically verify whether you are using the most current available documents by checking Immunize.org’s regularly updated Checklist of Current Versions of U.S. COVID-19 Vaccination Guidance and Clinic Support Tools: [www.immunize.org/catg.d/p3130.pdf](http://www.immunize.org/catg.d/p3130.pdf). This resource is updated as needed with the dates of the most currently available materials from CDC and FDA. Information from CDC is generally updated first on the CDC web page: Interim Clinical Considerations for Use of COVID-19 Vaccines in the United States: ([www.cdc.gov/covid/hcp/vaccine-considerations/index.html](http://www.cdc.gov/covid/hcp/vaccine-considerations/index.html)). Last reviewed: November 16, 2025 No. Simply administer the next dose that is currently recommended, using a vaccine from the same manufacturer, if feasible, even if previous doses in the series were an earlier formulation. Last reviewed: November 16, 2025 CDC guidance allows for doses given up to 4 days before the recommended interval to be counted as valid – such doses do not need to be repeated. However, people should not be routinely scheduled to receive a dose earlier than recommended. Schedulers should offer appointments beginning on the date of the recommended interval or later. Last reviewed: November 16, 2025 Beginning with the 2025–2026 season, a single dose of 2025–2026 Formula Nuvaxovid adjuvanted protein COVID-19 vaccine is recommended for all recipients age 12 through 64 years who are not moderately or severely immunocompromised, regardless of their vaccination history. Those age 65 years or older are recommended to receive a second dose of any 2025–2026 Formula COVID-19 vaccine 6 months after the first 2025–2026 Formula dose (minimum interval 2 months if using Comirnaty, Spikevax, or Nuvaxovid; minimum interval 3 months if using mNexspike). Last reviewed: November 16, 2025 An asymptomatic person who is scheduled for COVID-19 vaccination and is exposed to SARS-CoV-2 virus may be vaccinated. COVID-19 vaccination after exposure is not recommended as post-exposure prophylaxis, so vaccination should not be expected to prevent illness caused by past exposure. A person who is currently sick with a respiratory virus should defer vaccination until at least the recovery from the acute illness, and consider additional measures to prevent infecting others, in accordance with current CDC guidance. Healthcare facilities may have specific policies in place to reduce the risk of spread of respiratory viruses to healthcare staff and other patients. People who recently had SARS-CoV-2 infection and are due for a COVID-19 vaccine may consider delaying the dose by up to 3 months from symptom onset or positive test (if infection was asymptomatic). According to CDC, increasing the time between infection and vaccination may result in an improved immune response to vaccination. There is a low risk of reinfection in the weeks following an infection. A recipient’s individual risks for severe disease and current COVID-19 conditions in the community should be taken into consideration when deciding whether to delay vaccination up to 3 months after infection. Last reviewed: November 16, 2025 Routine administration of all age-appropriate doses of vaccines at the same visit, also known as coadministration, is acceptable for children, adolescents, and adults if there are no contraindications at the time of the healthcare visit. COVID-19 vaccine may also be coadministered with nirsevimab or clesrovimab (RSV preventive antibody for infants), given in different syringes and at different anatomical sites. COVID-19 vaccines may also be given at any interval before or after any other vaccination. There are special considerations for orthopoxvirus vaccination. There is no required minimum interval between receiving a dose of any COVID-19 vaccine and an orthopoxvirus vaccine, either Jynneos or ACAM2000 vaccine (e.g., for mpox prevention), regardless of which vaccine is administered first. However, use of Jynneos vaccine should be prioritized over ACAM2000 when co-administering a COVID-19 vaccine and an orthopoxvirus vaccine. People, particularly adolescent or young adult males, who are recommended to be vaccinated against both mpox and COVID-19 might consider waiting 4 weeks between vaccines. This is because of the observed risk for myocarditis and pericarditis after receipt of ACAM2000 orthopoxvirus vaccine and COVID-19 vaccines, and the hypothetical risk for myocarditis and pericarditis after Jynneos vaccine. However, if a patient’s risk for mpox or severe disease due to COVID-19 is increased, administration of mpox and COVID-19 vaccines should not be delayed. Last reviewed: November 16, 2025 Your patient may choose to receive the vaccines at the same visit or separately, without regard to the timing interval. When multiple vaccines are administered at a single visit, administer each injection in a different syringe and at a different injection site. For adolescents and adults, the deltoid muscle may be used for more than one injection, though injection sites should be at least one inch apart. It is generally preferable to administer reactogenic vaccines such as Shingrix and COVID-19 vaccine in different arms. However, if the patient prefers both injections in the same deltoid, that is also acceptable. Immunize.org has developed a one-page guide to administering multiple intramuscular vaccinations to an adult at one visit: [www.immunize.org/catg.d/p2030.pdf](http://www.immunize.org/catg.d/p2030.pdf). Last reviewed: November 16, 2025 The timing of CDC-recommended vaccination is unaffected by the receipt of COVID-19 monoclonal antibodies or convalescent plasma. Last reviewed: November 16, 2025 This page was updated on January 9, 2026 .
Shard	178 (laksa)
Root Hash	15214894206049953578
Unparsed URL	org,immunize!www,/ask-experts/topic/covid-19/ h80